46. 悪性関節リウマチ Disease details / Clinical trials / Drug dev / DR info

(+) erythromefloquine   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(+) isomer of racemic mefloquine   
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(+) isomer or racemic mefloquine   
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(+)erythromefloquine   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-   
   Pfizer Inc. 235 East 42nd Street, New York, NY10017
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-GR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-005036-24-BG   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-HU   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-CZ   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
      2007   Phase 2   EUCTR2006-005036-24-SK   Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
      2007   -   EUCTR2006-005036-24-SE   Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,   
   Pfizer Corporation Austria Ges.m.b.H.
      2005   -   EUCTR2004-002846-36-AT   Austria;Germany;Italy;Spain;
   Pfizer Global & Developement, Pfizer Limited
      2005   Phase 2   EUCTR2004-002846-36-SK   Austria;Germany;Italy;Slovakia;Spain;
   Pfizer Pharma GmbH
      2005   -   EUCTR2004-002846-36-DE   Germany;Italy;Spain;
   Pfizer, S.A.
      2005   Phase 2   EUCTR2004-002846-36-ES   Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-   
   Pfizer Inc. 235 East 42nd Street, New York, NY10017
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-GR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-005036-24-BG   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-HU   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-CZ   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
      2007   Phase 2   EUCTR2006-005036-24-SK   Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
      2007   -   EUCTR2006-005036-24-SE   Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile,   
   Pfizer Corporation Austria Ges.m.b.H.
      2005   -   EUCTR2004-002846-36-AT   Austria;Germany;Italy;Spain;
   Pfizer Global & Developement, Pfizer Limited
      2005   Phase 2   EUCTR2004-002846-36-SK   Austria;Germany;Italy;Slovakia;Spain;
   Pfizer Pharma GmbH
      2005   -   EUCTR2004-002846-36-DE   Germany;Italy;Spain;
   Pfizer, S.A.
      2005   Phase 2   EUCTR2004-002846-36-ES   Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1-   
   Pfizer S.A.
      2007   Phase 2   EUCTR2006-005035-19-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1-   
   Pfizer S.A.
      2007   Phase 2   EUCTR2006-005035-19-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(CDP6038   
   R-Pharm
      2017   Phase 3   EUCTR2015-005309-35-LV   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-HU   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-GB   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005307-83-LV   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-HU   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005308-27-DE   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-LT   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-HU   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International LLC
      2017   Phase 3   EUCTR2015-005309-35-PL   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-LT   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-DE   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-CZ   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-CZ   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005307-83-CZ   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-BG   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International, LLC.
      2017   Phase 3   EUCTR2015-005309-35-BG   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
0109-0012A 100 mg/ml   
   NOVO NORDISK
      2013   -   EUCTR2012-000610-11-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Novo Nordisk A/S
      2014   Phase 2   EUCTR2013-001492-20-PT   Ireland;Portugal;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-001492-20-ES   Ireland;Portugal;Spain;United Kingdom;
      2013   Phase 2   EUCTR2013-001492-20-GB   Belgium;Czech Republic;Germany;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2013   -   EUCTR2012-000610-11-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000610-11-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000609-58-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000609-58-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000610-11-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000609-58-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000609-58-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      -   -   EUCTR2012-000609-58-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 25 mg/ml   
   NOVO NORDISK
      2013   -   EUCTR2012-000610-11-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Novo Nordisk A/S
      2013   -   EUCTR2012-000610-11-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000610-11-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000609-58-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000609-58-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000610-11-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000609-58-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000609-58-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      -   -   EUCTR2012-000609-58-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 50 mg/ml   
   NOVO NORDISK
      2013   -   EUCTR2012-000610-11-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Novo Nordisk A/S
      2013   -   EUCTR2012-000610-11-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000610-11-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000609-58-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000609-58-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000610-11-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000609-58-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000609-58-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      -   -   EUCTR2012-000609-58-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0114-0006B   
   Novo Nordisk A/S
      2012   Phase 2   EUCTR2011-005376-42-ES   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
      2012   -   EUCTR2011-005376-42-LV   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
      2012   -   EUCTR2011-005376-42-HU   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
      2012   -   EUCTR2011-005376-42-BG   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
0881   
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
   Wyeth Pharmaceuticals France
      2008   Phase 4   EUCTR2007-000896-41-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001625-10-PL   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-DE   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-AT   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-000896-41-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000896-41-NL   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2010   Phase 4   EUCTR2008-002623-85-SE   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2010   -   EUCTR2007-000896-41-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2007-000896-41-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2008   Phase 4   EUCTR2007-000896-41-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   Phase 4   EUCTR2008-002623-85-FR   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2008-002623-85-ES   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
      2008   -   EUCTR2007-000896-41-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
1 ml NaCl   
   Vrije Universiteit Brussel
      2010   -   NCT01154647   Belgium;
1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c   
   Merck Sharp & Dohme (Sweden) AB
      2004   -   EUCTR2004-000074-31-SE   Sweden;
   Merck Sharp & Dohme BV
      2005   Phase 2   EUCTR2004-000074-31-BE   Belgium;Sweden;
118-42-3   
   Karolinska Institutet
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
13-valent pneumococcal conjugate vaccine   
   Region Skane
      2016   Phase 4   NCT03762824   -
15-O labeled water   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2001   Phase 1   NCT00014794   United States;
18F-FDG   
   GlaxoSmithKline
      2015   Phase 1   NCT02350426   United Kingdom;
18F-GE-180   
   GlaxoSmithKline
      2015   Phase 1   NCT02350426   United Kingdom;
18F]PEG-Folate   
   VU Medical Center, department of Rheumatology
      2020   Phase 4   EUCTR2018-004429-94-NL   Netherlands;
      2018   Phase 4   EUCTR2018-001114-15-NL   Netherlands;
2 million hMSC   
   MetroHealth Medical Center
      2017   Phase 1   NCT03186417   United States;
2-HOBA   
   Vanderbilt University Medical Center
      2022   Phase 2   NCT05274243   United States;
2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   Phase 4   EUCTR2013-004006-26-DK   Denmark;
23-Valent Pneumococcal Polysaccharide Vaccine   
   Genentech, Inc.
      2010   Phase 4   NCT01163747   United States;
23-valent pneumococcal polysaccharide vaccine   
   Genentech, Inc.
      2006   Phase 2   NCT00282308   United States;
   Region Skane
      2016   Phase 4   NCT03762824   -
2593   
   Aarhus University Hospital, Denmark
      2007   Phase 4   EUCTR2007-000082-38-DK   Denmark;
331731-18-1   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 4   EUCTR2014-001114-26-SE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-001114-26-NL   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-004019-37-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2013-004019-37-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   -   EUCTR2013-004019-37-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 4   EUCTR2014-001114-26-IT   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-IE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-HU   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-GR   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-GB   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-FR   Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-ES   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-DE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-AT   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-004019-37-RO   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   -   EUCTR2013-004019-37-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
   Abbott Japan Co., Ltd.
      -   -   EUCTR2014-004558-33-Outside-EU/EEA   Japan;
35565011   
   DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
      2016   Phase 3   EUCTR2015-000570-35-IT   Italy;
4 million hMSC   
   MetroHealth Medical Center
      2017   Phase 1   NCT03186417   United States;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide   
   Astellas Pharma Global Development
      2013   Phase 2   EUCTR2011-006021-23-CZ   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   Phase 2   EUCTR2011-006021-23-BG   Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   -   EUCTR2011-006021-23-HU   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2012   -   EUCTR2011-006021-23-BE   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
   Astellas Pharma Global Development Inc. (APGD)
      2013   Phase 2   EUCTR2011-006021-23-PL   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
42942019   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy;
5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019871-31-GB   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2010-019871-31-SK   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
      2011   Phase 3   EUCTR2010-019871-31-BE   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
      2011   -   EUCTR2010-019871-31-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
6 million hMSC   
   MetroHealth Medical Center
      2017   Phase 1   NCT03186417   United States;
6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate   
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
68Ga-BNOTA-PRGD2   
   Peking Union Medical College Hospital
      2012   Early Phase 1   NCT01940926   China;
68Ga-FAPI   
   Peking Union Medical College Hospital
      2020   Early Phase 1   NCT04514614   China;
68Ga-NEB   
   Peking Union Medical College Hospital
      2019   Phase 1   NCT04273334   China;
7-valent Pneumococcal Conjugate vaccine   
   Dept of Rheumatology, Lund University Hospital, Lund, Sweden
      2008   -   EUCTR2007-006539-29-SE   Sweden;
70930.00.00   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2012   -   EUCTR2012-000222-21-DE   Germany;
8594739041288   
   Merck & Co., Inc.
      2005   Phase 2   EUCTR2004-004302-24-CZ   Czech Republic;Finland;Germany;Italy;Spain;
89Zr-DFO-CZP   
   Robert Flavell, MD, PhD
      2018   Phase 1   NCT03546335   United States;
9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-GB   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-004834-33-BE   Belgium;Bulgaria;Latvia;Poland;United Kingdom;
9512   
   Center for Research and Development Uppsala University/County Council of Gävleborg
      2014   Phase 4   EUCTR2014-000993-20-SE   Sweden;
99mTc-3PRGD2   
   First Affiliated Hospital of Fujian Medical University
      2015   Phase 0   NCT02723760   China;
99mTc-S-HYNIC Certolizumab pegol   
   Ghent University Hospital
      2017   Phase 4   EUCTR2016-004300-65-BE   Belgium;
      2012   Phase 3   EUCTR2009-017998-37-BE   Belgium;
99mTc-rhAnnexin V-128   
   Advanced Accelerator Applications
      2014   Phase 1/Phase 2   NCT02328027   Switzerland;
A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs   
   University of Minnesota - Clinical and Translational Science Institute
      2004   -   NCT01600521   China;
AB1010   
   AB Science
      2014   -   EUCTR2010-020992-21-DE   Argentina;Bosnia and Herzegovina;Czech Republic;Germany;Greece;India;Mexico;Monaco;Morocco;Philippines;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Tunisia;Ukraine;United States;
      2012   Phase 3   EUCTR2010-020992-21-GR   Czech Republic;Germany;Greece;India;Monaco;Poland;Romania;Slovakia;Spain;Thailand;Turkey;United States;
      2011   Phase 3   EUCTR2010-020992-21-SK   Czech Republic;France;Germany;Greece;India;Poland;Romania;Slovakia;Spain;Thailand;Tunisia;Turkey;United States;
      2011   -   EUCTR2010-020992-21-ES   Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
      2011   -   EUCTR2010-020992-21-CZ   Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
ABA, open-label (OL)   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00095147   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
ABBV-105   
   AbbVie
      2019   Phase 2   NCT03823378   Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 2   NCT03682705   Belgium;Canada;Czechia;Germany;Hungary;Ireland;Poland;Puerto Rico;Spain;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-002306-31-HU   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
ABBV-105, A-1519938.0   
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-000666-10-HU   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-000666-10-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 2   EUCTR2018-000666-10-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABBV-154   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2021   Phase 2   EUCTR2020-005303-39-IT   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie
      2021   Phase 2   NCT04888585   Australia;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-005303-39-PL   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-NL   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-GR   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-ES   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-DE   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
ABBV-257   
   AbbVie
      2015   Phase 1   NCT02531178   Germany;
ABBV-3373   
   AbbVie
      2019   Phase 2   NCT03823391   Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-003053-21-PL   Israel;Poland;Puerto Rico;United States;
ABP 501   
   Amgen
      2014   Phase 3   NCT02114931   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 3   NCT01970475   Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
   Amgen Inc
      2014   Phase 3   EUCTR2013-000525-31-DE   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-000525-31-RO   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-PL   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-HU   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-GB   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-ES   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-CZ   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-BG   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
   Amgen Inc.
      2014   Phase 3   EUCTR2013-004654-13-RO   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-PL   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-GB   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-ES   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-DE   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-CZ   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-BG   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-004654-13-HU   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
ABP 710   
   Amgen
      2016   Phase 3   NCT02937701   Australia;Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Spain;United States;
ABP 710 - Biosimilar to infliximab   
   Amgen Inc.
      2016   Phase 3   EUCTR2014-004704-29-PL   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-HU   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-ES   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-DE   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-CZ   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-BG   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
ABP 798   
   Amgen
      2016   Phase 3   NCT02792699   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 - Biosimilar to rituximab   
   Amgen Inc
      2015   Phase 1;Phase 3   EUCTR2013-005543-90-BG   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-PL   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-HU   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-DE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 Biosimilar to Rituximab   
   Amgen Inc
      2017   Phase 1;Phase 3   EUCTR2013-005543-90-EE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABT 494   
   AbbVie Deutschland GmbH & Co. KG
      2014   Phase 2   EUCTR2013-003984-72-LV   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   Phase 2   EUCTR2013-003984-72-CZ   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   Phase 2   EUCTR2013-003530-33-NL   Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-LV   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-ES   Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002358-57-NL   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002358-57-CZ   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002358-57-BE   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-003984-72-SK   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   -   EUCTR2013-002358-57-HU   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co.KG
      2014   -   EUCTR2013-003984-72-HU   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   AbbVie Inc.
      2014   -   EUCTR2013-003984-72-ES   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   -   EUCTR2013-002358-57-ES   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABT-122   
   AbbVie
      2015   Phase 2   NCT02433340   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   NCT02141997   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
      2013   Phase 1   NCT01853033   United States;
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2014-001471-31-RO   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2014-001471-31-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2014-001471-31-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2014-001471-31-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2014-001471-31-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2013-004019-37-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2013-004019-37-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   -   EUCTR2013-004019-37-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-RO   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   -   EUCTR2013-004019-37-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
ABT-494   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2017   Phase 3   EUCTR2016-000933-37-IT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;European Union;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-IT   Argentina;Australia;Austria;Barbados;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie
      2014   Phase 2   NCT02049138   Australia;Belgium;Bulgaria;Chile;Czech Republic;Czechia;Hungary;Israel;Latvia;Mexico;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2   NCT01960855   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;New Zealand;Poland;Puerto Rico;Spain;United Kingdom;United States;
   AbbVie (prior sponsor, Abbott)
      2012   Phase 1   NCT01741493   United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-002306-31-HU   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-HU   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-000666-10-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-000933-37-BG   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-000666-10-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-SE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-PT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-NL   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-DE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-CZ   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-BE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-LV   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-HU   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-ES   Argentina;Australia;Belarus;Brazil;Canada;Chile;Colombia;European Union;Hungary;Israel;Korea, Democratic People's Republic of;Latvia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;United States;
      2016   Phase 3   EUCTR2015-003376-75-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-GR   Argentina;Australia;Austria;Belgium;Chile;Colombia;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-ES   Argentina;Australia;Austria;Chile;Colombia;European Union;Israel;Japan;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003335-35-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-SI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-NO   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-IE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-SI   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-RO   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-PT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-PL   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-LV   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-LT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-IE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-HU   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003334-27-HR   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-GR   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003334-27-GB   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-FI   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-ES   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-CZ   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-BG   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-BE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003333-95-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-ES   Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003333-95-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-ES   Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Norway;Poland;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003332-13-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   -   EUCTR2015-003332-13-NO   Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Hong Kong;Israel;Kazakhstan;Korea, Republic of;Malaysia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2015   Phase 3   EUCTR2015-003334-27-SK   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-003333-95-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-LV   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
ABT-Humira   
   Abbott GmbH & Co. KG
      2008   -   EUCTR2007-005905-23-GB   Germany;United Kingdom;
      2008   -   EUCTR2007-005905-23-DE   Germany;United Kingdom;
ABX464   
   Abivax
      2019   Phase 2   EUCTR2019-001578-27-HU   Hungary;
      2019   Phase 2   EUCTR2018-004677-27-HU   Belgium;Hungary;
      2019   Phase 2   EUCTR2018-004677-27-BE   Belgium;Hungary;
   Abivax S.A.
      2019   Phase 2   NCT04049448   Belgium;Czechia;France;Hungary;Poland;
      2019   Phase 2   NCT03813199   Belgium;Czechia;France;Hungary;Poland;
AC430   
   Daiichi Sankyo Inc.
      2010   Phase 1   NCT01287858   United States;
ACZ885   
   NOVARTIS FARMA
      2007   -   EUCTR2007-001665-15-IT   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2006-001553-10-IT   Germany;Italy;Netherlands;
   Novartis
      2007   Phase 2   NCT00554606   Belgium;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United States;
      2007   Phase 1/Phase 2   NCT00505089   Belgium;Germany;Netherlands;Poland;
      2003   Phase 1/Phase 2   NCT00619905   Germany;Netherlands;Switzerland;
   Novartis Farmacéutica S.A.
      2009   Phase 2   EUCTR2008-005320-81-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma AG
      2007   -   EUCTR2006-001550-27-FI   Austria;Finland;Germany;Spain;
      2007   -   EUCTR2006-001550-27-DE   Austria;Finland;Germany;Spain;
      2006   -   EUCTR2006-001550-27-BE   Austria;Belgium;Finland;Germany;Spain;
      2006   -   EUCTR2006-001550-27-AT   Austria;Finland;Germany;Spain;
   Novartis Pharma Services AG
      2009   -   EUCTR2008-005320-81-DE   Austria;Germany;Spain;
      2009   -   EUCTR2008-005320-81-BE   Austria;Belgium;Germany;Spain;
      2008   -   EUCTR2008-005320-81-AT   Austria;Germany;Spain;
      2007   -   EUCTR2007-001665-15-DE   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-000491-16-DE   Austria;Germany;Spain;
      2007   -   EUCTR2006-001553-10-DE   Germany;Italy;Netherlands;
ACZ885 (investigational)   
   Novartis
      2007   Phase 2   NCT00504595   Russian Federation;Spain;Switzerland;Turkey;
ACZ885 Drug Substance   
   Novartis Farmaceutica S.A.
      2007   -   EUCTR2007-001665-15-ES   Belgium;Germany;Italy;Netherlands;Spain;
   Novartis Farmacéutica S.A
      2007   -   EUCTR2006-004669-32-ES   Spain;
   Novartis Farmacéutica, S.A.
      2007   -   EUCTR2007-000491-16-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma Services AG
      2007   Phase 2   EUCTR2006-001553-10-BE   Belgium;Germany;Italy;Netherlands;
      2007   -   EUCTR2007-001665-15-NL   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-001665-15-BE   Belgium;Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-000491-16-BE   Austria;Belgium;Germany;Spain;
      2007   -   EUCTR2007-000491-16-AT   Austria;Germany;Spain;
      2007   -   EUCTR2006-004666-14-DE   Germany;
      2007   -   EUCTR2006-004666-14-BE   Belgium;Germany;
      2007   -   EUCTR2006-001553-10-NL   Germany;Italy;Netherlands;
AD 452   
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
   Sosei
      2005   Phase 2   NCT00141934   United States;
AD 452 18 mg tablet   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
AD 452 4.5 mg Tablet   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
AD 452 9 mg tablet   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
ADALIMUMAB HUMIRA   
   Pfizer Inc
      2020   Phase 4   EUCTR2019-000284-24-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2019   Phase 3   EUCTR2019-000284-24-LT   Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
ADALIMUMAB-EU   
   Pfizer Inc.
      2015   Phase 3   EUCTR2014-000352-29-HR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
ADL5859   
   Cubist Pharmaceuticals LLC
      2007   Phase 2   NCT00626275   United States;
AGM 719   
   Amgen
      2002   Phase 2   NCT00038298   United States;
AI-1000 G2   
   Hoffmann-La Roche
      2016   Phase 4   NCT02682823   United States;
AIN457   
   NOVARTIS FARMA
      2012   -   EUCTR2012-002760-27-IT   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000275-13-IT   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
   Novartis Farma S.p.A.
      2013   -   EUCTR2013-000944-25-IT   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
   Novartis Farmaceutica, S.A.
      2012   -   EUCTR2012-002760-27-ES   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Novartis Farmacéutica S.A.
      2011   -   EUCTR2011-000102-21-ES   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
   Novartis Pharma AG
      2012   -   EUCTR2012-002760-27-SK   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2012-002760-27-HU   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2012-002760-27-CZ   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2011-006058-94-PT   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2012   -   EUCTR2011-006058-94-GR   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2011   -   EUCTR2011-000275-13-HU   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000275-13-GB   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000275-13-BE   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000102-21-SK   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2010-024516-34-SK   Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
      2011   -   EUCTR2010-024516-34-HU   Bulgaria;Canada;Hungary;Italy;United States;
      2011   -   EUCTR2010-024516-34-BG   Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
   Novartis Pharma K.K.
      2013   Phase 3   JPRN-JapicCTI-132209   -
      2012   Phase 3   JPRN-JapicCTI-132091   -
   Novartis Pharma Services AG
      2013   -   EUCTR2012-002760-27-BG   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Novartis Pharma Services AG
      2013   -   EUCTR2013-000944-25-HU   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
      2013   -   EUCTR2011-006058-94-DE   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2012   -   EUCTR2012-002760-27-DE   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2011-006058-94-CZ   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2011   Phase 2   EUCTR2011-001220-38-GB   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   Phase 2   EUCTR2011-001220-38-BE   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   -   EUCTR2011-001220-38-DE   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   -   EUCTR2011-000102-21-HU   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-DE   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-CZ   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-BG   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2009   -   EUCTR2009-011000-34-SK   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-HU   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-DE   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-CZ   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-BE   Belgium;Czech Republic;Germany;Hungary;Slovakia;
   Novartis Pharmaceuticals
      2011   Phase 3   NCT01350804   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2005   Phase 1/Phase 2   NCT00669942   Belgium;Germany;Netherlands;Singapore;Spain;United States;
AIN457F   
   NOVARTIS FARMA
      2012   -   EUCTR2011-006058-94-IT   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2011   -   EUCTR2011-000102-21-IT   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2010-024516-34-IT   Bulgaria;Canada;Hungary;Italy;United States;
AK106-001616   
   Asahi Kasei Pharma Corporation
      2011   Phase 2   NCT01285752   Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-SK   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-HU   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2011   -   EUCTR2010-021558-21-GB   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-DE   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2010   -   EUCTR2010-021558-21-CZ   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2009   Phase 2   NCT00902369   Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
      2009   -   EUCTR2008-006075-75-HU   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-GB   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-DE   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-CZ   Czech Republic;Germany;Hungary;United Kingdom;
ALD518 monoclonal antibody (anti IL-6 mAb)   
   Alder Biopharmaceuticals, Inc
      2008   -   EUCTR2008-004931-39-PL   Poland;
ALX-0061   
   Ablynx
      2015   Phase 2   NCT02518620   Belgium;Bulgaria;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;
      2015   Phase 2   NCT02309359   Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   NCT02287922   Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
      2014   Phase 1   NCT02101073   Netherlands;
      2011   Phase 1/Phase 2   NCT01284569   Czech Republic;Czechia;Hungary;Netherlands;Poland;
   Ablynx NV
      2015   Phase 2   EUCTR2014-003034-42-HU   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-ES   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-DE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-BG   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-BE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003033-26-HU   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-ES   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-DE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-CZ   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-BG   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-BE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-HU   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-ES   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-DE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-CZ   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-BG   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-BE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
ALX-0061 Nanobody   
   Ablynx NV
      2011   -   EUCTR2010-022865-81-HU   Czech Republic;Hungary;
      2011   -   EUCTR2010-022865-81-CZ   Czech Republic;Hungary;
AMG 108   
   AMGEN S.P.A.
      2007   -   EUCTR2006-003698-29-IT   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-IT   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   Amgen
      2006   Phase 2   NCT00369473   Australia;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
      2006   Phase 2   NCT00293826   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;Sweden;United Kingdom;United States;
   Amgen Inc.
      2007   -   EUCTR2006-003698-29-LV   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-IE   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-HU   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-EE   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-AT   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2005-003558-83-LV   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2005-003558-83-IE   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2005-003558-83-EE   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2006-003698-29-SK   Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2006-003698-29-FR   Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-003558-83-SK   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-003558-83-GB   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-003558-83-ES   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-SE   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-NL   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-GB   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-CZ   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-BE   Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-SE   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-NL   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-CZ   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-BE   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-AT   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
AMG 162   
   DAIICHISANKYO Co.,Ltd.
      2013   Phase 3   JPRN-JapicCTI-132277   -
      2010   Phase 2   JPRN-JapicCTI-101263   -
AMG 357   
   Amgen
      2015   Phase 1   NCT02499315   United States;
AMG 570   
   Amgen
      2017   Phase 1   NCT03156023   Germany;United States;
AMG 592   
   Amgen
      2018   Phase 1/Phase 2   NCT03410056   Bulgaria;Germany;Poland;Spain;United States;
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-ES   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2017-001944-36-PL   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMG 714   
   Amgen
      2002   Phase 2   NCT00433875   -
AMG 719   
   Amgen
      2002   Phase 2   NCT00038298   United States;
AMG 827   
   Amgen
      2010   Phase 2   NCT01059448   Bulgaria;Canada;Czech Republic;Latvia;Mexico;Poland;United Kingdom;United States;
      2009   Phase 2   NCT00950989   Bulgaria;Canada;Czech Republic;Hungary;Latvia;Mexico;Poland;United Kingdom;United States;
      2008   Phase 1/Phase 2   NCT00771030   Canada;Mexico;United States;
   Amgen Inc
      2010   Phase 2   EUCTR2009-012566-32-HU   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-LV   Bulgaria;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-GB   Australia;Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-CZ   Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-BG   Bulgaria;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-012566-32-CZ   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-012566-32-BG   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2009   -   EUCTR2009-012566-32-PL   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2009   -   EUCTR2009-012566-32-LV   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2009   -   EUCTR2009-012566-32-GB   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
AMG592   
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-ES   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-BG   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2017-001944-36-PL   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMP-110   
   MedImmune LLC
      2014   Phase 1   NCT02277574   United States;
      2013   Phase 1   NCT01878123   United States;
AMT-101   
   Applied Molecular Transport Inc.
      2020   Phase 2   EUCTR2020-003955-14-DE   Germany;
AP1189   
   SynAct Pharma ApS
      2020   Phase 2   EUCTR2019-001185-15-NO   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
      2020   Phase 2   EUCTR2019-001185-15-BG   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
      2019   Phase 2   EUCTR2019-001185-15-SE   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
      2019   Phase 2   EUCTR2019-001185-15-DK   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
   SynAct Pharma Aps
      2019   Phase 2   NCT04004429   Denmark;Norway;
APLA12   
   VA Office of Research and Development
      2009   Phase 1   NCT01123655   United States;
ARA290   
   LUMC
      2011   -   EUCTR2010-023469-22-NL   Netherlands;
ARAVA   
   sanofi-aventis Groupe
      2008   -   EUCTR2007-000886-40-IT   Italy;Portugal;
ARAVA®   
   sanofi-aventis groupe
      2007   Phase 3   EUCTR2007-000886-40-CZ   Czech Republic;Italy;Portugal;
      2007   -   EUCTR2007-000886-40-PT   Italy;Portugal;
ARRY-371797, p38 inhibitor   
   Array Biopharma, now a wholly owned subsidiary of Pfizer
      2008   Phase 1   NCT00729209   United States;
ARRY-438162   
   Array BioPharma Inc.
      2008   -   EUCTR2007-007859-14-PL   Hungary;Poland;
      2008   -   EUCTR2007-007859-14-HU   Hungary;Poland;
ARRY-438162, MEK inhibitor   
   Array Biopharma, now a wholly owned subsidiary of Pfizer
      2008   Phase 2   NCT00650767   Argentina;Brazil;Hungary;Peru;Poland;Romania;United States;
ART621   
   Arana Therapeutics Ltd
      2009   Phase 2   NCT00928317   Argentina;Australia;Czech Republic;India;Malaysia;New Zealand;Poland;United States;
      2009   Phase 2   NCT00854685   Sri Lanka;
      2009   -   EUCTR2009-014824-40-CZ   Czech Republic;
      2009   -   EUCTR2008-006930-92-CZ   Czech Republic;
AS Domelock System   
   Zimmer Biomet
      2017   -   NCT03312465   Belgium;Germany;Switzerland;United Kingdom;
ASK8007   
   Astellas Pharma Inc
      2007   Phase 1/Phase 2   NCT00411424   Belgium;France;Hungary;Ireland;Netherlands;Spain;United Kingdom;
ASP015K   
   Astellas Pharma Global Development
      2013   Phase 2   EUCTR2011-006021-23-CZ   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   Phase 2   EUCTR2011-006021-23-BG   Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   -   EUCTR2011-006021-23-HU   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2012   -   EUCTR2011-006021-23-BE   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
   Astellas Pharma Global Development Inc. (APGD)
      2013   Phase 2   EUCTR2011-006021-23-PL   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide   
   Astellas Pharma Global Development, Inc. (APGD)
      2013   -   EUCTR2011-006020-20-PL   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006020-20-BG   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006018-15-PL   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006018-15-HU   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006018-15-BG   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   Phase 2   EUCTR2011-006018-15-BE   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   -   EUCTR2011-006020-20-HU   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   -   EUCTR2011-006020-20-CZ   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   -   EUCTR2011-006018-15-CZ   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
ASP1707   
   Astellas Pharma Global Development, Inc.
      2016   Phase 1   NCT02867306   Moldova, Republic of;
   Astellas Pharma Inc
      2016   Phase 2   NCT02884635   Japan;
ASP2408   
   Astellas Pharma Global Development, Inc.
      2012   Phase 1   NCT02052375   United States;
ASP2409   
   Astellas Pharma Global Development, Inc.
      2012   Phase 1   NCT02171143   United States;
ASP5094   
   Astellas Pharma Global Development, Inc.
      2016   Phase 1   NCT02698657   Poland;United States;
   Astellas Pharma Inc
      2017   Phase 2   NCT03257852   Japan;
ATI-450   
   Aclaris Therapeutics, Inc.
      2020   Phase 2   NCT04247815   United States;
ATN-103   
   Ablynx
      2010   Phase 2   NCT01063803   Canada;Hungary;Japan;Russian Federation;Serbia;South Africa;Switzerland;United States;
      2009   Phase 1/Phase 2   NCT00959036   Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland;United States;
   Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
      2010   -   EUCTR2009-015636-15-HU   Belgium;Canada;Germany;Hungary;Japan;Russian Federation;South Africa;Switzerland;United States;
      2010   -   EUCTR2008-007185-33-DE   Belgium;Germany;Hungary;Netherlands;United Kingdom;
      2010   -   EUCTR2008-007185-33-BE   Belgium;Germany;Hungary;Netherlands;United Kingdom;
   Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company
      2009   -   EUCTR2008-007185-33-GB   Belgium;Germany;Hungary;Netherlands;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2010   -   EUCTR2008-007185-33-NL   Belgium;Germany;Hungary;Netherlands;United Kingdom;
      2009   -   EUCTR2008-007185-33-HU   Belgium;Germany;Hungary;Netherlands;United Kingdom;
ATN-103 10 mg q4wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 10 mg q8wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 30 mg q4wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 80 mg q4wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 80 mg q8wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
AVE9897   
   Millennium Pharmaceuticals Inc
      2006   Phase 2   EUCTR2005-006165-14-GB   Czech Republic;Netherlands;United Kingdom;
      2006   -   EUCTR2005-006165-14-NL   Czech Republic;Netherlands;United Kingdom;
      2006   -   EUCTR2005-006165-14-CZ   Czech Republic;Netherlands;United Kingdom;
AZD5672   
   ASTRAZENECA
      2008   -   EUCTR2007-007539-14-IT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
   AstraZeneca
      2009   Phase 1   NCT00887770   United Kingdom;
      2009   Phase 1   NCT00871767   United Kingdom;
      2008   Phase 2   NCT00713544   Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
      2008   Phase 1   NCT00711074   United Kingdom;
   AstraZeneca AB
      2009   -   EUCTR2009-011044-20-GB   United Kingdom;
      2008   Phase 2   EUCTR2007-007539-14-SK   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
      2008   -   EUCTR2007-007539-14-PL   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-MT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-LV   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-HU   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-CZ   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-BG   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
AZD9056   
   AstraZeneca
      2009   Phase 1   NCT00920608   -
      2008   Phase 1   NCT00700986   United Kingdom;
      2007   Phase 2   NCT00520572   Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
AZD9056 hydrochloride   
   AstraZeneca AB
      2008   -   EUCTR2007-001420-12-CZ   Czech Republic;France;Poland;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-SK   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-FR   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   -   EUCTR2007-001420-12-SE   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-PL   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-BE   Belgium;Czech Republic;France;Poland;Sweden;
AZD9567   
   AstraZeneca
      2018   Phase 2   NCT03368235   Denmark;Netherlands;Sweden;
      2016   Phase 1   NCT02760316   Germany;United Kingdom;
AZD9567 Monohydrat   
   AstraZeneca
      2015   Phase 1   NCT02512575   Germany;
AZD9567 monohydrate   
   AstraZeneca AB
      2017   Phase 2   EUCTR2017-000838-64-SE   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-NL   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-DK   Denmark;Netherlands;Sweden;
Abatacept   
   AbbVie
      2017   Phase 3   NCT03086343   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Academisch Medisch Centrum Amsterdam
      2010   -   EUCTR2010-021435-14-NL   Netherlands;
   Arthritis & Rheumatic Disease Specialties Research
      2011   Phase 3   NCT01351480   United States;
   Astellas Pharma Inc
      2011   -   NCT01339481   United States;
   Astellas Pharma Korea, Inc.
      2019   Phase 4   NCT03737708   Korea, Republic of;
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-005102-68-IT   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2021   Phase 3   EUCTR2020-000350-96-IT   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Brigham and Women's Hospital
      2020   -   NCT04529902   United States;
      2020   -   NCT04529876   United States;
      2020   -   NCT04529863   United States;
   Bristol Myers Squibb International Corporation
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-IT   Denmark;Finland;France;Germany;Italy;Sweden;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2006   -   EUCTR2005-000784-26-IT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-000784-26-AT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-GB   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-ES   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-DE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-IE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-BE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
      -   -   EUCTR2005-000443-28-Outside-EU/EEA   Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
   Bristol-Myers Squibb
      2021   Phase 3   NCT04909801   Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2018   Phase 1   NCT03714022   United States;
      2017   -   NCT03457792   Germany;
      2017   -   NCT03188081   Italy;
      2016   -   NCT02037737   -
      2015   Phase 4   NCT02557100   Algeria;Canada;Mexico;United States;
      2015   Phase 3   NCT02504268   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;United States;
      2015   -   NCT02598466   -
      2014   -   NCT02169544   -
      2013   Phase 4   NCT01758198   Japan;
      2013   Phase 3   NCT01844895   -
      2013   Phase 1   NCT01890473   Argentina;Mexico;Peru;South Africa;United States;
      2012   -   NCT02090556   Australia;Austria;France;Germany;Greece;Italy;Monaco;Netherlands;Spain;Switzerland;United Kingdom;
      2010   Phase 3   NCT01142726   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Norway;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   Phase 1   NCT01221636   United States;
      2009   Phase 3   NCT00929864   Argentina;Canada;Chile;Peru;United States;
      2008   Phase 3   NCT00767325   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   -   NCT02109666   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Spain;Switzerland;
      2007   Phase 3   NCT00989235   -
      2007   Phase 3   NCT00547521   Australia;Brazil;Canada;Mexico;Peru;South Africa;United States;
      2007   Phase 3   NCT00533897   Argentina;Brazil;Canada;Mexico;South Africa;United States;
      2007   Phase 3   NCT00420199   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   NCT00409838   Korea, Republic of;
      2006   Phase 3   NCT00484289   Japan;
      2006   Phase 2   NCT00345748   Japan;
      2006   Phase 1/Phase 2   NCT00254293   United States;
      2005   Phase 3   NCT00124982   Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
      2005   Phase 3   NCT00122382   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2005   Phase 2   NCT00124449   Australia;Belgium;France;Germany;Italy;Mexico;Puerto Rico;Spain;United Kingdom;United States;
      2003   Phase 3   NCT00095173   Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
      2003   Phase 1   NCT00162201   United Kingdom;
      2002   Phase 3   NCT00048581   United States;
      2002   Phase 3   NCT00048568   United States;
      2000   Phase 2   NCT00162279   United States;
      2000   Phase 1/Phase 2   NCT00279760   Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2008   -   EUCTR2007-004241-15-IT   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-GB   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-ES   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-SE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-NL   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-DE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-BE   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-AT   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-005102-68-CZ   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-GB   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-ES   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-GB   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-ES   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-CZ   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-IE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-DE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-BE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-DE   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-BE   Belgium;Germany;Italy;Spain;United Kingdom;
   Bristol-Myers Squibb K.K.
      2013   Phase 4   JPRN-JapicCTI-132121   -
   Cambridge University Hospitals NHS Foundation Trust
      2018   Phase 2   NCT03084419   United Kingdom;
   Columbia University
      2019   Phase 4   NCT03619876   United States;
   Dr. Larry W. Moreland
      2015   Phase 4   NCT02353780   United States;
   Hokkaido University Hospital
      2013   -   JPRN-UMIN000010286   Japan;
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2016   Phase 1   NCT02805010   -
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Leiden University Medical Center
      2018   Phase 4   NCT03492658   Netherlands;
   Maldonado A Michael
      2021   Phase 3   JPRN-jRCT2071210068   Australia;France;Germany;Japan;Taiwan;USA;
   NHS Greater Glasgow and Clyde
      2016   Phase 4   NCT02652273   United Kingdom;
      2015   Phase 4   EUCTR2014-004419-35-GB   United Kingdom;
   NYU Langone Health
      2019   Phase 4   NCT03652961   United States;
   National Health Organization Nagoya Medical Center
      2010   -   JPRN-UMIN000011789   Japan;
   Novartis Pharmaceuticals
      2011   Phase 3   NCT01350804   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Osaka Medical College
      2014   -   JPRN-UMIN000013440   Japan;
   Shinshu University
      2018   Phase 2   NCT03784261   Japan;
   St George's, University of London
      2020   Phase 4   EUCTR2019-004468-23-GB   United Kingdom;
   St.Marianna University School of Medicine
      2014   -   JPRN-UMIN000015175   Japan;
   The Cleveland Clinic
      2013   Phase 2   NCT02027298   United States;
   The First Hospital, Jilin University
      2016   Phase 1 study   ChiCTR-IIR-16008693   China;
   University Hospital, Montpellier
      2016   -   NCT02547493   France;Monaco;
   University of California, Los Angeles
      2014   -   NCT02053727   United States;
      2011   Phase 3   NCT01299961   United States;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Occupational and Environmental Health, Japan
      2010   -   JPRN-UMIN000008756   Japan;
   University of Washington
      2019   Phase 4   NCT03882008   United States;
   Vastra Gotaland Region
      2017   -   NCT03440892   Sweden;
   Yokohama City University Graduate School of Medicine
      2014   -   JPRN-UMIN000015217   Japan;
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00095147   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
Abatacept (BMS-188667)   
   Bristol-Myers Squibb
      2011   Phase 1   NCT01439204   United States;
      2000   Phase 2   NCT00162266   Argentina;Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;South Africa;United Kingdom;United States;
Abatacept (IV)   
   Bristol Myers Squibb International Corporation
      2011   Phase 3   EUCTR2008-001523-57-NO   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-HU   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-DE   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-GB   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-ES   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   -   EUCTR2008-001523-57-DK   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001523-57-FR   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept (SC)   
   Bristol Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept + Methotrexate   
   Bristol-Myers Squibb K.K.
      2015   Phase 3   JPRN-JapicCTI-153081   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept + csDMARD   
   New York University School of Medicine
      2019   Phase 4   NCT03700021   United States;
Abatacept Injection   
   Fundacion Clinic per a la Recerca Biomédica
      2019   Phase 4   NCT03669367   -
   St George's, University of London
      2020   Phase 4   NCT04255134   United Kingdom;
   University of Erlangen-Nürnberg Medical School
      2019   Phase 2   NCT04120831   Germany;
Abatacept Placebo   
   Bristol-Myers Squibb K.K.
      2015   Phase 3   JPRN-JapicCTI-153081   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept Prefilled Syringe   
   Lille Catholic University
      2018   Phase 4   NCT03227419   France;
Abatacept combination product (ACP)   
   Bristol-Myers Squibb
      2009   Phase 3   NCT01173120   -
Abatacept, rituximab or tocilizumab   
   University Hospital, Strasbourg, France
      2009   Phase 4   NCT01000441   France;Monaco;
Acalabrutinib   
   Acerta Pharma BV
      2015   Phase 2   NCT02387762   United States;
Aceclofenac   
   Chung Shan Medical University
      2007   Phase 4   NCT04144101   -
Acellbia   
   Biocad
      2015   Phase 3   NCT02744196   -
Acetaminophen   
   Hoffmann-La Roche
      2011   Phase 4   NCT01382940   United States;
   Kojima Toshihisa
      2016   -   JPRN-jRCTs041180071   Japan;
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
   Nekoyama Miyao Hospital
      2016   -   JPRN-UMIN000018931   Japan;
   Osaka City University Medical School, Department of Orthopedic Surgery
      2014   -   JPRN-UMIN000012364   Japan;
   Yamaguchi University
      2018   -   JPRN-UMIN000031692   Japan;
Acetaminophen tablets   
   Maoxiang Group Jilin Pharmaceutical Co., Ltd.
      2014   Phase 2   NCT02029599   China;
Acide folique   
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
Actemra   
   F. Hoffmann- La Roche Ltd
      2009   -   EUCTR2008-000587-17-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Limited
      2007   -   EUCTR2007-001114-17-GB   United Kingdom;
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2008-006924-68-AT   Austria;Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-000587-17-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-000587-17-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-SE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   ROCHE
      2009   -   EUCTR2008-000587-17-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Actemra(EU-licensed)   
   Bio-Thera Solutions
      2018   Phase 3   NCT03830203   China;
Acthar   
   Veena Ranganath, MD, MS
      2017   Phase 4   NCT02541955   United States;
Acthar Gel   
   Mallinckrodt
      2016   Phase 4   NCT02919761   Argentina;Colombia;Mexico;Peru;Puerto Rico;United States;
Acthar Injectable Product   
   Attune Health Research, Inc.
      2018   Phase 3   NCT03511625   United States;
Active Stimulation   
   Galvani Bioelectronics
      2021   -   NCT05003310   United States;
Active comparator   
   Asahi Kasei Pharma Corporation
      2011   Phase 2   NCT01285752   Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
      2009   Phase 2   NCT00902369   Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
Acupuncture   
   Chinese Academy of Sciences
      2012   -   NCT01619176   China;
Acycloguanosine   
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Ad26.COV2.S   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Adalimuab, Etanercept, Tocilizumab, or Abatacept   
   Hanyang University
      2020   -   NCT04449224   Korea, Republic of;
Adalimumab   
    Department of Rheumatology and Clinical Immunology
   AbbVie
      2019   Phase 2   NCT03823391   Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
      2016   -   NCT02750800   Hungary;
      2016   -   NCT02668640   China;
      2015   Phase 4   NCT02198651   Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 3   NCT02629159   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   NCT02141997   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
      2013   -   NCT01768858   Austria;
      2007   Phase 1   NCT00650156   China;
   AbbVie (prior sponsor, Abbott)
      2012   Phase 2   NCT01561313   Belgium;Czech Republic;
      2012   Phase 2   NCT01502423   Australia;Canada;Germany;
      2012   -   NCT01736189   Japan;
      2010   Phase 4   NCT01185288   Puerto Rico;United States;
      2010   Phase 4   NCT01162421   Canada;
      2010   Phase 3   NCT01185301   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Poland;Puerto Rico;Spain;United States;
      2009   Phase 4   NCT00808509   Sweden;
      2000   Phase 3   NCT00195663   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
   Abbott
      2008   Phase 3   NCT00690573   Japan;
      2007   Phase 3   NCT01231321   Russian Federation;
      2007   Phase 3   NCT00647270   Australia;Canada;Germany;Puerto Rico;United Kingdom;United States;
      2007   Phase 2/Phase 3   NCT00538902   China;
      2006   Phase 4   NCT00420927   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Mexico;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2006   Phase 3   NCT00603993   Japan;
      2004   Phase 4   NCT00234897   United States;
      2004   Phase 3   NCT00235872   Japan;
      2004   Phase 2/Phase 3   NCT00647491   Japan;
      2004   -   NCT00650390   -
      2003   Phase 4   NCT00649922   -
      2003   Phase 3   NCT00647920   Taiwan;
      2003   Phase 3   NCT00235859   -
      2003   Phase 3   NCT00234936   -
      2003   Phase 3   NCT00234845   United States;
      2003   Phase 2   NCT00235833   Japan;
      2003   -   NCT00649545   -
      2003   -   NCT00234884   Australia;Austria;Belgium;France;Germany;Greece;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2002   Phase 3   NCT00448383   -
      2002   Phase 3   NCT00049751   United States;
      2002   -   NCT00650026   -
      2000   Phase 3   NCT00195702   Canada;United States;
      2000   Phase 3   NCT00195650   Canada;United States;
   Abbott GmbH & Co. KG
      2008   -   EUCTR2007-005905-23-GB   Germany;United Kingdom;
      2008   -   EUCTR2007-005905-23-DE   Germany;United Kingdom;
      2008   -   EUCTR2006-004139-31-NO   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-004139-31-GR   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-SK   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-HU   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-FR   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-SE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-NL   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-GB   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-ES   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-DE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-CZ   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-BE   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-AT   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
   Abbott Japan Co., Ltd.
      2009   Phase 3   JPRN-JapicCTI-090751   -
      2008   Phase 3   JPRN-JapicCTI-080587   -
   Abbott Scandinavia AB
      2008   -   EUCTR2008-004398-16-SE   Sweden;
   Amgen
      2013   Phase 3   NCT01970475   Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
   Astellas Pharma Korea, Inc.
      2019   Phase 4   NCT03737708   Korea, Republic of;
   AstraZeneca
      2011   Phase 2   NCT02092961   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
      2011   Phase 2   NCT01264770   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
   Biogen
      2006   Phase 2   NCT00298272   United States;
   Biologic Mate Study Group
      2014   -   JPRN-UMIN000015616   Japan;
   Bristol-Myers Squibb
      2021   Phase 3   NCT04909801   Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2015   Phase 4   NCT02557100   Algeria;Canada;Mexico;United States;
      2009   Phase 3   NCT00929864   Argentina;Canada;Chile;Peru;United States;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   CSL Behring
      2011   Phase 2   NCT01373151   Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
   Charité-Universitätsmedizin Berlin
   Cinnagen
      2015   Phase 3   NCT03172325   Iran, Islamic Republic of;
   Columbia University
      2019   Phase 4   NCT03619876   United States;
   Department of Rheumatosurgery, Osaka City University Medical School
      2009   Phase 4   JPRN-UMIN000002340   Japan;
   Dept. of Rhematology UMAS
      2005   -   EUCTR2005-000129-47-SE   Sweden;
   Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
      2011   -   JPRN-UMIN000013750   Japan;
   EMD Serono
      2007   Phase 2   NCT00595413   Germany;United States;
   Eli Lilly Japan K.K.
      -   Phase 3   JPRN-JapicCTI-132125   -
   Eli Lilly and Company
      2012   Phase 3   NCT01710358   Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2008   Phase 4   EUCTR2007-000593-24-GB   Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2010-023587-40-IT   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
   F.Hoffmann-La Roche Ltd
      2008   -   EUCTR2007-000593-24-SE   Sweden;United Kingdom;
   Fen Li
      2016   Phase 4   NCT02878161   -
   Genentech, Inc.
      2016   Phase 2   NCT02833350   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
      2010   Phase 2   NCT01225393   Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;Romania;Spain;United States;
   Georgetown University
      2013   Phase 4   NCT01793519   United States;
   Gilead Sciences
      2016   Phase 3   NCT02889796   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Glostrup University Hospital, Copenhagen
      2009   -   NCT01029613   Denmark;
   Goupe d'Etudes et de Recherche Clinique En Rhumatologie
      2004   Phase 4   NCT00291915   France;
   Hamed Rezaei
      2012   Phase 4   NCT01609205   Sweden;
   Heinrich-Heine University, Duesseldorf
      2014   Phase 3   NCT02150473   Germany;
   Hoffmann-La Roche
      2011   Phase 4   NCT01283971   Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   NCT01592292   Korea, Republic of;
      2010   Phase 4   NCT01119859   Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Norway;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Hvidovre University Hospital
      2005   Phase 4   NCT00216177   Denmark;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02019472   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
   Jonathan Graf
      2013   Phase 4   NCT01893996   United States;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Karolinska Institutet
      2010   -   NCT01197144   Sweden;
   Keio University
      2018   Phase 4   NCT03505008   Japan;Korea, Republic of;Taiwan;
      2011   Phase 4   NCT01270035   Japan;
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
   Leeds University
      2014   -   JPRN-UMIN000016928   Japan,Europe;
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2007-002536-29-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Maldonado A Michael
      2021   Phase 3   JPRN-jRCT2071210068   Australia;France;Germany;Japan;Taiwan;USA;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   Merck Serono International
      2008   Phase 2   EUCTR2007-002536-29-FR   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   Phase 2   EUCTR2007-002536-29-ES   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-PT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-GR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-DE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-CZ   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BG   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BE   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   Phase 2   EUCTR2007-002536-29-FI   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-SE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-AT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      -   -   EUCTR2007-002536-29-PL   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Merck Sharp & Dohme Corp.
      2008   -   NCT00724672   -
   Mianyang Hospital of Traditional Chinese Medicine
      2021   Phase 4   ChiCTR2100044045   China;
   NHS Greater Glasgow and Clyde
      2022   -   NCT05090124   -
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2009   Phase 4   NCT00837434   United States;
      2008   Phase 4   NCT00796705   United States;
   Novo Nordisk A/S
      2014   Phase 2   NCT02097264   Ireland;Portugal;Spain;United Kingdom;
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
   Osaka City University Medical School
      2012   -   JPRN-UMIN000010315   Japan;
      2010   -   JPRN-UMIN000003880   Japan;
   Osaka Medical College
      2015   -   JPRN-UMIN000016950   Japan;
   Ottawa Hospital Research Institute
      2022   Phase 4   NCT05153200   -
   PFIZER
      2008   -   EUCTR2007-002066-35-IT   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
   Pfizer
      2020   Phase 3   NCT04230213   Bosnia and Herzegovina;Bulgaria;Czechia;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2015   Phase 3   NCT02480153   Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 4   NCT02092467   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2007   Phase 2   NCT00550446   Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2007-002066-35-SK   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-GR   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-BG   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-HU   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-DE   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-CZ   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2009   -   EUCTR2008-008338-35-DE   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Reade Rheumatology Research Institute
      2020   Phase 4   NCT04251741   Netherlands;
      2020   Phase 4   NCT04222920   Netherlands;
      2020   Phase 4   NCT04194827   Netherlands;
   Rennes University Hospital
      2017   -   NCT03110094   France;
   Sanofi
      2015   Phase 3   NCT02332590   Chile;Czech Republic;Czechia;France;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   NCT01764997   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Skåne University Hospital
      2005   Phase 4   NCT01270087   Sweden;
   Takeda
      2015   Phase 2   NCT02393378   Czech Republic;Czechia;Estonia;Russian Federation;Spain;United Kingdom;
   TcLand Expression S.A.
      2016   -   NCT03016260   Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
   The Rheumatological Center of Helsinki
      2011   Phase 4   NCT01405326   Finland;
   University Hospital, Bordeaux
      2021   Phase 3   NCT04870203   France;Monaco;
   University Hospital, Rouen
      2006   Phase 4   NCT00234234   France;
   University Hospital, Tours
      2011   Phase 4   NCT01382160   France;
      2006   -   NCT00497614   France;
   University of Aarhus
      2007   Phase 3   NCT00660647   Denmark;
   University of Leeds
      2013   Phase 4   NCT02056184   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   Université de Sherbrooke
      2013   Phase 4   NCT02035800   Canada;
      2008   -   NCT00814866   Canada;
   Yazawa Rie
      2017   Phase 1   JPRN-jRCT2071200057   Japan;
   Yonemura Takuma
      2015   Phase 1   JPRN-jRCT2071200058   Japan;
   Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042440   China;
Adalimumab (ADA)   
   UCB Pharma SA
      2011   Phase 4   NCT01500278   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Adalimumab (HUMIRA®)   
   Abbott
      2006   -   NCT01078571   Spain;
Adalimumab (Humira)   
   Hvidovre University Hospital
      2004   Phase 4   NCT00696059   Denmark;
   R-Pharm
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (Humira®)   
   R-Pharm
      2017   Phase 3   EUCTR2015-005307-83-LV   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-LT   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-HU   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International LLC
      2016   Phase 3   EUCTR2015-005307-83-CZ   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-BG   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (up to 9 months exposure)   
   Abbott
      2005   Phase 4   NCT00233558   United States;
Adalimumab - GP2017   
   Sandoz
      2016   Phase 3   NCT02744755   Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab - US licensed Humira   
   Sandoz
      2016   Phase 3   NCT02744755   Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab 40 mg subcutaneous (SC) every other week (EOW)   
   Abbott
      2000   Phase 3   NCT00233571   -
Adalimumab 40mg q2w   
   R-Pharm
      2016   Phase 3   NCT02760407   Argentina;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab Injection   
   St George's, University of London
      2020   Phase 4   NCT04255134   United Kingdom;
Adalimumab PFS and Pen   
   Samsung Bioepis Co., Ltd.
      2015   Phase 2   NCT02565810   Poland;
Adalimumab delivered in Physiolis autoinjector   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab delivered in Physiolis syringe   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab delivered in current autoinjector   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab delivered in current syringe   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab with methotrexate   
   Pfizer
      2014   Phase 4   NCT02187055   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2013-004019-37-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2013-004019-37-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   -   EUCTR2013-004019-37-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-RO   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   -   EUCTR2013-004019-37-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
Adalimumab, current formulation   
   AbbVie (prior sponsor, Abbott)
      2012   Phase 2   NCT01712178   Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, new formulation   
   AbbVie (prior sponsor, Abbott)
      2012   Phase 2   NCT01712178   Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, plus prednisone   
   IRCCS Policlinico S. Matteo
      2007   Phase 4   NCT00480272   Italy;
Adalimumab-Pfizer   
   Pfizer Inc
      2020   Phase 4   EUCTR2019-000284-24-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2019   Phase 3   EUCTR2019-000284-24-LT   Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
   Pfizer Inc.
      2015   Phase 3   EUCTR2014-000352-29-HR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Adalimummab   
   Hvidovre Hospital
      2009   Phase 4   EUCTR2009-014394-41-DK   Denmark;
Adefovir   
   Department of general internal medicine, Kyushu-University hospital
      2012   -   JPRN-UMIN000018017   Japan;
Administration of Cimzia®   
   University Hospital, Ghent
      2012   Phase 3   NCT01590966   Belgium;
Agrippal S1 (Influenza vaccination)   
   Tel-Aviv Sourasky Medical Center
      2009   Phase 4   NCT01002716   Israel;
Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)   
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 4   EUCTR2010-021146-22-GB   United Kingdom;
Alendronat Teva   
   Aarhus University Hospital
      2015   Phase 2   EUCTR2015-003638-28-DK   Denmark;
Alendronate   
   Chinese University of Hong Kong
      2012   Phase 4   NCT01770106   Hong Kong;
   People's Hospital, Peking University
      2009   -   ChiCTR-TRC-09000473   China;
   University of Aarhus
      2015   Phase 2   NCT02944799   Denmark;
Alendronate versus alfacalcidol (1-alpha OH vitamin D)   
   UMC Utrecht
      2000   Phase 3   NCT00138983   Netherlands;
AlloRx   
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05003934   Antigua and Barbuda;
Allogeneic Mesenchymal Precursor Cells   
   Mesoblast, Ltd.
      2013   Phase 2   NCT01851070   Australia;United States;
Allopurinol   
   University of Dundee
      2005   Phase 4   EUCTR2005-000551-15-GB   United Kingdom;
Amoxapine & dipyridamole   
   CombinatoRx, Inc
      2004   -   EUCTR2004-001490-26-GB   Estonia;United Kingdom;
Amoxicilina   
   Dra Beatriz Lozano-Hospital Universitario de Canarias
      2018   Phase 4   EUCTR2017-003259-40-ES   Spain;
Anakinra   
   Amgen
      2001   Phase 2   NCT00037700   United States;
      2000   Phase 2   NCT00037648   United States;
   Prof. Roberto Giacomelli
      2013   Phase 4   NCT02236481   Italy;
   Swedish Orphan Biovitrum
      2012   -   NCT02915094   Germany;
   University of Athens
      2011   -   NCT01566201   Greece;
   Xi-jing Hospital, the 4th Military Medical University, Shanghai Changzheng Hospital
      2008   Phase 3 study   ChiCTR-TRC-09000383   China;
Anakinra (Kineret®)   
   Amgen
      2004   Phase 3   NCT00117091   -
Anakinra (r-metHuIL-1ra)   
   Amgen
      2005   Phase 4   NCT00111410   -
Anakinra and PEG sTNF-R1   
   Amgen
      2001   Phase 2   NCT00537667   -
Andecaliximab   
   Gilead Sciences
      2016   Phase 2   NCT02862574   Australia;Hungary;Taiwan;United States;
Angiotensin receptor blockers   
   Sherief Abd-Elsalam
      2018   Phase 3   NCT03770702   Egypt;
Anifrolumab   
   Josef Smolen, Univ. Prof. Dr.
      2018   Phase 2   NCT03435601   Austria;
Anifrolumab (MEDI-546)   
   Medical University of Vienna
      2017   Phase 2   EUCTR2017-001717-92-AT   Austria;Italy;Switzerland;
Anit human granulocyt-macrophage colony-stimulating factor (GM-CSF)monoclonal   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti IL 6 mAb   
   BRISTOL-M.SQUIBB
      2011   -   EUCTR2010-023956-99-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti IL-1beta antibody, subclass IgG4   
   Eli Lilly and Company Limited
      2007   -   EUCTR2005-002660-29-HU   Hungary;Spain;
Anti IL-1ß antibody, subclass IgG4   
   Eli Lilly and Company Limited
      2007   -   EUCTR2005-002660-29-HU   Hungary;Spain;
Anti LP40 antibody, subclass IgG4 LA294   
   Eli Lilly and Company
      2009   Phase 2   EUCTR2008-004875-23-FR   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-PL   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-HU   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-DE   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-BE   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-AT   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-001105-42-PL   Austria;Belgium;France;Germany;Poland;
      2008   Phase 2   EUCTR2008-001105-42-FR   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-DE   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-BE   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-AT   Austria;Belgium;France;Germany;Poland;
   Eli Lilly and Company limited
      2009   Phase 2   EUCTR2008-004894-16-HU   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-PL   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-DE   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-CZ   Czech Republic;Germany;Hungary;Poland;
Anti TNF + Meth   
   Hamad Medical Corporation
      2012   Phase 3   NCT01724268   Qatar;
Anti human granulocyte-macrophage colo   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000868-18-GB   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000868-18-IT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2021   Phase 3   EUCTR2019-000878-30-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000868-18-DE   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000867-26-DE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-PL   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-LT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-HU   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-GB   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-ES   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-CZ   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-PL   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-HU   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-GB   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-ES   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-EE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-BG   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LV   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-HU   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-GB   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-ES   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-CZ   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-000878-30-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody   
   GlaxoSmithKline Research & Development Limited
      2018   Phase 2   EUCTR2015-004386-91-PL   Germany;Poland;United States;
      2016   Phase 2   EUCTR2015-004386-91-DE   Germany;Poland;United States;
      2015   Phase 2   EUCTR2014-003453-34-PL   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-HU   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-GB   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-EE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-DE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-CZ   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF)monoclonal   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti-C5aR   
   Novo Nordisk A/S
      2012   -   EUCTR2009-011791-30-HU   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-011791-30-GB   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-DK   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-CZ   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
Anti-CD20 small modular immunopharmaceutical, WYE-400087   
   Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
      2010   -   EUCTR2009-010516-15-PL   Greece;Hungary;Poland;Spain;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2010   Phase 2   EUCTR2009-010516-15-GR   Greece;Hungary;Poland;Spain;
      2010   Phase 2   EUCTR2009-010516-15-ES   Greece;Hungary;Poland;Spain;
      2009   -   EUCTR2009-010516-15-HU   Greece;Hungary;Poland;Spain;
Anti-GM-CSF receptor alpha   
   MedImmune Ltd
      2010   -   EUCTR2009-014735-20-PL   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-LT   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-HU   Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
      2010   -   EUCTR2009-014735-20-CZ   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-BG   Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
      2009   -   EUCTR2009-014735-20-LV   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2009   -   EUCTR2009-014735-20-EE   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
Anti-IL-20   
   Novo Nordisk A/S
      2010   Phase 1   NCT01038674   Belgium;Poland;
      2008   Phase 1   NCT00818064   Netherlands;
Anti-IL-20 (109-0012)   
   NOVO NORDISK
      2011   -   EUCTR2010-021283-14-IT   Hungary;Italy;Portugal;Spain;United Kingdom;
   Novo Nordisk A/S
      2011   Phase 2   EUCTR2010-021283-14-PT   Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-HU   Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-GB   Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-ES   Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-021283-14-CZ   Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
Anti-IL-6 mAb   
   Bristol-Myers Squibb International Corporation
      2011   -   EUCTR2010-023956-99-NL   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal   
   BRISTOL-M.SQUIBB
      2011   -   EUCTR2010-023956-99-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal Antibody   
   Bristol-Myers Squibb International Corporation
      2011   -   EUCTR2010-023956-99-NL   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-TNF   
   Hospital Universitari Vall d'Hebron Research Institute
      2016   -   NCT02804204   Spain;
Anti-TNF Biologics Therapy   
   Queen Mary University of London
      2015   -   NCT02620189   United Kingdom;
Anti-TNF humanized antibody Fab fragment - PEG conjugate   
   UCB Pharma S.A.
      2008   -   EUCTR2007-000830-38-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-AT   Austria;France;Germany;Italy;Poland;
Anti-TNF humanized antibody Fab' fragment - PEG conjugate   
   UCB Pharma S.A.
      2009   -   EUCTR2007-005288-86-FR   France;
Anti-TNF suspended perioperatively   
   CHU de Quebec-Universite Laval
      2015   Phase 4   NCT02242474   Canada;
Anti-TNF therapy   
   Barts & The London NHS Trust
      2010   -   NCT02528292   United Kingdom;
Anti-TNF therapy (etanercept or adalimumab)   
   Imperial College London
      2010   -   NCT01060098   United Kingdom;
Anti-TNF-alpha   
   Hoffmann-La Roche
      2016   Phase 2   NCT03001219   Argentina;Austria;Colombia;Czech Republic;Czechia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
Anti-TNFa continued perioperatively   
   CHU de Quebec-Universite Laval
      2015   Phase 4   NCT02242474   Canada;
Anti-Tumor Necrosing Factor (TNF) Therapy   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00124982   Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
Anti-Tumor Necrosis Factor Alpha Drug (Product)   
   R.Bos
      2021   Phase 4   NCT04985435   Netherlands;
Anti-inflammatory drugs   
   Genentech, Inc.
      2007   Phase 3   NCT00443651   United States;
Anti-pandemic H1N1 influenza vaccine   
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil;
Anti-thymocyte globulin   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Anticorpo monoclonale anti GM-CSF umano   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2015   Phase 2   EUCTR2014-003453-34-IT   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R.   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-020065-24-ES   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
Antihistamine   
   Hoffmann-La Roche
      2011   Phase 4   NCT01382940   United States;
Antihuman granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000868-18-PL   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Apratastat   
   WYETH LEDERLE
      2005   -   EUCTR2004-000012-13-IT   Czech Republic;Estonia;Italy;
Apremilast   
   Amgen
      2010   Phase 2   NCT01285310   Czech Republic;Czechia;Poland;Spain;United States;
   Baylor Research Institute
      2010   Phase 2   NCT01250548   United States;
   Celgene Corporation
      2011   -   EUCTR2010-019926-15-CZ   Czech Republic;United States;
Arava   
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
   University Hospitals Leuven
      2009   Phase 4   EUCTR2008-007225-39-BE   Belgium;
   University of Leeds
      2006   Phase 4   EUCTR2005-004582-41-GB   United Kingdom;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)   
   Sandoz
      2002   Phase 1   NCT00946686   -
Arava 20 mg filmdrasjerte tabletter   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Arm B: Rituxan®/Mabthera®   
   Dr. Reddy's Laboratories Limited
      2020   Phase 3   NCT04268771   United States;
Arthroscopic synovectomy of the wrist   
   Maasstad Hospital
      2021   -   NCT04755127   Netherlands;
Arthroscopic synovial tissue biopsy   
   Nathan Wei, MD, FACP, FACR:
      2011   Phase 3   NCT01374971   United States;
Arthroscopy & saline irrigation alone   
   Newcastle University
      2012   Phase 1   NCT01352858   United Kingdom;
Artilog   
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Ascal(r) / carbasalate calcium   
   Leiden University Medical Center
      2006   -   EUCTR2006-001359-36-NL   Netherlands;
Asendis   
   CombinatoRx, Inc
      2004   -   EUCTR2004-001490-26-GB   Estonia;United Kingdom;
Aspirin 81mg tablet   
   Inova Health Care Services
      2018   Phase 4   NCT03699293   United States;
Aspirin Tablets   
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
Atacicept   
   EMD Serono
      2006   Phase 2   NCT00430495   Canada;United States;
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2007-002536-29-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Merck KGaA
      2008   Phase 2   NCT00664521   Finland;France;Netherlands;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-DE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
      2008   -   EUCTR2006-004140-23-GB   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 2   EUCTR2006-004140-23-SK   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-PT   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-CZ   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-BE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Serono SA, an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-FI   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch ofLaboratories Serono S.A. an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-SE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int.a branch of Laboratoires Serono SA an affiliate of Merck KgaA, Darmstadt, Germany
      2006   -   EUCTR2006-004140-23-NL   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono International
      2008   Phase 2   EUCTR2007-003647-75-FR   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2007-002536-29-FR   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   Phase 2   EUCTR2007-002536-29-ES   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003647-75-SE   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-NL   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-FI   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-002536-29-PT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-GR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-DE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-CZ   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BG   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BE   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   Phase 2   EUCTR2007-002536-29-FI   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-SE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-AT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      -   -   EUCTR2007-002536-29-PL   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Merck Serono International S.A.
      2007   -   EUCTR2006-004140-23-GR   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono SA - Geneva
      2008   Phase 2   EUCTR2007-003647-75-GB   Finland;France;Netherlands;Sweden;United Kingdom;
   Serono International S.A.
      2007   Phase 2   EUCTR2006-004140-23-ES   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-BG   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Atacicept: with loading dose   
   EMD Serono
      2007   Phase 2   NCT00595413   Germany;United States;
Atorvastatin   
   Gilead Sciences
      2020   Phase 1   NCT04608344   United States;
   Hospital Central Dr. Ignacio Morones Prieto
      2018   Phase 2   NCT04056039   Mexico;
   Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital
      2017   -   ChiCTR-INR-17011772   China;
   Pfizer
      2010   Phase 2   NCT01059864   Korea, Republic of;United States;
   University of California, Los Angeles
      2003   Phase 4   NCT00356473   -
Atorvastatin tablet   
   Chengdu PLA General Hospital
      2014   -   NCT02219191   China;
Auto-Injector Device (AID)   
   Sanofi
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
Autoinjector   
   Momenta Pharmaceuticals, Inc.
      2016   Phase 3   NCT02722044   United States;
   Samsung Bioepis Co., Ltd.
      2017   Phase 2   NCT03193957   Poland;
Autologous Peripheral Blood Stem Cell Transplantation   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Autologous adipose derived stem cells   
   Celltex Therapeutics Corporation
      2021   Phase 1/Phase 2   NCT04170426   -
Autologous apoptotic cells injection   
   Centre Hospitalier Universitaire de Besancon
      2021   Phase 1/Phase 2   NCT02903212   -
Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70   
   UMC Utrecht
      2021   Phase 1/Phase 2   NCT05251870   Netherlands;
Autologous mesenchymal stem cells   
   Mashhad University of Medical Sciences
      2016   Phase 1   NCT03333681   -
Autologous stromal vascular fraction cells   
   Translational Biosciences
      2013   Phase 1/Phase 2   NCT01885819   Panama;
Avelox- Moxifloxacin   
   AstraZeneca AB
      2009   -   EUCTR2009-011044-20-GB   United Kingdom;
Avelox®   
   AstraZeneca AB
      2009   -   EUCTR2009-011044-20-GB   United Kingdom;
Azathioprin   
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Azathioprine   
   Hoffmann-La Roche
      2013   Phase 3   NCT01941095   Greece;
   Sanofi
      2018   Phase 4   NCT03449758   France;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
B03BB01   
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
BAT1806   
   Bio-Thera Solutions
      2018   Phase 3   NCT03830203   China;
   Bio-Thera Solutions, Ltd.
      2019   Phase 3   EUCTR2018-002202-31-BG   Bulgaria;China;Georgia;Poland;Ukraine;
BAT1806 injection   
   Bio-Thera Solutions
      2018   Phase 1   NCT03606876   China;
BCD-055   
   Biocad
      2016   Phase 3   NCT02762838   Belarus;India;Russian Federation;
BCD-089   
   Biocad
      2019   Phase 3   NCT04227366   Russian Federation;
BCD-089, 162 mg, s/c, q2w   
   Biocad
      2018   Phase 2   NCT03455842   Belarus;Russian Federation;
BCD-089, 162 mg, s/c, qw   
   Biocad
      2018   Phase 2   NCT03455842   Belarus;Russian Federation;
BDMARD   
   CHU Saint-Etienne
      2020   Phase 4   EUCTR2019-003700-12-FR   France;
BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)   
   Medical University of Graz
      2012   Phase 4   NCT01602302   Austria;
BETAMETHASONE ACIBUTATE   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   -   EUCTR2013-003486-34-DK   Denmark;
   Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
      2017   Phase 4   EUCTR2017-003425-15-DK   Denmark;
BG00012   
   Biogen Idec
      2008   Phase 2   NCT00810836   Australia;Canada;Czech Republic;India;Poland;Slovakia;
   Biogen Idec Limited
      2009   Phase 2   EUCTR2008-004754-33-SK   Czech Republic;Poland;Slovakia;
      2009   -   EUCTR2008-004754-33-PL   Czech Republic;Poland;
      2009   -   EUCTR2008-004754-33-CZ   Czech Republic;Poland;
BG9924   
   Biogen Idec
      2007   Phase 2   NCT00523328   Belgium;Canada;United Kingdom;United States;
      2007   Phase 2   NCT00458861   United States;
      2005   Phase 2   NCT00292422   Poland;United States;
   Biogen Idec Ltd
      2007   Phase 2   EUCTR2006-005467-26-GB   Belgium;United Kingdom;
      2007   Phase 2   EUCTR2006-005466-39-GB   Hungary;United Kingdom;
      2007   -   EUCTR2007-000734-38-GB   United Kingdom;
      2007   -   EUCTR2007-000734-38-BE   Belgium;United Kingdom;
      2007   -   EUCTR2007-000733-19-HU   Hungary;United Kingdom;
      2007   -   EUCTR2007-000733-19-GB   Hungary;United Kingdom;
      2007   -   EUCTR2006-005467-26-BE   Belgium;United Kingdom;
      2007   -   EUCTR2006-005466-39-HU   Hungary;United Kingdom;
BGX-0214   
   Coherus BioSciences, Inc.
      2015   Phase 3   EUCTR2015-000665-30-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
BI 655064   
   Boehringer Ingelheim B.V
      2013   -   EUCTR2012-004090-16-NL   Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
   Boehringer Ingelheim España, S.A.
      2013   -   EUCTR2012-004090-16-ES   Australia;Czech Republic;Germany;Netherlands;New Zealand;Spain;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2013   -   EUCTR2012-004090-16-DE   Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
   Boehringer Ingelheim RCV GmbH & Co KG
      2013   Phase 1;Phase 2   EUCTR2012-004090-16-CZ   Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
BI 655064 high dose   
   Boehringer Ingelheim
      2012   Phase 1   NCT01751776   Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 low dose   
   Boehringer Ingelheim
      2012   Phase 1   NCT01751776   Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 medium dose   
   Boehringer Ingelheim
      2012   Phase 1   NCT01751776   Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 695500   
   Boehringer Ingelheim
      2013   Phase 3   NCT01955733   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Germany;Greece;Hungary;Ireland;Mexico;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2012   Phase 3   NCT01682512   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim International GmbH
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-NO   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002894-48-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GB   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-EE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
BI 695501   
   Boehringer Ingelheim
      2016   Phase 3   NCT02640612   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2015   Phase 3   NCT02137226   Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
   Boehringer Ingelheim International GmbH
      2016   Phase 3   EUCTR2015-002634-41-PL   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2016   Phase 3   EUCTR2015-002634-41-HU   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2016   Phase 3   EUCTR2015-002634-41-DE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2016   Phase 3   EUCTR2015-002634-41-BG   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2015   Phase 3   EUCTR2015-002634-41-ES   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-HU   Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-ES   Argentina;Belgium;Bulgaria;Chile;Colombia;Estonia;France;Germany;Hungary;Indonesia;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-EE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-DE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-BG   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
BI 695501 Autoinjector   
   Boehringer Ingelheim
      2016   Phase 2   NCT02636907   Poland;Ukraine;United States;
BI 695501 Prefilled syringe   
   Boehringer Ingelheim
      2016   Phase 2   NCT02636907   Poland;Ukraine;United States;
BIBR 796 BS   
   Boehringer Ingelheim
      2001   Phase 2   NCT02209779   -
BIIB023   
   Biogen Idec
      2008   Phase 1   NCT00771329   Russian Federation;Ukraine;United States;
BIIB057   
   Biogen Idec
      2012   Phase 2   NCT01652937   Canada;
BIIL 284 BS high dose   
   Boehringer Ingelheim
      2001   Phase 2   NCT02251210   -
BIIL 284 BS low dose   
   Boehringer Ingelheim
      2001   Phase 2   NCT02251210   -
BIIL 284 BS medium dose   
   Boehringer Ingelheim
      2001   Phase 2   NCT02251210   -
BIRB 796 BS, high dose   
   Boehringer Ingelheim
      2003   Phase 2   NCT02214888   -
BIRB 796 BS, low dose   
   Boehringer Ingelheim
      2003   Phase 2   NCT02214888   -
BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)   
   Bristol-Myers Squibb
      2016   Phase 1   NCT02762123   United States;
BMS-188667   
   Academisch Medisch Centrum Amsterdam
      2010   -   EUCTR2010-021435-14-NL   Netherlands;
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-005102-68-IT   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-IT   Belgium;Germany;Italy;Spain;United Kingdom;
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2021   Phase 3   EUCTR2020-000350-96-IT   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001275-50-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
   Bristol Myers Squibb International Corporation
      2011   Phase 3   EUCTR2008-001523-57-NO   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2008-001523-57-HU   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-DE   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-GB   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-ES   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   -   EUCTR2008-001523-57-DK   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001523-57-FR   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2005-000784-26-IT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-000784-26-AT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-GB   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-ES   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-DE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-IE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-BE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
      -   -   EUCTR2005-000443-28-Outside-EU/EEA   Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States;
   Bristol-Myers Squibb International Corporation
      2022   Phase 3   EUCTR2020-000350-96-DE   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-PL   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-FR   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-ES   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-CZ   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001275-50-RO   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2016   Phase 3   EUCTR2015-001275-50-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2016   Phase 3   EUCTR2015-001275-50-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-FI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-ES   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-CZ   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-GB   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-ES   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-SE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-NL   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-DE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-BE   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-AT   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-005102-68-CZ   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-GB   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-ES   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-GB   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-ES   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-CZ   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-IE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-DE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-BE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-DE   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-BE   Belgium;Germany;Italy;Spain;United Kingdom;
BMS-582949   
   Bristol Myers Squibb International Corporation
      2008   Phase 2   EUCTR2008-000170-20-FR   Czech Republic;France;Spain;
      2008   Phase 2   EUCTR2008-000170-20-ES   Czech Republic;France;Spain;
      2008   -   EUCTR2008-000170-20-CZ   Czech Republic;France;Spain;
   Bristol-Myers Squibb
      2008   Phase 2   NCT00605735   Argentina;Brazil;Czech Republic;France;Korea, Republic of;Mexico;Spain;Taiwan;United States;
BMS-582949 and Methotrexate   
   Bristol-Myers Squibb
      2005   Phase 1   NCT00162292   Mexico;United States;
BMS-817399   
   Bristol-Myers Squibb
      2011   Phase 2   NCT01404585   Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-002024-40-ES   Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
BMS-945429   
   BRISTOL-M.SQUIBB
      2011   -   EUCTR2010-023956-99-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
   Bristol-Myers Squibb International Corporation
      2014   -   EUCTR2013-003780-65-IT   Argentina;Australia;Canada;Czech Republic;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
      2014   -   EUCTR2013-003780-65-HU   Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
      2011   -   EUCTR2010-023956-99-NL   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
   CSL Behring
      2011   Phase 2   NCT01373151   Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS-986104   
   Bristol-Myers Squibb
      2014   Phase 1   NCT02211469   United States;
BMS-986142   
   Bristol-Myers Squibb
      2016   Phase 2   NCT02638948   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 1   NCT02762123   United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2015-002887-17-FR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-NL   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-BE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-AT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
   Bristol-Myers Squibb K.K.
      2016   Phase 2   JPRN-JapicCTI-163317   Japan, Asia except Japan, North America, South America, Europe, Oceania;
BMS-986195   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03262740   United States;
      2017   Phase 1   NCT03245515   Netherlands;
      2017   Phase 1   NCT03131973   United States;
      2016   Phase 1   NCT02705989   Australia;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BMS-986251   
   Bristol-Myers Squibb
      2017   Phase 1/Phase 2   NCT03329885   Netherlands;
BMS188667   
   Bristol Myers Squibb International Corporation
      2010   -   EUCTR2010-018674-20-IT   Denmark;Finland;France;Germany;Italy;Sweden;
BMS986142   
   Bristol-Myers Squibb International Corporation
      2016   Phase 2   EUCTR2015-002887-17-AT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS986195   
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BNP   
   Itabashi Chuo Medical Center
      2012   -   JPRN-UMIN000013885   Japan;
BNT162b2   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
BOW015   
   Epirus Biopharmaceuticals (Switzerland) GmbH
      2016   Phase 3   NCT02683564   -
BR9001   
   Boryung Pharmaceutical Co., Ltd
      2018   Phase 1   NCT03718611   Korea, Republic of;
BR900A   
   Boryung Pharmaceutical Co., Ltd
      2018   Phase 1   NCT03718611   Korea, Republic of;
BRL-049653   
   GlaxoSmithKline Research & Development Ltd.
      2005   -   EUCTR2004-000482-35-LT   Lithuania;United Kingdom;
      2004   Phase 2   EUCTR2004-000482-35-GB   Lithuania;United Kingdom;
BT061   
   Biotest
      2010   Phase 2   NCT01481493   Czech Republic;Germany;Hungary;Italy;Latvia;Poland;Spain;
   Biotest AG
      2013   Phase 2   EUCTR2013-000114-38-CZ   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-SK   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-LT   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-HU   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-EE   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-DE   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-BG   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2012   -   EUCTR2010-018485-24-LV   Czech Republic;Germany;Hungary;Latvia;Spain;
      2012   -   EUCTR2010-018485-24-HU   Czech Republic;Germany;Hungary;Latvia;Spain;
      2011   -   EUCTR2010-018485-24-ES   Czech Republic;Germany;Hungary;Latvia;Spain;
      2011   -   EUCTR2010-018485-24-DE   Czech Republic;Germany;Hungary;Latvia;Spain;
      2010   -   EUCTR2010-018485-24-CZ   Czech Republic;Germany;Hungary;Latvia;Spain;
BT061 (CD4 monoclonal antibody)   
   Biotest AG
      2008   -   EUCTR2008-001241-26-HU   Bulgaria;Hungary;
      2008   -   EUCTR2008-001241-26-BG   Bulgaria;Hungary;
BT971   
   Biotest AG
      2008   -   EUCTR2008-001241-26-HU   Bulgaria;Hungary;
      2008   -   EUCTR2008-001241-26-BG   Bulgaria;Hungary;
BTK Inhibitor   
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2015-002887-17-FR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-NL   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-BE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BTT-1023   
   Biotie Therapies Corp.
      2009   Phase 1   NCT00851240   Bulgaria;
BUMEKIZUMAB   
   UCB Celltech, UK Registered Branch of UCB Pharma SA
      2015   -   EUCTR2014-003307-30-SK   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Background Treatment   
   Galvani Bioelectronics
      2021   -   NCT05003310   United States;
Baminercept alfa   
   Biogen Idec
      2007   Phase 2   NCT00664716   Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baminercept alfa (BG9924)   
   Biogen Idec
      2007   Phase 2   NCT00664573   Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baricitinib   
   Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo college of Medicine
      2020   -   JPRN-UMIN000040094   Japan;
   Eli Lilly Japan K.K.
      -   Phase 3   JPRN-JapicCTI-142405   -
      -   Phase 3   JPRN-JapicCTI-132156   -
      -   Phase 3   JPRN-JapicCTI-132138   -
      -   Phase 3   JPRN-JapicCTI-132134   -
      -   Phase 3   JPRN-JapicCTI-132125   -
   Eli Lilly and Company
      2020   Phase 4   NCT04086745   United States;
      2019   Phase 4   NCT03915964   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   NCT02265705   Argentina;Brazil;China;
      2014   Phase 3   EUCTR2012-003686-17-SI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-003686-17-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT01885078   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT01721044   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002339-27-GB   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   Phase 3   EUCTR2012-002324-32-GB   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002324-32-BE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-GB   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-DK   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-BE   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-SI   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-GB   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-DE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002339-27-SK   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-PT   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-HU   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-DE   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-CZ   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-BE   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002324-32-SE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-PT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-GR   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-DE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-AT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-PL   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-NL   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-HR   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-GR   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-AT   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-SK   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-PT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-NL   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LV   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-HU   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-GR   Argentina;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-CZ   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-BE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2012   Phase 3   NCT01721057   Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   NCT01711359   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Puerto Rico;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2012   Phase 3   NCT01710358   Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2011   Phase 2   NCT01469013   Japan;
   Galvani Bioelectronics
      2021   -   NCT05003310   United States;
   Lilly S.A.
      2013   -   EUCTR2012-003686-17-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002339-27-ES   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002323-15-ES   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-ES   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Transparency in Healthcare
      2019   Phase 4   EUCTR2019-000505-72-NL   Netherlands;
   University of Erlangen-Nürnberg Medical School
      2018   Phase 3   NCT03701789   Germany;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
Baricitinib Oral Tablet [Olumiant]   
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 4   NCT05238896   France;
Baricitinib treatment   
   University Hospital, Bordeaux
      2021   Phase 3   NCT04870203   France;Monaco;
Baricitinib, olumiant®   
   Shinshu University
      2018   Phase 2   NCT03755466   Japan;
Belatacept   
   Bristol-Myers Squibb
      2000   Phase 1/Phase 2   NCT00279760   Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
Belimumab   
   Human Genome Sciences Inc.
      2005   Phase 2   NCT00583557   Poland;United States;
      2003   Phase 2   NCT00071812   United States;
   Human Genome Sciences Inc., a GSK Company
      2009   Phase 4   NCT00931086   United States;
Benepali   
   Biogen
      2017   -   NCT03327454   Germany;
      2017   -   NCT03100734   Germany;
   Department of Clinical Biochemestry, Aarhus University Hospital
      2015   Phase 4   EUCTR2015-004173-32-DK   Denmark;
   University of Leeds
      2019   Phase 4   NCT03813771   United Kingdom;
      2018   Phase 4   EUCTR2016-002344-16-GB   United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Bi 695500   
   Boehringer Ingelheim International GmbH
      2014   Phase 3   EUCTR2013-002622-23-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002622-23-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Bicain spinal   
   Helsinki University Central Hospital
      2016   Phase 4   EUCTR2016-002035-15-FI   Finland;
Bimekizumab   
   UCB Biopharma Sprl
      2016   Phase 2   EUCTR2016-000393-37-BG   Bulgaria;Georgia;Hungary;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;United Kingdom;
   UCB Celltech
      2015   Phase 2   NCT02430909   Czech Republic;Czechia;Hungary;Moldova, Republic of;Poland;Russian Federation;Slovakia;United Kingdom;
   UCB Celltech, UK Registered Branch of UCB Pharma SA
      2015   Phase 2   EUCTR2014-003307-30-GB   Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
      2015   -   EUCTR2014-003307-30-SK   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Binyrebarkhormon   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   -   EUCTR2013-003486-34-DK   Denmark;
Binyrebsrkhormon   
   Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
      2017   Phase 4   EUCTR2017-003425-15-DK   Denmark;
Biodmards   
   Pfizer
      2012   -   NCT01438892   United States;
Biologic Agents   
   Simon Krabbe
      2006   -   NCT03496831   -
Biologic DMARD   
   Seoul National University Hospital
      2013   -   NCT01965132   Korea, Republic of;
Biologic TNFi   
   Pfizer
      2009   Phase 3   NCT00853385   Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
Biologic/targeted therapy   
   Tuen Mun Hospital
      2022   -   NCT05182203   China;
Biological Drug   
   Sohag University
      2022   -   NCT05267431   Egypt;
Biological agents   
   Astellas Pharma Inc
      2012   -   NCT01870908   Japan;
Biological disease-modifying antirheumatic drugs (bDMARDs)   
   Universidade Nova de Lisboa
      2020   -   NCT04973787   Portugal;
Biologics   
   Shinshu University
      2018   Phase 2   NCT03755466   Japan;
Biosimilar   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada;
   Opal Rheumatology Ltd.
      2018   -   NCT03470688   Australia;
Biosimilar Infliximab   
   Hikma Pharmaceuticals LLC
      2017   -   NCT03348046   Jordan;
   Janssen Scientific Affairs, LLC
      2016   -   NCT02728934   United States;
Biosimilar infliximab   
   Diakonhjemmet Hospital
      2014   Phase 4   NCT02148640   Norway;
Biosimilar product to adalimumab   
   Amgen Inc
      2014   Phase 3   EUCTR2013-000525-31-DE   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-000525-31-RO   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-PL   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-HU   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-GB   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-ES   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-CZ   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-BG   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Blood   
   Centre Hospitalier Universitaire, Amiens
      2013   -   NCT02894047   France;
Blood Collection for PK Testing (15 Mins Before Injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (15 minutes post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (18-20 hours post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (180 minutes post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (60 minutes post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (after injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood sample   
   Centre Hospitalier Universitaire de Saint Etienne
      2020   Phase 4   NCT04470453   France;
      2018   Phase 4   NCT03445871   France;
   University Hospital, Bordeaux
      2018   -   NCT03550833   France;
Blood samples   
   Assistance Publique Hopitaux De Marseille
      2011   Phase 3   NCT01954381   France;
Blood sampling   
   University Hospital, Toulouse
      2021   -   NCT05039216   France;
Blood sampling from infant   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from mother   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood tests   
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04584541   France;
Boostrix®   
   Eli Lilly and Company
      2011   -   EUCTR2010-022205-17-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
Bortezomib   
   Charite University, Berlin, Germany
      2014   Phase 2   NCT02102594   Germany;
Bovine intesastinal alkaline phosphatase (bIAP)   
   Alloksys Life Sciences B.V.
      2011   -   EUCTR2008-007346-63-GB   United Kingdom;
Branebrutinib   
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Breast milk sampling   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02154425   France;Netherlands;Switzerland;United States;
Bredinin tablet   
   Chong Kun Dang Pharmaceutical
      2013   Phase 2   NCT02005757   Korea, Republic of;
Bucillamine   
   BASIC study group
      2007   -   JPRN-UMIN000000837   Japan;
   Higashi-Hiroshima Memorial Hospital
      2009   Phase 4   JPRN-UMIN000002169   Japan;
   Japan Association of Rheumatologists in Private Practice
      2010   -   JPRN-UMIN000003807   Japan;
   KONAMON Study Group
      2013   -   JPRN-UMIN000007404   Japan;
   National hospital organization Chiba east national hospital Clinical Research Center
      2013   -   JPRN-UMIN000012690   Japan;
   Saitama Medical University
      2007   Phase 4   NCT00716248   Japan;
   Sanofi
      2015   Phase 3   NCT02373202   Japan;
   St Luke'
   Tokyo Medical and Dental University
      2012   -   JPRN-UMIN000006702   Japan;
   s International Hospital
Bupivacaine hydrochloride (Marcaine, Pfizer)   
   Sohag University
      2020   Phase 4   NCT04361513   Egypt;
Buprenorphine Transdermal Patch   
   Mundipharma Pharmaceuticals Sdn. Bhd.
      2013   Phase 4   NCT02519387   Malaysia;
Buprenorphine transdermal patch   
   Mundipharma Pte Ltd.
      2013   Phase 4   NCT01961271   Hong Kong;Korea, Republic of;Philippines;
C-Stem™ AMT Femoral Component (standard and high off-set variants)   
   DePuy International
      2006   Phase 4   NCT00872573   United Kingdom;
C. albicans   
   Genentech, Inc.
      2006   Phase 2   NCT00282308   United States;
C10AA05   
   Reade
      2015   Phase 4   EUCTR2013-005524-42-NL   Netherlands;
CAM-3001   
   MedImmune Limited
      2013   Phase 2   EUCTR2011-005649-10-GB   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
   MedImmune Ltd
      2013   Phase 2   EUCTR2011-005648-93-SK   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2011-005648-93-GB   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2013   -   EUCTR2011-005649-10-SK   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-PT   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-HU   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-DE   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-CZ   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005648-93-PT   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-GR   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-ES   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-DE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-BG   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005649-10-GR   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005649-10-ES   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005648-93-HU   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005648-93-EE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005648-93-CZ   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005634-19-PL   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-HU   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-ES   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-EE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-DE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-CZ   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-BG   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2010   -   EUCTR2009-014735-20-PL   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-LT   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-HU   Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
      2010   -   EUCTR2009-014735-20-CZ   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-BG   Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
      2009   -   EUCTR2009-014735-20-LV   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2009   -   EUCTR2009-014735-20-EE   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2008   Phase 1   NCT00771420   Germany;
CAPTURE   
   Dept. of orthopedic surgery, Osaka Medical College
      2014   -   JPRN-UMIN000012650   Japan;
   GlaxoSmithKline
      2017   -   NCT03285191   United Kingdom;
CC-10004   
   Celgene Corporation
      2011   -   EUCTR2010-019926-15-CZ   Czech Republic;United States;
CC-292   
   Celgene
      2013   Phase 2   NCT01975610   United States;
CCI-779   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   Phase 2   NCT00076206   United States;
CCR1 Antagonist   
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-002024-40-ES   Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
CCX 354-C   
   ChemoCentryx
      2009   Phase 1/Phase 2   NCT01027728   Belgium;Romania;
CCX-354-C   
   ChemoCentryx
      2010   Phase 2   NCT01242917   Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
CCX354-C   
   ChemoCentryx
      2010   Phase 2   NCT01242917   Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
   ChemoCentryx, Inc.
      2010   Phase 2   EUCTR2010-019964-36-BE   Belgium;Czech Republic;Germany;Hungary;
      2010   -   EUCTR2010-019964-36-HU   Belgium;Czech Republic;Hungary;
      2010   -   EUCTR2010-019964-36-DE   Belgium;Czech Republic;Germany;Hungary;
      2010   -   EUCTR2010-019964-36-CZ   Belgium;Czech Republic;Germany;Hungary;
CDMARD   
   Eli Lilly and Company
      2013   Phase 3   NCT01721044   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   NCT01721057   Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
CDP 6038 SC   
   UCB Pharma
      2009   Phase 1/Phase 2   NCT01009242   Germany;United States;
CDP6038   
   R-Pharm
      2016   Phase 3   EUCTR2014-004719-36-BG   Belarus;Bulgaria;Russian Federation;Turkey;
   UCB BIOSCIENCES, Inc.
      2011   Phase 2   NCT01296711   Belgium;United Kingdom;United States;
   UCB Biosciences Inc
      2011   -   EUCTR2010-022224-77-GB   Belgium;United Kingdom;United States;
   UCB Biosciences, Inc
      2011   -   EUCTR2010-020839-39-GB   United Kingdom;United States;
   UCB Biosciences, Inc.
      2011   Phase 2   EUCTR2010-022224-77-BE   Belgium;United Kingdom;United States;
   UCB Biosciences, Inc. A Member of the UCB Group of Companies
      2011   Phase 2   EUCTR2010-020839-39-BE   Belgium;United Kingdom;United States;
   UCB Celltech
      2009   -   EUCTR2009-010813-57-DE   Germany;
   UCB Pharma
      2010   Phase 2   NCT01242488   Belgium;United Kingdom;United States;
      2009   Phase 1/Phase 2   NCT01009242   Germany;United States;
CDP870   
   Astellas Pharma Inc
      2011   Phase 3   NCT02586246   Japan;
   Celltech R&D Ltd
      2005   Phase 3   EUCTR2004-002993-49-FI   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
      2005   -   EUCTR2004-002993-49-LV   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-HU   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-GB   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-002993-49-DE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-BE   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
   Korea Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT00993317   Korea, Republic of;
   Otsuka Pharmaceutical Co., Ltd.
      2008   Phase 3   NCT00791921   Japan;
      2008   Phase 2/Phase 3   NCT00791999   Japan;
   UCB Celltech
      2007   -   EUCTR2004-002993-49-EE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2006   Phase 3   EUCTR2005-002629-30-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2006   -   EUCTR2005-002629-30-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002326-63-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2005   Phase 3   EUCTR2005-002326-63-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2005   Phase 3   EUCTR2004-002993-49-SK   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
      2005   -   EUCTR2005-002326-63-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2005-002326-63-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2004-002993-49-LT   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-CZ   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
   UCB Inc
      2006   -   EUCTR2005-002629-30-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-CZ   Czech Republic;Estonia;Latvia;Lithuania;
   UCB Pharma
      2003   Phase 3   NCT00548834   -
      2002   Phase 3   NCT00544154   -
   UCB Pharma S.A.
      2011   -   EUCTR2009-013758-33-NL   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-SE   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-DK   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2007-000830-38-PL   Austria;France;Germany;Italy;Poland;
      2009   -   EUCTR2007-005288-86-FR   France;
      2009   -   EUCTR2007-000828-40-PL   Austria;France;Germany;Italy;Poland;
      2008   Phase 3   EUCTR2007-000828-40-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-AT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-AT   Austria;France;Germany;Italy;Poland;
      2005   -   EUCTR2005-002326-63-CZ   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2004-002993-49-SE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
   UCB Pharma SA
      2015   -   EUCTR2011-002067-20-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-002067-20-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-PT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-IE   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-SE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-IE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-GB   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-NL   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-HU   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-ES   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-DE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-CZ   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-AT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-005427-28-FR   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-NL   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-IT   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-ES   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-DE   France;Germany;Italy;Netherlands;Spain;
   UCB S.A. (Casa Madre)
      2008   -   EUCTR2007-000830-38-IT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-IT   Austria;France;Germany;Italy;Poland;
CDP870 Fab'-PEG   
   UCB Celltech
      2005   Phase 3   EUCTR2005-001350-24-SK   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
   UCB Inc.
      2005   -   EUCTR2005-001350-24-LV   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-LT   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-HU   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-FI   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-EE   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-CZ   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
CE 224,535   
   Pfizer
      2009   Phase 1   NCT00838058   United States;
CE-224,535   
   PFIZER S.A.
      2008   Phase 2   EUCTR2008-000327-25-ES   Czech Republic;Poland;Spain;
   Pfizer
      2009   Phase 1   NCT00838058   United States;
      2008   Phase 2/Phase 3   NCT00628095   Chile;Czech Republic;Korea, Republic of;Mexico;Poland;Spain;United States;
      2007   Phase 1   NCT00446784   United States;
   Pfizer Inc. 235 East 42nd Street NY10017
      2008   Phase 2   EUCTR2008-000327-25-PL   Czech Republic;Poland;Spain;
      2008   -   EUCTR2008-000327-25-CZ   Czech Republic;Poland;Spain;
CELBESTA®   
   Dong-A ST Co., Ltd.
      2015   Phase 4   NCT02780323   Korea, Republic of;
CELEBREX   
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX 200MG 20CPS   
   GLAXO SMITHKLINE
      2005   -   EUCTR2005-000158-61-IT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX®   
   Dong-A ST Co., Ltd.
      2015   Phase 4   NCT02780323   Korea, Republic of;
CERTOLUZIMAB PEGOL   
   UCB PHARMA
      2011   -   EUCTR2011-000385-35-IT   Italy;
CF101   
   Can-Fite BioPharma
      2017   Phase 3   NCT02647762   Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
      2010   Phase 2   NCT01034306   Bulgaria;Israel;
      2008   Phase 2   NCT00556894   Bulgaria;Czech Republic;Czechia;Former Serbia and Montenegro;Israel;Poland;Serbia;Ukraine;
      2006   Phase 2   NCT00280917   Bulgaria;Former Serbia and Montenegro;Israel;Poland;Romania;Serbia;Ukraine;United States;
   Can-Fite BioPharma Ltd.
      2008   -   EUCTR2007-006527-13-BG   Bulgaria;
   Can-Fite BioPharma, Ltd.
      2019   Phase 3   EUCTR2016-003682-26-PL   Bosnia and Herzegovina;Bulgaria;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
CFZ533   
   Novartis Pharmaceuticals
      2013   Phase 1   NCT02089087   Taiwan;United States;
CH-1504   
   Chelsea Therapeutics
      2008   Phase 2   NCT00658047   Canada;
CH-4051   
   Chelsea Therapeutics
      2010   Phase 2   NCT01116141   -
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-CZ   Bulgaria;Czech Republic;
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
CHS-0214   
   COHERUS BIOSCIENCES, INC.
      2015   Phase 3   EUCTR2015-000665-30-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
   Coherus BioSciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-PL   Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-GB   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Coherus BioSciences, Inc.
      2015   Phase 3   EUCTR2015-000665-30-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
   Coherus Biosciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-IT   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-HU   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-ES   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-DE   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Coherus Biosciences, Inc.
      2015   Phase 3   NCT02486939   Japan;
      2014   Phase 3   NCT02115750   Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
   DAIICHISANKYO Co.,Ltd.
      2014   Phase 3   JPRN-JapicCTI-142621   -
CIMZIA (Certolizumab Pegol)   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI   
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
CKD-374 5mg Tab.   
   Chong Kun Dang Pharmaceutical
      2019   Phase 1   NCT03858725   Korea, Republic of;
CKD-506   
   Chong Kun Dang Pharmaceutical
      2018   Phase 2   NCT04204603   Czechia;Georgia;Poland;Russian Federation;Ukraine;
   Chong Kun Dang Pharmaceutical Corporation (CKD)
      2018   Phase 2   EUCTR2018-001377-24-CZ   Czech Republic;Georgia;Poland;Russian Federation;Ukraine;
CLS Brevius stem with Kinectiv technology   
   Zimmer Biomet
      2011   -   NCT03410940   Italy;Poland;Spain;
CMAB008   
   Shanghai Biomabs Pharmaceutical Co., Ltd.
      2018   Phase 3   NCT03478111   China;
CNTO 136   
   Centocor, Inc.
      2008   Phase 2   NCT00718718   Argentina;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Taiwan;Ukraine;United States;
   Janssen-Cilag International N.V.
      2014   Phase 3   EUCTR2013-001417-32-LT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-HU   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-ES   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-DE   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
CNTO 136 IgG   
   Centocor B.V.
      2009   -   EUCTR2007-006603-20-HU   Hungary;
CNTO 148   
   CENTOCOR
      2010   -   EUCTR2009-010582-23-IT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-AT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
   Janssen Pharmaceutical K.K.
      2008   Phase 3   NCT00771251   Japan;
      2008   Phase 3   NCT00727987   Japan;
CNTO 1959 + MTX (Group 4)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01645280   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 + MTX (Group 5)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01645280   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 IgG   
   Janssen-Cilag International NV
      2013   -   EUCTR2011-001122-18-BG   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   Phase 2   EUCTR2011-001122-18-CZ   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   -   EUCTR2011-001122-18-HU   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO 6785   
   Janssen Research & Development, LLC
      2013   Phase 2   NCT01909427   Argentina;Colombia;Czech Republic;Philippines;Poland;Russian Federation;Thailand;
CNTO1275   
   Janssen-Cilag International NV
      2013   -   EUCTR2011-001122-18-BG   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   Phase 2   EUCTR2011-001122-18-CZ   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   -   EUCTR2011-001122-18-HU   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO136   
   Centocor B.V.
      2009   -   EUCTR2007-006603-20-HU   Hungary;
   JANSSEN-CILAG INTERNATIONAL N.V.
      2012   -   EUCTR2010-022243-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2015   Phase 3   EUCTR2012-001176-10-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-LT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-HU   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-ES   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-DE   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2012-001176-10-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-022242-24-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2013   -   EUCTR2010-022243-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022243-38-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022242-24-LT   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2012   -   EUCTR2010-022243-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
CNTO148   
   CENTOCOR
      2006   Phase 3   EUCTR2004-003295-10-IT   Austria;Hungary;Italy;Spain;United Kingdom;
   Centocor B.V.
      2010   -   EUCTR2008-006064-11-HU   Hungary;Lithuania;
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2009   -   EUCTR2008-006064-11-LT   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
CNTO6785   
   Janssen-Cilag International NV
      2013   -   EUCTR2012-003629-40-CZ   Argentina;China;Colombia;Czech Republic;India;Philippines;Poland;Russian Federation;Thailand;
COVID-19 Vaccine (ChAdOx1-S [recombinant])   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA Vaccine (nucleoside modified)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine (nucleoside-modified)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine Moderna (CX-024414)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 vaccine   
   Paul R Fortin
      2022   Phase 2/Phase 3   NCT05236491   -
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
CP 690,550   
   PFIZER
      2005   -   EUCTR2004-002846-36-IT   Germany;Italy;Spain;
   PFIZER INC
      2017   Phase 3   EUCTR2016-001825-15-IT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Poland;Slovakia;Spain;
   Pfizer
      2009   Phase 3   NCT00853385   Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
   Pfizer Inc.
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-SK   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-CZ   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-PL   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-GB   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BG   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BE   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
CP 690550 MR   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
CP-195,543   
   Pfizer
      2006   Phase 2   NCT00424294   United States;
CP-690, 550 - 10   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2016   Phase 3;Phase 4   EUCTR2014-000358-13-DE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-HR   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-ES   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-RO   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LV   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LT   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-GB   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-EE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-CZ   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-BG   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
CP-690,55-10   
   Arthritis Alapítvány
      2016   -   EUCTR2015-002523-26-HU   Hungary;
CP-690,550   
   PFIZER
      2010   Phase 3   EUCTR2009-016987-34-ES   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Poland;Slovakia;Spain;Sweden;
      2008   -   EUCTR2007-002066-35-IT   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2007   Phase 2   EUCTR2006-005035-19-IT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-001984-31-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
   Pfizer
      2016   Phase 4   NCT02831855   Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2012   Phase 1   NCT01484561   Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2011   Phase 2   NCT01359150   Poland;United States;
      2010   Phase 3   NCT01039688   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   Phase 2   NCT01059864   Korea, Republic of;United States;
      2009   Phase 3   NCT00960440   Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
      2009   Phase 3   NCT00856544   Australia;Chile;China;Colombia;Croatia;Denmark;Finland;Germany;Greece;Malaysia;Mexico;Poland;Russian Federation;Slovakia;Spain;Sweden;Thailand;United Kingdom;United States;Venezuela;
      2009   Phase 3   NCT00853385   Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
      2009   Phase 3   NCT00847613   Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Greece;India;Japan;Korea, Republic of;Mexico;Poland;Taiwan;Ukraine;United States;Venezuela;
      2009   Phase 3   NCT00814307   Brazil;Bulgaria;Chile;Colombia;Czech Republic;Dominican Republic;Germany;India;Malaysia;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;Ukraine;United States;
      2009   Phase 2   NCT00687193   Japan;
      2008   Phase 3   NCT00661661   Japan;
      2008   Phase 2   NCT00603512   Japan;
      2007   Phase 3   NCT00413699   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;United States Minor Outlying Islands;
      2007   Phase 2   NCT00550446   Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
      2007   Phase 2   NCT00413660   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Hungary;Mexico;Poland;Slovakia;Spain;Sweden;Turkey;United States;
      2007   -   NCT00414661   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Dominican Republic;Finland;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;Ukraine;United States;
      2005   Phase 2   NCT00147498   Austria;Belgium;Brazil;Canada;Germany;Italy;Mexico;Slovakia;Spain;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2010   Phase 2;Phase 3   EUCTR2006-005035-19-HU   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-007023-26-GR   Bulgaria;Czech Republic;Greece;Poland;
      2009   -   EUCTR2008-008337-11-GB   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007023-26-PL   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2008-007023-26-BG   Bulgaria;Czech Republic;Poland;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
      2009   -   EUCTR2008-008337-11-DE   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2011   -   EUCTR2010-020890-18-CZ   Czech Republic;Hungary;
      2009   Phase 3   EUCTR2008-008337-11-SK   Denmark;Finland;Germany;Greece;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008338-35-CZ   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-008337-11-SE   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008337-11-GR   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008337-11-FI   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008337-11-DK   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007788-17-CZ   Bulgaria;Czech Republic;Germany;
      2009   -   EUCTR2008-007023-26-CZ   Bulgaria;Czech Republic;Poland;
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-020890-18-HU   Czech Republic;Hungary;
      2010   -   EUCTR2009-014296-40-IT   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-008337-11-PL   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
   Pfizer Inc. 235 East 42nd Street, New York, NY10017
      2009   Phase 2;Phase 3   EUCTR2006-006373-25-GB   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2006-006373-25-FI   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-GR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-006373-25-GR   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-006373-25-BG   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-005036-24-BG   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-006373-25-CZ   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-005036-24-HU   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-CZ   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2010   Phase 3   EUCTR2009-014296-40-FR   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2010   -   EUCTR2009-016987-34-SE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-PL   Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
      2010   -   EUCTR2009-016987-34-HU   Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
      2010   -   EUCTR2009-014296-40-IE   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2010   -   EUCTR2009-014296-40-GB   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2010   -   EUCTR2009-014296-40-BE   Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Spain;Sweden;Taiwan;Tanzania, United Republic of;United Kingdom;United States;
      2010   -   EUCTR2009-014296-40-AT   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-008338-35-SK   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-008338-35-DK   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2009-014296-40-DE   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-GB   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-FI   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-DE   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-BG   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-007788-17-DE   Bulgaria;Czech Republic;Germany;
      2009   -   EUCTR2008-007788-17-BG   Bulgaria;Czech Republic;Germany;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
      2010   Phase 3   EUCTR2009-016987-34-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   Phase 3   EUCTR2009-016987-34-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
   Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
      2007   Phase 2   EUCTR2006-005036-24-SK   Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
      2007   -   EUCTR2006-005036-24-SE   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK
      2007   Phase 2   EUCTR2006-006373-25-SK   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006373-25-SE   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006373-25-AT   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
   Pfizer S.A.
      2009   Phase 3   EUCTR2009-014296-40-ES   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2007   Phase 2   EUCTR2006-005035-19-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
   Pfizer, S.A
      2009   Phase 3   EUCTR2008-008338-35-ES   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
   Pfizer, S.A.
      2009   -   EUCTR2008-008337-11-ES   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006373-25-ES   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
CP-690,550 (tasocitinib)   
   Pfizer
      2011   Phase 1   NCT01262118   Hungary;United States;
CP-690,550 (tofacitinib)   
   Pfizer
      2005   Phase 1   NCT01745055   United States;
CP-690,550 + methotrexate   
   Pfizer
      2009   Phase 2   NCT00976599   United States;
CP-690,550 – 10   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2014   -   EUCTR2014-000706-34-GB   Germany;Hungary;United Kingdom;United States;
CP-690,550-10   
   Pfizer Inc, 235 East 42nd Street, New York 10017
      2013   -   EUCTR2011-005689-39-HU   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2007-002066-35-SK   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2010   Phase 2;Phase 3   EUCTR2006-005035-19-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2   EUCTR2007-002066-35-GR   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-BG   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-HU   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-DE   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-CZ   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-SK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
   Pfizer Inc.
      2017   Phase 2   EUCTR2016-002337-30-SK   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-CZ   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2011-005689-39-SK   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-NL   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-DE   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   Phase 2   EUCTR2011-005689-39-ES   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   -   EUCTR2011-005689-39-CZ   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc., 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2017   Phase 2   EUCTR2016-002337-30-HU   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-HR   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-ES   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-DE   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-BG   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-PL   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
CP-690-550   
   Pfizer
      2007   Phase 2   NCT00550446   Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
CP690,550   
   Pfizer Corporation Austria Ges.m.b.H.
      2005   -   EUCTR2004-002846-36-AT   Austria;Germany;Italy;Spain;
   Pfizer Global & Developement, Pfizer Limited
      2005   Phase 2   EUCTR2004-002846-36-SK   Austria;Germany;Italy;Slovakia;Spain;
   Pfizer Pharma GmbH
      2005   -   EUCTR2004-002846-36-DE   Germany;Italy;Spain;
   Pfizer, S.A.
      2005   Phase 2   EUCTR2004-002846-36-ES   Austria;Germany;Italy;Slovakia;Spain;
CR 1   
   Pfizer
      2008   Phase 1   NCT00782600   United States;
CR 2   
   Pfizer
      2008   Phase 1   NCT00782600   United States;
CR 3   
   Pfizer
      2008   Phase 1   NCT00782600   United States;
CR0686   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086   
   Rottapharm Biotech
      2017   Phase 2   NCT03163966   Czechia;
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-PL   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-DK   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-CZ   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-BG   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086Z   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-PL   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-DK   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-CZ   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-BG   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CRx-102   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001930-18-EE   Estonia;
   CombinatoRx, Incorporated
      2008   -   EUCTR2007-004399-38-LT   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-GB   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-EE   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-LT   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-HU   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-GB   Estonia;Hungary;Lithuania;United Kingdom;
      2007   -   EUCTR2007-003069-42-EE   Estonia;Hungary;Lithuania;United Kingdom;
   Zalicus
      2004   Phase 2   NCT00747214   -
CRx-102 (2.7/180)   
   Zalicus
      2007   Phase 2   NCT00551707   Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-102 (2.7/360)   
   Zalicus
      2007   Phase 2   NCT00551707   Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-139   
   CombinatoRx, Inc.
      2006   Phase 2   EUCTR2004-004995-35-GB   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2006   -   EUCTR2004-004995-35-DK   Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-004995-35-CZ   Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-004995-35-AT   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
CRx-150   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001490-26-EE   Estonia;United Kingdom;
      2004   -   EUCTR2004-001490-26-GB   Estonia;United Kingdom;
CT- P10   
   CELLTRION, Inc.
      2014   Phase 3   EUCTR2013-004555-21-SK   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-PT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-LV   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-HU   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-GR   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-DE   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
CT-P10   
   Celltrion
      2014   Phase 3   NCT02149121   Austria;Korea, Republic of;
CT-P13   
   CELLTRION, INC.
      2012   -   EUCTR2011-004468-31-IT   Austria;Bosnia and Herzegovina;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Spain;Ukraine;United Kingdom;
   CELLTRION, Inc
      2012   Phase 3   EUCTR2011-004468-31-GB   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   Phase 3   EUCTR2011-004468-31-ES   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-PL   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-LV   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-LT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2011   -   EUCTR2011-004468-31-SK   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2010   Phase 3   EUCTR2010-018646-31-SK   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018646-31-ES   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-PT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-LV   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-LT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Indonesia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
      2010   -   EUCTR2010-018646-31-IT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-GB   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-BG   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-AT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   Celltrion
      2018   Phase 3   NCT03707535   China;
      2016   Phase 3   NCT03147248   Korea, Republic of;
   Celltrion, Inc
      2017   Phase 1;Phase 3   EUCTR2016-002125-11-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-LV   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-HU   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-EE   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Hungary;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
   Pfizer
      2015   -   NCT02605642   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom;
CT-P17   
   CELLTRION, Inc.
      2019   Phase 3   EUCTR2019-000660-25-PL   Poland;
   Celltrion, Inc
      2019   Phase 3   EUCTR2018-001690-25-LT   Bulgaria;Hungary;Lithuania;Peru;Poland;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-PL   Bosnia and Herzegovina;Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Russian Federation;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-HU   Bosnia and Herzegovina;Bulgaria;Hungary;Lithuania;Peru;Poland;Russian Federation;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-BG   Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Ukraine;
CT-P17 SC   
   Celltrion
      2018   Phase 3   NCT03789292   Bulgaria;
CT-P17 SC AI (adalimumab)   
   Celltrion
      2019   Phase 3   NCT04171414   Poland;
CTLA4Ig   
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-002620-18-IT   Belgium;Germany;Italy;Spain;United Kingdom;
   Bristol Myers Squibb International Corporation
      2011   Phase 3   EUCTR2008-001523-57-NO   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2008-001523-57-HU   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-DE   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-GB   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-ES   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   -   EUCTR2008-001523-57-DK   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001523-57-FR   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2005-000784-26-AT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-GB   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-ES   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-DE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-IE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-BE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-GB   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-ES   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-SE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-NL   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-DE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-BE   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-005102-68-CZ   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-GB   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-ES   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-GB   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-ES   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-CZ   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-IE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-DE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-BE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-DE   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-BE   Belgium;Germany;Italy;Spain;United Kingdom;
CZP   
   Astellas Pharma Inc
      2011   Phase 3   NCT01451203   Japan;
Caffeine   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Janssen Research & Development, LLC
      2012   Phase 1   NCT01636557   Germany;Korea, Republic of;Moldova, Republic of;South Africa;
   R-Pharm International, LLC
      2021   Phase 1   NCT04246762   Bulgaria;Moldova, Republic of;
Calcitriol   
   Atlanta VA Medical Center
      2007   -   NCT00427804   United States;
   Guangdong Provincial Hospital of Chinese Medicine
      2016   -   ChiCTR-IPR-16009029   China;
   The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042329   China;
Calcium   
   Centre Hospitalier Universitaire de Nimes
      2016   -   NCT02636829   France;
   University of Aarhus
      2015   Phase 2   NCT02944799   Denmark;
Calcium and cholecalciferol   
   University of Missouri-Columbia
      1995   Phase 3   NCT00570934   United States;
Calcium carbonate   
   Children's Hospital Medical Center, Cincinnati
      1996   Phase 2   NCT00000429   United States;
Calcium citrate   
   Brigham and Women's Hospital
      2011   Phase 4   NCT01400516   United States;
Canakinumab   
   NOVARTIS FARMA
      2007   -   EUCTR2007-001665-15-IT   Germany;Italy;Netherlands;Spain;
   Novartis
      2006   Phase 2   NCT00424346   Austria;Belgium;Canada;Finland;Germany;Spain;United States;
   Novartis Farmacéutica S.A.
      2009   Phase 2   EUCTR2008-005320-81-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma Services AG
      2009   -   EUCTR2008-005320-81-DE   Austria;Germany;Spain;
      2009   -   EUCTR2008-005320-81-BE   Austria;Belgium;Germany;Spain;
      2008   -   EUCTR2008-005320-81-AT   Austria;Germany;Spain;
Canakinumab (investigational)   
   Novartis
      2007   Phase 2   NCT00487825   Belgium;Germany;Italy;Netherlands;Spain;United States;
Canakinumab (proposed)   
   Novartis Farmaceutica S.A.
      2007   -   EUCTR2007-001665-15-ES   Belgium;Germany;Italy;Netherlands;Spain;
   Novartis Farmacéutica S.A
      2007   -   EUCTR2006-004669-32-ES   Spain;
   Novartis Farmacéutica, S.A.
      2007   -   EUCTR2007-000491-16-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma Services AG
      2007   -   EUCTR2007-001665-15-NL   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-001665-15-DE   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-001665-15-BE   Belgium;Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-000491-16-DE   Austria;Germany;Spain;
      2007   -   EUCTR2007-000491-16-BE   Austria;Belgium;Germany;Spain;
      2007   -   EUCTR2007-000491-16-AT   Austria;Germany;Spain;
      2007   -   EUCTR2006-004666-14-DE   Germany;
      2007   -   EUCTR2006-004666-14-BE   Belgium;Germany;
Canakinumab Injection   
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
Cannabidiol by capsules twice daily   
   University of California, Los Angeles
      2021   Phase 1/Phase 2   NCT04911127   United States;
Cannabidiol tablet   
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark;
Cannabis   
   University Hospital, Clermont-Ferrand
      2020   -   NCT04402554   France;
Carbon Modular Radial Head   
   Ascension Orthopedics, Inc.
      2009   -   NCT00825409   United States;
Carbon Modular Radial Head replacement   
   Integra LifeSciences Corporation
      2009   -   NCT02405234   United States;
Celebra   
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebra (celecoxib)   
   University of Dundee
      2007   Phase 4   EUCTR2007-000012-90-DK   Denmark;Netherlands;United Kingdom;
Celebrex   
   Daewon Pharmaceutical Co., Ltd.
      2010   Phase 3   NCT01781702   -
   Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
      2019   Phase 4   EUCTR2018-004539-54-DE   Germany;
   GlaxoSmithKline Research & Development Limited
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   University of Dundee
      2011   -   EUCTR2007-000012-90-NL   Denmark;Netherlands;United Kingdom;
      2008   Phase 4   EUCTR2007-000012-90-GB   Denmark;Netherlands;United Kingdom;
Celebrex 200 mg Hartkapseln   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebrex 200 mg capsule, hard   
   GlaxoSmithKline Research & Development Limited
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Celecoxib   
   GLAXO SMITHKLINE
      2005   -   EUCTR2005-000158-61-IT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-LT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-DE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-LV   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-HU   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-DK   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   Guangdong Provincial Hospital of Chinese Medicine
      2016   -   ChiCTR-IPR-16009029   China;
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
   Mito medical center, Mito Kyodo General Hospital, University of Tsukuba
      2014   Phase 4   JPRN-UMIN000014624   Japan;
   National Institute of Mental Health (NIMH)
      2019   Phase 1/Phase 2   NCT03912428   United States;
   Pfizer
      2006   Phase 2   NCT00424294   United States;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2006   Phase 4   NCT00346216   Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine;United States;
      2005   Phase 4   NCT00141102   Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   University of Dundee
      2007   Phase 4   NCT00447759   Denmark;Netherlands;United Kingdom;
Celecoxib 200mg capsule   
   Inova Health Care Services
      2018   Phase 4   NCT03699293   United States;
Ceramic on Ceramic articulation   
   Zimmer Biomet
      2013   -   NCT02036931   France;Germany;Ireland;Netherlands;Spain;United States;
Ceramic on Polyethylene articulation   
   Zimmer Biomet
      2013   -   NCT02036931   France;Germany;Ireland;Netherlands;Spain;United States;
Certolizumab   
   Brigham and Women's Hospital
      2016   -   NCT02714881   United States;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Rochester
      2010   -   NCT01098201   United States;
Certolizumab Pegol (CZP)   
   Nathan Wei, MD, FACP, FACR:
      2011   Phase 3   NCT01374971   United States;
   UCB Pharma
      2010   Phase 4   NCT01255761   United States;
      2010   Phase 3   NCT01235598   Denmark;Netherlands;Poland;Sweden;
   UCB Pharma SA
      2011   Phase 4   NCT01500278   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Certolizumab Pegol + Methotrexate (MTX)   
   UCB Pharma
      2012   Phase 3   NCT01521923   Argentina;Australia;Austria;Belgium;Canada;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Mexico;Monaco;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States;
Certolizumab Pegol 200 MG/ML [Cimzia]   
   RenJi Hospital
      2020   -   NCT04569890   China;
Certolizumab pegol   
   Astellas Pharma Inc
      2009   Phase 3   NCT00851318   Japan;
      2009   Phase 3   NCT00850343   Japan;
   Celltech R&D Ltd
      2005   -   EUCTR2004-002993-49-LV   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-HU   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-GB   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-002993-49-DE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-BE   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
   Oklahoma Medical Research Foundation
      2010   Phase 3   NCT01213017   United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   UCB Biopharma SRL
      2021   Phase 1   NCT04740814   United States;
   UCB Celltech
      2007   -   EUCTR2004-002993-49-EE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2006   Phase 3   EUCTR2005-002629-30-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2006   -   EUCTR2005-002629-30-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002326-63-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2005   Phase 3   EUCTR2005-002326-63-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2005   Phase 3   EUCTR2005-001350-24-SK   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
      2005   Phase 3   EUCTR2004-002993-49-SK   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
      2005   -   EUCTR2005-002326-63-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2005-002326-63-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2004-002993-49-LT   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-CZ   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
   UCB Inc
      2006   -   EUCTR2005-002629-30-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-CZ   Czech Republic;Estonia;Latvia;Lithuania;
   UCB Inc.
      2005   -   EUCTR2005-001350-24-LV   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-LT   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-HU   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-FI   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-EE   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-CZ   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
   UCB Italy s.p.a.
      2011   Phase 4   NCT01443364   Italy;
   UCB Pharma
      2009   Phase 4   NCT00993668   United States;
      2008   Phase 3   NCT00753454   Canada;United States;
      2008   Phase 3   NCT00674362   Austria;France;Germany;Italy;Poland;
      2007   Phase 4   NCT00580840   Austria;Canada;France;United States;
   UCB Pharma S.A.
      2010   -   EUCTR2007-000830-38-PL   Austria;France;Germany;Italy;Poland;
      2009   -   EUCTR2007-005288-86-FR   France;
      2009   -   EUCTR2007-000828-40-PL   Austria;France;Germany;Italy;Poland;
      2008   Phase 3   EUCTR2007-000828-40-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-AT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-AT   Austria;France;Germany;Italy;Poland;
      2005   -   EUCTR2005-002326-63-CZ   Czech Republic;Estonia;Latvia;Lithuania;
   UCB Pharma SA
      2009   Phase 3   EUCTR2008-005427-28-FR   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-NL   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-IT   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-ES   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-DE   France;Germany;Italy;Netherlands;Spain;
   UCB S.A. (Casa Madre)
      2008   -   EUCTR2007-000830-38-IT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-IT   Austria;France;Germany;Italy;Poland;
Certolizumab pegol (CDP870)   
   UCB Pharma
      2005   Phase 3   NCT00152386   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Israel;Latvia;Russian Federation;Ukraine;United States;
Certolizumab pegol (CDP870, tradename Cimzia)   
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)   
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
Certolizumab pegol (CZP)   
   UCB Pharma
      2008   Phase 3   NCT00717236   Canada;France;Germany;Italy;Netherlands;Spain;United States;
   UCB Pharma S.A.
      2011   -   EUCTR2009-013758-33-NL   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-SE   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-DK   Denmark;Netherlands;Sweden;
Cetrorelix   
   Betanien Hospital
      2008   Phase 2   NCT00667758   Norway;
Cevidoplenib   
   Oscotec Inc.
      2019   Phase 2   EUCTR2018-003330-32-PL   Czech Republic;Korea, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
Chicken type II collagen   
   National Eye Institute (NEI)
      1997   Phase 1   NCT00001614   United States;
Chimeric Human-Murine IgG1    
   Centocor BV
      2009   Phase 4   EUCTR2007-003288-36-GB   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-003288-36-ES   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 4   EUCTR2007-003288-36-FR   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-NL   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-FI   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-DE   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-AT   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
Chimeric human/mouse anti-CD-20 monoclonal antibody   
   Samsung Electronics Co. Ltd.
      2012   -   EUCTR2011-004171-36-PL   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-HU   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-GB   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-ES   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-CZ   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
Chloroquine   
   Hoffmann-La Roche
      2013   Phase 3   NCT01941095   Greece;
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
   Sanofi
      2018   Phase 4   NCT03449758   France;
   University of Alberta
      2020   -   NCT04347798   Canada;
Cholecalciferol   
   University Hospital, Clermont-Ferrand
      2011   Phase 3   NCT02243800   France;
Chong Kun Dang Tofacitinib Tablet   
   Chong Kun Dang Pharmaceutical
      2019   Phase 1   NCT03868072   Korea, Republic of;
Chromium   
   Akiyama Haruhiko
      2011   Phase 4   JPRN-jRCTs032180273   Japan;
   Kume Shinichiro
      2012   Phase 4   JPRN-jRCTs032180245   Japan;
   Zimmer Biomet
      2009   -   NCT03681639   Germany;
Ciclosporin   
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
   PFIZER
      2007   -   EUCTR2007-001984-31-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
Cimzia   
   Karolinska Institutet
      2015   Phase 4   NCT02466581   Sweden;
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   Phase 4   EUCTR2011-004720-35-DK   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
      2012   Phase 4   NCT01491815   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
   Kings College London
      2008   Phase 4   EUCTR2007-005464-26-GB   United Kingdom;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
   Michael Schiff, MD
      2010   Phase 4   NCT01147341   United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   The Karolinska Institute, ClinTRID
      2017   Phase 4   EUCTR2011-004720-35-NL   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2012   -   EUCTR2011-004720-35-SE   Sweden;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   The Karolinska Instutute, ClinTRID
      2013   Phase 4   EUCTR2011-004720-35-IS   Denmark;Finland;Iceland;Norway;Sweden;
   UCB Celltech, UK Registered Branch of UCB Pharma SA
      2015   Phase 2   EUCTR2014-003307-30-HU   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
      2015   Phase 2   EUCTR2014-003307-30-GB   Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
      2015   Phase 2   EUCTR2014-003307-30-CZ   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
      2015   -   EUCTR2014-003307-30-SK   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
   UCB PHARMA SA/NV.
      2012   -   EUCTR2011-002067-20-IT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-IT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   UCB Pharma SA
      2015   -   EUCTR2011-002067-20-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-002067-20-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-PT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-IE   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-SE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-IE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-GB   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-NL   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-HU   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-ES   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-DE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-CZ   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-AT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
   University of California, San Francisco
      2013   -   NCT01773681   United States;
   Universitätsklinikum Erlangen
      2015   Phase 3   EUCTR2013-000337-13-PT   Germany;Portugal;Serbia;United States;
      2013   Phase 3   EUCTR2013-000337-13-DE   Germany;Portugal;Serbia;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Cimzia 200 mg injeksjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Cimzia 200 mg solution for injection   
   Ghent University Hospital
      2012   Phase 3   EUCTR2009-017998-37-BE   Belgium;
Cimzia®   
   UCB Pharma S.A.
      2011   -   EUCTR2009-013758-33-NL   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-SE   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-DK   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2007-000830-38-PL   Austria;France;Germany;Italy;Poland;
Citalopram   
   Vrije Universiteit Brussel
      2010   -   NCT01154647   Belgium;
Classic DMARDs treatment group   
   Zhang, Xiao, M.D.
      2013   -   NCT01915537   China;
Clazakizumab   
   Bristol-Myers K.K.
      2014   Phase 2   JPRN-JapicCTI-142497   -
      2011   Phase 2   JPRN-JapicCTI-111628   -
   CSL Behring
      2012   Phase 2   NCT02015520   Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
Clindamycin   
   Hammersmith Hospitals NHS trust
      2005   Phase 3   EUCTR2004-004893-96-GB   United Kingdom;
Clofarabine   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Co-medication: Synthetic DMARDs   
   Diakonhjemmet Hospital
      2013   Phase 4   NCT01881308   Norway;
Cobalt   
   Akiyama Haruhiko
      2011   Phase 4   JPRN-jRCTs032180273   Japan;
   Kume Shinichiro
      2012   Phase 4   JPRN-jRCTs032180245   Japan;
   Zimmer Biomet
      2009   -   NCT03681639   Germany;
Cobalt™ Bone Cement   
   Zimmer Biomet
      2006   -   NCT00589485   United States;
Cobiprostone   
   Sucampo Pharma Americas, LLC
      2007   Phase 2   NCT00597818   United States;
Cod liver oil   
   National Institute of Nutrition and Seafood Research, Norway
      2008   -   NCT00805116   Norway;
Coenzyme Q10   
   the Second Hospital of Shanxi Medical University
      2017   -   ChiCTR-IPR-17010325   China;
Colchicine   
   Hospital Central Dr. Ignacio Morones Prieto
      2018   Phase 2   NCT04056039   Mexico;
Colecalciferol   
   AZIENDA OSPEDALIERA ORDINE MAURIZIANO
      2010   Phase 3   EUCTR2009-015835-34-IT   Italy;
Collect of 10 ml of peripheric blood for DNA extraction   
   Centre Hospitalier Universitaire de Fort-de-France
      2010   -   NCT01111357   Martinique;
Combination Product: Exercise, and methotrexate   
   Cairo University
      2020   -   NCT04758689   Egypt;
Combination Product: Laser, exercise, and methotrexate   
   Cairo University
      2020   -   NCT04758689   Egypt;
Combination Product: Methotrexate   
   Jiangsu Alphamab Biopharmaceuticals Co., Ltd
      2019   Phase 2   NCT04038970   China;
Combination Steroid   
   All India Institute of Medical Sciences, New Delhi
      2009   Phase 3   NCT01870128   India;
Combination fish oil and borage seed oil   
   National Center for Complementary and Integrative Health (NCCIH)
      2006   Phase 3   NCT00072982   United States;
Combination of Minocycline and MTX or MTX alone   
   University of Nebraska
      2001   Phase 3   NCT00579644   -
Comirnaty   
   Sint Maartenskliniek
      2021   Phase 4   EUCTR2021-000710-42-NL   Netherlands;
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
Commercial Formulation Etanercept   
   Amgen
      2016   Phase 3   NCT02986139   Puerto Rico;United States;
Comparator: Diclofenac sodium   
   Organon and Co
      2003   Phase 3   NCT00250445   -
      2003   Phase 3   NCT00092742   United States;
Comparator: diclofenac   
   Organon and Co
      2006   Phase 2   NCT00264147   Canada;Colombia;Puerto Rico;Switzerland;United States;
Comparator: naproxen tablet   
   Merck Sharp & Dohme Corp.
      2004   Phase 4   NCT00157872   China;
Computed Tomography   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Control   
   Chengdu PLA General Hospital
      2013   Phase 2   NCT02254655   China;
   Laval University
      2022   -   NCT04688398   -
Control group   
   University of Erlangen-Nürnberg Medical School
      2009   Phase 3   NCT02779114   Germany;
Control intervention (no dexamethasone)   
   University of Calgary
      2016   -   NCT02666443   Canada;
Conventional DMARD combination   
   Karolinska Institutet
      2002   Phase 4   NCT00764725   -
Conventional DMARDs   
   Ain Shams University
      2019   Phase 2   NCT03863405   Egypt;
Conventional Synthetic DMARD   
   SetPoint Medical Corporation
      2021   Phase 3   NCT04539964   United States;
Conventional syringe - BD Ref 309604   
   University of New Mexico
      2004   -   NCT00651625   United States;
Corn oil capsules   
   Zhejiang University
      2014   -   NCT02173587   China;
Corticosteroid and non-biological agents.   
   University of Athens
      2017   -   NCT03288584   Greece;
Corticosteroid or NSAID   
   Hoffmann-La Roche
      2007   Phase 4   NCT00462345   Korea, Republic of;
Corticosteroids   
   Genentech, Inc.
      2003   Phase 2   NCT00074438   United States;
Corticotrophin 80 units   
   Gaylis, Norman B., M.D.
      2013   Phase 4   NCT01948388   United States;
Creatine   
   Bangor University
      2013   -   NCT01767844   United Kingdom;
Creatinine   
   Affiliated Hospital of North Sichuan Medical College
      2018   -   ChiCTR1800018637   China;
CsDMARD(s)   
   GlaxoSmithKline
      2020   Phase 3   NCT04333147   Argentina;Australia;Belgium;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Hungary;India;Japan;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
CsDMARDs   
   Gilead Sciences
      2016   Phase 3   NCT02873936   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   GlaxoSmithKline
      2019   Phase 3   NCT04134728   Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   NCT03970837   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Hoffmann-La Roche
      2014   Phase 3   NCT02001987   France;
Cura-100   
   Cura Biotech LLC
      2007   Phase 1/Phase 2   NCT00455208   United States;
Curcumin (Longvida™)   
   University of California, Los Angeles
      2010   Phase 0   NCT00752154   United States;
Cyclophosphamide   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Hoffmann-La Roche
      2001   Phase 2   NCT02693210   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
Cyclosporin A   
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
Cyclosporine   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Cyklokapron®   
   University Hospital of North Tees and Hartlepool
      2009   -   EUCTR2009-012141-34-GB   United Kingdom;
D2E7   
   Reade
      2019   Phase 4   EUCTR2019-001793-28-NL   Netherlands;
      2019   Phase 1;Phase 4   EUCTR2019-001554-25-NL   Netherlands;
D569 Tab.   
   Chong Kun Dang Pharmaceutical
      2019   Phase 1   NCT03858725   Korea, Republic of;
DECORTIN (PREDNISONA) 5 MG COMPRIMIDOS   
   Pfizer S.A.
      2009   Phase 2   EUCTR2009-013223-37-ES   Czech Republic;Hungary;Spain;
DELTACORTENE FORTE*10CPR   
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
DEPALGOS*20+325MG 28CPR RP   
   A.U.S.L. RIMINI
      2006   -   EUCTR2006-004062-13-IT   Italy;
DEXA scan   
   University of Texas Southwestern Medical Center
      2006   -   NCT00286689   United States;
DIBASE*IM OS 2F 1ML 300000UI/M   
   AZIENDA OSPEDALIERA ORDINE MAURIZIANO
      2010   Phase 3   EUCTR2009-015835-34-IT   Italy;
DMARD   
   Amgen
      2001   -   NCT00116714   United States;
   Hoffmann-La Roche
      2013   Phase 3   NCT01995201   Ireland;Portugal;Spain;
      2011   Phase 4   NCT01251120   Finland;
DMARD Therapy   
   Amgen
      2011   Phase 4   NCT01313208   Canada;United States;
   Zalicus
      2004   Phase 2   NCT00747214   -
DMARD cessation   
   Newcastle-upon-Tyne Hospitals NHS Trust
      2014   -   NCT02219347   United Kingdom;
DMARD maintenance   
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 4   NCT00780793   France;
DMARDS   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00783536   Mexico;
DMARDs   
   Columbia University
      2011   Phase 4   NCT01548768   United States;
   Hoffmann-La Roche
      2014   Phase 3   NCT02046603   United Kingdom;
      2013   Phase 4   NCT01715831   Brazil;
      2013   Phase 3   NCT01941940   Italy;
      2009   Phase 3   NCT00996606   Italy;
   JW Pharmaceutical
      2010   Phase 3   NCT01256736   Korea, Republic of;
      2009   Phase 3   NCT01211834   Korea, Republic of;
   Mycenax Biotech Inc.
      2013   Phase 3   NCT01787149   Taiwan;
   Sun Yat-sen University
      2018   Phase 4   NCT04066803   China;
DMARDs (disease-modifying antirheumatic drugs)   
   Hoffmann-La Roche
      2009   Phase 4   NCT00996203   Russian Federation;
DMARDs (methotrexate   
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
DMARDs or Biologics   
   Pfizer
      2009   -   NCT00929357   Denmark;
DRL_RI   
   Dr. Reddy's Laboratories Limited
      2014   Phase 1/Phase 2   NCT02296775   India;Ukraine;
DW1809-1   
   Daewon Pharmaceutical Co., Ltd.
      2020   Phase 1   NCT05214690   Korea, Republic of;
      2020   Phase 1   NCT05214677   Korea, Republic of;
DW1809-T2   
   Daewon Pharmaceutical Co., Ltd.
      2020   Phase 1   NCT05214690   Korea, Republic of;
DWP422   
   Daewoong Pharmaceutical Co. LTD.
      2012   Phase 1   NCT01635686   Korea, Republic of;
Dacortin ®   
   Zalicus, Inc.
      2012   -   EUCTR2011-002392-41-HU   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-002392-41-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-PL   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-HU   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-BG   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Daily supplementation   
   Adeline BLOT
      2018   -   NCT04696718   France;
Dalacin C phosphate   
   Hammersmith Hospitals NHS trust
      2005   Phase 3   EUCTR2004-004893-96-GB   United Kingdom;
Decortin   
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-023782-22-CZ   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
      2011   -   EUCTR2010-023782-22-DE   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2010-023782-22-SK   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2011   -   EUCTR2010-023782-22-HU   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2011   -   EUCTR2010-023782-22-BG   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer, S.L.U.
      2011   -   EUCTR2010-023782-22-ES   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Decortin 5mg tablets   
   Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
      2009   -   EUCTR2007-006150-25-DE   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
      2008   -   EUCTR2007-006150-25-HU   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2008   Phase 2   EUCTR2007-006150-25-FR   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   Phase 2   EUCTR2007-006150-25-BE   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-NL   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-AT   Austria;Belgium;France;Germany;Hungary;Netherlands;
Decortin®   
   Pfizer Inc.
      2009   Phase 2   EUCTR2009-013223-37-CZ   Czech Republic;Hungary;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2009   -   EUCTR2009-013223-37-HU   Hungary;Spain;
   Pfizer S.A.
      2009   Phase 2   EUCTR2009-013223-37-ES   Czech Republic;Hungary;Spain;
Decrease Tocilizumab, Abatacept   
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 4   NCT01557374   France;
Defanyl 50 and   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001490-26-EE   Estonia;United Kingdom;
Dekavil   
   Philogen S.p.A.
      2015   Phase 2   EUCTR2013-005418-37-DE   Germany;Italy;Switzerland;
      2014   -   EUCTR2013-005418-37-IT   Germany;Italy;
Deltacortril Enteric   
   GlaxoSmithKline Research & Development Limited
      2005   Phase 2   EUCTR2005-001977-82-GB   United Kingdom;
Denosumab   
   Amgen
      2011   Phase 1   NCT01294397   United States;
      2004   Phase 2   NCT00095498   United States;
   Chinese University of Hong Kong
      2017   Phase 2   NCT03239080   China;
      2012   Phase 4   NCT01770106   Hong Kong;
   DAIICHISANKYO Co.,Ltd.
      2013   Phase 3   JPRN-JapicCTI-132277   -
      2010   Phase 2   JPRN-JapicCTI-101263   -
   Daiichi Sankyo Company, Limited
      2018   -   JPRN-UMIN000030575   Japan;
   Daiichi Sankyo, Inc.
      2013   -   NCT01973569   Japan;
   Hokkaido Medical Center for Rheumatic Diseases
      2017   -   JPRN-UMIN000028376   Japan;
   Indiana University
      2019   Phase 1/Phase 2   NCT02418273   United States;
   Kawakami Atsushi
      2018   Phase 4   JPRN-jRCTs071180018   Japan;
   Osaka City University Graduate School of Medicine
      2018   -   JPRN-UMIN000030828   Japan;
   Yokohama City University Medical Center
      2014   -   JPRN-UMIN000014737   Japan;
Depemedrone   
   University Hospital Birmingham
      2007   Phase 4   NCT00523692   United Kingdom;
Depo Medrol   
   Sun Pharma Global FZE
      2016   Phase 3   EUCTR2015-002924-17-BE   Belgium;Netherlands;
      2015   Phase 3   EUCTR2015-002924-17-NL   Belgium;Netherlands;
Depo medrol   
   Attune Health Research, Inc.
      2018   Phase 3   NCT03511625   United States;
Depo-Medrone   
   University Hospitals Birmingham NHS Foundation Trust
      2006   Phase 4   EUCTR2006-001428-38-GB   United Kingdom;
Dexamethason   
   UMC Utrecht
      2010   -   EUCTR2009-017051-10-NL   Netherlands;
Dexmedetomidine   
   West China Hospital, Sichuan University
      2021   Phase 0   ChiCTR2000036316   China;
      2021   Phase 0   ChiCTR2000036164   china;
Dextromethorphan hydrobromide   
   Taichung Veterans General Hospital
      2010   -   NCT02368093   -
Diacerein   
   TRB Chemedica
      2010   Phase 2   NCT01264211   Thailand;
Diazepam, melatonin   
   Kobe University
      2006   -   NCT00287794   Japan;
Diclofenac   
   Mallinckrodt
      2012   -   NCT01579890   -
   Northumbria Healthcare NHS Foundation Trust
      2010   Phase 4   NCT01067430   United Kingdom;
   University of Dundee
      2007   Phase 4   NCT00447759   Denmark;Netherlands;United Kingdom;
Diclofenac + Omeprazole   
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2005   Phase 4   NCT00141102   Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
Diclofenac sodium   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Dietary Fiber Supplementation   
   University Hospital, Montpellier
      2020   -   NCT04421313   France;
Dietary supplement omega3 fatty acids aand vitamins   
   Physicians Committee for Responsible Medicine
      2011   -   NCT01544101   United States;
Digoxin   
   AstraZeneca
      2011   Phase 1   NCT01355354   United Kingdom;
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Tanta University
      2021   Phase 2   NCT04834557   -
Dihuang   
   Shanghai Traditional Chinese Medicine Hospital
      2020   Phase 0   ChiCTR2000037675   China;
Dimeythl Fumarate   
   Biogen Idec Limited
      2009   Phase 2   EUCTR2008-004754-33-SK   Czech Republic;Poland;Slovakia;
      2009   -   EUCTR2008-004754-33-PL   Czech Republic;Poland;
      2009   -   EUCTR2008-004754-33-CZ   Czech Republic;Poland;
Dipotassium Salt   
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-CZ   Bulgaria;Czech Republic;
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Diprofos Depot   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   -   EUCTR2013-003486-34-DK   Denmark;
   Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
      2017   Phase 4   EUCTR2017-003425-15-DK   Denmark;
Dipyridamole   
   CombinatoRx, Incorporated
      2008   -   EUCTR2007-004399-38-LT   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-GB   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-EE   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-LT   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-HU   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-GB   Estonia;Hungary;Lithuania;United Kingdom;
      2007   -   EUCTR2007-003069-42-EE   Estonia;Hungary;Lithuania;United Kingdom;
   Zalicus
      2011   Phase 2   NCT01369745   United States;
      2007   Phase 2   NCT00551707   Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
   Zalicus, Inc.
      2012   -   EUCTR2011-002392-41-HU   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-002392-41-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Dipyridamole and Amoxapine   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001490-26-EE   Estonia;United Kingdom;
Disease modified antirheumatic drugs or biological agents   
   Nanfang Hospital of Southern Medical University
      2018   -   NCT03508713   -
Disease-modifying anti-rheumatic drugs   
   Hoffmann-La Roche
      2005   Phase 3   NCT00720798   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Disease-modifying antirheumatic drug   
   Pfizer
      2010   Phase 3   NCT01039688   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
Disease-modifying antirheumatic drugs (DMARDs)   
   Astellas Pharma China, Inc.
      2018   Phase 3   NCT03660059   China;Korea, Republic of;Taiwan;
   Hoffmann-La Roche
      2010   Phase 3   NCT01194414   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
DnaJ peptide   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1999   Phase 2   NCT00000435   United States;
Dolquine   
   Fundació Clínic per a la Recerca Biomèdica
      2019   Phase 4   EUCTR2017-004543-20-ES   Spain;
Donepezil   
   RenJi Hospital
      2018   Phase 3   NCT02927522   China;
Doppler ultrasound.   
   Assistance Publique Hopitaux De Marseille
      2011   Phase 3   NCT01954381   France;
Dose level 1   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Dose level 2   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Dose level 3   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Dose level 4   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Double-blind Abatacept   
   Bristol-Myers Squibb
      2002   Phase 3   NCT00048932   United States;
Double-blind adalimumab   
   Abbott
      2009   Phase 3   NCT00870467   Japan;
Doxycycline   
   Hong Kong Baptist University
      2015   -   ChiCTR-OPB-15007284   China;
   New York University School of Medicine
      2010   -   NCT01198509   United States;
Doxycycline Tablets   
   Assiut University
      2019   -   NCT03194204   Egypt;
Dr. Reddy’s Rituximab (DRL_RI)   
   Dr. Reddy’s Laboratories S.A.
      2020   Phase 3   EUCTR2019-002810-37-PL   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-LT   Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-DE   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
Dronabinol capsule   
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark;
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom   
   Groupe Hospitalier Pitie-Salpetriere
      2018   -   NCT03480529   France;
Drug protocol   
   Federal University of São Paulo
      2014   -   NCT04752748   -
Drug treatment   
   Xijing Hospital
      2019   -   NCT04037111   China;
Dummy Qing Re Huo Xue (QRHX)   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT04170504   -
E-Device   
   UCB Biopharma S.P.R.L.
      2017   Phase 3   NCT03357471   United States;
E1-Hip Bearing   
   Zimmer Biomet
      2013   -   NCT02087449   Korea, Republic of;
E6011   
   Eisai Co., Ltd.
      2016   Phase 2   NCT02960490   Japan;
      2016   Phase 2   NCT02960438   Japan;
      2014   Phase 1/Phase 2   NCT02196558   Japan;
EC 3.1.3.1   
   Alloksys Life Sciences B.V.
      2011   -   EUCTR2008-007346-63-GB   United Kingdom;
EMEA/H/C/004214   
   Erasmus Medical Center
      2022   Phase 4   EUCTR2021-004131-84-NL   Netherlands;
EMEA/H/C000262   
   University Hospitals Leuven
      2013   -   EUCTR2012-004631-22-BE   Belgium;
ENBREL (Etanercept)   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL   
   AMGEN INC.
      2016   Phase 3   EUCTR2014-004868-38-IT   Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
ENBREL 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
ENBREL 25MG PFS INJ.   
   Daewoong Pharmaceutical Co. LTD.
      2012   Phase 1   NCT01635686   Korea, Republic of;
ENBREL*SC 4FL 25MG+4SIR 1ML   
   WYETH LEDERLE
      2004   -   EUCTR2004-000563-96-IT   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2008   -   EUCTR2007-000896-41-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4FL 50MG+4SIR+4AGHI+   
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2008   -   EUCTR2007-000896-41-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 25MG 0,5ML+8TAM   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-IT   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 50MG 1ML+8TAMP   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-IT   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL®   
   Amgen
      2002   -   NCT00116727   United States;
ENIA11   
   Mycenax Biotech Inc.
      2012   Phase 3   NCT01709760   Taiwan;
EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)   
   Rabin Medical Center
      2011   -   NCT01274910   Israel;
ERB-041   
   WYETH LEDERLE
      2005   -   EUCTR2005-001319-23-IT   Hungary;Italy;Spain;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
      2005   Phase 2   EUCTR2005-001319-23-ES   Hungary;Italy;Spain;
      2005   -   EUCTR2005-001319-23-HU   Hungary;Italy;Spain;
ERMM-1   
   CIS bio international
      2007   Phase 4   EUCTR2006-006380-22-DE   Germany;
ESAOTE MyLab60   
   University Hospital, Rouen
      2011   Phase 4   NCT01765374   France;
ETN   
    Research Center, the University of Tokyo
   22nd Century Medical &
   TAP Corporation
      2009   -   JPRN-UMIN000002687   Japan,Asia(except Japan);
ETN Alone   
   Japan Biological Agent Study Integrated Consortium
      2005   Phase 4   NCT00688103   Japan;
ETN+MTX   
   Japan Biological Agent Study Integrated Consortium
      2005   Phase 4   NCT00688103   Japan;
EU-Humira   
   Fresenius Kabi SwissBioSim GmbH
      2017   Phase 3   NCT03052322   Bulgaria;Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom;
EU-approved RoActemra   
   Fresenius Kabi SwissBioSim GmbH
      2020   Phase 3   NCT04512001   Bulgaria;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
EU/1/99/126/017   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
EU/1/99/126/020   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Ebetrexat   
   Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und Rehabilitation
      2008   -   EUCTR2007-006288-56-AT   Austria;
Edoxaban   
   Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
      2016   -   JPRN-UMIN000026819   Japan;
   Yokohama City University School of Medicine
      2012   -   JPRN-UMIN000018101   Japan;
Efalizumab   
   XOMA (US) LLC
      2002   Phase 2   NCT00034203   United States;
Efexor XL 75 mg (venlafaxine)   
   Newcastle upon Tyne Hospitals NHS Trust
      2005   -   EUCTR2004-002482-20-GB   United Kingdom;
Eldecalcitol   
   Department of Orthopaedic Surgery Shinshu University School of Medicine
      2016   -   JPRN-UMIN000022364   Japan;
Enalapril Maleate   
   University of Guadalajara
      2017   Phase 2   NCT03667131   Mexico;
Enbrel   
   AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
      2018   Phase 3   EUCTR2017-004079-30-IT   Belgium;Italy;Portugal;Spain;
   Amgen
      2000   Phase 4   NCT00132418   United States;
   Amgen Inc.
      2017   Phase 3   EUCTR2014-004868-38-DE   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-PT   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-HU   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-GR   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-FR   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-ES   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-BG   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2015   Phase 3   EUCTR2014-004868-38-CZ   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
   AstraZeneca AB
      2008   Phase 2   EUCTR2007-007539-14-SK   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
      2008   -   EUCTR2007-007539-14-PL   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-MT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-LV   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-HU   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-CZ   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-BG   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-001420-12-CZ   Czech Republic;France;Poland;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-SK   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-FR   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   -   EUCTR2007-001420-12-SE   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-PL   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-BE   Belgium;Czech Republic;France;Poland;Sweden;
   Biogen
      2017   -   NCT03100734   Germany;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   Coherus BioSciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-PL   Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-GB   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Coherus Biosciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-IT   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-HU   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-ES   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-DE   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   DAIICHISANKYO Co.,Ltd.
      2014   Phase 3   JPRN-JapicCTI-142621   -
   Department of Clinical Biochemestry, Aarhus University Hospital
      2015   Phase 4   EUCTR2015-004173-32-DK   Denmark;
   Derby Hospitals NHS Foundation Trust
      2008   Phase 4   EUCTR2006-006562-42-GB   United Kingdom;
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 4   EUCTR2018-003351-37-IT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Eli Lilly and Company
      2020   Phase 3;Phase 4   EUCTR2018-003351-37-FR   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-PL   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-NL   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-LT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-HU   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GR   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GB   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DK   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DE   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-AT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2008   Phase 4   EUCTR2007-000593-24-GB   Sweden;United Kingdom;
   F.Hoffmann-La Roche Ltd
      2008   -   EUCTR2007-000593-24-SE   Sweden;United Kingdom;
   Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
      2019   Phase 4   EUCTR2018-004539-54-DE   Germany;
   Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   Phase 4   EUCTR2018-004558-30-PT   Portugal;Spain;
      2020   Phase 4   EUCTR2018-004558-30-DK   Denmark;Portugal;Spain;
      2019   Phase 4   EUCTR2018-004558-30-ES   Spain;
   Greater Glasgow Health Board
      2006   Phase 4   EUCTR2006-000363-28-GB   United Kingdom;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Joint Research & Development Office (QMUL)
      2018   Phase 3   EUCTR2017-004079-30-PT   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-ES   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-BE   Belgium;Italy;Portugal;Spain;
      2014   Phase 3   EUCTR2014-003529-16-GB   United Kingdom;
   Joint Stock Company Farmak
      2018   Phase 3   NCT04079374   Ukraine;
   Kings College London
      2008   Phase 4   EUCTR2007-005464-26-GB   United Kingdom;
   LG Life Sciences
      2015   Phase 3   NCT02357069   Japan;Korea, Republic of;
   Lilly S.A
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-ES   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
   NHS Greater Glasgow and Clyde
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   National Eye Institute (NEI)
      1999   Phase 2   NCT00001862   United States;
   Pfizer
      2020   -   NCT04428424   Iraq;
      2011   -   NCT01411215   China;
   Pfizer Inc.
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 4   EUCTR2012-003644-71-BE   Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;New Zealand;Poland;Russian Federation;Spain;
      2013   -   EUCTR2012-003644-71-ES   Australia;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 EAst 42nd Street, New York, NY 10017, United States
      2013   -   EUCTR2012-003644-71-NL   Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
      2015   Phase 1   NCT02481180   China;
   Sorrento Therapeutics, Inc.
      2021   Phase 1   NCT04559412   United States;
   University Hospital Birmingham NHS Foundation Trust
      2007   Phase 4   EUCTR2006-006275-21-GB   United Kingdom;
   University Hospitals Birmingham NHS Foundation Trust
      2006   Phase 4   EUCTR2006-001428-38-GB   United Kingdom;
   University Hospitals Leuven
      2013   -   EUCTR2012-004631-22-BE   Belgium;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
   Wyeth Pharmaceuticals France
      2008   Phase 4   EUCTR2007-001625-10-ES   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   Phase 4   EUCTR2007-000896-41-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001625-10-PL   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-DE   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-AT   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-000896-41-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000896-41-NL   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-DE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2008   -   EUCTR2007-000896-41-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2010   -   EUCTR2007-000896-41-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2007-000896-41-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   Phase 4   EUCTR2007-000896-41-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
      2008   -   EUCTR2007-000896-41-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   -   NCT00245934   -
   YL Biologics Ltd
      2016   Phase 3   EUCTR2015-002809-12-BG   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-LV   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-HU   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-ES   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-CZ   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
Enbrel (Etanercept)   
   Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
      -   -   EUCTR2012-001171-37-Outside-EU/EEA   Canada;United States;
      -   -   EUCTR2012-001145-40-Outside-EU/EEA   Canada;United States;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2004   -   NCT00484809   -
Enbrel (etanercept)   
   EMS
      2013   Phase 3   NCT01394913   Brazil;
   Pfizer
      2007   -   NCT00503139   Japan;
   Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
      2009   -   EUCTR2008-005450-20-BE   Belgium;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   NCT01895309   Poland;United Kingdom;
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   -   NCT00503503   -
Enbrel 25 mg powder and solvent for solution for injection   
   Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
      2010   -   EUCTR2007-006657-63-IS   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-SE   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-FI   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-DK   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
   Wyeth Pharmaceuticals France
      2010   Phase 4   EUCTR2007-006657-63-HU   Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 25mg PFS   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50 mg powder and solvent for solution for injection   
   Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
      2010   -   EUCTR2007-006657-63-IS   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-SE   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-FI   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-DK   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
   Wyeth Pharmaceuticals France
      2010   Phase 4   EUCTR2007-006657-63-HU   Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 50 mg solution for injection in pre-filled syringe   
   Hexal AG
      2016   Phase 3   EUCTR2012-002009-23-HU   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2012-002009-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-SK   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-PL   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LV   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-GB   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-ES   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2015   Phase 3   EUCTR2013-004569-16-DE   Bulgaria;Colombia;Croatia;Germany;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;South Africa;
   sanofi-aventis Recherche & Développement
      2013   Phase 3   EUCTR2012-001984-66-NO   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001984-66-GB   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LV   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-IT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-HU   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-GR   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-FI   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-ES   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-DE   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-CZ   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Enbrel 50mg PFS   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50mg pre-filled pen   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Enbrel 50mg pre-filled syringe   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Enbrel Auto Injector   
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2006-006591-37-GR   Austria;Greece;
      2008   -   EUCTR2006-006591-37-AT   Austria;Greece;
      2007   Phase 3   EUCTR2006-005137-38-GB   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-005137-38-FR   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-006591-37-BE   Austria;Belgium;Greece;
      2007   -   EUCTR2006-005137-38-SE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-FI   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-DK   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel Pre-filled syringe   
   Wyeth Pharmaceuticals France
      2007   Phase 3   EUCTR2006-005137-38-FR   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel liquid   
   Amgen
      2005   Phase 3   NCT00249041   Canada;United States;
Enbrel pre-filled pen   
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
Enbrel pre-filled syringe   
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
Enbrel, Benepali, Erelzi   
   Reade
      2019   Phase 4   EUCTR2019-001754-25-NL   Netherlands;
Enbrel®   
   Amgen
      2002   -   NCT00121056   -
      2000   -   NCT00078793   Canada;United States;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-020065-24-NL   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-LV   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-HU   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GR   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-ES   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-AT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-LT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
   ROCHE
      2011   Phase 4   EUCTR2010-020065-24-IT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Czech Republic;Ecuador;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-LT   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Enbrel® 50 mg Solution for Injection in Pre-filled Syringe   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2011-005448-87-HU   Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
      2012   -   EUCTR2011-005448-87-CZ   Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
Engineered humanized monoclonal anti-human CD19 antibody.   
   Xencor Inc.
      2012   Phase 2   EUCTR2012-003057-29-HU   Czech Republic;Hungary;Slovakia;
      2012   -   EUCTR2012-003057-29-SK   Czech Republic;Hungary;Slovakia;
Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml)   
   Xencor Inc.
      2013   -   EUCTR2012-003057-29-CZ   Czech Republic;Hungary;Slovakia;
Enoxaparin   
   Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
      2016   -   JPRN-UMIN000026819   Japan;
Entanercept   
   Peking University First Hospital
      2015   -   NCT02320630   China;
Entecavir   
   Department of general internal medicine, Kyushu-University hospital
      2012   -   JPRN-UMIN000018017   Japan;
   Seoul National University Hospital
      2012   Phase 3   NCT01694264   Korea, Republic of;
   Taipei Veterans General Hospital, Taiwan
      2013   Phase 4   NCT01907230   Taiwan;
Epaxal   
   HY, HUS
      2011   -   EUCTR2009-016055-22-SE   Finland;Sweden;
      2009   -   EUCTR2009-016055-22-FI   Finland;Sweden;
Epinephrine   
   Nekoyama Miyao Hospital
      2017   -   JPRN-UMIN000029759   Japan;
      2017   -   JPRN-UMIN000029003   Japan;
Epoetin alfa   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2004   Phase 2   NCT00236678   -
   Ortho Biotech Products, L.P.
      2005   Phase 2   NCT00123149   -
Erbium citrate   
   CIS bio international
      2007   Phase 4   EUCTR2006-006380-22-DE   Germany;
Ergocalciferol   
   Johns Hopkins University
      2009   -   NCT01426347   United States;
Ergocalciferol 1.25 mg tablet   
   Tanta University
      2019   Phase 4   NCT04472481   Egypt;
Esbriet   
   University Hospitals of Leicester NHS Trust
      2017   Phase 2   EUCTR2017-000149-30-GB   Australia;Canada;United Kingdom;United States;
Esomeprazole   
   AstraZeneca
      2007   Phase 3   NCT00595517   Japan;
      2007   Phase 3   NCT00542789   Japan;
      -   Phase 3   JPRN-JapicCTI-080565   -
      -   Phase 3   JPRN-JapicCTI-080531   -
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
Eszopiclone   
   Sunovion
      2004   Phase 3   NCT00367965   United States;
Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab   
   Reade
      2019   Phase 4   EUCTR2019-001754-25-NL   Netherlands;
Etanercept   
   Amgen
      2013   Phase 4   NCT01927757   Canada;Puerto Rico;United States;
      2011   Phase 4   NCT01313208   Canada;United States;
      2011   Phase 1   NCT01294397   United States;
      2008   Phase 4   NCT00654368   Canada;
      2006   Phase 4   NCT00346294   United States;
      2006   Phase 3   NCT00413452   Canada;United States;
      2006   Phase 1   NCT00361634   United Kingdom;United States;
      2005   Phase 4   NCT00115219   United States;
      2005   Phase 3   NCT00249041   Canada;United States;
      2004   Phase 4   NCT00099554   Canada;United States;
      2004   Phase 4   NCT00094341   United States;
      2001   Phase 3   NCT00078806   Canada;United States;
      2000   Phase 3   NCT03781375   -
      1998   Phase 3   NCT00356590   Canada;United States;
      1997   Phase 3   NCT00357903   Canada;United States;
      1997   Phase 2/Phase 3   NCT03780959   -
   AryoGen Pharmed Co.
      2014   -   NCT04582084   Iran, Islamic Republic of;
   Astellas Pharma Inc
      2014   Phase 3   NCT02308163   Japan;Korea, Republic of;Taiwan;
   AstraZeneca
      2008   Phase 2   NCT00713544   Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
      2007   Phase 2   NCT00520572   Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
   AstraZeneca AB
      2008   Phase 2   EUCTR2007-007539-14-SK   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
      2008   -   EUCTR2007-007539-14-PL   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-MT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-LV   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-HU   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-CZ   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-BG   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-001420-12-CZ   Czech Republic;France;Poland;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-SK   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-FR   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   -   EUCTR2007-001420-12-SE   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-PL   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-BE   Belgium;Czech Republic;France;Poland;Sweden;
   Biogen
      2006   Phase 2   NCT00298272   United States;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   Coherus BioSciences, Inc.
      2015   Phase 3   EUCTR2015-000665-30-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
   Coherus Biosciences, Inc.
      2014   Phase 3   NCT02115750   Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
   DAIICHISANKYO Co.,Ltd.
      2014   Phase 3   JPRN-JapicCTI-142621   -
   Department of Rheumatology and infectious disease, Kitasato university school of medicine
      2012   -   JPRN-UMIN000008572   Japan;
   Department of Rheumatosurgery, Osaka City University Medical School
      2009   Phase 4   JPRN-UMIN000002340   Japan;
   Dept. of orthopedic surgery, Osaka Medical College
      2012   -   JPRN-UMIN000012613   Japan;
   Derby Hospitals NHS Foundation Trust
      2008   Phase 4   EUCTR2006-006562-42-GB   United Kingdom;
   Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
      2011   -   JPRN-UMIN000013750   Japan;
   Dr. Frank Behrens
      2019   Phase 4   NCT04485325   Germany;
   F. Hoffmann-La Roche Ltd
      2008   Phase 4   EUCTR2007-000593-24-GB   Sweden;United Kingdom;
   F.Hoffmann-La Roche Ltd
      2008   -   EUCTR2007-000593-24-SE   Sweden;United Kingdom;
   Faiq Gorial
      2017   Phase 1/Phase 2   NCT03160001   Iraq;
   Fen Li
      2016   Phase 4   NCT02878161   -
   Gema Biotech S.A.
      2016   Phase 3   NCT03403140   Argentina;
      2016   Phase 3   NCT03332719   Argentina;
   Georgetown University
      2013   Phase 4   NCT01793519   United States;
   Greater Glasgow Health Board
      2006   Phase 4   EUCTR2006-000363-28-GB   United Kingdom;
   Hanwha Chemical
      2010   Phase 3   NCT01270997   Korea, Republic of;
   Hoffmann-La Roche
      2011   Phase 4   NCT01331837   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Czechia;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   NCT01592292   Korea, Republic of;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Innovaderm Research Inc.
      2014   Phase 4   NCT02109289   Canada;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Johoku Biological Summit
      2006   Phase 4   JPRN-C000000452   Japan;
   Joint Stock Company Farmak
      2018   Phase 3   NCT04079374   Ukraine;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Kawakami Atsushi
      2020   Phase 4   JPRN-jRCTs071200054   Japan;
      2020   Phase 4   JPRN-jRCTs071190046   Japan;
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
   Lawson Health Research Institute
      2020   Phase 4   NCT03976245   Canada;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   Merck Sharp & Dohme Corp.
      2008   -   NCT00724672   -
   NHS Greater Glasgow and Clyde
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2009   Phase 4   NCT00837434   United States;
      2008   Phase 4   NCT00796705   United States;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 2   NCT00034060   United States;
   Osaka City University Medical School
      2011   Phase 4   JPRN-UMIN000008164   Japan;
   Pfizer
      2018   -   NCT04267614   Iraq;
      2015   Phase 3   NCT02378506   Bulgaria;Croatia;Germany;Greece;Hungary;Poland;Russian Federation;Serbia;Slovakia;South Africa;
      2015   -   NCT02486302   Germany;
      2014   Phase 4   NCT02092467   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   -   NCT02202837   Belgium;
      2013   Phase 4   NCT01783015   Australia;Belgium;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
      2013   -   NCT01558089   Greece;
      2012   Phase 4   NCT01578850   Brazil;China;Colombia;Czech Republic;Egypt;Hungary;Jordan;Lebanon;Malaysia;Mexico;Philippines;Qatar;Romania;Russian Federation;Saudi Arabia;South Africa;Taiwan;Thailand;Ukraine;United Arab Emirates;
      2012   -   NCT01646385   -
      2012   -   NCT01623752   -
      2011   -   NCT01557322   -
      2009   Phase 4   NCT00913458   France;Germany;Ireland;Italy;Monaco;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Switzerland;United Kingdom;
      2009   Phase 4   NCT00858780   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2008   Phase 4   NCT00565409   Australia;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;Former Serbia and Montenegro;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;
      2006   Phase 3   NCT00445770   Japan;
      2006   -   NCT00488475   Germany;
      2004   -   NCT00195403   Korea, Republic of;
      2004   -   NCT00195338   Luxembourg;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Samsung Bioepis Co., Ltd.
      2017   Phase 2   NCT03193957   Poland;
   Sanofi
      2013   Phase 3   NCT01764997   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Takarazuka city hospital
      2014   -   JPRN-UMIN000013362   Japan;
   Team RA, Rheumatosurgery, Osaka City University Medical School
      2008   -   JPRN-UMIN000001798   Japan;
   University of Alabama at Birmingham
      2004   Phase 4   NCT00259610   United States;
   University of California, Davis
      2017   -   NCT03178955   United States;
   University of Leeds
      2011   Phase 4   NCT02433184   United Kingdom;
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Pittsburgh
      2009   Phase 4   NCT01009879   United States;
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
   VA Office of Research and Development
      2007   -   NCT00405275   Canada;United States;
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2007-000896-41-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2010   Phase 4   EUCTR2008-002623-85-SE   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   Phase 4   EUCTR2008-002623-85-FR   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2008-002623-85-ES   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002623-85-IT   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00768053   France;Monaco;
      2007   Phase 3   NCT00484237   Japan;
      2007   Phase 3   NCT00418717   Japan;
      2006   Phase 3   NCT00443950   China;
      2004   Phase 4   NCT00252668   -
      2004   Phase 4   NCT00195494   United States;
      2003   Phase 4   NCT00546533   -
      2003   -   NCT00195377   Spain;
      2003   -   NCT00195364   Spain;
      2000   Phase 3   NCT00393471   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Portugal;Romania;Spain;Sweden;United Kingdom;
Etanercept (ETN)   
   University of Leeds
      2006   Phase 4   NCT01303874   United Kingdom;
Etanercept (Enbrel)   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Etanercept (EnbrelTM)   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00706797   Austria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;United States;
Etanercept + Methotrexate   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00783536   Mexico;
Etanercept , Methotrexate   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 4   NCT00422227   Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;
Etanercept / Autoinjector A   
   Amgen
      2013   Phase 3   NCT01901185   United States;
Etanercept 50 MG/ML   
   P. Verschueren
      2018   Phase 4   NCT03649061   Belgium;
Etanercept Auto-Injector   
   Wyeth Pharmaceuticals France
      2007   -   EUCTR2006-005137-38-DE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Liquid   
   Amgen
      2004   Phase 3   NCT00110903   -
Etanercept Optimal dosing   
   Duke University
      2023   Phase 1   NCT04585711   United States;
Etanercept Pre-filled syringe   
   Wyeth Pharmaceuticals France
      2007   -   EUCTR2006-005137-38-DE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Treatment   
   Assistance Publique Hopitaux De Marseille
      2011   Phase 3   NCT02164214   France;
Etanercept biosimilar   
   TcLand Expression S.A.
      2016   -   NCT03016260   Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
Etanercept or adalimumab   
   University of Glasgow
      2010   Phase 4   NCT01021735   United Kingdom;
Etanercept pre-filled syringe sq injection   
   Amgen
      2015   Phase 3   NCT02373813   Argentina;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
Etanercept via Autoinjector A   
   Amgen
      2013   Phase 4   NCT01875991   Canada;United States;
Etanercept via Autoinjector B   
   Amgen
      2013   Phase 4   NCT01875991   Canada;United States;
Etanercept, methotrexate and depomedrone   
   University Hospital Birmingham
      2007   Phase 4   NCT00523692   United Kingdom;
Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc   
   Pfizer
      2013   -   NCT01932372   Japan;
Etoricoxib   
   Chung Shan Medical University
      2007   Phase 4   NCT04144101   -
   Northumbria Healthcare NHS Foundation Trust
      2010   Phase 4   NCT01067430   United Kingdom;
   Organon and Co
      2010   Phase 3   NCT01208181   Argentina;Austria;Canada;Colombia;Czech Republic;Finland;Germany;Guatemala;India;Lithuania;Mexico;Panama;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2006   Phase 2   NCT00264147   Canada;Colombia;Puerto Rico;Switzerland;United States;
      2006   -   NCT01685424   United States;
Eupatilin   
   Seoul National University Boramae Hospital
      2021   Phase 4   NCT04885751   -
Evobrutinib   
   Merck KGaA
      2017   Phase 2   EUCTR2017-000384-32-CZ   Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2017   Phase 2   EUCTR2017-000384-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
Exhaled nitric oxide assessment   
   GlaxoSmithKline
      2004   -   NCT00242853   United Kingdom;
Experimental: Arm A: DRL_RI   
   Dr. Reddy's Laboratories Limited
      2020   Phase 3   NCT04268771   United States;
Extracorporeal Photopheresis   
   Mallinckrodt
      2003   Phase 2   NCT00221000   Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa;United States;
F8IL10   
   Philogen S.p.A.
      2015   Phase 2   EUCTR2013-005418-37-DE   Germany;Italy;Switzerland;
      2014   Phase 2   NCT02270632   Germany;Italy;Switzerland;
      2014   -   EUCTR2013-005418-37-IT   Germany;Italy;
      2011   Phase 1   NCT02076659   Italy;
FANG(30)   
   Juan C. Bertoglio, MD
      2006   Phase 2   NCT00749645   Chile;
FB704A   
   Fountain Biopharma Inc.
      2019   Phase 1   NCT03890302   United States;
FBL-MTX   
   SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd
      2021   Phase 1   NCT05117593   Portugal;
FKB327   
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   NCT02405780   Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-ES   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000109-11-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000109-11-BG   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   NCT02260791   Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2014-000109-11-ES   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2014-000109-11-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 AI   
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   EUCTR2014-000110-61-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 PFS   
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   EUCTR2014-000110-61-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FMT+MTX   
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03944096   China;
FPA008   
   Five Prime Therapeutics, Inc.
      2013   Phase 1   NCT01962337   Hungary;Netherlands;Poland;
FR104   
   OSE Immunotherapeutics
      2015   Phase 1   NCT02800811   Belgium;
FURESTEM-RA Inj   
   Kang Stem Biotech Co., Ltd.
      2018   Phase 1/Phase 2   NCT03618784   Korea, Republic of;
FURESTEM-RA Inj.   
   Kang Stem Biotech Co., Ltd.
      2016   -   NCT03106259   Korea, Republic of;
      2014   Phase 1   NCT02221258   Korea, Republic of;
FX125L   
   Funxional Therapeutics Ltd
      2011   -   EUCTR2011-005036-26-GB   United Kingdom;
Faecal microbiota transplantation   
   Torkell Ellingsen
      2022   Phase 2   NCT04924270   -
Faecal sampling   
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04292067   France;
Famotidine   
   Hoshigaoka Koseinenkin Hospital
      2009   -   JPRN-UMIN000004271   Japan;
Fang yi qing feng shi granule   
   Maoxiang Group Jilin Pharmaceutical Co., Ltd.
      2014   Phase 2   NCT02029599   China;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
Fentanyl   
   Yamaguchi University
      2018   -   JPRN-UMIN000031692   Japan;
Fentanyl transdermal patch   
   Janssen Pharmaceutica N.V., Belgium
      2001   Phase 4   NCT00524160   -
Ferrograd Folic Tablets   
   University of Leeds
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
Fexofenadine   
   October 6 University
      2022   Phase 1/Phase 2   NCT05264025   -
Filgotinib   
   DeparShinshu University School of Medicine
      2021   -   JPRN-UMIN000043547   Japan;
   GILEAD SCIENCES INCORPORATED
      2017   Phase 3   EUCTR2016-000568-41-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Galapagos NV
      2021   -   NCT04871919   Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
      2019   Phase 2   NCT03926195   Belgium;Bosnia and Herzegovina;Bulgaria;Czechia;Estonia;Georgia;Latvia;Poland;Spain;Ukraine;
      2017   Phase 3   NCT03025308   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   NCT02065700   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
   Gilead Sciences
      2020   Phase 1   NCT04608344   United States;
      2018   Phase 1   NCT03417778   Germany;New Zealand;United States;
      2016   Phase 3   NCT02889796   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02886728   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02873936   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 2   NCT02885181   Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
   Kawakami Atsushi
      2021   -   JPRN-jRCTs071200107   Japan;
   R.Bos
      2021   Phase 4   NCT04985435   Netherlands;
Filgotinib 200mg/day   
   Atsushi Kawakami
      2021   Phase 3   NCT05090410   Japan;
Filgrastim   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Fish oil supplement   
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2004   Phase 2   NCT00094562   United States;
Fish oil, gamma-linolenic acid   
   Charite University, Berlin, Germany
      2008   Phase 2   NCT01179971   -
Fludarabine   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1998   Phase 2   NCT00001677   United States;
Fluorescence Imaging   
   University Medical Center Groningen
      2022   Phase 1   NCT03938701   Netherlands;
Flurbiprofen   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
Focetria   
   Div KIR AMC
      2010   -   EUCTR2009-016789-10-NL   Netherlands;
Focetria (Monovalent MF59-Adjuvanted vaccine)   
   Tel-Aviv Sourasky Medical Center
      2009   Phase 2   NCT01006681   -
Folate   
   Biogen
      2006   Phase 2   NCT00298272   United States;
   Genentech, Inc.
      2006   Phase 3   NCT00299104   United States;
      2006   Phase 3   NCT00266227   United States;
      2005   Phase 3   NCT00299130   United States;
      2005   Phase 2   NCT00243412   United States;
   Hoffmann-La Roche
      2011   Phase 4   NCT01283971   Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2007   Phase 4   NCT00462345   Korea, Republic of;
FolateScan (Technetium Tc 99mEC20)   
   Mayo Clinic
      2006   Phase 2   NCT00588393   United States;
Folic (or folinic) acid   
   GlaxoSmithKline
      2019   Phase 3   NCT03980483   Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 2   NCT02799472   Germany;Poland;United States;
Folic acid   
   Biocad
      2016   Phase 3   NCT02762838   Belarus;India;Russian Federation;
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
      2015   Phase 2   NCT02504671   Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
   Hoffmann-La Roche
      2009   Phase 1   NCT00965653   Canada;New Zealand;Spain;United Kingdom;
   Kaneko Yuko
      2018   Phase 4   JPRN-jRCT1031180088   Japan;South Korea;Taiwan;
   Kojima Toshihisa
      2020   -   JPRN-jRCTs041200048   Japan;
   Sanofi
      2014   Phase 3   NCT02293902   Japan;
      2013   Phase 1   NCT01850680   Japan;
   Takahashi Nobunori
      2020   -   JPRN-jRCT1041190125   Japan;
   The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042659   China;
      2021   Phase 0   ChiCTR2100042329   China;
   The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041819   China;
   University of Alabama at Birmingham
      1996   Phase 2   NCT00000395   United States;
   University of Dundee
      2005   Phase 4   EUCTR2005-000551-15-GB   United Kingdom;
   University of Leeds
      2006   Phase 4   NCT01308255   United Kingdom;
   Yunnan Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041894   China;
   Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine)
      2021   Phase 0   ChiCTR2100042328   China;
   Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042440   China;
   Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041821   China;
Folic acid or folate   
   Hoffmann-La Roche
      2007   Phase 3   NCT00578305   Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;United Kingdom;
Folic/folinic acid   
   Sanofi
      2010   Phase 2   NCT01217814   Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
   Takeda
      2014   Phase 2   NCT02379091   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Germany;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;
Folimet   
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Folinic acid   
   University of Alabama at Birmingham
      1996   Phase 2   NCT00000395   United States;
Fontolizumab   
   PDL BioPharma, Inc.
      2005   Phase 2   NCT00281294   United States;
FosD   
   ASTRAZENECA
      2011   -   EUCTR2010-020892-22-IT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020745-27-IT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020744-35-IT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   Astra Zeneca AB
      2010   -   EUCTR2010-020743-12-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2013   -   EUCTR2010-020892-22-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020744-35-DE   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-020745-27-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-GB   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-FR   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-BE   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   -   EUCTR2010-020892-22-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-PT   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-ES   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020745-27-PT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-PT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-LV   Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-LT   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-GB   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-ES   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-CZ   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020743-12-HU   Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
Fosfamatinib Disodium   
   RIGEL PHARMACEUTICALS INC
      2009   -   EUCTR2008-000744-13-IT   Bulgaria;France;Germany;Italy;
Fostamatinib   
   AstraZeneca
      2012   Phase 2   NCT01640054   Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
      2012   Phase 2   NCT01569074   Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
      2012   Phase 2   NCT01563978   Argentina;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   Phase 1   NCT01725230   United States;
      2011   Phase 3   NCT01242514   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 2   NCT02092961   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
      2011   Phase 2   NCT01264770   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   Phase 1   NCT01355354   United Kingdom;
      2011   Phase 1   NCT01336218   United States;
      2011   Phase 1   NCT01311622   United Kingdom;
      2011   Phase 1   NCT01309854   United States;
      2011   Phase 1   NCT01276262   United Kingdom;
      2010   Phase 3   NCT01197755   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   NCT01197534   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   NCT01197521   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 1   NCT01245790   United States;
      -   Phase 2   JPRN-JapicCTI-121990   -
      -   Phase 2   JPRN-JapicCTI-121843   -
Fostamatinib 50 mg blue film-coated tablet   
   AstraZeneca AB
      2012   -   EUCTR2011-006070-73-DE   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-CZ   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-BG   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
Fostamatinib Disodium   
   AstraZeneca AB
      2009   -   EUCTR2008-000744-13-BG   Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
      2008   Phase 2   EUCTR2008-000744-13-BE   Belgium;Bulgaria;France;Germany;Italy;
      -   -   EUCTR2008-000744-13-DE   Belgium;Bulgaria;France;Germany;Italy;
   Rigel Pharmaceuticals, Inc
      2009   -   EUCTR2008-000744-13-FR   Bulgaria;France;Germany;Italy;
   Rigel Pharmaceuticals, Inc.
      2008   -   EUCTR2008-000743-34-FR   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-DE   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-BE   Belgium;France;Germany;Italy;
      2008   -   EUCTR2008-000742-30-PL   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-HU   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-BG   Bulgaria;Hungary;Poland;
Fostamatinib Disodium (R935788)   
   AstraZeneca
      2008   Phase 2   NCT00805467   Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
Fostamatinib disodium   
   ASTRAZENECA
      2011   -   EUCTR2010-020892-22-IT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020745-27-IT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020744-35-IT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   Astra Zeneca AB
      2010   -   EUCTR2010-020743-12-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2013   -   EUCTR2010-020892-22-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-006070-73-DE   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-CZ   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-BG   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2011   Phase 2   EUCTR2010-023692-26-SK   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023692-26-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020744-35-DE   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-020745-27-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-GB   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-FR   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-BE   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   -   EUCTR2010-020892-22-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-PT   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-ES   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020745-27-PT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-PT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-LV   Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-LT   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-GB   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-ES   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-CZ   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020743-12-HU   Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
      -   -   EUCTR2010-023692-26-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
Fostamatinib disodium (R935788)   
   Rigel Pharmaceuticals
      2008   Phase 2   NCT00665925   Bulgaria;Colombia;Israel;Mexico;Poland;Romania;United States;
      2008   Phase 2   NCT00665626   Belgium;Brazil;Colombia;France;Germany;Italy;Peru;United States;
Fresenius-Kabi)   
   Humanis Klinikum Niederosterreich
      2004   Phase 3   NCT00412256   Austria;
G1567970   
   Galapagos NV
      2020   Phase 2   EUCTR2020-000658-83-BG   Bulgaria;Georgia;Poland;Ukraine;
GB224   
   Genor Biopharma Co., Ltd.
      2019   Phase 1   NCT04179513   China;
      2017   Phase 1   NCT04178070   China;
GB242   
   Genor Biopharma Co., Ltd.
      2017   Phase 3   NCT04178850   China;
GCK   
   Zhejiang Hisun Pharmaceutical Co. Ltd.
      2017   Phase 1   NCT03755258   China;
GDC-0853   
   Genentech, Inc.
      2016   Phase 2   NCT02983227   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
      2016   Phase 2   NCT02833350   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
      2016   Phase 2   EUCTR2016-000335-40-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GDC-0853 RO7010939   
   Genentech, Inc.
      2016   Phase 2   EUCTR2016-000498-19-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GFI 38518168-AEK-B-007   
   Janssen-Cilag International NV
      2009   -   EUCTR2009-012118-27-NL   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-GB   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-ES   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-CZ   Czech Republic;Netherlands;Spain;United Kingdom;
GLPG0259   
   Galápagos NV
      2010   -   EUCTR2009-015898-12-NL   Belgium;Netherlands;
      2010   -   EUCTR2009-015898-12-BE   Belgium;Netherlands;
GLPG0259 (Part B)   
   Galapagos NV
      2010   Phase 2   NCT01211249   Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0259 oral capsule   
   Galapagos NV
      2010   Phase 2   NCT01211249   Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0634   
   Galapagos NV
      2019   Phase 2   EUCTR2018-003933-14-LV   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-EE   Bulgaria;Czech Republic;Estonia;Latvia;Poland;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-CZ   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-BE   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2017   Phase 2   EUCTR2012-003655-11-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003635-31-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   Phase 2   NCT01894516   Argentina;Australia;Austria;Bulgaria;Chile;Colombia;Germany;Guatemala;Hungary;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2013   Phase 2   NCT01888874   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2012   Phase 2   NCT01668641   Hungary;Moldova, Republic of;Russian Federation;Ukraine;
      2011   Phase 2   NCT01384422   Moldova, Republic of;
   Galapagos SASU
      2012   -   EUCTR2011-005008-14-HU   European Union;Hungary;Moldova, Republic of;Russian Federation;Ukraine;
   Gilead Sciences Inc.
      2014   Phase 2   EUCTR2012-003655-11-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
GLPG3970   
   Galapagos NV
      2020   Phase 2   NCT04577781   Bulgaria;Georgia;Poland;Ukraine;
      2020   Phase 2   EUCTR2020-000658-83-BG   Bulgaria;Georgia;Poland;Ukraine;
GOL   
   University Medical Center Utrecht (UMCU)
      2016   Phase 4   EUCTR2015-004858-17-NL   Netherlands;
GP2013   
   Hexal AG
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-GB   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-021184-32-EE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2011   Phase 2   EUCTR2010-021184-32-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2011   Phase 2   EUCTR2010-021184-32-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2010   Phase 2   EUCTR2010-021184-32-FR   Austria;Belgium;Bulgaria;Estonia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2010   Phase 2   EUCTR2010-021184-32-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2010   Phase 2   EUCTR2010-021184-32-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
   Hexal AG (a Sandoz company)
      2015   Phase 3   EUCTR2012-003876-38-PL   Germany;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2012-003876-38-HU   Germany;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2012-003876-38-DE   Germany;Hungary;Poland;United States;
   Sandoz
      2011   Phase 1/Phase 2   NCT01274182   Argentina;Austria;Belgium;Brazil;Estonia;France;Germany;Hungary;India;Italy;Romania;Spain;Turkey;United States;
GP2013 - A Proposed biosimilar rituximab   
   Sandoz
      2015   Phase 3   NCT02514772   Germany;Hungary;Poland;United States;
GP2015   
   Hexal AG
      2016   Phase 3   EUCTR2012-002009-23-HU   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2012-002009-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-SK   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-PL   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LV   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-GB   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-ES   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
   Sandoz
      2015   Phase 3   NCT02638259   Bulgaria;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
GP2017   
   HEXAL AG
      2016   Phase 3   EUCTR2015-003433-10-IT   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
   Hexal, AG
      2016   Phase 3   EUCTR2015-003433-10-HU   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-GB   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-ES   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-DE   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-CZ   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
GRC 4039   
   Glenmark Pharmaceuticals SA
      2011   -   EUCTR2011-000107-40-GB   India;Philippines;Poland;Sri Lanka;United Kingdom;
GS-5745   
   Gilead Sciences
      2014   Phase 1   NCT02176876   Czech Republic;Hungary;
   Gilead Sciences, Inc.
      2017   Phase 2   EUCTR2016-000897-39-HU   Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
      2017   Phase 2   EUCTR2016-000897-39-DE   Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
      2017   Phase 2   EUCTR2016-000897-39-BE   Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
GS-6034   
   GILEAD SCIENCES INCORPORATED
      2017   Phase 3   EUCTR2016-000568-41-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Galapagos NV
      2017   Phase 3   EUCTR2016-003630-25-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2012-003655-11-HU   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   Phase 2   EUCTR2012-003655-11-BG   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   Phase 2   EUCTR2012-003655-11-BE   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2013   Phase 2   EUCTR2012-003655-11-LV   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      -   Phase 3   EUCTR2016-003630-25-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      -   Phase 2   EUCTR2012-003655-11-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
   Gilead Sciences Inc.
      2014   Phase 2   EUCTR2012-003655-11-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
   Gilead Sciences, Inc.
      2018   Phase 3   EUCTR2016-003630-25-NL   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-HU   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-GB   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-PL   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-NL   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-FR   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-ES   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-DE   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-BE   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000569-21-HU   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000569-21-GB   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001496-75-PL   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001496-75-CZ   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GS-9876   
   Gilead Sciences
      2016   Phase 2   NCT02885181   Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
   Gilead Sciences, Inc.
      2016   Phase 2   EUCTR2016-001496-75-PL   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001496-75-CZ   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GSK 3196165   
   GlaxoSmithKline Research & Development Limited
      2021   Phase 3   EUCTR2019-000878-30-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-000878-30-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
GSK1827771   
   GlaxoSmithKline
      2007   Phase 1   NCT00539760   United States;
GSK1841157   
   GlaxoSmithKline Research & Development Ltd
      2008   Phase 1;Phase 2   EUCTR2008-002046-27-FR   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-DE   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-BE   Belgium;France;Germany;Spain;
   GlaxoSmithKline S.A.
      2008   -   EUCTR2008-002046-27-ES   Belgium;France;Germany;Spain;
GSK2982772   
   GlaxoSmithKline
      2016   Phase 2   NCT02858492   Germany;Italy;Poland;Russian Federation;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000912-13-PL   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-GB   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-DE   Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK2982772A, where A denotes the free base   
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000912-13-PL   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-GB   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-DE   Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK3117391   
   GlaxoSmithKline
      2016   Phase 2   NCT02965599   Mexico;Poland;Romania;
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2015-005800-27-PL   Poland;Romania;Russian Federation;
GSK3152314A   
   GlaxoSmithKline
      2008   Phase 2   NCT00674635   Australia;Former Serbia and Montenegro;New Zealand;Russian Federation;Serbia;Ukraine;United Kingdom;
GSK315234   
   GlaxoSmithKline Research & Development Ltd
      2008   -   EUCTR2006-000923-32-GB   United Kingdom;
GSK315234 Injection 100mg/mL   
   GlaxoSmithKline Research & Development Limited
      2010   Phase 2   EUCTR2009-012055-19-FR   Belgium;France;Ireland;United Kingdom;
      2010   -   EUCTR2009-012055-19-IE   Belgium;France;Ireland;United Kingdom;
      2010   -   EUCTR2009-012055-19-GB   Belgium;France;Ireland;United Kingdom;
      2010   -   EUCTR2009-012055-19-BE   Belgium;France;Ireland;United Kingdom;
GSK3196165   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000868-18-IT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-IT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003453-34-IT   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
   GlaxoSmithKline
      2016   Phase 2   NCT02799472   Germany;Poland;United States;
      2015   Phase 2   NCT02504671   Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
   GlaxoSmithKline Research & Development Limited
      2020   Phase 3   EUCTR2019-000868-18-DE   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000867-26-DE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-PL   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-LT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-HU   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-GB   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-ES   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-CZ   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-PL   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-HU   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-GB   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-ES   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-EE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-BG   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LV   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-HU   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-GB   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-ES   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-CZ   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2015-004386-91-PL   Germany;Poland;United States;
      2016   Phase 2   EUCTR2015-004386-91-DE   Germany;Poland;United States;
      2015   Phase 2   EUCTR2014-003453-34-PL   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-HU   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-GB   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-EE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-DE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-CZ   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
GSK3196165 (Otilimab)   
   GlaxoSmithKline
      2019   Phase 3   NCT04134728   Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   NCT03980483   Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT03970837   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
GSK3196165 Dose 1   
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
GSK3196165 Dose 2   
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
GSK3196165 Dose 3   
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
GSK706769   
   GlaxoSmithKline
      2010   Phase 2   NCT00979771   Netherlands;
   GlaxoSmithKline Research & Development Limited
      2009   -   EUCTR2009-012204-42-IE   Belgium;Ireland;
      2009   -   EUCTR2009-012204-42-BE   Belgium;Ireland;
GW274150   
   GlaxoSmithKline
      2006   Phase 2   NCT00379990   Serbia;United Kingdom;
      2005   Phase 2   NCT00370435   United Kingdom;
GW274150 Tablets   
   GlaxoSmithKline Research & Development Limited
      2005   Phase 2   EUCTR2005-001977-82-GB   United Kingdom;
GW406381   
   GLAXO SMITHKLINE
      2005   -   EUCTR2005-000158-61-IT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline
      2005   Phase 3   NCT00113308   Argentina;Austria;Belgium;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-LT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-DE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-LV   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-HU   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-DK   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2004   -   EUCTR2004-000106-41-SE   Sweden;
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW406381X   
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-LT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-DE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-LV   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-HU   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-DK   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW856553   
   GlaxoSmithKline
      2007   Phase 1   NCT00517543   United States;
      2006   Phase 2   NCT00393146   Romania;Russian Federation;Spain;
      2005   Phase 2   NCT00256919   Bulgaria;Germany;Spain;Sweden;Ukraine;
   GlaxoSmithKline Research & Development Ltd
      2005   -   EUCTR2005-002969-37-SE   Germany;Spain;Sweden;
      -   -   EUCTR2005-002969-37-DE   Germany;Spain;Sweden;
   GlaxoSmithKline S.A.
      2005   Phase 2   EUCTR2005-002969-37-ES   Germany;Spain;Sweden;
Gadobutrol   
   GlaxoSmithKline
      2015   Phase 1   NCT02350426   United Kingdom;
Gadolinium   
   Tokyo Medical and Dental University
      2013   -   JPRN-UMIN000012399   Japan;
Gamma-Linolenic acid   
   FDA Office of Orphan Products Development
      1994   -   NCT00004420   -
Geleli   
   Peking University People's Hospital
      2022   -   NCT05240859   China;
General anesthesia with tourniquet   
   Riku Antero Palanne
      2016   -   NCT03364088   Finland;
General anesthesia without tourniquet   
   Riku Antero Palanne
      2016   -   NCT03364088   Finland;
Gerilimzumab   
   Bird Rock Bio, Inc.
      2018   Phase 2   NCT02795299   -
Ginger   
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
Ginseng   
   Zhejiang Provincal Hospital of TCM
      2019   Phase 2   ChiCTR1900026257   China;
Ginsenoside   
   Institute of Clinical Pharmacology, Central South University
      2015   Phase 1 study   ChiCTR-IPR-15006107   China;
      2015   Phase 1 study   ChiCTR-IPR-15005787   China;
      2014   Phase 1 study   ChiCTR-TRC-14004824   China;
GlucoCorticoid   
   University Hospital, Toulouse
      2017   Phase 4   NCT02997605   France;
Glucocorticoid Agent   
   Hoffmann-La Roche
      2017   -   NCT03291457   Belgium;
Glucocorticoids (permitted,not necessary)   
   Fen Li
      2016   Phase 4   NCT02878161   -
Glucophage (metformin)   
   Queen Mary University of London
      2010   Phase 2   EUCTR2008-005708-18-GB   United Kingdom;
Gold   
   Affiliated Hospital of North Sichuan Medical College
      2018   -   ChiCTR1800018637   China;
   Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
      2011   -   ChiCTR-DDT-12002268   China;
   Peking University People's Hospital
      2012   -   ChiCTR-DDT-12002658   China;
Golimumab   
   CENTOCOR
      2010   -   EUCTR2009-010582-23-IT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2004-003295-10-IT   Austria;Hungary;Italy;Spain;United Kingdom;
   Centocor B.V.
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
   Centocor BV
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Centocor, Inc.
      2010   Phase 3   NCT01248780   China;
      2009   Phase 3   NCT00973479   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
      2007   Phase 1   NCT01362153   United States;
      2006   Phase 3   NCT00361335   Argentina;Australia;Belgium;Colombia;Germany;Hungary;Latvia;Lithuania;Malaysia;Malta;Mexico;New Zealand;Peru;Poland;Russian Federation;Ukraine;United States;
      2006   Phase 3   NCT00299546   Australia;Austria;Canada;Finland;France;Germany;Netherlands;New Zealand;Spain;Switzerland;United Kingdom;United States;
      2005   Phase 3   NCT00264550   Argentina;Australia;Brazil;Canada;Chile;Germany;Hungary;India;Korea, Republic of;Mexico;New Zealand;Poland;Taiwan;Turkey;United States;
      2003   Phase 2   NCT00207714   -
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States;
   Janssen Inc.
      2019   -   NCT03729349   Canada;
   Janssen-Cilag, S.A.
      2015   -   NCT02414984   Colombia;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   MedImmune LLC
      2013   Phase 2   NCT01715896   Argentina;Colombia;Czech Republic;France;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Serbia;Slovakia;Spain;Turkey;United Kingdom;
   MedImmune Ltd
      2013   -   EUCTR2011-005649-10-PT   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2010   -   EUCTR2009-011137-26-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   Osaka City University Medical School
      2012   Phase 4   JPRN-UMIN000009425   Japan;
   Osaka Medical College
      2015   -   JPRN-UMIN000016950   Japan;
   Peking Union Medical College Hospital
      2019   -   NCT04188249   China;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Rheumatology, Internal MedicineJuntendo University School of Medicine, Juntendo Koshigaya Hospital
      2013   -   JPRN-UMIN000014485   Japan;
   Sanofi
      2010   Phase 2   NCT01217814   Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
   Schering-Plough Research Institute, A Division of Schering Corporation
      2010   Phase 3   EUCTR2009-011137-26-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-PL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-SK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-ES   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-IE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   Shering Plough Research Institute, A division of Schering Plough Corporation
      2010   -   EUCTR2009-011137-26-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   St.Marianna University School of Medicine
      2013   -   JPRN-UMIN000011891   Japan;
   Takarazuka city hospital
      2014   -   JPRN-UMIN000016844   Japan;
   TcLand Expression S.A.
      2016   -   NCT03016260   Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
Golimumab 100 mg injections   
   Centocor, Inc.
      2005   Phase 3   NCT00264537   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab 2 mg/kg IV   
   Janssen Biotech, Inc.
      2013   Phase 3   NCT01962974   Argentina;Brazil;Canada;Colombia;Mexico;United States;
      2009   Phase 3   NCT01004432   Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg SC   
   Janssen Biotech, Inc.
      2009   Phase 3   NCT01004432   Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg injections   
   Centocor, Inc.
      2005   Phase 3   NCT00264537   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab Final Vialed Product (FVP)   
   Centocor B.V.
      2010   -   EUCTR2008-006064-11-HU   Hungary;Lithuania;
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-AT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2008-006064-11-LT   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
Golimumab Intravenous   
   Janssen Inc.
      2015   -   NCT02390700   Canada;
Golimumab Intravenous (IV)   
   Janssen Scientific Affairs, LLC
      2016   -   NCT02728934   United States;
Golimumab Liquid in Vial   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab Liquid in prefilled syringe   
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Golimumab Pre-Filled Syringe   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab liquid in prefilled pen   
   Janssen Biologics B.V.
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or Prefilled Syringe   
   Janssen Biologics B.V.
      2009   -   EUCTR2009-010582-23-AT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or prefilled syringe   
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab pre-filled syringe   
   Centocor B.V.
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
Golimumab prefilled pen   
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab prefilled pen or prefilled syringe   
   Janssen Biologics B.V.
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Grapefruit   
   Department of Rheumatology and Clinical Immunology, Kyoto University Hospital
      2014   -   JPRN-UMIN000013546   Japan;
Green tea group   
   King Saud University
      2015   -   NCT03719469   -
Group 1 or Orencia treated group   
   University of California, Los Angeles
      2012   Phase 4   NCT01717846   United States;
Guna-Anti Interleukin 1   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Antiinterleukin 1 alfa   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Antiinterleukin 1 beta   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Interleukin 10   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Interleukin 4   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
H.P. Acthar Gel   
   Ronald J. Rapoport, MD
      2014   -   NCT02434757   United States;
H.P. Acthar gel   
   Iraj Sabahi Research Inc.
      2017   Phase 4   NCT03082573   United States;
H02AB04   
   Leiden University medical Centre
      2015   Phase 2   EUCTR2014-004472-35-NL   Netherlands;
H02AB07   
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
HA20 (IMMU-106)   
   Nycomed GmbH
      2011   -   EUCTR2010-022378-15-GB   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-CZ   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HA20 (Immu-106)   
   Nycomed GmbH
      2011   -   EUCTR2010-022378-15-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2010-022378-15-ES   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-DE   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HB-adMSCs   
   Hope Biosciences
      2018   Phase 1/Phase 2   NCT03691909   United States;
HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA)   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HBVAXPRO® 40 micrograms   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HCQ   
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   Peking University First Hospital
      2015   -   NCT02320630   China;
   Qilu Hospital of Shandong University
      2017   Phase 4   NCT03855007   China;
HD-TIV   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2016   Phase 4   NCT02936180   Canada;
HE3286   
   Harbor Therapeutics
      2008   Phase 1/Phase 2   NCT00712114   United States;
HEPATITIS B VACCINE (RDNA)   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HEPATITIS B VIRUS SURFACE ANTIGEN RECOMBINANT (S PROTEIN)   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HL237   
   Hanlim Pharm. Co., Ltd.
      2018   Phase 1   NCT03896594   Korea, Republic of;
      2017   Phase 1   NCT03278470   Korea, Republic of;
HL237 tablet   
   Hanlim Pharm. Co., Ltd.
      2020   Phase 2   NCT04638426   Korea, Republic of;
HLX01   
   Shanghai Henlius Biotech
      2018   Phase 3   NCT03522415   China;
      2016   Phase 1/Phase 2   NCT03355872   -
HM71224 Multiple ascending dose   
   Hanmi Pharmaceutical Company Limited
      2013   Phase 1   NCT01765478   Netherlands;
HM71224 food effect   
   Hanmi Pharmaceutical Company Limited
      2013   Phase 1   NCT01765478   Netherlands;
HM71224 single ascending dose   
   Hanmi Pharmaceutical Company Limited
      2013   Phase 1   NCT01765478   Netherlands;
HMPL-523   
   Hutchison Medipharma Limited
      2014   Phase 1   NCT02105129   Australia;
HUC-MSC + DMARDs   
   Shenzhen Hornetcorn Bio-technology Company, LTD
      2016   Phase 1   NCT02643823   China;
HUC-MSC infusion (BC-U001)   
   Beijing Baylx Biotech Co., Ltd.
      2021   Phase 1/Phase 2   NCT04971980   China;
HUC-MSC suspension   
   Baylx Inc.
      2020   Phase 1   NCT03828344   -
HUMIRA   
   CHRU de TOURS
      2010   -   EUCTR2010-021449-28-FR   France;
   FRANCISCO J. BLANCO GARCÍA
      2013   -   EUCTR2012-004482-40-ES   Spain;
   Helsingin reumakeskus
      2010   -   EUCTR2009-017325-19-FI   Finland;
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2007-002536-29-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Pfizer Inc.
      2015   Phase 3   EUCTR2014-000352-29-HR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
HUMIRA (ADALIMUMAB)   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL   
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
HUMIRA 40 mg solución inyectable en jeringa precargada   
   Abbott GmbH & Co. KG
      2011   -   EUCTR2010-019514-24-ES   Austria;Czech Republic;Germany;Spain;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-023587-40-ES   Denmark;Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2010   Phase 4   EUCTR2009-015845-21-ES   Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   GENENTECH, Inc
      2011   -   EUCTR2010-021577-37-ES   Bulgaria;Germany;Hungary;Spain;
   Pfizer, S.A
      2009   Phase 3   EUCTR2008-008338-35-ES   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
HUMIRA*SC 2SIR+F 40MG 0,8ML+2T   
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
HYDROXYCHLOROQUINE SULFATE   
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
HZT-501   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2009   Phase 3   NCT00984815   United States;
      2007   Phase 3   NCT00613106   United States;
Havrix   
   HY, HUS
      2011   -   EUCTR2009-016055-22-SE   Finland;Sweden;
Hematopoietic Stem Cell Transplantation   
   Northwestern University
      2002   Phase 1   NCT00282412   United States;
Hemay007 1200 mg QD group   
   Tianjin Hemay Pharmaceutical Co.,Ltd
      2021   Phase 2   NCT05247216   China;
Hemay007 600 mg QD group   
   Tianjin Hemay Pharmaceutical Co.,Ltd
      2021   Phase 2   NCT05247216   China;
Hemay007 800 mg QD group   
   Tianjin Hemay Pharmaceutical Co.,Ltd
      2021   Phase 2   NCT05247216   China;
Hepatitis A vaccine ( HAVRIX or EPAXAL)   
   Lars Rombo
      2009   Phase 2   NCT01360970   Finland;Sweden;
Hepatitis A vaccine and tetanus vaccine   
   University of Zurich
      2013   -   NCT01947465   Switzerland;
Herpes Zoster Vaccine   
   University of Alabama at Birmingham
      2016   Phase 2   NCT02538341   United States;
      2014   Phase 2   NCT01967316   United States;
      2013   Phase 2   NCT02538757   United States;
High dose ORTD-1   
   Oryn Therapeutics, LLC
      2021   Phase 1   NCT04286789   United States;
High dose of BIIL 284 BS tablets   
   Boehringer Ingelheim
      2000   Phase 1   NCT02247375   -
High dose vehicle control   
   Oryn Therapeutics, LLC
      2021   Phase 1   NCT04286789   United States;
High frequency ultrasonography   
   GlaxoSmithKline
      2004   -   NCT00242853   United Kingdom;
High-resolution peripheral quantitative computed tomography (HR-pQCT)   
   University of California, San Francisco
      2013   -   NCT01773681   United States;
HrIL-2 active   
   Peking University People's Hospital
      2015   Phase 2   NCT02467504   China;
HuMax-CD20   
   GENMAB A/S
      2007   -   EUCTR2007-002945-18-IT   Czech Republic;Italy;
   Genmab A/S
      2008   Phase 3   EUCTR2007-002951-18-FR   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-SE   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-DK   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002950-42-BE   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   Phase 3   EUCTR2007-002951-18-IT   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-002951-18-ES   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-002951-18-NL   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-002950-42-LT   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-HU   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-ES   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002945-18-CZ   Czech Republic;
      2006   -   EUCTR2004-003771-37-HU   Hungary;
   GlaxoSmithKline Research & Development
      2008   Phase 3   EUCTR2007-002951-18-GB   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-DE   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002950-42-GB   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2008   Phase 1;Phase 2   EUCTR2008-002046-27-FR   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-DE   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-BE   Belgium;France;Germany;Spain;
      2007   Phase 2   EUCTR2007-004878-31-GB   Denmark;Hungary;United Kingdom;
      2007   -   EUCTR2007-004878-31-DK   Denmark;Hungary;United Kingdom;
   GlaxoSmithKline Research & Development Ltd.
      2008   -   EUCTR2007-004878-31-HU   Denmark;Hungary;United Kingdom;
   GlaxoSmithKline Research and Development
      2008   -   EUCTR2007-002950-42-PL   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-CZ   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
   GlaxoSmithKline S.A.
      2008   -   EUCTR2008-002046-27-ES   Belgium;France;Germany;Spain;
HuMax-CD4   
   Emergent Product Development Seattle LLC
      2002   Phase 2/Phase 3   NCT00042406   Canada;United States;
Huang qi gui zhi wu wu granule   
   Cui xuejun
      2018   Phase 2/Phase 3   NCT03593837   -
Human Anti-TNF IgG1 Monoclonal Antibody   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Human Anti-TNFalfa   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Human Recombinant IgG1, lambda   
   MorphoSys AG
      2010   -   EUCTR2007-006129-29-PL   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2010   -   EUCTR2007-006129-29-NL   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2010   -   EUCTR2007-006129-29-BG   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2009   -   EUCTR2007-006129-29-DE   Bulgaria;Germany;Netherlands;Poland;Ukraine;
Human anti TNF-alpha monoclonal   
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti TNF-alpha monoclonal antibody   
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti-IL6 monoclonal antibody   
   JANSSEN-CILAG INTERNATIONAL N.V.
      2012   -   EUCTR2010-022243-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2015   Phase 3   EUCTR2012-001176-10-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-022242-24-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2013   -   EUCTR2010-022243-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022243-38-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022242-24-LT   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2012   -   EUCTR2010-022243-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
Human anti-TNF-alpha monoclonal antibody   
   Centocor B.V.
      2010   -   EUCTR2008-006064-11-HU   Hungary;Lithuania;
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2009   -   EUCTR2009-010582-23-AT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2008-006064-11-LT   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Human monoclonal antibody directed against CD20 on B-cells   
   Genmab A/S
      2006   -   EUCTR2004-003771-37-HU   Hungary;
Humanised anti-CD 20 antibody   
   Nycomed GmbH
      2011   -   EUCTR2010-022378-15-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2010-022378-15-GB   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-ES   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-DE   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-CZ   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
Humanised anti-CD4 IgG1 monoclonal   
   Biotest AG
      2012   -   EUCTR2010-018485-24-LV   Czech Republic;Germany;Hungary;Latvia;Spain;
      2012   -   EUCTR2010-018485-24-HU   Czech Republic;Germany;Hungary;Latvia;Spain;
      2011   -   EUCTR2010-018485-24-ES   Czech Republic;Germany;Hungary;Latvia;Spain;
      2011   -   EUCTR2010-018485-24-DE   Czech Republic;Germany;Hungary;Latvia;Spain;
      2010   -   EUCTR2010-018485-24-CZ   Czech Republic;Germany;Hungary;Latvia;Spain;
Humanized TNFa monoclonal antibody   
   Shenyang Sunshine Pharmaceutical Co., LTD.
      2015   Phase 1   NCT02460393   China;
Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody   
   NovImmune S.A.
      2017   Phase 2   EUCTR2016-005017-45-PL   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
      2017   Phase 2   EUCTR2016-005017-45-HU   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
      2017   Phase 2   EUCTR2016-005017-45-GB   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
      2017   Phase 2   EUCTR2016-005017-45-BG   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
Humira   
   AbbVie Deutschland GmbH & Co. KG
      2011   -   EUCTR2010-019514-24-CZ   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
   Abbott GmbH & Co. KG
      2011   Phase 3   EUCTR2010-019514-24-BE   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
      2011   -   EUCTR2010-019514-24-DE   Argentina;Austria;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
      2011   -   EUCTR2010-019514-24-AT   Argentina;Austria;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
      2008   -   EUCTR2006-004139-31-NO   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-004139-31-GR   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-SK   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-HU   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-FR   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-SE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-NL   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-GB   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-ES   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-DE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-CZ   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-BE   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-AT   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
   Abbott Scandinavia AB
      2008   -   EUCTR2008-004398-16-SE   Sweden;
   Amgen Inc
      2014   Phase 3   EUCTR2013-000525-31-DE   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-000525-31-RO   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-PL   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-HU   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-GB   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-ES   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-CZ   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-BG   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
   AstraZeneca AB
      2011   Phase 2   EUCTR2010-023692-26-SK   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023692-26-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      -   -   EUCTR2010-023692-26-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
   BRISTOL-M.SQUIBB
      2011   -   EUCTR2010-023956-99-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2021   Phase 3   EUCTR2020-000350-96-IT   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Boehringer Ingelheim International GmbH
      2014   Phase 3   EUCTR2012-002945-40-HU   Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-ES   Argentina;Belgium;Bulgaria;Chile;Colombia;Estonia;France;Germany;Hungary;Indonesia;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-EE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-DE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-BG   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
   Bristol-Myers Squibb International Corporation
      2022   Phase 3   EUCTR2020-000350-96-DE   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-PL   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-FR   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-ES   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-CZ   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2011   -   EUCTR2010-023956-99-NL   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   Celltrion, Inc
      2019   Phase 3   EUCTR2018-001690-25-LT   Bulgaria;Hungary;Lithuania;Peru;Poland;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-PL   Bosnia and Herzegovina;Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Russian Federation;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-HU   Bosnia and Herzegovina;Bulgaria;Hungary;Lithuania;Peru;Poland;Russian Federation;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-BG   Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Ukraine;
   Department of Clinical Biochemestry, Aarhus University Hospital
      2015   Phase 4   EUCTR2015-004173-32-DK   Denmark;
   Dept. of Rhematology UMAS
      2005   -   EUCTR2005-000129-47-SE   Sweden;
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 4   EUCTR2018-003351-37-IT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Eli Lilly and Company
      2020   Phase 3;Phase 4   EUCTR2018-003351-37-FR   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-PL   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-NL   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-LT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-HU   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GR   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GB   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DK   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DE   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-AT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-SI   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-GB   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-DE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-SK   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-PT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-NL   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LV   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-HU   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-GR   Argentina;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-CZ   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-BE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2008   Phase 4   EUCTR2007-000593-24-GB   Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2010-023587-40-IT   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
   F.Hoffmann-La Roche Ltd
      2008   -   EUCTR2007-000593-24-SE   Sweden;United Kingdom;
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   EUCTR2014-000110-61-ES   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000109-11-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000109-11-BG   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2014-000109-11-ES   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2014-000109-11-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
   GENENTECH, Inc
      2011   -   EUCTR2010-021577-37-DE   Bulgaria;Germany;Hungary;Spain;
      2011   -   EUCTR2010-021577-37-BG   Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Spain;United States;
      2010   -   EUCTR2010-021577-37-HU   Bulgaria;Germany;Hungary;Spain;
   GILEAD SCIENCES INCORPORATED
      2017   Phase 3   EUCTR2016-000568-41-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Genentech, Inc.
      2016   Phase 2   EUCTR2016-000335-40-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
   HEXAL AG
      2016   Phase 3   EUCTR2015-003433-10-IT   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
   Hexal, AG
      2016   Phase 3   EUCTR2015-003433-10-HU   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-GB   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-ES   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-DE   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-CZ   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
   Hvidovre Hospital
      2009   Phase 4   EUCTR2009-014394-41-DK   Denmark;
   Hvidovre Hospital, Dept. Rheumatology
      2006   -   EUCTR2005-001633-14-SE   Denmark;Sweden;
      2005   -   EUCTR2005-001633-14-DK   Denmark;Sweden;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Janssen-Cilag International N.V.
      2014   Phase 3   EUCTR2013-001417-32-LT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-HU   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-ES   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-DE   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
   Karolinska Institute
      2010   Phase 4   EUCTR2009-017163-42-SE   Sweden;
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
   Kings College London
      2008   Phase 4   EUCTR2007-005464-26-GB   United Kingdom;
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   Lilly S.A
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-ES   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Lilly S.A.
      2013   -   EUCTR2012-002322-73-ES   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
   Merck KGaA
      2017   Phase 3   EUCTR2016-002852-26-GB   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002852-26-DE   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;
      2017   Phase 3   EUCTR2016-002852-26-BG   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;
      2016   Phase 3   EUCTR2016-002852-26-LT   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002852-26-HU   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002852-26-CZ   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;
   Merck Serono International
      2008   Phase 2   EUCTR2007-002536-29-FR   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   Phase 2   EUCTR2007-002536-29-ES   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-PT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-GR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-DE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-CZ   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BG   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BE   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   Phase 2   EUCTR2007-002536-29-FI   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-SE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-AT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      -   -   EUCTR2007-002536-29-PL   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   NHS Greater Glasgow and Clyde
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   Novo Nordisk A/S
      2014   Phase 2   EUCTR2013-001492-20-PT   Ireland;Portugal;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-001492-20-ES   Ireland;Portugal;Spain;United Kingdom;
      2013   Phase 2   EUCTR2013-001492-20-GB   Belgium;Czech Republic;Germany;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   PFIZER
      2008   -   EUCTR2007-002066-35-IT   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
   Pfizer Inc.
      2009   -   EUCTR2008-008338-35-CZ   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2009   Phase 3   EUCTR2008-008338-35-SK   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-008338-35-DK   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-GB   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-FI   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-DE   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-BG   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   St George's, University of London
      2020   Phase 4   EUCTR2019-004468-23-GB   United Kingdom;
   The Karolinska Institute, ClinTRID
      2012   Phase 4   EUCTR2012-002573-62-SE   Sweden;
   UCB PHARMA SA/NV.
      2012   -   EUCTR2011-002067-20-IT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
   UCB Pharma SA
      2015   -   EUCTR2011-002067-20-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-002067-20-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-PT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-IE   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
   University Hospital Birmingham NHS Foundation Trust
      2007   Phase 4   EUCTR2006-006275-21-GB   United Kingdom;
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
   University of Leeds, Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine
      2015   Phase 4   EUCTR2013-002777-22-IT   Denmark;France;Germany;Hungary;Italy;Japan;Spain;United Kingdom;
      2014   Phase 4   EUCTR2013-002777-22-HU   Denmark;France;Germany;Hungary;Italy;Japan;Spain;United Kingdom;
      2014   Phase 4   EUCTR2013-002777-22-ES   Denmark;France;Germany;Hungary;Italy;Japan;Spain;United Kingdom;
      2014   Phase 4   EUCTR2013-002777-22-DK   Denmark;France;Germany;Hungary;Italy;Japan;Spain;United Kingdom;
      2013   Phase 4   EUCTR2013-002777-22-GB   Denmark;France;Germany;Hungary;Italy;Japan;Spain;United Kingdom;
      2013   Phase 4   EUCTR2013-002777-22-DE   Denmark;France;Germany;Hungary;Italy;Japan;Spain;United Kingdom;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Humira (adalimumab)   
   Aarhus University Hospital, Denmark
      2007   Phase 4   EUCTR2007-000082-38-DK   Denmark;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-003053-21-PL   Israel;Poland;Puerto Rico;United States;
   Abbott
      2006   Phase 4   NCT00761514   Puerto Rico;
   Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
      2009   -   EUCTR2008-005450-20-BE   Belgium;
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   NCT02167139   Lithuania;Poland;
Humira (adalimumab) 40 mg in 0.4 ml s.c. injection   
   Gilead Sciences, Inc.
      2017   Phase 3   EUCTR2016-000568-41-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Humira (adalimumab) 40 mg s.c. injection   
   Gilead Sciences, Inc.
      2017   Phase 3   EUCTR2016-000568-41-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Humira (adalimumab) 40mg in 0.4 ml s.c. injection   
   Gilead Sciences, Inc.
      2017   Phase 3   EUCTR2016-000568-41-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Humira (adalimumab) 40mg in 0.4ml s.c.injection   
   Gilead Sciences, Inc.
      2017   Phase 3   EUCTR2016-000568-41-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Humira 40 mg solution for injection in pre-filled syringe   
   AbbVie Deutschland GmbH & Co. KG
      2012   -   EUCTR2012-000535-36-DE   Belgium;Czech Republic;Germany;Poland;Puerto Rico;Romania;Slovakia;United States;
   Abbott GmbH & Co. KG
      2012   Phase 2   EUCTR2012-000535-36-BE   Belgium;Czech Republic;Germany;Poland;Puerto Rico;Romania;Slovakia;United States;
      2012   -   EUCTR2012-000535-36-SK   Belgium;Czech Republic;Germany;Poland;Puerto Rico;Romania;Slovakia;United States;
      2012   -   EUCTR2012-000535-36-PL   Belgium;Czech Republic;Germany;Poland;Puerto Rico;Romania;Slovakia;United States;
      2012   -   EUCTR2012-000535-36-CZ   Belgium;Czech Republic;Germany;Poland;Puerto Rico;Romania;Slovakia;United States;
      2012   -   EUCTR2011-003953-25-DE   Australia;Canada;Germany;
      2012   -   EUCTR2011-002275-41-CZ   Belgium;Czech Republic;
      2012   -   EUCTR2011-002275-41-BE   Belgium;Czech Republic;
      2008   -   EUCTR2007-005905-23-GB   Germany;United Kingdom;
      2008   -   EUCTR2007-005905-23-DE   Germany;United Kingdom;
   R-Pharm
      2017   Phase 3   EUCTR2015-005307-83-LV   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-LT   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-HU   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International LLC
      2016   Phase 3   EUCTR2015-005307-83-CZ   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-BG   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   Takeda Development Centre Europe Ltd.
      2015   Phase 2   EUCTR2014-002945-23-GB   Czech Republic;Estonia;Russian Federation;Spain;United Kingdom;
      2015   Phase 2   EUCTR2014-002945-23-ES   Czech Republic;Estonia;Latvia;Russian Federation;Spain;United Kingdom;
      2015   Phase 2   EUCTR2014-002945-23-CZ   Czech Republic;Estonia;Russian Federation;Spain;United Kingdom;
      2014   Phase 2   EUCTR2014-002945-23-EE   Czech Republic;Estonia;Russian Federation;Spain;United Kingdom;
   sanofi-aventis Recherche & Développement
      2013   Phase 3   EUCTR2012-001984-66-NO   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001984-66-GB   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LV   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-IT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-HU   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-GR   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-FI   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-ES   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-DE   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-CZ   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Humira 40 mg/0.8 ml solution for injection   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 4   EUCTR2014-001114-26-SE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-001114-26-NL   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-IT   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-IE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-HU   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-GR   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-GB   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-FR   Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-ES   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-DE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-AT   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Abbott Japan Co., Ltd.
      -   -   EUCTR2014-004558-33-Outside-EU/EEA   Japan;
Humira 40mg Injektionslösung   
   Heinrich-Heine-Universität Düsseldorf
      2014   Phase 3   EUCTR2013-004604-19-DE   Germany;
Humira 40mg solution for injection in pre-filled syringe   
   R-Pharm
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Humira 40mg solution for injection in pre-filled syringe (adalimumab)   
   Newcastle-upon-Tyne Hospitals NHS Foundation Trust
      2007   Phase 4   EUCTR2006-006127-40-GB   United Kingdom;
Humira 40mg/0.8 ml solution for injection for paediatric use   
   Abbott Laboratories
      -   -   EUCTR2011-001661-40-Outside-EU/EEA   United States;
Humira 40mg/0.8ml solution for injection in pre-filled syringe   
   AbbVie Deutschland GmbH & Co. KG
      2016   Phase 3   EUCTR2015-003333-95-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003333-95-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-ES   Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003333-95-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-003333-95-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Humira SC   
   Celltrion
      2018   Phase 3   NCT03789292   Bulgaria;
Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2016   Phase 3;Phase 4   EUCTR2014-000358-13-DE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-HR   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-ES   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-RO   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LV   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LT   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-GB   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-EE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-CZ   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-BG   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-PL   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Humira, 40 mg solution for injection in pre-filled syringe   
   sanofi-aventis recherche & développement
      2015   Phase 3   EUCTR2014-002541-22-HU   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-ES   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-DE   Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-CZ   Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2014-002541-22-GB   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi   
   Reade
      2019   Phase 4   EUCTR2019-001793-28-NL   Netherlands;
      2019   Phase 1;Phase 4   EUCTR2019-001554-25-NL   Netherlands;
Humira®   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-023587-40-DK   Denmark;European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-SE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-NL   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-GR   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-FI   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-DE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2010   Phase 4   EUCTR2009-015845-21-GB   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 4   EUCTR2009-015845-21-BE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-SE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-PT   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-GR   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-FI   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-DE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-CZ   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   NCT02405780   Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   Phase 3   NCT02260791   Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
   LG Life Sciences
      2016   Phase 3   NCT02746380   Japan;Korea, Republic of;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2007-002066-35-SK   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-GR   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-BG   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-HU   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-CZ   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
Humira® (adalimumab)   
   Aarhus University Hospital, Denmark
      2007   Phase 4   EUCTR2007-000082-38-DK   Denmark;
Humira® 40 mg Injektionslösung in Fertigspritze   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2008   -   EUCTR2007-002066-35-DE   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
Humira® 40 mg solution for injection in pre-filled syringe   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2007-002066-35-SK   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-GR   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-BG   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-HU   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-CZ   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2016   Phase 3;Phase 4   EUCTR2014-000358-13-DE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-HR   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-ES   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-RO   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LV   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LT   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-GB   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-EE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-CZ   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-BG   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-PL   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Hyaluronic acid   
   Kojima Toshihisa
      2020   -   JPRN-jRCTs041200048   Japan;
      2016   -   JPRN-jRCTs041180071   Japan;
   Takahashi Nobunori
      2020   -   JPRN-jRCT1041190125   Japan;
Hydrocortisone   
   CHU Toulouse
      2016   Phase 4   EUCTR2016-001618-18-FR   France;
Hydroxychloroquine   
   Assiut University
      2020   -   NCT04389320   Egypt;
   Brigham and Women's Hospital
      2020   -   NCT04691505   United States;
      2010   Phase 3   NCT01132118   United States;
   General Hospital of Chengdu Military Region
      2014   Phase 1 study   ChiCTR-TRC-14004520   China;
   Hoffmann-La Roche
      2013   Phase 3   NCT01941095   Greece;
   Indonesia University
      2017   -   NCT03085940   Indonesia;
   Jawaharlal Institute of Postgraduate Medical Education & Research
      2016   Phase 3   NCT02930343   India;
      2015   Phase 4   NCT02644499   India;
   Kaneko Yuko
      2017   Phase 2-3   JPRN-jRCTs031180050   Japan;
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2016   Phase 2   NCT02603146   United States;
   North Glasgow NHS Trust
      2004   -   EUCTR2004-002006-30-GB   United Kingdom;
   RenJi Hospital
      2020   -   NCT04569890   China;
   Sanofi
      2018   Phase 4   NCT03449758   France;
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
      2013   Phase 3   NCT01768572   Argentina;Belgium;Brazil;Czech Republic;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   NCT01709578   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
   The Affiliated ZhuZhou Hospital Of XiangYa School Of Medicine CSU.
      2019   Phase 4   ChiCTR2000032534   China;
   University of Alabama at Birmingham
      2004   Phase 4   NCT00259610   United States;
   University of Alberta
      2020   -   NCT04347798   Canada;
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
   University of Leeds
      2019   Phase 4   NCT03813771   United Kingdom;
      2011   Phase 4   NCT02433184   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   VA Office of Research and Development
      2007   -   NCT00405275   Canada;United States;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 4   NCT00422227   Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;
Hydroxycholoquine   
   VU University Medical Center
      2013   Phase 4   EUCTR2013-003658-26-NL   Netherlands;
Hydroxycloroquina   
   Fundacion Clinic per a la Recerca Biomédica
      2019   Phase 4   NCT03669367   -
Hylase   
   Assiut University
      2017   -   NCT03394131   Egypt;
Hyperbaric Oxygen   
   David Grant U.S. Air Force Medical Center
      2017   -   NCT02984943   United States;
IB-MECA   
   Can-Fite BioPharma Ltd.
      2008   -   EUCTR2007-006527-13-BG   Bulgaria;
   Can-Fite BioPharma, Ltd.
      2019   Phase 3   EUCTR2016-003682-26-PL   Bosnia and Herzegovina;Bulgaria;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
ICG-Pulsion   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   Phase 4   EUCTR2013-004006-26-DK   Denmark;
ICP-022   
   Innocare Pharma Australia Pty Ltd
      2017   Phase 1   NCT03189017   Australia;
IDEC-C2B8 (rituximab)   
   Biogen
      2006   Phase 2   NCT00298272   United States;
IL-2   
   the Second Hospital of Shanxi Medical University
      2016   -   ChiCTR-INR-16009546   China;
IL-6 receptor inhibitor, humanized monoclonal antibody   
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2010-018375-22-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2010-018375-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
IL-6 receptor inhibitor, recombinant humanized monoclonal antibody   
   F Hoffmann La-Roche AG
      2006   -   EUCTR2005-002909-23-SI   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   F Hoffmann La-Roche Ltd.
      2006   -   EUCTR2005-002909-23-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2006   -   EUCTR2005-002909-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   F Hoffmann-La Roche Ltd.
      2009   -   EUCTR2008-001847-20-SE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-001847-20-DE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2008-001847-20-GB   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-LV   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-DK   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
   F. Hoffmann La-Roche Ltd
      -   -   EUCTR2005-002423-13-BG   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Switzerland;Thailand;
   F. Hoffmann La-Roche Ltd.
      2005   Phase 3   EUCTR2004-003733-14-FI   Australia;Brazil;China;Denmark;Finland;France;Greece;Italy;Mexico;Norway;Poland;South Africa;Spain;United States;
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2009-012759-12-SE   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-PT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-FI   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DK   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-AT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
   Roche Austria GmbH
      2011   -   EUCTR2011-001863-39-AT   Austria;
   Roche Products Limited
      2012   Phase 4   EUCTR2011-005260-20-GB   United Kingdom;
   Roche a/s
      2011   -   EUCTR2011-002363-15-DK   Denmark;Iceland;
IL-6R Monoclonal Antibody Injection   
   Beijing VDJBio Co., LTD.
      2021   Phase 1/Phase 2   NCT05232396   China;
ILV-094   
   Pfizer
      2009   Phase 2   NCT00883896   Belgium;Colombia;Croatia;Denmark;Germany;Hungary;Japan;Mexico;Netherlands;Romania;Russian Federation;United States;
   Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer company
      2009   -   EUCTR2008-006936-37-DE   Belgium;Germany;Hungary;Netherlands;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
      2009   Phase 2   EUCTR2008-006936-37-BE   Belgium;Germany;Hungary;Netherlands;
      2009   -   EUCTR2008-006936-37-NL   Belgium;Germany;Hungary;Netherlands;
      2009   -   EUCTR2008-006936-37-HU   Belgium;Germany;Hungary;Netherlands;
INCB018424   
   Incyte Corporation
      2007   Phase 2   NCT00550043   Poland;United States;
INCB028050   
   Incyte Corporation
      2009   Phase 2   NCT00902486   Czech Republic;Czechia;United States;
INCB028050 phosphate salt   
   Incyte Corporation
      2009   -   EUCTR2009-011206-42-CZ   Czech Republic;
INCB047986   
   Incyte Corporation
      2014   Phase 2   NCT02151474   United States;
INN - FILGOTINIB   
   Gilead Sciences Inc.
      2014   Phase 2   EUCTR2012-003655-11-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
INN not available   
   GlaxoSmithKline Research & Development Limited
      2018   Phase 2   EUCTR2015-004386-91-PL   Germany;Poland;United States;
      2016   Phase 2   EUCTR2015-004386-91-DE   Germany;Poland;United States;
      2015   Phase 2   EUCTR2014-003453-34-PL   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-HU   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-GB   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-EE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-DE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-CZ   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
IPI 145   
   Infinity Pharmaceuticals, Inc
      2013   Phase 2   EUCTR2012-003724-20-RO   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-003724-20-HU   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-003724-20-DE   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-003724-20-BG   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
IPI-145   
   Infinity Pharmaceuticals, Inc
      2013   Phase 2   EUCTR2012-003724-20-RO   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-003724-20-HU   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-003724-20-DE   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-003724-20-BG   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
   SecuraBio
      2013   Phase 2   NCT01851707   Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine;
IR Prednisone   
   Merck KGaA, Darmstadt, Germany
      2004   Phase 3   NCT00146640   Germany;Poland;
IRAK 4   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SK   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
IS (B cell depletion therapy)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MMF or MPA)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MTX)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
ISIS 104838   
   Isis Pharmaceuticals
      2002   Phase 2   NCT00048321   Canada;United States;
ISIS CRP Rx   
   Isis Pharmaceuticals
      2011   Phase 2   NCT01414101   Canada;Russian Federation;
ITIS diet   
   University of California, San Diego
      2018   -   NCT04999683   United States;
IV Abatacept   
   Rüdiger B. Müller
      2013   Phase 4   NCT01846975   Switzerland;
IV golimumab   
   Merck Sharp & Dohme Corp.
      2009   Phase 3   NCT00975130   Argentina;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Monaco;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;
Ianalumab   
   Novartis Pharmaceuticals
      2018   Phase 1   NCT03574545   Germany;Jordan;
Ibandronate   
   Yeong-Wook Song
      2010   Phase 4   NCT01287533   Korea, Republic of;
Ibuprofen   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2007   Phase 3   NCT00613106   United States;
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2006   Phase 4   NCT00346216   Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine;United States;
Iguratimod   
   Anhui Medical University
      2008   Phase 3 study   ChiCTR-TRC-10000850   China;
   Eisai Co., Ltd.
      2012   -   NCT01850966   Japan;
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2013   Phase 4   NCT02275299   China;
      2012   Phase 4   NCT01893151   China;
      2012   Phase 4   NCT01554917   China;
      2012   Phase 4   NCT01548001   China;
   Osaka Medical College
      2017   -   JPRN-UMIN000027719   Japan;
   Qilu Hospital of Shandong University
      2021   Phase 0   ChiCTR2100048699   China;
      2020   Phase 4   NCT04928066   China;
      2017   Phase 4   NCT03855007   China;
   Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)
      2012   -   JPRN-JapicCTI-152782   -
Iguratimod (Careram)   
   Eisai Co., Ltd.
      2012   -   JPRN-JapicCTI-132051   -
Imatinib   
   Novartis Pharmaceuticals
      2004   Phase 2   NCT00154336   Austria;Canada;Finland;United Kingdom;
Immune ablation and hematopoietic stem cell transplant   
   Richard Burt, MD
      1997   Phase 1   NCT00278551   United States;
Immunoscintigraphy with radiolabeled Cimzia®.   
   University Hospital, Ghent
      2012   Phase 3   NCT01590966   Belgium;
Immunosporin   
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Impact   
   Assistance Publique - Hôpitaux de Paris
      2021   -   NCT05124782   France;
   Lawson Health Research Institute
      2016   -   NCT02742597   Canada;
   The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
      2020   Phase 1   ChiCTR2000034924   China;
Implant Procedure   
   SetPoint Medical Corporation
      2021   Phase 3   NCT04539964   United States;
Inactivated hepatitis A virus   
   HY, HUS
      2011   -   EUCTR2009-016055-22-SE   Finland;Sweden;
Indocyanine green   
   Tokyo Medical and Dental University
      2013   -   JPRN-UMIN000012399   Japan;
Indocyanine green(ICG)   
   Shanghai University of Traditional Chinese Medicine
      2014   -   NCT02876874   China;
Infliximab   
    Shanghai Changzheng Hospital
   Amgen
      2016   Phase 3   NCT02937701   Australia;Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Spain;United States;
   Bristol Myers Squibb International Corporation
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
   CELLTRION, Inc
      2012   Phase 3   EUCTR2011-004468-31-GB   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   Phase 3   EUCTR2011-004468-31-ES   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-PL   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-LV   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-LT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2011   -   EUCTR2011-004468-31-SK   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2010   -   EUCTR2010-018646-31-IT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   Celltrion
      2012   Phase 3   NCT01571219   Korea, Republic of;United Kingdom;
      2010   Phase 3   NCT01217086   Korea, Republic of;
   Centocor BV
      2009   Phase 4   EUCTR2007-003288-36-GB   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-003288-36-ES   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 4   EUCTR2007-003288-36-FR   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-NL   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-FI   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-DE   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-AT   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
   Centocor Ortho Biotech Services, L.L.C.
      2008   Phase 4   NCT00714493   Austria;Belgium;Canada;Finland;France;Germany;Israel;Netherlands;Spain;United Kingdom;United States;
      2001   Phase 4   NCT00246064   -
   Centocor, Inc.
      2004   Phase 3   NCT00236028   -
      2003   Phase 2   NCT00207714   -
      2001   Phase 3   NCT00036387   United States;
      2001   Phase 3   NCT00036374   United States;
      1997   Phase 3   NCT00269867   -
   Chiba University
      2016   Phase 4   NCT02770794   Japan;
      2016   -   JPRN-UMIN000021929   Japan;
   Chiba University Hospital
      2012   Phase 2   JPRN-UMIN000015297   Japan;
      2012   Phase 2   JPRN-UMIN000007806   Japan;
   Chinese University of Hong Kong
      2008   -   NCT00901550   China;
   Department of Orthopaedic surgery, Tohoku University Hospital
      2013   -   JPRN-UMIN000009887   Japan;
   Department of Rheumatosurgery, Osaka City University Medical School
      2009   Phase 4   JPRN-UMIN000002340   Japan;
   Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
      2011   -   JPRN-UMIN000013750   Japan;
   Fen Li
      2016   Phase 4   NCT02878161   -
   Genentech, Inc.
      2009   Phase 2   NCT00808210   United States;
   Genor Biopharma Co., Ltd.
      2017   Phase 3   NCT04178850   China;
   Georgetown University
      2013   Phase 4   NCT01793519   United States;
   Greater Glasgow Health Board
      2006   Phase 4   EUCTR2006-000363-28-GB   United Kingdom;
   Hoffmann-La Roche
      2011   -   NCT01592292   Korea, Republic of;
   Hvidovre University Hospital
      2005   Phase 4   NCT00216177   Denmark;
   Ikeda Kei
      2016   Phase 4   JPRN-jRCTs031180001   Japan;
   Inoue Hospital
      2016   -   JPRN-UMIN000021492   Japan;
   Institute of Health Biosciences,The University of Tokushima Graduate School
      2014   -   JPRN-UMIN000014311   Japan;
   Integrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.
      2006   Phase 3   EUCTR2005-001889-13-FR   Austria;Belgium;Denmark;France;Germany;Netherlands;Portugal;Sweden;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Karolinska Institute
      2008   -   EUCTR2008-005212-40-SE   Sweden;
   Karolinska Institutet
      2006   -   NCT05051137   Sweden;
   Kawakami Atsushi
      2021   Phase 4   JPRN-jRCTs071200007   Japan;
      2020   Phase 4   JPRN-jRCTs071190030   Japan;
   Keio University
      2012   -   JPRN-UMIN000007432   Japan;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   Merck Sharp & Dohme Corp.
      2011   Phase 2   NCT01313520   Moldova, Republic of;Romania;
      2008   -   NCT00741104   -
      2008   -   NCT00724672   -
      2007   Phase 3   NCT00521924   Austria;
      2006   -   NCT00724243   Slovakia;
      2005   Phase 3   NCT00202852   Korea, Republic of;
      2005   -   NCT00705289   -
      2004   -   NCT00725621   Austria;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 2   NCT00029042   United States;
      2000   Phase 2   NCT00006292   United States;
   National Sciences Foundation of China
      2008   -   ChiCTR-CCC-10001054   China;
   Nichi-Iko Pharmaceutical Co., Ltd.
      2016   Phase 3   NCT02990806   Czechia;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Nichi-Iko Pharmaceutical Co.,Ltd.
      2013   Phase 3   NCT01927263   Japan;
      2012   Phase 1   NCT01567358   Japan;
   Osaka Medical College
      2015   -   JPRN-UMIN000016950   Japan;
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2004   -   EUCTR2005-000492-18-IT   Italy;
   Patrick Durez
      2007   -   NCT01245361   Belgium;
   Peking Union Medical College Hospital
      2010   Phase 4   NCT01282528   China;
   People's Hospital, Beijing University
   Pfizer
      2014   Phase 3   NCT02222493   Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Czechia;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Jordan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Rheumatosurgery, Osaka City University Medical School
      2006   -   JPRN-UMIN000000512   Japan;
   Saitama Medical Center. Saitama Medical University
      2012   -   JPRN-UMIN000007786   Japan;
   Schering Plough Research Institute, a Division of Schering Corporation
      2006   Phase 3   EUCTR2005-001889-13-BE   Austria;Belgium;Denmark;France;Germany;Netherlands;Portugal;Sweden;
      2006   -   EUCTR2005-001889-13-PT   Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
   Schering-Plough Research Institute (SPRI)
      2007   -   EUCTR2005-001889-13-DE   Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
   Schering-Plough Research Institute, a division of Schering Corporation
      2005   -   EUCTR2005-001889-13-SE   Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
   Taizhou Mabtech Pharmaceutical Co.,Ltd
      2020   Phase 1   NCT04779892   China;
   Takarazuka city hospital
      2014   -   JPRN-UMIN000016844   Japan;
   University Hospital, Tours
      2007   -   NCT00840957   France;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
      2006   Phase 4   NCT01308255   United Kingdom;
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Rochester
      2007   Phase 4   NCT00462072   United States;
   Xian-Janssen Pharmaceutical Ltd.
      2007   Phase 4   NCT00896168   -
Infliximab (INF) + MTX, DB   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00095147   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
Infliximab (Remicade)   
   Merck Sharp & Dohme Corp.
      2003   Phase 4   NCT00794898   -
Infliximab + methotrexate (MTX)   
   Merck Sharp & Dohme Corp.
      2006   Phase 3   NCT00732875   -
Infliximab Control   
   Merck Sharp & Dohme Corp.
      2006   Phase 3   NCT00394589   Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey;
Infliximab Increased Dose   
   Merck Sharp & Dohme Corp.
      2006   Phase 3   NCT00394589   Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey;
Infliximab Increased Frequency   
   Merck Sharp & Dohme Corp.
      2006   Phase 3   NCT00394589   Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey;
Infliximab [infliximab biosimilar 3]   
   Pfizer
      2019   -   NCT03885037   Japan;
Infliximab biosimilar   
   TcLand Expression S.A.
      2016   -   NCT03016260   Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
Infliximab group   
   Zhang, Xiao, M.D.
      2013   -   NCT01915537   China;
Infliximab, etanercept   
   Centocor Ortho Biotech Services, L.L.C.
      2003   Phase 3   NCT00317538   -
Infliximab, etanercept, adalimumab   
   University Hospital, Strasbourg, France
      2009   Phase 4   NCT01000441   France;Monaco;
Infliximab, methylprednisolone, methotrexate   
   Université Catholique de Louvain
      2003   Phase 4   NCT00396747   Belgium;
Infliximab-EU   
   Pfizer Inc.
      2015   Phase 3   EUCTR2013-004148-49-FR   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-PL   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-HU   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-GB   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-DE   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-CZ   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
Infliximab-Pfizer   
   Pfizer Inc.
      2015   Phase 3   EUCTR2013-004148-49-FR   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-PL   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-HU   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-GB   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-DE   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-CZ   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
Influenza vaccine   
   Bassett Healthcare
      2014   Phase 4   NCT02311855   United States;
   Tel-Aviv Sourasky Medical Center
      2005   -   NCT00466037   -
Influvac   
   Radboud University Nijmegen Medical Centre
      2008   -   EUCTR2008-001282-28-NL   Netherlands;
Infusion without ALD518'   
   CSL Behring
      2008   Phase 2   NCT00867516   Canada;Georgia;India;Poland;Russian Federation;Serbia;
Innovator infliximab   
   Diakonhjemmet Hospital
      2014   Phase 4   NCT02148640   Norway;
Insulin   
   Assiut University
      2017   -   NCT03394131   Egypt;
Integra TITAN™ Total Shoulder Generation 1.0   
   Smith & Nephew, Inc.
      2017   -   NCT03245320   United States;
Integra Titan Modular Shoulder System 2.5   
   Smith & Nephew, Inc.
      2017   -   NCT03250767   United States;
Integrative Medicine   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2014   Phase 2/Phase 3   NCT02551575   China;
Intra-articular Compound Betamethasone   
   Chinese PLA General Hospital
      2017   Phase 4   NCT03215407   -
Intra-articular Tocilizumab   
   Chinese PLA General Hospital
      2017   Phase 4   NCT03215407   -
Intra-articular corticosteroid injection   
   Maasstad Hospital
      2021   -   NCT04755127   Netherlands;
Intra-articular injection of etanercept   
   Centre Hospitalier Universitaire de Nice
      2005   Phase 3   NCT00522184   France;
Intra-articular injection of steroid   
   Centre Hospitalier Universitaire de Nice
      2005   Phase 3   NCT00522184   France;
Intraarticular betamethasone   
   Hvidovre University Hospital
      1998   Phase 4   NCT00209859   Denmark;
Intraarticular dexamethasone   
   Charite University, Berlin, Germany
      2004   Phase 1/Phase 2   NCT00244153   Germany;
Intraarticular injection   
   Federal University of São Paulo
      2004   Phase 2   NCT00506896   Brazil;
Intraarticular morphine   
   Charite University, Berlin, Germany
      2004   Phase 1/Phase 2   NCT00244153   Germany;
Intravenous (IV) Abatacept   
   Bristol-Myers Squibb
      2008   Phase 3   NCT00559585   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
Intravenous (IV) abatacept   
   Bristol-Myers Squibb
      2009   Phase 2/Phase 3   NCT01001832   Japan;
Intravenous Dexamethasone   
   University of Calgary
      2016   -   NCT02666443   Canada;
Iodine   
   Fukui General Hospital
      2012   -   JPRN-UMIN000033222   Japan;
Itacitinib   
   Incyte Corporation
      2012   Phase 2   NCT01626573   Puerto Rico;United States;
JAK 3   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
JAK 3 Ritlecitinib   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SK   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
JAK1 / JAK2 Inhibitor   
   Eli Lilly and Company
      2011   -   EUCTR2010-022504-42-HU   Argentina;Croatia;Czech Republic;Hungary;India;Mexico;Peru;Poland;Romania;Ukraine;United Kingdom;United States;
JAK1 / JAK2 Inhibtor   
   Eli Lilly and Company
      2011   Phase 2   EUCTR2010-022504-42-GB   Hungary;United Kingdom;
      2011   -   EUCTR2010-022504-42-HU   Argentina;Croatia;Czech Republic;Hungary;India;Mexico;Peru;Poland;Romania;Ukraine;United Kingdom;United States;
JHL1101   
   JHL Biotech, Inc.
      2017   Phase 1   NCT03161457   Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;Russian Federation;Taiwan;Ukraine;United Kingdom;
JNJ 38518168   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2010   Phase 2   NCT00941707   Belgium;Czech Republic;Ireland;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;
JNJ-16240159-AAC   
   Janssen-Cilag International N.V.
      2007   -   EUCTR2006-003983-73-CZ   Czech Republic;Germany;
   Janssen-Cliag International N.V.
      -   -   EUCTR2006-003983-73-DE   Czech Republic;Germany;
JNJ-38518168   
   Janssen Research & Development, LLC
      2013   Phase 2   NCT01862224   Moldova, Republic of;United States;
JNJ-38518168 (10 mg)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01679951   Argentina;Chile;Colombia;Czech Republic;Czechia;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
JNJ-38518168 (3 mg)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01679951   Argentina;Chile;Colombia;Czech Republic;Czechia;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
JNJ-38518168 (30 mg)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01679951   Argentina;Chile;Colombia;Czech Republic;Czechia;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
JNJ-38518168 / MTX   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2011   Phase 1   NCT01450982   United States;
JNJ-38518168 50-mg Over Encapsulated Tablet   
   Janssen-Cilag International NV
      2009   -   EUCTR2009-012118-27-NL   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-GB   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-ES   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-CZ   Czech Republic;Netherlands;Spain;United Kingdom;
JNJ-38518168-AEK - Over Encapsulated Tablet -   
   Janssen-Cilag International NV
      2010   -   EUCTR2009-012118-27-BE   Belgium;Czech Republic;Netherlands;Spain;United Kingdom;
JNJ-38518168-ZBQ - film-coated tablet -   
   Janssen-Cilag International NV
      2013   Phase 2   EUCTR2011-002840-29-RO   Argentina;Chile;Colombia;Czech Republic;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
      2012   -   EUCTR2011-002840-29-LV   Argentina;Chile;Colombia;Czech Republic;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
      2012   -   EUCTR2011-002840-29-HU   Argentina;Chile;Colombia;Czech Republic;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
      2012   -   EUCTR2011-002840-29-CZ   Argentina;Chile;Colombia;Czech Republic;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
JNJ-39758979 (10 mg)   
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01480388   United States;
JNJ-39758979 (100 mg)   
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01480388   United States;
JNJ-39758979 (30 mg)   
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01480388   United States;
JNJ-39758979 (300 mg)   
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01480388   United States;
JNJ-39758979 / MTX   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2011   Phase 1   NCT01442545   Germany;United States;
JNJ-39758979-AAC - enteric coated tablet -   
   Janssen-Cilag International NV
      2012   -   EUCTR2011-002849-36-LV   Argentina;Chile;Colombia;Czech Republic;Japan;Latvia;Malaysia;Mexico;Poland;Romania;Russian Federation;Singapore;Ukraine;United States;
JNJ-40346527   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01597739   Argentina;Bulgaria;Chile;Czech Republic;Hungary;Korea, Republic of;Poland;Russian Federation;Singapore;Ukraine;
JNJ-40346527-AAC - capsule -   
   Janssen-Cilag International NV
      2012   -   EUCTR2011-004529-28-PL   Bulgaria;Hungary;Poland;
      2012   -   EUCTR2011-004529-28-HU   Argentina;Bulgaria;Chile;Czech Republic;Hungary;Korea, Republic of;Poland;Russian Federation;Singapore;Ukraine;
      2012   -   EUCTR2011-004529-28-CZ   Argentina;Bulgaria;Chile;Czech Republic;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;
      2012   -   EUCTR2011-004529-28-BG   Bulgaria;Hungary;Poland;
JNJ-67484703   
   Janssen Research & Development, LLC
      2021   Phase 1   NCT04985812   Georgia;Hungary;Moldova, Republic of;Spain;Ukraine;United States;
JNJ-80202135   
   Janssen-Cilag International NV
      2021   Phase 2   EUCTR2021-000510-42-ES   Germany;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000510-42-DE   Germany;Poland;Spain;United Kingdom;United States;
JTE-051   
   Akros Pharma Inc.
      2017   Phase 2   EUCTR2015-003140-39-PL   Argentina;Bulgaria;Colombia;Mexico;Peru;Poland;Romania;Russian Federation;Ukraine;United States;
      2016   Phase 2   NCT02919475   Argentina;Bulgaria;Colombia;Mexico;Peru;Poland;Romania;Russian Federation;Ukraine;United States;
      2016   Phase 2   EUCTR2015-003140-39-BG   Argentina;Bulgaria;Colombia;Mexico;Peru;Poland;Romania;Russian Federation;Ukraine;United States;
Jing Si Herbal Tea LIQUID PACKETS   
   Buddhist Tzu Chi General Hospital
      2022   -   NCT05257174   Taiwan;
Juanbi pill   
   Cui xuejun
      2018   Phase 2/Phase 3   NCT02885597   China;
Jyseleca 100 mg film-coated tablets   
   Galapagos NV
      2017   Phase 3   EUCTR2016-003630-25-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Jyseleca 200 mg film-coated tablets   
   Galapagos NV
      2017   Phase 3   EUCTR2016-003630-25-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
K-832   
   Kowa Research Europe Ltd
      2004   -   EUCTR2004-000362-12-CZ   Czech Republic;
KB003   
   KaloBios Pharmaceuticals
      2010   Phase 2   NCT00995449   United States;
KC706   
   Kémia, Inc.
      2006   -   EUCTR2006-002645-37-HU   Hungary;
KINERET*SC 7SIR 100MG 0,67ML   
   OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA
      2013   Phase 4   EUCTR2012-005370-62-IT   Italy;
KN019,   
   Jiangsu Alphamab Biopharmaceuticals Co., Ltd
      2019   Phase 2   NCT04038970   China;
KR002524   
   Kémia, Inc.
      2006   -   EUCTR2006-002645-37-HU   Hungary;
Kenalog   
   Trafford NHS Trust
      2008   -   EUCTR2007-006729-28-GB   United Kingdom;
Ketoprofen   
   Hokusuikai Kinen Hospital
      2018   -   JPRN-UMIN000033059   Japan;
   Nekoyama Miyao Hospital
      2013   -   JPRN-UMIN000012257   Japan;
   Nekoyama miyao hospital
      2012   -   JPRN-UMIN000011181   Japan;
      2012   -   JPRN-UMIN000010902   Japan;
Kevzara   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000868-18-IT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2020   Phase 3   EUCTR2019-000868-18-DE   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-PL   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-LT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-HU   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-GB   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-ES   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-CZ   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
   University of Southern Denmark
      2021   Phase 1;Phase 2   EUCTR2020-005998-27-DK   Denmark;
Keyhole limpet hemocyanin   
   Genentech, Inc.
      2006   Phase 2   NCT00282308   United States;
Kineret®   
   Amgen
      2002   -   NCT00121056   -
Kineret® (Anakinra)   
   Amgen
      2002   Phase 4   NCT00121043   -
Kolbet   
   Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)
      2012   -   JPRN-JapicCTI-152782   -
Kunxian Capsule   
   Chinese SLE Treatment And Research Group
      2015   Phase 4   NCT02764515   China;
L-000124467 (freebase)   
   Merck Sharp & Dohme (Sweden) AB
      2004   -   EUCTR2004-000074-31-SE   Sweden;
   Merck Sharp & Dohme BV
      2005   Phase 2   EUCTR2004-000074-31-BE   Belgium;Sweden;
L-000124467-009J (succinat   
   Merck Sharp & Dohme (Sweden) AB
      2004   -   EUCTR2004-000074-31-SE   Sweden;
   Merck Sharp & Dohme BV
      2005   Phase 2   EUCTR2004-000074-31-BE   Belgium;Sweden;
L-000883191   
   Merck & Co. Inc.
      2005   Phase 2   EUCTR2004-004302-24-ES   Czech Republic;Finland;Germany;Italy;Spain;
      2005   -   EUCTR2004-004302-24-DE   Czech Republic;Finland;Germany;Italy;Spain;
   Merck & Co., Inc.
      2005   Phase 2   EUCTR2004-004302-24-CZ   Czech Republic;Finland;Germany;Italy;Spain;
   Suomen MSD Oy
      2005   -   EUCTR2004-004302-24-FI   Czech Republic;Finland;Germany;Italy;Spain;
L-001069957   
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
L-883191   
   MERCK SHARP DOHME
      2005   Phase 2   EUCTR2004-004302-24-IT   Czech Republic;Finland;Germany;Italy;Spain;
L-arginine   
   RenJi Hospital
      2021   Phase 2   NCT04535427   China;
L01BA01   
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2010   Phase 4   EUCTR2008-002623-85-SE   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   Phase 4   EUCTR2008-002623-85-FR   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2008-002623-85-ES   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
L01X CO2   
   Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)
      2016   Phase 4   EUCTR2012-002535-28-NL   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
L01XC02   
   CELLTRION, Inc.
      2014   Phase 3   EUCTR2013-004555-21-SK   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-PT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-LV   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-HU   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-GR   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-DE   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
L04 AB04   
   Abbott GmbH & Co. KG
      2012   -   EUCTR2011-003953-25-DE   Australia;Canada;Germany;
L04041)   
   R-Pharm
      2017   Phase 3   EUCTR2015-005309-35-LV   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-HU   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-GB   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005307-83-LV   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-HU   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005308-27-DE   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-LT   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-HU   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International LLC
      2017   Phase 3   EUCTR2015-005309-35-PL   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-LT   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-DE   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-CZ   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-CZ   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005307-83-CZ   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-BG   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International, LLC.
      2017   Phase 3   EUCTR2015-005309-35-BG   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
L04AA11   
   Wyeth Pharmaceuticals France
      2007   -   EUCTR2006-005137-38-DE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
L04AA24   
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
L04AB01   
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
L04AB04   
   Hexal, AG
      2016   Phase 3   EUCTR2015-003433-10-HU   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-GB   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-ES   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-DE   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-CZ   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2016   Phase 3;Phase 4   EUCTR2014-000358-13-DE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-HR   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-ES   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-RO   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LV   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LT   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-GB   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-EE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-CZ   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-BG   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-PL   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
L04AB05   
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
L04AC07   
   F Hoffmann-La Roche Ltd.
      2009   -   EUCTR2008-001847-20-GR   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-EE   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2014-004673-16-DE   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Switzerland;Turkey;
   Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)
      2016   Phase 4   EUCTR2012-002535-28-NL   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
L04AX03   
   Leiden University medical Centre
      2015   Phase 2   EUCTR2014-004472-35-NL   Netherlands;
LB-P6   
   LISCure Biosciences
      2021   Phase 1   NCT05053165   Australia;
LB-P8   
   LISCure Biosciences
      2021   Phase 1   NCT05053165   Australia;
LBAL   
   LG Life Sciences
      2016   Phase 3   NCT02746380   Japan;Korea, Republic of;
LBEC0101   
   LG Life Sciences
      2016   Phase 3   NCT02715908   Korea, Republic of;
      2015   Phase 3   NCT02357069   Japan;Korea, Republic of;
LD-aminopterin   
   Syntrix Biosystems, Inc.
      2013   Phase 2   NCT01724931   Ukraine;
LNP1955   
   Lupin Limited
      2017   Phase 2   EUCTR2016-001532-35-BG   Bulgaria;Hungary;Poland;
      2016   Phase 2   EUCTR2016-001532-35-HU   Bulgaria;Hungary;
LO4AB04   
   R-Pharm
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
LTS   
   Shanghai Pharmaceuticals Holding Co., Ltd
      2014   Phase 1/Phase 2   NCT02202395   China;
LX3305   
   Lexicon Pharmaceuticals
      2009   Phase 1   NCT00847886   United States;
LX3305 BID   
   Lexicon Pharmaceuticals
      2011   Phase 1   NCT01417052   United States;
LX3305 Dihydrate   
   Lexicon Pharmaceuticals, Inc.
      2009   -   EUCTR2009-012705-19-HU   Bulgaria;Czech Republic;Hungary;
      2009   -   EUCTR2009-012705-19-CZ   Bulgaria;Czech Republic;Hungary;
      2009   -   EUCTR2009-012705-19-BG   Bulgaria;Czech Republic;Hungary;
LX3305 QD   
   Lexicon Pharmaceuticals
      2011   Phase 1   NCT01417052   United States;
LX3305 high dose   
   Lexicon Pharmaceuticals
      2009   Phase 2   NCT00903383   Bulgaria;Czech Republic;Hungary;Poland;Serbia;United States;
LX3305 low dose   
   Lexicon Pharmaceuticals
      2009   Phase 2   NCT00903383   Bulgaria;Czech Republic;Hungary;Poland;Serbia;United States;
LX3305 mid dose   
   Lexicon Pharmaceuticals
      2009   Phase 2   NCT00903383   Bulgaria;Czech Republic;Hungary;Poland;Serbia;United States;
LY2127399   
   Eli Lilly and Company
      2013   -   EUCTR2012-001618-40-PL   Argentina;Czech Republic;Poland;Russian Federation;United States;
      2012   Phase 2   NCT01576549   United States;
      2012   -   EUCTR2012-001618-40-CZ   Argentina;Czech Republic;Poland;Russian Federation;United States;
      2011   Phase 3   NCT01215942   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sri Lanka;Taiwan;Ukraine;United States;
      2011   Phase 3   NCT01202773   Argentina;Australia;Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   Phase 3   NCT01202760   Argentina;Australia;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   Phase 3   EUCTR2010-022208-36-ES   Bulgaria;Germany;Greece;Hungary;Italy;Lithuania;Poland;Spain;
      2011   -   EUCTR2010-022208-36-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022208-36-LT   Bulgaria;Germany;Greece;Hungary;Italy;Lithuania;Poland;Spain;
      2011   -   EUCTR2010-022208-36-IT   Bulgaria;Germany;Greece;Hungary;Italy;Lithuania;Poland;Spain;
      2011   -   EUCTR2010-022208-36-HU   Bulgaria;Germany;Greece;Hungary;Italy;Lithuania;Poland;Spain;
      2011   -   EUCTR2010-022208-36-GR   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022208-36-DE   Bulgaria;Germany;Greece;Hungary;Italy;Lithuania;Poland;Spain;
      2011   -   EUCTR2010-022208-36-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022207-22-PL   Argentina;Australia;Brazil;Colombia;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Spain;Taiwan;United States;
      2011   -   EUCTR2010-022207-22-IT   Germany;Greece;Italy;Poland;Spain;
      2011   -   EUCTR2010-022207-22-GR   Germany;Greece;Italy;Poland;Spain;
      2011   -   EUCTR2010-022207-22-ES   Germany;Greece;Italy;Poland;Spain;
      2011   -   EUCTR2010-022207-22-DE   Argentina;Australia;Brazil;Colombia;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Spain;Taiwan;United States;
      2011   -   EUCTR2010-022206-40-PL   Argentina;Australia;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022206-40-LT   Argentina;Australia;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022206-40-HU   Bulgaria;Hungary;Lithuania;Poland;
      2011   -   EUCTR2010-022206-40-BG   Argentina;Australia;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-LT   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-HU   Bulgaria;Hungary;Lithuania;Poland;
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2010   Phase 3   NCT01198002   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2010   Phase 3   EUCTR2010-022206-40-SK   Argentina;Australia;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2010   Phase 1   NCT01253291   Japan;
      2009   Phase 2   NCT00837811   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Hungary;India;Mexico;Poland;Puerto Rico;Romania;Slovakia;Ukraine;United States;
      2009   Phase 2   EUCTR2008-004875-23-FR   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-PL   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-HU   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-DE   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-BE   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-AT   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-001105-42-PL   Austria;Belgium;France;Germany;Poland;
      2008   Phase 2   NCT00785928   Argentina;Australia;Brazil;Canada;Chile;Czech Republic;Germany;Hungary;India;Mexico;Poland;Romania;Slovakia;Ukraine;United States;
      2008   Phase 2   NCT00689728   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Mexico;Poland;Puerto Rico;United States;
      2008   Phase 2   EUCTR2008-001105-42-FR   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-DE   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-BE   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-AT   Austria;Belgium;France;Germany;Poland;
      2006   Phase 2   NCT00308282   Romania;
   Eli Lilly and Company limited
      2009   Phase 2   EUCTR2008-004894-16-HU   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-PL   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-DE   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-CZ   Czech Republic;Germany;Hungary;Poland;
LY2127399 (Tabalumab)   
   Eli Lilly and Company
      2009   Phase 1   NCT01253226   Japan;
LY2189102   
   Eli Lilly and Company
      2005   Phase 1/Phase 2   NCT00380744   Argentina;Hungary;Poland;Spain;United States;
   Eli Lilly and Company Limited
      2007   -   EUCTR2005-002660-29-HU   Hungary;Spain;
LY2439821   
   Eli Lilly and Company
      2010   Phase 1   NCT01253265   Japan;
      2010   Phase 1   NCT01236118   Japan;
      2009   Phase 2   NCT00966875   Argentina;Chile;Germany;Hungary;India;Korea, Republic of;Peru;Poland;Romania;Russian Federation;Taiwan;United States;
      2009   -   EUCTR2009-009696-34-DE   Argentina;Chile;Germany;India;Korea, Republic of;Peru;Poland;Romania;Russian Federation;Taiwan;
LY3009104   
   ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP)
      2021   Phase 4   EUCTR2020-005773-27-FR   France;
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 4   EUCTR2018-003351-37-IT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   ELI LILLY AND COMPANY
      2013   -   EUCTR2012-002339-27-IT   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002324-32-IT   Argentina;Austria;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2012   -   EUCTR2012-002323-15-IT   Argentina;Australia;Austria;Belgium;Canada;Croatia;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
   Eli Lilly and Company
      2020   Phase 3;Phase 4   EUCTR2018-003351-37-FR   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-PL   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-NL   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-LT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-HU   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GR   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GB   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DK   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DE   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-AT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-003686-17-SI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-003686-17-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002339-27-GB   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   Phase 3   EUCTR2012-002324-32-GB   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002324-32-BE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-GB   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-DK   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-BE   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-SI   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-GB   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-DE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002339-27-SK   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-PT   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-HU   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-DE   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-CZ   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-BE   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002324-32-SE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-PT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-GR   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-DE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-AT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-PL   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-NL   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-HR   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-GR   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-AT   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-SK   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-PT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-NL   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LV   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-HU   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-GR   Argentina;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-CZ   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-BE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-022504-42-GB   Hungary;United Kingdom;
      2011   -   EUCTR2010-022504-42-HU   Argentina;Croatia;Czech Republic;Hungary;India;Mexico;Peru;Poland;Romania;Ukraine;United Kingdom;United States;
      2010   Phase 2   NCT01185353   Argentina;Croatia;Czech Republic;Czechia;Hungary;India;Mexico;Peru;Poland;Romania;Ukraine;United Kingdom;United States;
   Lilly S.A
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-ES   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Lilly S.A.
      2013   -   EUCTR2012-003686-17-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002339-27-ES   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002323-15-ES   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-ES   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
LY3090106 - IV   
   Eli Lilly and Company
      2013   Phase 1   NCT01925157   Bulgaria;Hungary;Moldova, Republic of;Poland;Romania;United States;
LY3090106 - SQ   
   Eli Lilly and Company
      2013   Phase 1   NCT01925157   Bulgaria;Hungary;Moldova, Republic of;Poland;Romania;United States;
LY3337641   
   Eli Lilly and Company
      2017   Phase 2   EUCTR2015-003289-97-DE   Argentina;Australia;Austria;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Slovakia;South Africa;Spain;United States;
      2016   Phase 2   NCT02628028   Argentina;Australia;Austria;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Slovakia;South Africa;Spain;United States;
      2016   Phase 2   EUCTR2015-003289-97-SK   Argentina;Australia;Austria;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Slovakia;South Africa;Spain;United States;
      2016   Phase 2   EUCTR2015-003289-97-PL   Argentina;Australia;Austria;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Slovakia;South Africa;Spain;United States;
      2016   Phase 2   EUCTR2015-003289-97-AT   Argentina;Australia;Austria;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Slovakia;South Africa;Spain;United States;
   Lilly S.A.
      2017   Phase 2   EUCTR2015-003289-97-ES   Argentina;Australia;Austria;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Slovakia;South Africa;Spain;United States;
LY3462817   
   Eli Lilly and Company
      2021   Phase 2   NCT04634253   Czechia;Hungary;Mexico;Poland;Puerto Rico;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002673-10-PL   Czech Republic;Czechia;Hungary;Mexico;Poland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002673-10-HU   Czech Republic;Czechia;Hungary;Mexico;Poland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002673-10-CZ   Czech Republic;Czechia;Hungary;Mexico;Poland;United Kingdom;United States;
Lacosamide   
   Indiana University School of Medicine
      2014   Phase 2   NCT02342977   United States;
Lamivudine   
   Department of general internal medicine, Kyushu-University hospital
      2012   -   JPRN-UMIN000018017   Japan;
Land exercises   
   Federal University of São Paulo
      2009   Phase 3   NCT01447264   Brazil;
Lantarel   
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Large protein molecule   
   Halozyme Therapeutics
      2006   Phase 4   NCT00369187   United States;
Ledertrexate   
   University Hospitals Leuven
      2009   Phase 4   EUCTR2008-007225-39-BE   Belgium;
Ledertrexato   
   Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   Phase 4   EUCTR2018-004558-30-PT   Portugal;Spain;
      2020   Phase 4   EUCTR2018-004558-30-DK   Denmark;Portugal;Spain;
Leflunomide   
   Anhui Provincial Hospital Department of Rheumatism
      2011   -   ChiCTR-TRC-11001789   China;
   Chinese Academy of Sciences
      2012   -   NCT01619176   China;
   Genentech, Inc.
      2010   Phase 2   NCT01225393   Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;Romania;Spain;United States;
      2007   Phase 3   NCT00476996   Argentina;Australia;Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Panama;Peru;Poland;Slovakia;Slovenia;Spain;Sweden;Switzerland;Taiwan;United States;
   Hoffmann-La Roche
      2013   Phase 3   NCT01941095   Greece;
   Institute of Acupuncture-Moxibustion and Meridian, Shanghai University of Traditional Chinese Medicine
      2013   -   ChiCTR-TRC-13003948   China;
   Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
      2012   -   ChiCTR-TRC-12001859   China;
   Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences
      2010   Phase 1 study   ChiCTR-TRC-10001014   China;
   Jawaharlal Institute of Postgraduate Medical Education & Research
      2016   Phase 3   NCT02930343   India;
      2015   Phase 4   NCT02644499   India;
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2013   Phase 4   NCT02275299   China;
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
   P. Verschueren
      2009   Phase 4   NCT01172639   Belgium;
   People's Hospital, Peking University
      2009   -   ChiCTR-TRC-09000472   China;
   Sanofi
      2018   Phase 4   NCT03449758   France;
      2015   Phase 3   NCT02373202   Japan;
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
      2013   Phase 3   NCT01768572   Argentina;Belgium;Brazil;Czech Republic;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   NCT01709578   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
      2007   Phase 3   NCT00596206   Czech Republic;Italy;Korea, Republic of;Portugal;Romania;
      2004   Phase 4   NCT00280644   Turkey;
      2003   Phase 4   NCT00563849   Korea, Republic of;
   Shanxi Medical University
      2012   -   NCT01617590   China;
   Singapore General Hospital
      2012   Phase 4   NCT01659242   Singapore;
   The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
      2013   -   NCT01774877   China;
   The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041819   China;
   The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
      2009   Phase 1+Phase 2   ChiCTR-TRC-12003871   China;
      2007   Phase 2 study   ChiCTR-TRC-11001755   China;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
   University of Leeds
      2006   Phase 4   EUCTR2005-004582-41-GB   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 4   NCT00422227   Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;
   Yunnan Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041894   China;
   Yunnan Hospital of Traditional Chinese Medicine /The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041777   China;
   Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041821   China;
   Yunnan Traditional Chinese Medicine Hospital
      2021   Phase 0   ChiCTR2100041909   China;
   sanofi-aventis Groupe
      2008   -   EUCTR2007-000886-40-IT   Italy;Portugal;
Leflunomide (permitted, not necessary)   
   Fen Li
      2016   Phase 4   NCT02878161   -
Leflunomide 10 milligram (MG)   
   P. Verschueren
      2018   Phase 4   NCT03649061   Belgium;
Leflunomide 20 mg Tablets (Geneva Pharmaceutical)   
   Sandoz
      2002   Phase 1   NCT00946686   -
Leflunomide 20Mg Tab   
   Assiut University
      2018   -   NCT04022525   Egypt;
Leflunomide-Sulfasalazine-Hydroxychloroquine   
   University of Nebraska
      1999   Phase 3   NCT00579878   United States;
Leflunomidum   
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
Leucovorin   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
Levobupivacaine   
   Daiyukai General Hospital
      2020   Phase 3   JPRN-UMIN000040054   Japan;
      2019   Phase 3   JPRN-UMIN000037359   Japan;
      2018   Phase 3   JPRN-UMIN000031890   Japan;
Levofloxacin   
   The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
      2020   Phase 1   ChiCTR2000034924   China;
Lidocaine   
   Department of Pain, Guizhou Provincial People's Hospita
      2020   Phase 0   ChiCTR2000033004   China;
   Kojima Toshihisa
      2020   -   JPRN-jRCTs041200048   Japan;
      2016   -   JPRN-jRCTs041180071   Japan;
   Takahashi Nobunori
      2020   -   JPRN-jRCT1041190125   Japan;
Lingzhi and Sen Miao San   
   Chinese University of Hong Kong
      2005   Phase 2   NCT00432484   China;
Lipitor®   
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Lisinopril   
   Research and Development Department, Addenbrookes NHS Foundation Trust
      2006   Phase 4   EUCTR2005-005295-32-GB   United Kingdom;
Lodotra®   
   Mundipharma Korea Ltd
      2013   Phase 4   NCT02072200   Korea, Republic of;
   Nitec Pharma AG
      2008   Phase 3   EUCTR2007-003508-36-GB   Germany;Hungary;United Kingdom;
      2008   -   EUCTR2007-003508-36-HU   Germany;Hungary;United Kingdom;
Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03262740   United States;
Long-chain n-3 PUFA   
   University of Jena
      2013   -   NCT01742468   Germany;
Long-circulating liposomal prednisolone   
   Radboud University
      2005   Phase 2   NCT00241982   Netherlands;
Loratadine   
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
Losartan   
   MD, PhD, Annemarie Lyng Svensson
      2014   -   NCT02246257   Denmark;
Losec   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Losec Capsules   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Lovastatin   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00302952   United States;
Low dose ORTD-1   
   Oryn Therapeutics, LLC
      2021   Phase 1   NCT04286789   United States;
Low dose of BIIL 284 BS tablets   
   Boehringer Ingelheim
      2000   Phase 1   NCT02247375   -
Low dose vehicle control   
   Oryn Therapeutics, LLC
      2021   Phase 1   NCT04286789   United States;
Loxoprofen   
   Peking University People's Hospital
      2015   Phase 2   NCT02467504   China;
Lumiracoxib   
   Novartis
      2004   Phase 3   NCT00170872   -
Luo-Fu-Shan Plaster   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2021   -   NCT04884880   China;
Lymphoseek   
   Navidea Biopharmaceuticals Ltd
      2020   Phase 2   EUCTR2018-003418-41-GB   European Union;United Kingdom;United States;
M2591 25 mg QD   
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT03233230   Argentina;Brazil;Bulgaria;Chile;Colombia;Czechia;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
M281   
   Janssen-Cilag International NV
      2021   Phase 2   EUCTR2021-000510-42-ES   Germany;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000510-42-DE   Germany;Poland;Spain;United Kingdom;United States;
M2951   
   EMD Serono Research & Development Institute, Inc.
      2016   Phase 2   NCT02784106   Germany;United States;
   Merck KGaA
      2017   Phase 2   EUCTR2017-000384-32-CZ   Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2017   Phase 2   EUCTR2017-000384-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2016   Phase 2   EUCTR2016-000064-42-SK   Bulgaria;Czech Republic;Estonia;Hungary;Poland;Romania;Slovakia;South Africa;Ukraine;
      2016   Phase 2   EUCTR2016-000064-42-HU   Bulgaria;Czech Republic;Estonia;Hungary;Poland;Romania;Slovakia;South Africa;Ukraine;
      2016   Phase 2   EUCTR2016-000064-42-CZ   Bulgaria;Czech Republic;Estonia;Hungary;Poland;Romania;Slovakia;South Africa;Ukraine;
      2016   Phase 2   EUCTR2016-000064-42-BG   Bulgaria;Czech Republic;Estonia;Hungary;Poland;Romania;Slovakia;Ukraine;United States;
M2951 50 mg BID   
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT03233230   Argentina;Brazil;Bulgaria;Chile;Colombia;Czechia;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
M2951 75 mg QD   
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT03233230   Argentina;Brazil;Bulgaria;Chile;Colombia;Czechia;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
M923   
   Momenta Pharmaceuticals, Inc.
      2016   Phase 3   NCT02722044   United States;
MABTHERA 500 mg concentrado para solución para perfusión   
   F Hoffmann-La Roche Ltd
      2009   Phase 2   EUCTR2008-005525-11-ES   France;Germany;Greece;Netherlands;Spain;United Kingdom;
   ROCHE FARMA, S.A.
      2009   -   EUCTR2008-002381-55-ES   Spain;
MABTHERA*EV 1FL 50ML   
   A.O. UNIVERSITARIA INTEGRATA DI VERONA
      2012   -   EUCTR2011-006001-10-IT   Italy;
MBS2320   
   Modern Biosciences plc
      2017   Phase 2   NCT03139136   Georgia;Moldova, Republic of;Romania;
      2015   Phase 1   NCT02480946   United Kingdom;
MC1   
   National Institute of Mental Health (NIMH)
      2019   Phase 1/Phase 2   NCT03912428   United States;
MDA   
   Zenjinkai Shimin-no-mori Hospital
      2015   -   JPRN-UMIN000020833   Japan;
MDX-1100   
   Bristol-Myers Squibb
      2008   Phase 2   NCT01017367   Romania;Ukraine;
MDX-1342   
   Bristol-Myers Squibb
      2008   Phase 1   NCT00639834   Germany;Hungary;Poland;Ukraine;United Kingdom;United States;
MEDI-522   
   MedImmune LLC
      2003   Phase 2   NCT00069017   Canada;United States;
MEDI5117   
   Novo Nordisk A/S
      2012   Phase 1   NCT01559103   Germany;United Kingdom;United States;
METFORMINE ARROW   
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
METHOTREXAT Lederle - Tabletten   
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
METHOTREXATE 2.5 mg tablets   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-PL   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-DK   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-CZ   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-BG   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
METHOTREXATE DISODIUM   
   CHU Saint-Etienne
      2020   Phase 4   EUCTR2019-003700-12-FR   France;
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
   University Hospitals Leuven
      2009   Phase 4   EUCTR2008-007225-39-BE   Belgium;
METHOTREXATE HOSPIRA 2,5 mg tablety   
   Bristol Myers Squibb International Corporation
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
METHOTREXATE HOSPIRA 2.5 mg tablety   
   Bristol Myers Squibb International Corporation
      2010   -   EUCTR2010-018674-20-IT   Denmark;Finland;France;Germany;Italy;Sweden;
METHOTREXATE SODIUM   
   F Hoffmann-La Roche Ltd
      2008   -   EUCTR2008-001847-20-ES   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   Phase 4   EUCTR2018-004558-30-PT   Portugal;Spain;
      2020   Phase 4   EUCTR2018-004558-30-DK   Denmark;Portugal;Spain;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
METHOTREXATE*100CPR 2,   
   F. Hoffmann - La Roche Ltd.
      2005   -   EUCTR2005-002395-15-IT   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
METHOTREXATE*10MG/1,33ML 4S   
   ROCHE
      2005   -   EUCTR2005-000884-25-IT   Germany;Iceland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-003741-40-IT   Germany;Hungary;Italy;
      2004   -   EUCTR2004-003733-14-IT   Denmark;Finland;Italy;Spain;
METHOTREXATE*15MG/2ML 4SIR   
   ROCHE
      2005   -   EUCTR2005-000884-25-IT   Germany;Iceland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-003741-40-IT   Germany;Hungary;Italy;
      2004   -   EUCTR2004-003733-14-IT   Denmark;Finland;Italy;Spain;
METHOTREXATE*2,5MG 25CPR   
   ROCHE
      2005   -   EUCTR2005-000884-25-IT   Germany;Iceland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-003741-40-IT   Germany;Hungary;Italy;
      2004   -   EUCTR2004-003733-14-IT   Denmark;Finland;Italy;Spain;
METHOTREXATE*20MG/2,66ML 4S   
   ROCHE
      2005   -   EUCTR2005-000884-25-IT   Germany;Iceland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-003741-40-IT   Germany;Hungary;Italy;
      2004   -   EUCTR2004-003733-14-IT   Denmark;Finland;Italy;Spain;
METHOTREXATE*25CPR 2,   
   F. Hoffmann - La Roche Ltd.
      2005   -   EUCTR2005-002395-15-IT   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   ROCHE
      2005   -   EUCTR2005-001138-33-IT   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-IT   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
METHOTREXATE*7,5MG/ML 4SIR.   
   ROCHE
      2005   -   EUCTR2005-000884-25-IT   Germany;Iceland;Italy;Sweden;United Kingdom;
METHYLPREDNISOLONE ACETATE   
   Leiden University medical Centre
      2015   Phase 2   EUCTR2014-004472-35-NL   Netherlands;
METHYLPREDNISOLONE SODIUM SUCCINATE   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2008   Phase 2   EUCTR2007-006150-25-FR   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   Phase 2   EUCTR2007-006150-25-BE   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-NL   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-AT   Austria;Belgium;France;Germany;Hungary;Netherlands;
METOTRESSATO SALE SODICO   
   GILEAD SCIENCES INCORPORATED
      2017   Phase 3   EUCTR2016-000568-41-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
METOTREXATO SANDOZ - 2.5 MG COMPRESSE 50 COMPRESSE IN FLACONE PP   
   AMGEN INC.
      2016   Phase 3   EUCTR2014-004868-38-IT   Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
METOTREXATO SODIO   
   F Hoffmann-La Roche Ltd
      2008   -   EUCTR2008-001847-20-ES   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
METOTREXATO-LEDERLE 2,5 MG COMPRIMIDOS   
   Wyeth Pharmaceuticals
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
MH004 Ia()   
   Minghui Pharmaceutical Pty Ltd
      2021   Phase 1   NCT04815148   -
MH004 Ib-1()   
   Minghui Pharmaceutical Pty Ltd
      2021   Phase 1   NCT04815148   -
MH004 Ib-2()   
   Minghui Pharmaceutical Pty Ltd
      2021   Phase 1   NCT04815148   -
MK-0663   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019871-31-GB   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2010-019871-31-SK   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
      2011   Phase 3   EUCTR2010-019871-31-BE   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
      2011   -   EUCTR2010-019871-31-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
MK-0873   
   Merck Sharp & Dohme Corp.
      2005   Phase 2   NCT00132769   Belgium;Canada;Czech Republic;Finland;Germany;Italy;Norway;Spain;Switzerland;
MK-8457   
   MERCK SHARP & DOHME CORP.
      2013   -   EUCTR2012-000439-17-LV   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2012-000439-17-LT   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
   Merck Sharp & Dohme Corp.
      2012   Phase 2   NCT01651936   Australia;Colombia;Denmark;France;Greece;Hungary;Italy;Korea, Republic of;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
      2012   Phase 2   NCT01569152   Canada;Chile;Denmark;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Moldova, Republic of;Peru;Poland;South Africa;Taiwan;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2012   -   EUCTR2012-000439-17-DK   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2012-002181-12-IT   Australia;Austria;Brazil;Colombia;Denmark;Greece;Hungary;Italy;New Zealand;Peru;South Africa;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002181-12-HU   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000439-17-DE   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2012-002181-12-GR   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2012-002181-12-GB   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2012-002181-12-ES   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as
      2013   -   EUCTR2012-002181-12-SE   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2012-002181-12-DK   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck)
      2013   -   EUCTR2012-002181-12-AT   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.
      2013   -   EUCTR2012-000439-17-HU   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
   Merck, Sharpe & Dohme Corp., a subsidiary of Merck & Co. Inc (hereafter referred to as Merck)
      2012   -   EUCTR2012-000439-17-GB   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
MK-8457 (free acid)   
   Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2012-000439-17-PL   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
MK-8808   
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
MK0359   
   Merck Sharp & Dohme Corp.
      2002   Phase 2   NCT00482417   -
MK0663, etoricoxib   
   Organon and Co
      2003   Phase 3   NCT00250445   -
      2003   Phase 3   NCT00092742   United States;
MK0812 / Duration of Treatment: 12 Weeks   
   Merck Sharp & Dohme Corp.
      2004   Phase 2   NCT00542022   -
MK0966   
   Merck Sharp & Dohme Corp.
      2004   Phase 4   NCT00157872   China;
MK8457   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2012   -   EUCTR2012-002181-12-ES   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
MLN3897   
   Millennium Pharmaceuticals Inc
      2006   Phase 2   EUCTR2005-006165-14-GB   Czech Republic;Netherlands;United Kingdom;
      2006   -   EUCTR2005-006165-14-NL   Czech Republic;Netherlands;United Kingdom;
      2006   -   EUCTR2005-006165-14-CZ   Czech Republic;Netherlands;United Kingdom;
MLTA3698A   
   GENENTECH, Inc
      2011   -   EUCTR2010-021577-37-ES   Bulgaria;Germany;Hungary;Spain;
      2011   -   EUCTR2010-021577-37-DE   Bulgaria;Germany;Hungary;Spain;
      2011   -   EUCTR2010-021577-37-BG   Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Spain;United States;
      2010   -   EUCTR2010-021577-37-HU   Bulgaria;Germany;Hungary;Spain;
   Genentech, Inc.
      2010   Phase 2   NCT01225393   Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;Romania;Spain;United States;
MM-093   
   Merrimack Pharmaceuticals
      2007   Phase 2   NCT00458146   United States;
      2005   Phase 2   NCT00105976   United States;
MOR103   
   MorphoSys AG
      2010   -   EUCTR2007-006129-29-PL   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2010   -   EUCTR2007-006129-29-NL   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2010   -   EUCTR2007-006129-29-BG   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2009   Phase 1/Phase 2   NCT01023256   Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2009   -   EUCTR2007-006129-29-DE   Bulgaria;Germany;Netherlands;Poland;Ukraine;
MORAb-022   
   Morphotek
      2013   Phase 1   NCT01357759   Netherlands;United States;
MORPHINE SULFATE   
   Charité University medicine Berlin
      2015   Phase 2   EUCTR2015-000538-31-DE   Germany;
MP-435(dose1) + Methotrexate   
   Mitsubishi Tanabe Pharma Corporation
      2010   Phase 2   NCT01143337   Japan;
MR Prednisone   
   Merck KGaA, Darmstadt, Germany
      2004   Phase 3   NCT00146640   Germany;Poland;
MR prednisone   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2008   Phase 3   NCT00650078   Canada;Germany;Hungary;Poland;United Kingdom;United States;
MRA   
   F Hoffmann La-Roche AG
      2007   -   EUCTR2005-002909-23-PT   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-002909-23-GB   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-SI   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2006   -   EUCTR2005-002909-23-NO   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-IS   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-FI   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002909-23-ES   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F Hoffmann-La Roche AG
      2006   -   EUCTR2005-002909-23-DE   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F. Hoffmann La-Roche AG
      2005   Phase 3   EUCTR2005-001138-33-NO   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   Phase 3   EUCTR2005-001138-33-ES   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   Phase 3   EUCTR2004-005210-37-ES   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   Phase 3   EUCTR2004-003741-40-SK   Austria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-001138-33-PT   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-LT   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-DK   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2004-005210-37-SE   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-FI   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-DE   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-CZ   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-003741-40-HU   Germany;Hungary;Italy;
      2005   -   EUCTR2004-003741-40-DE   Germany;Hungary;Italy;
      2005   -   EUCTR2004-003733-14-ES   Denmark;Finland;Italy;Spain;
      2004   -   EUCTR2004-003741-40-AT   Austria;Germany;Hungary;Italy;
      -   -   EUCTR2005-001138-33-SI   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
   F. Hoffmann La-Roche Ltd
      2005   -   EUCTR2005-002423-13-SK   Austria;Bulgaria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-002423-13-HU   Bulgaria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-002423-13-AT   Austria;Bulgaria;Germany;Hungary;Italy;Slovakia;
   F. Hoffmann-La Roche AG
      2005   Phase 3   EUCTR2005-000884-25-IS   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-000884-25-GB   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   -   EUCTR2005-000884-25-SE   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   -   EUCTR2005-000884-25-DE   Germany;Iceland;Italy;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2005   -   EUCTR2005-002423-13-DE   Bulgaria;Germany;Hungary;Italy;Slovakia;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2010-019912-18-ES   Bulgaria;Greece;Hungary;Spain;
      2011   -   EUCTR2010-019912-18-GR   Bulgaria;Greece;Hungary;Spain;
MRA (Tocilizumab)   
   Chugai Pharmaceutical
      2004   Phase 3   NCT00144534   -
      2003   Phase 3   NCT00144508   -
MRA (tocilizumab)   
   Chugai Pharmaceutical Co., Ltd.
      -   Phase 3   JPRN-JapicCTI-050018   -
      -   Phase 3   JPRN-JapicCTI-050016   -
MRA(Tocilizumab)   
   Chugai Pharmaceutical
      2006   Phase 3   NCT00380601   Japan;
      2005   Phase 3   NCT00144586   -
      2005   -   NCT00144573   -
      2005   -   NCT00144560   -
      2004   Phase 3   NCT00144547   -
      2004   Phase 3   NCT00144521   -
      2001   Phase 2   NCT00144651   -
MRA, Actemra   
   F Hoffmann La-Roche Ltd.
      2005   -   EUCTR2004-003733-14-DK   Denmark;Finland;Italy;Spain;
MRA-SC   
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 3   JPRN-JapicCTI-142505   -
MRC375   
   Molecular Research Center, Inc.
      2011   Phase 2   NCT01408602   United States;
MSB11022   
   Fresenius Kabi SwissBioSim GmbH
      2019   Phase 1   NCT04018599   United States;
      2017   Phase 3   NCT03052322   Bulgaria;Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom;
   Merck KGaA
      2017   Phase 3   EUCTR2016-002852-26-GB   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002852-26-DE   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;
      2017   Phase 3   EUCTR2016-002852-26-BG   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;
      2016   Phase 3   EUCTR2016-002852-26-LT   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002852-26-HU   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002852-26-CZ   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United Kingdom;
MSB11456   
   Fresenius Kabi SwissBioSim GmbH
      2021   Phase 3   EUCTR2019-004369-42-DE   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2020   Phase 3   NCT04512001   Bulgaria;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-SK   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-PL   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-HU   Bulgaria;Czech Republic;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2020   Phase 3   EUCTR2019-004369-42-CZ   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-BG   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
MT203   
   Takeda Development Centre Europe Ltd.
      2015   Phase 2   EUCTR2014-002945-23-GB   Czech Republic;Estonia;Russian Federation;Spain;United Kingdom;
      2015   Phase 2   EUCTR2014-002945-23-ES   Czech Republic;Estonia;Latvia;Russian Federation;Spain;United Kingdom;
      2015   Phase 2   EUCTR2014-002945-23-CZ   Czech Republic;Estonia;Russian Federation;Spain;United Kingdom;
      2015   Phase 2   EUCTR2013-002805-76-BG   Bulgaria;Czech Republic;Japan;Poland;Russian Federation;Spain;United Kingdom;
      2014   Phase 2   EUCTR2014-002945-23-EE   Czech Republic;Estonia;Russian Federation;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-002805-76-GB   Bulgaria;Czech Republic;Germany;Japan;Poland;Russian Federation;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-002805-76-ES   Argentina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002805-76-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-002805-76-CZ   Bulgaria;Czech Republic;Japan;Poland;Russian Federation;Spain;United Kingdom;
MTRX1011A   
   Genentech, Inc.
      2008   Phase 1   NCT00718588   United States;
MTX   
    Research Center, the University of Tokyo
    Shanghai Changzheng Hospital
   22nd Century Medical &
   Anhui Provincial Hospital Department of Rheumatism
      2011   -   ChiCTR-TRC-11001789   China;
   Antares Pharma Inc.
      2012   Phase 2   NCT01618968   United States;
   Bristol Myers Squibb International Corporation
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
   CHU Saint-Etienne
      2020   Phase 4   EUCTR2019-003700-12-FR   France;
   Can-Fite BioPharma
      2017   Phase 3   NCT02647762   Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
   Centocor, Inc.
      2003   Phase 2   NCT00207714   -
   China Academy of Chinese Medical Science Guang'an Men Hospital
      2007   -   ChiCTR-TRC-09000377   China;
   China-Japan Friendship Hospital
      2018   -   ChiCTR1800014404   China;
   Chugai Pharmaceutical
      2004   Phase 3   NCT00144521   -
   Department of Internal Medicien and Rheumatology, Juntendo University School of Medicine
      2012   -   JPRN-UMIN000008281   Japan;
   Department of Orthopaedic Surgery,Graduate School of Medicine, Osaka City University Medical School
      2013   Phase 4   JPRN-UMIN000012073   Japan;
   Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University
      2011   -   JPRN-UMIN000005590   Japan;
   Genentech, Inc.
      2016   Phase 2   NCT02833350   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
   Gilead Sciences
      2016   Phase 3   NCT02889796   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02886728   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   GlaxoSmithKline
      2016   Phase 2   NCT02799472   Germany;Poland;United States;
      2015   Phase 2   NCT02504671   Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
   Guangdong Provincial Hospital of Chinese Medicine
      2015   -   ChiCTR-IPR-15007415   China;
      2015   -   ChiCTR-IOR-15007418   China;
   Guangdong Provincial Hospital of Chinese Medicine
      2016   -   ChiCTR-IPR-16009029   China;
      2016   -   ChiCTR-INR-16009031   China;
      2015   -   ChiCTR-IPR-15007368   China;
   Hoffmann-La Roche
      2017   Phase 3   NCT03155347   China;
   Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences
      2013   -   ChiCTR-TRC-13002981   -
   Japan Community Healthcare Organization
      2011   -   JPRN-UMIN000024507   Japan;
   Kaneko Yuko
      2018   Phase 4   JPRN-jRCT1031180088   Japan;South Korea;Taiwan;
   Kawakami Atsushi
      2021   Phase 4   JPRN-jRCTs071200079   Japan;
      2021   -   JPRN-jRCTs071200107   Japan;
   Keio University School of Medicine, Japan.
      2015   -   JPRN-UMIN000017495   Japan;
   Keio University School of MedicineDivision of Rheumatology, Department of Internal Medicine
      2018   -   JPRN-UMIN000030584   Japan,Asia(except Japan);
   Keio UniversityFukuoka Tokushukai Hospital
      2017   -   JPRN-UMIN000027250   Japan;
   Kojima Toshihisa
      2020   -   JPRN-jRCTs041200048   Japan;
      2016   -   JPRN-jRCTs041180071   Japan;
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000036094   China;
   Maldonado A Michael
      2021   Phase 3   JPRN-jRCT2071210068   Australia;France;Germany;Japan;Taiwan;USA;
   Merck Sharp & Dohme Corp.
      2005   Phase 3   NCT00202852   Korea, Republic of;
   Miyazaki Yusuke
      2019   Phase 4   JPRN-jRCTs071190001   Japan;
   Nagoya University Hospital
      2016   -   JPRN-UMIN000021247   Japan;
   Nanjing Drum Tower Hospital
      2019   Phase 4   ChiCTR1900021686   China;
   Osaka City University Medical School
      2012   Phase 4   JPRN-UMIN000009425   Japan;
      2012   -   JPRN-UMIN000009535   Japan;
      2010   -   JPRN-UMIN000003880   Japan;
   Osaka City University Medical School, Department of Orthopedic Surgery
      2015   Phase 2   JPRN-UMIN000016606   Japan;
   Osaka Medical College
      2017   -   JPRN-UMIN000027719   Japan;
   POEM study group
      2009   -   JPRN-UMIN000002175   Japan;
   Peking University First Hospital
      2015   -   NCT02320630   China;
   Peking University People's Hospital
      2015   Phase 2   NCT02467504   China;
   People's Hospital, Beijing University
   People's Hospital, Peking University
      2009   -   ChiCTR-TRC-09000473   China;
   Philogen S.p.A.
      2014   Phase 2   NCT02270632   Germany;Italy;Switzerland;
   Qiang Shu
      2015   Phase 4   NCT02837978   China;
   Qilu Hospital of Shandong University
      2017   Phase 4   NCT03855007   China;
   Renji Hospital, Shanghai Jiaotong University School of Medicine
      2009   Phase 4   ChiCTR2100043373   china;
   School of Medicine, University of Occupational and Environmental Health, Japan
      2014   -   JPRN-UMIN000015462   Japan;
      2008   -   JPRN-UMIN000001281   Japan;
   Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare
      2016   -   JPRN-UMIN000024025   Japan;
   Shanghai Biomabs Pharmaceutical Co., Ltd.
      2018   Phase 3   NCT03478111   China;
   Shanghai Materia Medica Bioengineering Institute
      2004   Phase 3 study   ChiCTR-TRC-08000093   China;
   Shanghai Renji Hospital
      2010   -   ChiCTR-IPR-14005684   China;
   Shanghai Traditional Medicine University Affiliated Guanghua Hospital
      2018   -   ChiCTR1800019277   China;
   Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2020   Phase 0   ChiCTR2000036141   China;
   Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
      2020   Phase 0   ChiCTR2000037008   China;
   SinoMab Pty Ltd
      2017   Phase 3   NCT04312815   China;
   Sun Yat-sen University
      2018   Phase 4   NCT04066803   China;
   TAP Corporation
      2009   -   JPRN-UMIN000002687   Japan,Asia(except Japan);
   Takahashi Nobunori
      2020   -   JPRN-jRCT1041190125   Japan;
   The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042329   China;
   The First Hospital Affiliated to Henan University of TCM
      2017   -   ChiCTR-INR-16010290   China;
   Tianjin First Central Hospital
      2018   -   ChiCTR1800015615   China;
   Tokyo Medical and Dental University
      2012   -   JPRN-UMIN000006702   Japan;
   University Medical Center Utrecht (UMCU)
      2016   Phase 4   EUCTR2015-004858-17-NL   Netherlands;
   University of Occupational and Environmental Health, Japan
      2010   -   JPRN-UMIN000008756   Japan;
   Xi-jing Hospital, the 4th Military Medical University, Shanghai Changzheng Hospital
      2008   Phase 3 study   ChiCTR-TRC-09000383   China;
   Xiao Lianbo
      2014   Phase 2 study   ChiCTR1800019290   China;
   Yokohama Minami Kyousai Hospital
      2016   -   JPRN-UMIN000021157   Japan;
   Yokohama Minami Kyousai HospitalSanten Pharmaceutical CO.,Ltd.
      2013   -   JPRN-UMIN000012473   Japan;
   Zenjinkai Shimin-no-mori Hospital
      2015   -   JPRN-UMIN000020833   Japan;
   Zhejiang Chinese Medical University
      2015   -   ChiCTR-INR-16009274   China;
   Zhejinag University of f Chinese Medicine
      2020   Phase 0   ChiCTR2000030247   China;
   hiroshima clinic
      2015   Phase 4   JPRN-UMIN000024143   Japan;
   theThird Affiliated Hospital of Sun Yat-sen University
      2019   Phase 1 study   ChiCTR1800018338   China;
MTX Goldshield Tablets   
   AbbVie Deutschland GmbH & Co. KG
      2011   -   EUCTR2010-019514-24-CZ   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
MTX HEXAL 2,5 mg Tabletten   
   AbbVie Deutschland GmbH & Co. KG
      2016   Phase 3   EUCTR2015-003376-75-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
MTX HEXAL 2,5mg Tabletten   
   AbbVie Deutschland GmbH & Co. KG
      2016   Phase 3   EUCTR2015-003334-27-RO   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
MTX HEXAL Tablets   
   AbbVie Deutschland GmbH & Co. KG
      2011   -   EUCTR2010-019514-24-CZ   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
   Abbott GmbH & Co. KG
      2011   Phase 3   EUCTR2010-019514-24-BE   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
      2011   -   EUCTR2010-019514-24-ES   Austria;Czech Republic;Germany;Spain;
      2011   -   EUCTR2010-019514-24-DE   Argentina;Austria;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
      2011   -   EUCTR2010-019514-24-AT   Argentina;Austria;Canada;Czech Republic;Germany;Puerto Rico;Spain;United States;
MTX plus anti-TNF   
   Karolinska Institutet
      2002   Phase 4   NCT00764725   -
MTX start   
   Region Skane
      2016   -   NCT03775824   -
MTX therapy   
   NYU Langone Health
      2016   Phase 4   NCT02874092   United States;
MabThera   
   AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
      2018   Phase 3   EUCTR2017-004079-30-IT   Belgium;Italy;Portugal;Spain;
   Amgen Inc
      2017   Phase 1;Phase 3   EUCTR2013-005543-90-EE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2015   Phase 1;Phase 3   EUCTR2013-005543-90-BG   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-PL   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-HU   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-DE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
   Archigen Biotech Limited
      2016   Phase 1   NCT02819726   Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;India;Korea, Republic of;Mexico;Poland;Spain;United States;
   CELLTRION, Inc.
      2014   Phase 3   EUCTR2013-004555-21-SK   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-PT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-LV   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-HU   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-GR   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-DE   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
   Celltrion
      2014   Phase 3   NCT02149121   Austria;Korea, Republic of;
   Cliniques Universitaires Saint-Luc
      2006   -   EUCTR2006-005386-19-BE   Belgium;
   Dr. Reddy's Laboratories Limited
      2014   Phase 1/Phase 2   NCT02296775   India;Ukraine;
   Dr. Reddy’s Laboratories S.A.
      2020   Phase 3   EUCTR2019-002810-37-PL   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-LT   Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-DE   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
   F Hoffmann-La Roche Ltd
      2009   Phase 2   EUCTR2008-005525-11-GR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-005525-11-FR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-NL   France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-DE   France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-005525-11-GB   France;Germany;Greece;Netherlands;Spain;United Kingdom;
   F. Hoffman- La Roche Ltd.
      2008   -   EUCTR2007-001585-33-GR   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
   F. Hoffman-La Roche Ltd.
      2007   Phase 3   EUCTR2007-001585-33-FR   Czech Republic;Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2007   Phase 3   EUCTR2007-001585-33-CZ   Czech Republic;Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2007   -   EUCTR2007-001585-33-NL   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2007   -   EUCTR2007-001585-33-LV   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2007   -   EUCTR2007-001585-33-LT   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2007   -   EUCTR2007-001585-33-ES   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2007   -   EUCTR2007-001585-33-EE   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2007   -   EUCTR2007-001585-33-DK   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
   F. Hoffmann - La Roche Ltd.
      2005   -   EUCTR2005-002395-15-IT   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd.
      2008   -   EUCTR2007-001585-33-DE   Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;
      2006   Phase 3   EUCTR2005-002396-33-GB   Belgium;Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-002395-15-GB   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003632-22-ES   Spain;
      2006   -   EUCTR2005-002396-33-SK   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-HU   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-FI   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-DE   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002395-15-SE   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-FI   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-DK   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-DE   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-CZ   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002392-32-DE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-002396-33-BE   Belgium;Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-002392-32-IE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-002392-32-GB   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   -   EUCTR2005-002396-33-ES   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2005   -   EUCTR2005-002395-15-ES   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002395-15-BE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002392-32-SI   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   -   EUCTR2005-002392-32-SE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
   Gedeon Richter Plc
      2015   Phase 1;Phase 3   EUCTR2014-003255-54-CZ   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Israel;Poland;Romania;Russian Federation;Spain;Ukraine;
   JHL Biotech, Inc.
      2017   Phase 1   NCT03161457   Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;Russian Federation;Taiwan;Ukraine;United Kingdom;
   Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)
      2016   Phase 4   EUCTR2012-002535-28-NL   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2015   Phase 4   EUCTR2012-002535-28-ES   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2014   Phase 4   EUCTR2012-002535-28-BE   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2013   Phase 4   EUCTR2012-002535-28-GB   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London
      2015   Phase 4   EUCTR2012-002535-28-IT   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2014   Phase 4   EUCTR2012-002535-28-PT   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Joint Research & Development Office (QMUL)
      2018   Phase 3   EUCTR2017-004079-30-PT   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-ES   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-BE   Belgium;Italy;Portugal;Spain;
      2014   Phase 3   EUCTR2014-003529-16-GB   United Kingdom;
   Mabion S.A.
      2021   Phase 3   EUCTR2020-002765-34-BE   Belgium;Bulgaria;Georgia;Poland;Serbia;Ukraine;
      2013   -   EUCTR2012-003194-25-LT   Croatia;Georgia;Lithuania;Poland;Romania;Russian Federation;Serbia;Ukraine;
   Medical University of Vienna
      -   -   EUCTR2015-002156-27-AT   Austria;
   NHS Greater Glasgow and Clyde
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   Pfizer
      2012   Phase 2   NCT01526057   Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
   Sandoz
      2011   Phase 1/Phase 2   NCT01274182   Argentina;Austria;Belgium;Brazil;Estonia;France;Germany;Hungary;India;Italy;Romania;Spain;Turkey;United States;
   Sint Maartenskliniek
      2020   Phase 4   EUCTR2020-002507-19-NL   Netherlands;
      2016   Phase 4   EUCTR2016-002908-15-NL   Netherlands;
   South Tees Hospitals NHS Foundation Trust
      2011   Phase 4   EUCTR2010-020499-50-GB   United Kingdom;
MabThera (rituximab)   
   Gedeon Richter Plc.
      2015   Phase 1   NCT02371096   -
MabThera 500 mg (10 mg/ml) concentrate for solution for infusion   
   Merck Serono International
      2008   -   EUCTR2007-003647-75-SE   Finland;France;Netherlands;Sweden;United Kingdom;
   Merck Serono SA - Geneva
      2008   Phase 2   EUCTR2007-003647-75-GB   Finland;France;Netherlands;Sweden;United Kingdom;
MabThera 500 mg (10mg/ml)   
   Division of Clinically Immunology and Rheumatology, AMC
      2009   -   EUCTR2009-010955-29-NL   Netherlands;
MabThera 500 mg Konzentrat zur Herstellung einer Infusionslösung   
   Roche Pharma AG
      2007   -   EUCTR2006-006746-33-DE   Germany;
      2006   -   EUCTR2006-001000-37-DE   Germany;
MabThera 500 mg concentrate for solution for infusion   
   Boehringer Ingelheim International GmbH
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-NO   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002894-48-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GB   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-EE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Roche (Hungary) Ltd.
      2006   -   EUCTR2006-004673-98-HU   Hungary;
MabThera infusions   
   Teva Pharmaceutical Industries
      2010   Phase 1/Phase 2   NCT01123070   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
MabThera/Rituxan   
   Hoffmann-La Roche
      2003   Phase 3   NCT00468546   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom;United States;
MabThera®   
   ARCHIGEN BIOTECH LIMITED
      2017   Phase 1;Phase 3   EUCTR2014-005368-13-IT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
   Archigen Biotech Limited
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-HU   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-ES   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-DE   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
   Biointegrator LLC
      2016   Phase 1   NCT03061838   Russian Federation;
   Boehringer Ingelheim
      2012   Phase 3   NCT01682512   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Hexal AG (a Sandoz company)
      2015   Phase 3   EUCTR2012-003876-38-PL   Germany;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2012-003876-38-HU   Germany;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2012-003876-38-DE   Germany;Hungary;Poland;United States;
   Johann Wolfgang Goethe-Universität Frankfurt/M.
      2010   -   EUCTR2009-015950-39-DE   Germany;
   Mabion S.A.
      2014   Phase 3   EUCTR2012-003194-25-HR   Croatia;Georgia;Lithuania;Poland;Romania;Russian Federation;Serbia;Ukraine;
   Mabion SA
      2021   Phase 3   NCT04680962   -
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2013   Phase 2   EUCTR2012-003223-38-GB   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-003223-38-DE   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-003223-38-ES   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2011-002896-40-PL   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-002896-40-GB   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      -   Phase 2   EUCTR2011-002896-40-ES   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US
      2012   -   EUCTR2011-002896-40-DE   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
   Samsung Electronics Co. Ltd.
      2012   -   EUCTR2011-004171-36-PL   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-HU   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-GB   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-ES   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-CZ   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
MabThera® (rituximab)   
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
MabThera®, 100 mg Concentrado para solución para perfusión   
   Teva Pharmaceutical Industries
      2012   -   EUCTR2011-005021-48-ES   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
MabThera®, 100 mg concentrate for solution for infusion   
   Teva Pharmaceutical Industries
      2012   -   EUCTR2011-005021-48-PL   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-NL   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-HU   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-CZ   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-BG   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
MabionCD20   
   Mabion S.A.
      2021   Phase 3   EUCTR2020-002765-34-BE   Belgium;Bulgaria;Georgia;Poland;Serbia;Ukraine;
      2014   Phase 3   EUCTR2012-003194-25-HR   Croatia;Georgia;Lithuania;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-003194-25-LT   Croatia;Georgia;Lithuania;Poland;Romania;Russian Federation;Serbia;Ukraine;
MabionCD20 (candidate biosimilar to rituximab)   
   Mabion SA
      2021   Phase 3   NCT04680962   -
Mabthera (rituximab)   
   Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
      2009   -   EUCTR2008-005450-20-BE   Belgium;
Mabthera 500 mg Concentrate for solution for infusion   
   Roche Pharma AG
      2011   -   EUCTR2010-022049-88-DE   Germany;
Magnesium   
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
Magnetic Resonance Imaging (MRI)   
   University of California, San Francisco
      2013   -   NCT01773681   United States;
Manufacturerd by Cambridge Therapeutic Antibody Centre, Burroughs Wellcome, Glaxo Wellcome)   
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 4   EUCTR2010-021146-22-GB   United Kingdom;
Maraviroc   
   PFIZER
      2007   -   EUCTR2007-001035-58-IT   Italy;Portugal;Spain;
   Pfizer
      2007   Phase 2   NCT00427934   Australia;Germany;India;Italy;Mexico;Portugal;Spain;Ukraine;United States;
   Pfizer Inc, 235 East 42nd Street,New York, NY 10017
      2007   -   EUCTR2007-001035-58-PT   Italy;Portugal;Spain;
   Pfizer, S. A.
      2007   Phase 2   EUCTR2007-001035-58-ES   Italy;Portugal;Spain;
Masitinib   
   AB Science
      2011   Phase 2/Phase 3   NCT01410695   Czech Republic;Czechia;France;United States;
      2007   Phase 2   NCT00913432   -
Masitinib (AB1010)   
   AB Science
      2004   Phase 2   NCT00831922   -
Masitinib mesylate   
   AB Science
      2014   -   EUCTR2010-020992-21-DE   Argentina;Bosnia and Herzegovina;Czech Republic;Germany;Greece;India;Mexico;Monaco;Morocco;Philippines;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Tunisia;Ukraine;United States;
      2012   Phase 3   EUCTR2010-020992-21-GR   Czech Republic;Germany;Greece;India;Monaco;Poland;Romania;Slovakia;Spain;Thailand;Turkey;United States;
      2011   Phase 3   EUCTR2010-020992-21-SK   Czech Republic;France;Germany;Greece;India;Poland;Romania;Slovakia;Spain;Thailand;Tunisia;Turkey;United States;
      2011   -   EUCTR2010-020992-21-ES   Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
      2011   -   EUCTR2010-020992-21-CZ   Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
Mavrilimumab   
   MedImmune LLC
      2013   Phase 2   NCT01715896   Argentina;Colombia;Czech Republic;France;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Serbia;Slovakia;Spain;Turkey;United Kingdom;
      2013   Phase 2   NCT01712399   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Israel;Mexico;Poland;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   NCT01706926   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2010   Phase 2   NCT01050998   Bulgaria;Czech Republic;Czechia;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Serbia;Ukraine;
   MedImmune Limited
      2013   Phase 2   EUCTR2011-005649-10-GB   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
   MedImmune Ltd
      2013   Phase 2   EUCTR2011-005648-93-SK   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2011-005648-93-GB   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2013   -   EUCTR2011-005649-10-SK   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-PT   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-HU   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-DE   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-CZ   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005648-93-PT   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-GR   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-ES   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-DE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-BG   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005649-10-GR   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005649-10-ES   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005648-93-HU   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005648-93-EE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005648-93-CZ   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005634-19-PL   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-HU   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-ES   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-EE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-DE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-CZ   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-BG   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2010   -   EUCTR2009-014735-20-PL   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-LT   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-CZ   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2009   -   EUCTR2009-014735-20-LV   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2009   -   EUCTR2009-014735-20-EE   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
Maxtrex   
   ELI LILLY AND COMPANY
      2013   -   EUCTR2012-002324-32-IT   Argentina;Austria;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
Medium THC/medium CBD   
   Brown University
      2022   Phase 2   NCT04269993   -
Medrol   
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
Medrol 4 mg tablets   
   N.V. Roche S.A.
      2010   Phase 4   EUCTR2010-019694-15-BE   Belgium;
Medrol A 16 mg tablets   
   N.V. Roche S.A.
      2010   Phase 4   EUCTR2010-019694-15-BE   Belgium;
Melatonin   
   Shunichi Shiozawa
      2013   -   JPRN-UMIN000018816   Japan;
Meloxicam   
   Boehringer Ingelheim
      2003   -   NCT02184052   -
      2002   Phase 3   NCT00042068   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Korea, Republic of;Russian Federation;Taiwan;Ukraine;United States;
      2001   -   NCT02180516   -
      2000   Phase 3   NCT00279747   Austria;Belgium;France;Germany;Italy;Russian Federation;United Kingdom;
   Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University
      2019   Phase 1   ChiCTR1900027855   China;
      2019   Phase 1   ChiCTR1900025021   China;
Meloxicam ampoule   
   Boehringer Ingelheim
      2004   Phase 3   NCT00239382   China;
Meloxicam oral suspension   
   Boehringer Ingelheim
      2000   Phase 3   NCT00034853   Argentina;Brazil;Mexico;Ukraine;United States;
Meloxicam tablet   
   Boehringer Ingelheim
      2004   Phase 3   NCT00239382   China;
Meriva   
   University of Arizona
      2015   Phase 1   NCT02543931   United States;
Mesalazine   
   Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
      2011   -   JPRN-UMIN000005362   Japan;
Mesenchymal cell transplantation   
   Royan Institute
      2009   Phase 2/Phase 3   NCT01873625   Iran, Islamic Republic of;
Metal Radial Head   
   Ascension Orthopedics, Inc.
      2009   -   NCT00825409   United States;
Metal Radial Head replacement   
   Integra LifeSciences Corporation
      2009   -   NCT02405234   United States;
Metal on Polyethylene articulation   
   Zimmer Biomet
      2013   -   NCT02036931   France;Germany;Ireland;Netherlands;Spain;United States;
Metex   
    Department of Rheumatology and Clinical Immunology
   Charité-Universitätsmedizin Berlin
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
Metex 10 mg/ml Injektionslösung, Fertigspritze   
   medac Gesellschaft für klinische Spezialpräparate mbH
      -   -   EUCTR2007-003591-19-DE   Germany;
Metex 10mg Tabletten   
   4SC AG
      2009   -   EUCTR2009-012953-39-PL   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-CZ   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-BG   Bulgaria;Czech Republic;Poland;
Metex 2,5mg Tabletten   
   4SC AG
      2009   -   EUCTR2009-012953-39-PL   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-CZ   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-BG   Bulgaria;Czech Republic;Poland;
Metex 50 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Metex 7,5mg Tabletten   
   4SC AG
      2009   -   EUCTR2009-012953-39-PL   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-CZ   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-BG   Bulgaria;Czech Republic;Poland;
Metex Pen   
   Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   Phase 4   EUCTR2018-004558-30-PT   Portugal;Spain;
      2020   Phase 4   EUCTR2018-004558-30-DK   Denmark;Portugal;Spain;
Metex®   
   Abbott GmbH & Co. KG
      2008   -   EUCTR2006-004139-31-NO   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-SK   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-HU   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-FR   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-SE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-NL   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-GB   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-ES   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-DE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-CZ   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-BE   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-AT   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
Metex® 50 mg/ml Injektionslösung, Fertigspritze   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2012   -   EUCTR2012-000222-21-DE   Germany;
Metformin   
   Ain Shams University
      2019   Phase 2   NCT03863405   Egypt;
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
   Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital
      2017   -   ChiCTR-INR-17011772   China;
   MD, PhD, Annemarie Lyng Svensson
      2014   -   NCT02246257   Denmark;
   Sadat City University
      2019   Phase 1/Phase 2   NCT04068246   Egypt;
   the Second Hospital of Shanxi Medical University
      2017   -   ChiCTR-IPR-17010325   China;
Metformin treatment   
   University Hospital, Bordeaux
      2020   Phase 2   NCT04196868   France;
Metformin/CP-690,550   
   Pfizer
      2011   Phase 1   NCT01405118   Belgium;
Methorexate   
   University Hospitals Birmingham NHS Foundation Trust
      2006   Phase 4   EUCTR2006-001428-38-GB   United Kingdom;
Methotrexaat   
   Leiden University medical Centre
      2015   Phase 2   EUCTR2014-004472-35-NL   Netherlands;
Methotrexat   
   Biocad
      2019   Phase 3   NCT04227366   Russian Federation;
   GlaxoSmithKline Research & Development Ltd
      -   -   EUCTR2005-002969-37-DE   Germany;Spain;Sweden;
Methotrexat 2,5 mg Tabletten medac   
   Novartis Pharma Services AG
      2007   -   EUCTR2006-001553-10-DE   Germany;Italy;Netherlands;
Methotrexat HEXAL® 2,5 mg Tabletten   
   Eli Lilly and Company
      2013   Phase 3   EUCTR2012-002324-32-GB   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002324-32-BE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-SE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-PT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-DE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-AT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
Methotrexat Lederle 2.5mg tablets   
   Roche Austria GmbH
      2011   -   EUCTR2011-001863-39-AT   Austria;
Methotrexate   
   4SC AG
      2009   Phase 2   NCT01010581   Bulgaria;Czech Republic;Poland;Romania;
   AB Science
      2011   Phase 2/Phase 3   NCT01410695   Czech Republic;Czechia;France;United States;
   AMGEN INC.
      2016   Phase 3   EUCTR2014-004868-38-IT   Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
   AbbVie
      2016   Phase 3   NCT02706951   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;Estonia;Greece;Hungary;Israel;Italy;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   NCT02706873   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
   AbbVie (prior sponsor, Abbott)
      2010   Phase 4   NCT01185288   Puerto Rico;United States;
      2010   Phase 4   NCT01162421   Canada;
      2010   Phase 3   NCT01185301   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Poland;Puerto Rico;Spain;United States;
      2009   Phase 4   NCT00808509   Sweden;
      2000   Phase 3   NCT00195663   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
   Abbott
      2006   Phase 4   NCT00420927   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Mexico;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2005   Phase 4   NCT00233558   United States;
      2003   Phase 3   NCT00235859   -
      2003   Phase 3   NCT00234936   -
      2003   Phase 3   NCT00234845   United States;
   Abbott GmbH & Co. KG
      2008   -   EUCTR2006-004139-31-GR   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
   Abivax S.A.
      2019   Phase 2   NCT03813199   Belgium;Czechia;France;Hungary;Poland;
   Ablynx
      2015   Phase 2   NCT02309359   Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
      2009   Phase 1/Phase 2   NCT00959036   Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland;United States;
   Aclaris Therapeutics, Inc.
      2020   Phase 2   NCT04247815   United States;
   All India Institute of Medical Sciences, New Delhi
      2009   Phase 3   NCT01870128   India;
   Amgen
      2013   Phase 4   NCT01927757   Canada;Puerto Rico;United States;
      2008   Phase 4   NCT00654368   Canada;
      2000   Phase 3   NCT03781375   -
   Anhui Provincial Hospital Department of Rheumatism
      2011   -   ChiCTR-TRC-11001789   China;
   Astellas Pharma Inc
      2017   Phase 2   NCT03257852   Japan;
      2016   Phase 2   NCT02884635   Japan;
      2014   Phase 3   NCT02305849   Japan;
      2012   Phase 2   NCT01554696   Belgium;Bulgaria;Colombia;Czech Republic;Czechia;Hungary;Mexico;Poland;United States;
      2010   Phase 1   NCT01754805   United States;
      2009   Phase 3   NCT00851318   Japan;
      2002   Phase 3   NCT00036153   Canada;United States;
   Astellas Pharma Korea, Inc.
      2019   Phase 4   NCT03737708   Korea, Republic of;
   AstraZeneca
      2009   Phase 1   NCT00920608   -
   Bio Logic Mate Study Group
      2012   -   JPRN-UMIN000009088   Japan;
   Biocad
      2016   Phase 3   NCT02762838   Belarus;India;Russian Federation;
      2015   Phase 3   NCT02744196   -
   Biogen
      2006   Phase 2   NCT00298272   United States;
   Biologic Mate Study Group
      2014   -   JPRN-UMIN000015616   Japan;
   Bird Rock Bio, Inc.
      2018   Phase 2   NCT02795299   -
   Brigham and Women's Hospital
      2020   -   NCT04691505   United States;
   Bristol-Myers Squibb
      2021   Phase 3   NCT04909801   Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 1   NCT03131973   United States;
      2016   Phase 2   NCT02638948   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2015   Phase 4   NCT02557100   Algeria;Canada;Mexico;United States;
      2015   Phase 3   NCT02504268   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;United States;
      2013   Phase 4   NCT01758198   Japan;
      2010   Phase 3   NCT01142726   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Norway;Poland;Russian Federation;South Africa;Sweden;United States;
      2008   Phase 3   NCT00767325   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2007   Phase 3   NCT00409838   Korea, Republic of;
      2005   Phase 3   NCT00122382   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2002   Phase 3   NCT00048568   United States;
   CENTOCOR
      2006   Phase 3   EUCTR2004-003295-10-IT   Austria;Hungary;Italy;Spain;United Kingdom;
   CHU Saint-Etienne
      2018   Phase 4   EUCTR2017-004348-39-FR   France;
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
   CSL Behring
      2011   Phase 2   NCT01373151   Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
   Centocor, Inc.
      2008   Phase 2   NCT00718718   Argentina;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Taiwan;Ukraine;United States;
      2006   Phase 3   NCT00361335   Argentina;Australia;Belgium;Colombia;Germany;Hungary;Latvia;Lithuania;Malaysia;Malta;Mexico;New Zealand;Peru;Poland;Russian Federation;Ukraine;United States;
      2005   Phase 3   NCT00264550   Argentina;Australia;Brazil;Canada;Chile;Germany;Hungary;India;Korea, Republic of;Mexico;New Zealand;Poland;Taiwan;Turkey;United States;
   Central Hospital of Jinhua
      2014   Phase 4   ChiCTR1900026116   China;
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-CZ   Bulgaria;Czech Republic;
   China Academy of Chinese Medical Science Guang'an Men Hospital
      2007   -   ChiCTR-TRC-09000377   China;
   Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
      2010   Phase 4   ChiCTR1900024107   China;
   Chinese Academy of Sciences
      2012   -   NCT01619176   China;
   Chinese SLE Treatment And Research Group
      2015   Phase 4   NCT02764515   China;
   Chinese University of Hong Kong
      2008   -   NCT00901550   China;
   Chugai Pharmaceutical
      2008   Phase 2   NCT00779220   Japan;
   Cinnagen
      2015   Phase 3   NCT03172325   Iran, Islamic Republic of;
   Cui xuejun
      2018   Phase 2/Phase 3   NCT02885597   China;
   Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University
      2013   -   JPRN-UMIN000010126   Japan;
   Department of Medical Pharmaceutics , Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama
      2015   -   JPRN-UMIN000015433   Japan;
   Department of Orthopaedic Surgery,Graduate School of Medicine, Osaka City University Medical School
      2013   Phase 4   JPRN-UMIN000012073   Japan;
   Dr. Mohammad Mamun Khan
      2019   Phase 4   NCT04464642   Bangladesh;
   Eli Lilly Japan K.K.
      -   Phase 3   JPRN-JapicCTI-132134   -
   Eli Lilly and Company
      2012   Phase 3   NCT01711359   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Puerto Rico;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2012   Phase 3   NCT01710358   Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2011   Phase 2   NCT01469013   Japan;
      2010   Phase 3   NCT01198002   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2010   Phase 2   NCT01185353   Argentina;Croatia;Czech Republic;Czechia;Hungary;India;Mexico;Peru;Poland;Romania;Ukraine;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2006   -   EUCTR2005-002396-33-FI   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002395-15-FI   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Flinders University
      2017   Phase 4   NCT03254589   Australia;
   GILEAD SCIENCES INCORPORATED
      2017   Phase 3   EUCTR2016-000568-41-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Gema Biotech S.A.
      2016   Phase 3   NCT03332719   Argentina;
   Genentech, Inc.
      2010   Phase 4   NCT01163747   United States;
      2010   Phase 2   NCT01225393   Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;Romania;Spain;United States;
      2009   Phase 2   NCT00808210   United States;
      2008   Phase 3   NCT00673920   United States;
      2007   Phase 3   NCT00485589   United States;
      2007   Phase 3   NCT00476996   Argentina;Australia;Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Panama;Peru;Poland;Slovakia;Slovenia;Spain;Sweden;Switzerland;Taiwan;United States;
      2006   Phase 3   NCT00406419   United States;
      2006   Phase 3   NCT00299104   United States;
      2006   Phase 3   NCT00266227   United States;
      2006   Phase 2   NCT00282308   United States;
      2005   Phase 3   NCT00299130   United States;
      2005   Phase 2   NCT00243412   United States;
      2003   Phase 2   NCT00074438   United States;
   General Hospital of Chengdu Military Region
      2014   Phase 1 study   ChiCTR-TRC-14004520   China;
   Gilead Sciences
      2016   Phase 2   NCT02885181   Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
      2016   Phase 2   NCT02862574   Australia;Hungary;Taiwan;United States;
   GlaxoSmithKline
      2019   Phase 3   NCT03980483   Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 1/Phase 2   NCT03028467   Japan;
   Goupe d'Etudes et de Recherche Clinique En Rhumatologie
      2004   Phase 4   NCT00291915   France;
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT04170504   -
      2019   Phase 2/Phase 3   NCT04136262   China;
   Guangdong Provincial Hospital of Chinese Medicine
      2015   -   ChiCTR-IPR-15007368   China;
   Hoffmann-La Roche
      2016   Phase 2   NCT03001219   Argentina;Austria;Colombia;Czech Republic;Czechia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2015   -   NCT02608112   France;
      2014   Phase 3   NCT02046616   Denmark;Finland;Norway;Sweden;
      2014   Phase 3   NCT02046603   United Kingdom;
      2014   Phase 3   NCT02001987   France;
      2014   Phase 3   NCT01987479   Netherlands;
      2013   Phase 4   NCT01878318   Venezuela;
      2013   Phase 3   NCT01995201   Ireland;Portugal;Spain;
      2013   Phase 3   NCT01941095   Greece;
      2013   Phase 3   NCT01855789   United States;
      2012   Phase 3   NCT01587989   Austria;
      2011   Phase 4   NCT01399697   Spain;
      2011   Phase 4   NCT01382940   United States;
      2011   Phase 4   NCT01283971   Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   NCT01353859   Greece;Indonesia;
      2011   Phase 3   NCT01235507   Bosnia and Herzegovina;
      2010   Phase 4   NCT01117129   Spain;
      2010   Phase 3   NCT01063062   Egypt;
      2010   Phase 3   NCT01034137   Netherlands;
      2009   Phase 3   NCT01007435   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, The Former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   Phase 3   NCT00810199   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Monaco;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2009   Phase 3   NCT00754572   Argentina;Brazil;Chile;Colombia;Costa Rica;Ecuador;Mexico;Peru;Uruguay;Venezuela;
      2009   Phase 1   NCT00965653   Canada;New Zealand;Spain;United Kingdom;
      2008   Phase 4   NCT01000610   Tunisia;
      2007   Phase 4   NCT00934648   Morocco;
      2007   Phase 4   NCT00576433   Russian Federation;
      2007   Phase 4   NCT00504777   Taiwan;
      2007   Phase 4   NCT00502853   Italy;
      2007   Phase 4   NCT00462345   Korea, Republic of;
      2007   Phase 4   NCT00424502   Hungary;
      2007   Phase 3   NCT00578305   Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;United Kingdom;
      2007   Phase 3   NCT00535782   Canada;Puerto Rico;United Kingdom;United States;
      2006   Phase 3   NCT02006706   Serbia;
      2006   Phase 3   NCT00502996   Argentina;Brazil;Chile;Colombia;Ecuador;El Salvador;Mexico;Peru;Uruguay;Venezuela;
      2006   Phase 2   NCT00422942   Netherlands;Spain;
      2005   Phase 3   NCT00109408   Argentina;Australia;Canada;China;Croatia;Denmark;Former Serbia and Montenegro;France;Israel;Italy;Lithuania;Mexico;Norway;Peru;Portugal;Serbia;Slovenia;South Africa;Spain;United States;
      2005   Phase 3   NCT00106548   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;France;Germany;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Spain;Switzerland;Thailand;
      2005   Phase 3   NCT00106535   Australia;Brazil;China;Denmark;Finland;France;Greece;Italy;Mexico;Norway;Poland;Puerto Rico;South Africa;Spain;Switzerland;United States;
      2005   Phase 3   NCT00106522   Australia;Belgium;Canada;France;Germany;Iceland;Italy;Mexico;Netherlands;Puerto Rico;Sweden;Switzerland;United Kingdom;United States;
      2005   Phase 1   NCT00365001   New Zealand;United States;
      2004   Phase 3   NCT02097745   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom;United States;
      2003   Phase 3   NCT00468546   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom;United States;
      2002   Phase 2   NCT02093026   Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Germany;Israel;Italy;Mexico;New Zealand;Poland;Spain;Sweden;United Kingdom;United States;
      2001   Phase 2   NCT02693210   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
   Hvidovre University Hospital
      1998   Phase 4   NCT00209859   Denmark;
   Institute of Acupuncture-Moxibustion and Meridian, Shanghai University of Traditional Chinese Medicine
      2013   -   ChiCTR-TRC-13003948   China;
   Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences
      2013   -   ChiCTR-TRC-13002981   -
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of;
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01679951   Argentina;Chile;Colombia;Czech Republic;Czechia;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;United States;
   Japan Association of Rheumatologists in Private Practice
      2010   -   JPRN-UMIN000003807   Japan;
   Jawaharlal Institute of Postgraduate Medical Education & Research
      2016   Phase 3   NCT02930343   India;
      2015   Phase 4   NCT02644499   India;
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2016   Phase 3   NCT02722694   China;
      2013   Phase 4   NCT02275299   China;
      2012   Phase 4   NCT01548001   China;
   Johoku Biological Summit
      2006   Phase 4   JPRN-C000000452   Japan;
   Juan Carlos Nieto
      2018   -   NCT03535519   Spain;
   KONAMON Study Group
      2013   -   JPRN-UMIN000007404   Japan;
   Keio University
      2018   Phase 4   NCT03505008   Japan;Korea, Republic of;Taiwan;
      2012   -   JPRN-UMIN000007432   Japan;
      2009   -   JPRN-UMIN000002744   Japan;
   Keio University Hospital
      2015   -   JPRN-UMIN000018848   Japan;
   King Edward Medical University
      2017   Phase 4   NCT04177173   Pakistan;
   Kinki University Faculty of Medicine, Division of Hematology and Rheumatology
      2012   -   JPRN-UMIN000007380   Japan;
   Korea Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT00993317   Korea, Republic of;
   Leiden University Medical Center
      2018   Phase 4   NCT03492658   Netherlands;
   Lexicon Pharmaceuticals
      2009   Phase 1   NCT00847886   United States;
   Longhua Hospital Shanghai University of Traditional Chinese Medicine
      2018   Phase 4   ChiCTR1900026079   China;
   Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation
      2008   Phase 4   NCT00695188   Austria;
   Maoxiang Group Jilin Pharmaceutical Co., Ltd.
      2014   Phase 2   NCT02029599   China;
   Merck Sharp & Dohme Corp.
      2012   Phase 2   NCT01651936   Australia;Colombia;Denmark;France;Greece;Hungary;Italy;Korea, Republic of;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
      2012   Phase 2   NCT01569152   Canada;Chile;Denmark;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Moldova, Republic of;Peru;Poland;South Africa;Taiwan;United Kingdom;United States;
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
      2010   -   NCT01313858   Germany;
   Modern Biosciences plc
      2015   Phase 1   NCT02480946   United Kingdom;
   Mycenax Biotech Inc.
      2012   Phase 3   NCT01709760   Taiwan;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1998   Phase 2   NCT00001677   United States;
   Nordic Pharma SAS
      2015   Phase 3   NCT02553018   France;
   North Glasgow NHS Trust
      2004   -   EUCTR2004-002006-30-GB   United Kingdom;
   Novartis Pharmaceuticals
      2004   Phase 2   NCT00154336   Austria;Canada;Finland;United Kingdom;
   Nuon Therapeutics, Inc.
      2009   -   EUCTR2008-006917-25-GB   Bulgaria;Czech Republic;Germany;Poland;United Kingdom;
   P. Verschueren
      2009   Phase 4   NCT01172639   Belgium;
   Patrick Durez
      2010   -   NCT01245452   Belgium;
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03589833   China;
      2012   Phase 2/Phase 3   NCT01613079   China;
   Peking University First Hospital
      2021   Phase 4   ChiCTR2100048185   China;
   Pfizer
      2016   Phase 4   NCT02831855   Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2013   -   NCT01558089   Greece;
      2008   Phase 4   NCT00565409   Australia;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;Former Serbia and Montenegro;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;
      2007   Phase 1   NCT00446784   United States;
      2006   Phase 3   NCT00445770   Japan;
      2006   Phase 2   NCT00424294   United States;
   Philogen S.p.A.
      2011   Phase 1   NCT02076659   Italy;
   Postgraduate Institute of Medical Education and Research
      2011   Phase 4   NCT01404429   India;
   ROCHE
      2006   -   EUCTR2005-003694-25-IT   Czech Republic;Italy;Spain;
   Rheumatosurgery, Osaka City University Medical School
      2006   -   JPRN-UMIN000000512   Japan;
   Rottapharm Biotech
      2017   Phase 2   NCT03163966   Czechia;
   Saitama Medical Center. Saitama Medical University
      2012   -   JPRN-UMIN000007786   Japan;
   Saitama Medical University
      2007   Phase 4   NCT00716248   Japan;
   Sanofi
      2018   Phase 4   NCT03449758   France;
      2014   Phase 3   NCT02293902   Japan;
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
      2013   Phase 3   NCT01768572   Argentina;Belgium;Brazil;Czech Republic;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   NCT01764997   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2013   Phase 1   NCT01850680   Japan;
      2012   Phase 3   NCT01709578   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
      2010   Phase 2/Phase 3   NCT01061736   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Philippines;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
   Seoul National University Hospital
      2016   -   NCT02897011   Korea, Republic of;
      2015   Phase 4   NCT02748785   Korea, Republic of;
   Shanghai Guanghua Integrated traditional Chinese and Western Medicine Hospital
      2021   Phase 0   ChiCTR2100046373   China;
   Shanghai Traditional Chinese Medicine Hospital
      2020   Phase 0   ChiCTR2000037675   China;
   Shanxi Medical University
      2012   -   NCT01617590   China;
   SinoMab Pty Ltd
      2014   Phase 2   NCT04192617   China;
   St Luke'
   TIPharma
      2007   -   EUCTR2007-002976-32-NL   Netherlands;
   Takarazuka city hospital
      2014   -   JPRN-UMIN000013362   Japan;
   Takeda
      2015   Phase 2   NCT02393378   Czech Republic;Czechia;Estonia;Russian Federation;Spain;United Kingdom;
      2014   Phase 2   NCT02379091   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Germany;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;
   The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042659   China;
   The Affiliated ZhuZhou Hospital Of XiangYa School Of Medicine CSU.
      2019   Phase 4   ChiCTR2000032534   China;
   The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
      2019   -   ChiCTR1900024902   China;
   The First Affiliated Hospital of Third Military Medical University
      2016   -   ChiCTR-IPR-16008793   China;
   The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041819   China;
   The First Hospital, Jilin University, Changchun
      2014   -   ChiCTR-BOC-16008925   China;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   The Ministry of Science and Technology of the People's Republic of China
      2010   -   ChiCTR-TRC-10000989   China;
   The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
      2020   Phase 4   ChiCTR2100050865   China;
   The Second Hospital of Shanxi Medical University
      2019   Phase 4   ChiCTR1900024261   China;
   The people's hospital, Yichun City
      2014   -   ChiCTR-RNC-14004887   China;
   UCB Pharma
      2009   Phase 1/Phase 2   NCT01009242   Germany;United States;
   UCB Pharma SA
      2012   Phase 3   NCT01519791   Argentina;Australia;Austria;Belgium;Canada;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Mexico;Monaco;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States;
   UCB Pharma SA, Belgium
      2014   Phase 3   NCT02151851   China;
   University of Alabama at Birmingham
      2004   Phase 4   NCT00259610   United States;
      1996   Phase 2   NCT00000395   United States;
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
   University of Leeds
      2019   Phase 4   NCT03813771   United Kingdom;
      2013   Phase 4   NCT04157010   United Kingdom;
      2011   Phase 4   NCT02433184   United Kingdom;
      2006   Phase 4   NCT01308255   United Kingdom;
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
      2001   Phase 3   NCT00579644   -
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
   VA Office of Research and Development
      2007   -   NCT00405275   Canada;United States;
   Vastra Gotaland Region
      2020   Phase 4   NCT04311567   Sweden;
      2017   -   NCT03440892   Sweden;
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2007-000896-41-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2008   -   EUCTR2007-000896-41-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00706797   Austria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;United States;
      2004   Phase 4   NCT00252668   -
      2004   Phase 4   NCT00195494   United States;
   Xian-Janssen Pharmaceutical Ltd.
      2007   Phase 4   NCT00896168   -
   Yunnan Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041894   China;
   Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine)
      2021   Phase 0   ChiCTR2100042328   China;
   Yunnan Hospital of Traditional Chinese Medicine /The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041777   China;
   Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042440   China;
   Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041821   China;
   Yunnan Traditional Chinese Medicine Hospital
      2021   Phase 0   ChiCTR2100041909   China;
   medac GmbH
      2019   Phase 3   JPRN-JapicCTI-194928   Japan;
   s International Hospital
Methotrexate 'Lederle' 2,5mg tablets   
   Roche Nederland B.V.
      2009   -   EUCTR2009-013316-12-NL   Netherlands;
Methotrexate 'Lederle' 2.5mg Tablets   
   F Hoffmann-La Roche Ltd
      2008   Phase 3   EUCTR2008-001847-20-FR   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-NL   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-ES   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   F Hoffmann-La Roche Ltd.
      2009   -   EUCTR2008-001847-20-SE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-001847-20-GR   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-001847-20-DE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2008-001847-20-GB   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-LV   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-EE   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-DK   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2010   Phase 3   EUCTR2009-012759-12-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-SE   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-PT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-IE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-HU   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-GR   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-ES   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-FI   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DK   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-AT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
   Roche Farma, S.A.
      -   -   EUCTR2011-001626-15-ES   Spain;
   Roche Products Limited
      2012   Phase 4   EUCTR2011-005260-20-GB   United Kingdom;
Methotrexate 'Lederle' Tablets   
   F. Hoffmann-La Roche Ltd.
      2009   Phase 3   EUCTR2009-012759-12-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Methotrexate (MTX)   
   Antares Pharma Inc.
      2011   Phase 1/Phase 2   NCT01737944   United States;
   Astellas Pharma Global Development, Inc.
      2016   Phase 1   NCT02867306   Moldova, Republic of;
   Astellas Pharma Inc
      2011   Phase 3   NCT01451203   Japan;
   Bristol-Myers Squibb
      2007   Phase 3   NCT00547521   Australia;Brazil;Canada;Mexico;Peru;South Africa;United States;
   Centocor, Inc.
      2010   Phase 3   NCT01248780   China;
      2009   Phase 3   NCT00973479   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
   Chelsea Therapeutics
      2010   Phase 2   NCT01116141   -
      2008   Phase 2   NCT00658047   Canada;
   Janssen Biotech, Inc.
      2009   Phase 3   NCT01004432   Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
   Janssen Pharmaceutical K.K.
      2008   Phase 3   NCT00727987   Japan;
   Maria Stoenoiu
      2015   Phase 3   NCT02837146   Belgium;
   Novartis
      2007   Phase 2   NCT00487825   Belgium;Germany;Italy;Netherlands;Spain;United States;
   Novartis Pharma Services AG
      2007   -   EUCTR2006-001553-10-DE   Germany;Italy;Netherlands;
   Pfizer
      2011   -   NCT01557322   -
      2005   Phase 1   NCT01745055   United States;
   Sanofi
      2010   Phase 2   NCT01217814   Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
   UCB Pharma SA
      2011   Phase 4   NCT01500278   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Methotrexate (Metoject® prefilled pen)   
   medac GmbH
      2012   Phase 1   NCT01871961   United States;
Methotrexate (stable dose)   
   Hoffmann-La Roche
      2012   Phase 4   NCT01661140   United Kingdom;
Methotrexate (tapering dose)   
   Hoffmann-La Roche
      2012   Phase 4   NCT01661140   United Kingdom;
Methotrexate + Infliximab   
   Université Catholique de Louvain
      2003   Phase 4   NCT00396747   Belgium;
Methotrexate + Methylprednisolone   
   Université Catholique de Louvain
      2003   Phase 4   NCT00396747   Belgium;
Methotrexate + biologic administration   
   University Hospital, Strasbourg, France
      2016   Phase 4   NCT02714634   France;
Methotrexate + salazopyrine + hydroxychloroquine administration   
   University Hospital, Strasbourg, France
      2016   Phase 4   NCT02714634   France;
Methotrexate - Amneal   
   Amneal Pharmaceuticals, LLC
      2016   Phase 1   NCT02940561   India;
Methotrexate - DAVA   
   Amneal Pharmaceuticals, LLC
      2016   Phase 1   NCT02940561   India;
Methotrexate - Delay   
   University Hospital, Montpellier
      2013   Phase 3   NCT01942174   France;Monaco;
Methotrexate - Immediate   
   University Hospital, Montpellier
      2013   Phase 3   NCT01942174   France;Monaco;
Methotrexate - etanercept - prednisolone arm   
   Seattle Children's Hospital
      2007   Phase 4   NCT00443430   United States;
Methotrexate 10 mg tablets   
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Methotrexate 2.5 mg tablets   
   AbbVie Deutschland GmbH & Co. KG
      2016   Phase 3   EUCTR2015-003376-75-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003334-27-RO   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Eli Lilly and Company
      2013   Phase 3   EUCTR2012-002324-32-BE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-SE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-PT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-DE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-AT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
Methotrexate 2.5mg Tablets   
   AbbVie Deutschland GmbH & Co. KG
      2016   Phase 3   EUCTR2015-003376-75-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003334-27-RO   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Eli Lilly and Company
      2013   Phase 3   EUCTR2012-002324-32-GB   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002324-32-BE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-SE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-PT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-DE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-AT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
   Roche Products Limited
      2012   Phase 4   EUCTR2011-005260-20-GB   United Kingdom;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2010   Phase 4   EUCTR2008-002623-85-SE   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   Phase 4   EUCTR2008-002623-85-FR   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2008-002623-85-ES   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Methotrexate 2.5mg Tablets BP   
   PFIZER INC
      2017   Phase 3   EUCTR2016-001825-15-IT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Poland;Slovakia;Spain;
   Pfizer Inc.
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-SK   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-CZ   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-PL   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-GB   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BG   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BE   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
Methotrexate 50mg/ml solution for injection, pre-filled syringe   
   medac Gesellschaft für klinische Spezialpräparate mbH
      -   -   EUCTR2007-003591-19-DE   Germany;
Methotrexate Disodium   
   F. Hoffmann-La Roche Ltd.
      2010   Phase 3   EUCTR2009-012759-12-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-IE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-HU   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-GR   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-ES   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-DE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      -   -   EUCTR2005-002969-37-DE   Germany;Spain;Sweden;
   Roche Farma, S.A.
      -   -   EUCTR2011-001626-15-ES   Spain;
Methotrexate Ebewe   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2015   Phase 3   EUCTR2015-001275-50-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
   Bristol-Myers Squibb International Corporation
      2016   Phase 3   EUCTR2015-001275-50-RO   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2016   Phase 3   EUCTR2015-001275-50-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2016   Phase 3   EUCTR2015-001275-50-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-FI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-ES   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-CZ   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
Methotrexate Lederle 2.5 mg Tablets   
   ROCHE
      2009   -   EUCTR2008-001847-20-IT   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
Methotrexate Pfizer 2,5 mg tabletter   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Methotrexate Placebo   
   Bristol-Myers Squibb K.K.
      2015   Phase 3   JPRN-JapicCTI-153081   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Methotrexate Sodium   
   PFIZER
      2010   Phase 3   EUCTR2009-016987-34-ES   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Poland;Slovakia;Spain;Sweden;
Methotrexate Sodium 2.5mg Tablets   
   F. Hoffmann-La Roche Ltd
      2006   Phase 2   EUCTR2005-003694-25-ES   Czech Republic;Italy;Spain;
      2006   -   EUCTR2005-003694-25-CZ   Czech Republic;Italy;Spain;
Methotrexate Sodium Tablets   
   Pfizer Inc.
      2011   -   EUCTR2010-020890-18-CZ   Czech Republic;Hungary;
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-020890-18-HU   Czech Republic;Hungary;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2010   Phase 4   EUCTR2008-002623-85-SE   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
      2008   -   EUCTR2007-000896-41-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Methotrexate Sodium tablets   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   Phase 4   EUCTR2008-002623-85-FR   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Methotrexate ``Lederle`` 2.5mg tablets   
   F. Hoffmann-La Roche Ltd.
      2009   Phase 3   EUCTR2009-012759-12-IT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Methotrexate as methotrexate disodium   
   F Hoffmann-La Roche Ltd.
      2009   -   EUCTR2008-001847-20-SE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-001847-20-DE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2008-001847-20-GB   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-LV   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-DK   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2009-012759-12-SE   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-PT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-FI   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DK   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-AT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
   Roche Austria GmbH
      2011   -   EUCTR2011-001863-39-AT   Austria;
   Roche Products Limited
      2012   Phase 4   EUCTR2011-005260-20-GB   United Kingdom;
Methotrexate capsules   
   Centocor, Inc.
      2005   Phase 3   NCT00264537   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Methotrexate disodium   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2012   -   EUCTR2012-000222-21-DE   Germany;
      -   -   EUCTR2007-003591-19-DE   Germany;
Methotrexate plus ENBREL or ENBREL alone   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   Phase 4   NCT00244556   -
Methotrexate plus ERB-041 for 12 weeks   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   Phase 2   NCT00141830   Canada;Hungary;Italy;Mexico;Spain;United States;
Methotrexate plus sulfasalazine   
   Singapore General Hospital
      2012   Phase 4   NCT01659242   Singapore;
Methotrexate pre-filled pen   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2012   -   EUCTR2012-000222-21-DE   Germany;
Methotrexate prefilled pen   
   medac GmbH
      2012   Phase 3   NCT01793259   Germany;
Methotrexate prefilled syringe   
   medac GmbH
      2012   Phase 3   NCT01793259   Germany;
Methotrexate sodium   
   F. Hoffmann La-Roche AG
      2005   -   EUCTR2005-001138-33-LT   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
Methotrexate sodium 2.5mg tablets   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2016   Phase 3;Phase 4   EUCTR2014-000358-13-DE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-HR   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-ES   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-RO   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LV   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LT   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-GB   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-EE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-CZ   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-BG   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-PL   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Methotrexate sodium tablets   
   Centocor B.V.
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   F. Hoffmann La-Roche AG
      2005   Phase 3   EUCTR2005-001138-33-NO   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   Phase 3   EUCTR2005-001138-33-ES   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-PT   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-DK   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      -   -   EUCTR2005-001138-33-SI   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Methotrexate tablets   
   Gilead Sciences, Inc.
      2017   Phase 3   EUCTR2016-000570-37-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Methotrexate treatment   
   University Hospital, Bordeaux
      2020   Phase 2   NCT04196868   France;
Methotrexate ® 2.5mg Tablets   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
Methotrexate(MTX)   
   Shanghai Henlius Biotech
      2018   Phase 3   NCT03522415   China;
Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol   
   Millennium Pharmaceuticals Inc
      2006   -   EUCTR2005-006165-14-NL   Czech Republic;Netherlands;United Kingdom;
Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.   
   Millennium Pharmaceuticals Inc
      2006   Phase 2   EUCTR2005-006165-14-GB   Czech Republic;Netherlands;United Kingdom;
      2006   -   EUCTR2005-006165-14-CZ   Czech Republic;Netherlands;United Kingdom;
Methotrexate(necessary)   
   Fen Li
      2016   Phase 4   NCT02878161   -
Methotrexate, Leucovorin and BMS-986142   
   Bristol-Myers Squibb
      2015   Phase 1   NCT02456844   -
Methotrexate,Adalimumab   
   Bristol-Myers K.K.
      2011   Phase 2   JPRN-JapicCTI-111628   -
Methotrexate-Lachema   
   Wyeth Pharmaceuticals
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Methotrexate-Sulfasalazine-Hydroxychloroquine   
   University of Nebraska
      1999   Phase 3   NCT00579878   United States;
Methotrexate® 2.5 mg tablets   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-PL   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-DK   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-CZ   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-BG   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
Methotrextate   
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-CZ   Bulgaria;Czech Republic;
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Methoxsalen   
   Mallinckrodt
      2003   Phase 2   NCT00221000   Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa;United States;
   THERAKOS
      2005   -   EUCTR2004-001825-69-IT   Italy;
Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-beta-Dribofuronamide   
   Can-Fite BioPharma Ltd.
      2008   -   EUCTR2007-006527-13-BG   Bulgaria;
Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide   
   Can-Fite BioPharma Ltd.
      2008   -   EUCTR2007-006527-13-BG   Bulgaria;
Methylaminopterin   
   Centocor B.V.
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
Methylene blue mediated Photodynamic therapy   
   Zohaib Akram
      2019   -   NCT05122117   Saudi Arabia;
Methylprednisolone   
   Biogen
      2006   Phase 2   NCT00298272   United States;
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Genentech, Inc.
      2009   Phase 2   NCT00808210   United States;
      2006   Phase 3   NCT00299104   United States;
      2005   Phase 3   NCT00299130   United States;
      2005   Phase 2   NCT00243412   United States;
   Hoffmann-La Roche
      2011   Phase 4   NCT01382940   United States;
      2011   Phase 4   NCT01219933   Belgium;
      2008   Phase 4   NCT01000610   Tunisia;
      2007   Phase 3   NCT00578305   Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;United Kingdom;
      2006   Phase 3   NCT02006706   Serbia;
      2002   Phase 2   NCT02093026   Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Germany;Israel;Italy;Mexico;New Zealand;Poland;Spain;Sweden;United Kingdom;United States;
   Hokusuikai Kinen Hospital
      2018   -   JPRN-UMIN000033059   Japan;
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
   Nekoyama Miyao Hospital
      2017   -   JPRN-UMIN000029759   Japan;
      2017   -   JPRN-UMIN000029003   Japan;
      2013   -   JPRN-UMIN000012257   Japan;
   Nekoyama miyao hospital
      2012   -   JPRN-UMIN000011181   Japan;
      2012   -   JPRN-UMIN000010902   Japan;
   Pfizer
      2008   Phase 2   NCT00634933   Austria;Belgium;Canada;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;United States;
   University of Leeds
      2007   Phase 3   EUCTR2006-005640-81-GB   United Kingdom;
      2006   Phase 4   NCT01308255   United Kingdom;
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
      2006   Phase 4   EUCTR2005-004582-41-GB   United Kingdom;
Methylprednisolone Sodium Succinate   
   Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
      2009   -   EUCTR2007-006150-25-DE   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
      2008   -   EUCTR2007-006150-25-HU   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
Methylprednisone   
   Genentech, Inc.
      2006   Phase 2   NCT00282308   United States;
Metoject   
   Karolinska Institutet
      2014   Phase 4   EUCTR2011-004720-35-DK   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
   The Karolinska Institute, ClinTRID
      2012   -   EUCTR2011-004720-35-SE   Sweden;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   The Karolinska Instutute, ClinTRID
      2013   Phase 4   EUCTR2011-004720-35-IS   Denmark;Finland;Iceland;Norway;Sweden;
Metotab®   
   Abbott GmbH & Co. KG
      2008   -   EUCTR2006-004139-31-GR   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
Metotrexat Orion   
   Västra Götalandsregionen
      2020   Phase 4   EUCTR2019-004179-38-SE   Sweden;
Metotrexato   
   Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   Phase 4   EUCTR2018-004558-30-PT   Portugal;Spain;
      2020   Phase 4   EUCTR2018-004558-30-DK   Denmark;Portugal;Spain;
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2008   -   EUCTR2007-000896-41-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Metronidazol   
   Dra Beatriz Lozano-Hospital Universitario de Canarias
      2018   Phase 4   EUCTR2017-003259-40-ES   Spain;
Mextrex   
   University of Leeds
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
Micellar Paclitaxel for Injection   
   Angiotech Pharmaceuticals
      2002   Phase 2   NCT00055133   United States;
Microgynon® 30 (Oral contraceptive)   
   AstraZeneca
      2011   Phase 1   NCT01276262   United Kingdom;
Midazolam   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Janssen Research & Development, LLC
      2012   Phase 1   NCT01636557   Germany;Korea, Republic of;Moldova, Republic of;South Africa;
   R-Pharm International, LLC
      2021   Phase 1   NCT04246762   Bulgaria;Moldova, Republic of;
Milnacipran   
   Brigham and Women's Hospital
      2011   Phase 4   NCT01207453   United States;
   University of California, Los Angeles
      2010   Phase 4   NCT01225991   United States;
Minocycline   
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
Minodronate   
   Department of Orthopaedic Surgery Shinshu University School of Medicine
      2016   -   JPRN-UMIN000022364   Japan;
Minodronic acid   
   Osaka University Graduate School of Medicine
      2012   -   JPRN-UMIN000011087   Japan;
Misoprostol   
   Korea Otsuka Pharmaceutical Co.,Ltd.
      2007   Phase 3   NCT00576706   Korea, Republic of;
Mizoribine   
   Sanofi
      2015   Phase 3   NCT02373202   Japan;
Modal   
   Peking Union Medical College Hospital
      2019   -   NCT04297475   China;
Moderna mRNA-1273   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Montelukast   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Sherief Abd-Elsalam
      2018   Phase 3   NCT03770923   Egypt;
Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142   
   Bristol-Myers Squibb
      2015   Phase 1   NCT02456844   -
Morphine   
   Hokusuikai Kinen Hospital
      2018   -   JPRN-UMIN000033059   Japan;
   Nekoyama Miyao Hospital
      2013   -   JPRN-UMIN000012257   Japan;
   Nekoyama miyao hospital
      2012   -   JPRN-UMIN000011181   Japan;
      2012   -   JPRN-UMIN000010902   Japan;
Morphine Hexal   
   Charité University medicine Berlin
      2015   Phase 2   EUCTR2015-000538-31-DE   Germany;
Morphinsulfat   
   Charité University medicine Berlin
      2015   Phase 2   EUCTR2015-000538-31-DE   Germany;
Moxifloxacin   
   AstraZeneca
      2009   Phase 1   NCT00887770   United Kingdom;
MultiSpectral Imaging System   
   University of Rochester
      2019   Phase 1   NCT04046146   United States;
      2015   Phase 1   NCT02680067   United States;
Multigrain powder (S)   
   Universiti Sains Malaysia
      2019   -   NCT04033809   Malaysia;
Mushroom extract   
   Egil Johnson
      2016   -   NCT01815411   Norway;
Mussel oil capsules   
   Zhejiang University
      2014   -   NCT02173587   China;
N-3 LC-PUFA   
   University of Jena
      2004   -   NCT00638950   Germany;
N.A.   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2016   Phase 3   EUCTR2015-003332-13-IT   Argentina;Australia;Austria;Barbados;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Eli Lilly and Company
      2009   -   EUCTR2009-009696-34-DE   Argentina;Chile;Germany;India;Korea, Republic of;Peru;Poland;Romania;Russian Federation;Taiwan;
   Neovacs SA
      2010   -   EUCTR2009-012041-35-BE   Argentina;Belgium;Bulgaria;Chile;Croatia;France;Romania;
NC-503 (Anti-amyloidotic (AA) Agent)   
   Bellus Health Inc
      2001   Phase 2/Phase 3   NCT00035334   Finland;France;Israel;Italy;Lithuania;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
NI-0101   
   NovImmune S.A.
      2017   Phase 2   EUCTR2016-005017-45-PL   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
      2017   Phase 2   EUCTR2016-005017-45-HU   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
      2017   Phase 2   EUCTR2016-005017-45-GB   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
      2017   Phase 2   EUCTR2016-005017-45-BG   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;United Kingdom;
   NovImmune SA
      2017   Phase 2   NCT03241108   Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia;
NI-071   
   Nichi-Iko Pharmaceutical Co., Ltd.
      2017   Phase 3   EUCTR2016-001064-11-PL   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001064-11-GB   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001064-11-ES   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001064-11-CZ   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02990806   Czechia;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Nichi-Iko Pharmaceutical Co.,Ltd.
      2013   Phase 3   NCT01927263   Japan;
NNC 0109-0000-0012   
   NOVO NORDISK
      2011   -   EUCTR2010-021283-14-IT   Hungary;Italy;Portugal;Spain;United Kingdom;
   Novo Nordisk A/S
      2011   Phase 2   EUCTR2010-021283-14-PT   Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-HU   Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-GB   Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-ES   Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-021283-14-CZ   Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
NNC 0141-0000-0100   
   Innate Pharma
      2011   Phase 1   NCT01370902   Germany;
NNC 0142-0000-0002   
   Novo Nordisk A/S
      2010   -   EUCTR2010-019261-28-DE   Germany;
NNC 0151-0000-0000   
   Novo Nordisk A/S
      2011   Phase 2   NCT01223911   Czech Republic;Denmark;Hungary;Poland;Romania;United Kingdom;
      2008   Phase 1   NCT02151409   Netherlands;
NNC 142-0002   
   Novo Nordisk A/S
      2010   -   EUCTR2010-019261-28-DE   Germany;
NNC0109-0012   
   Novo Nordisk A/S
      2014   Phase 2   NCT02097264   Ireland;Portugal;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-001492-20-PT   Ireland;Portugal;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-001492-20-ES   Ireland;Portugal;Spain;United Kingdom;
      2013   Phase 2   EUCTR2013-001492-20-GB   Belgium;Czech Republic;Germany;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2012   Phase 2   NCT01636843   Argentina;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
      2012   Phase 2   NCT01636817   Argentina;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Hungary;Italy;Mexico;Poland;Spain;United Kingdom;United States;
NNC0114-0000-0005   
   Novo Nordisk A/S
      2010   Phase 1   NCT01208506   Germany;
NNC0114-0006   
   Novo Nordisk A/S
      2012   Phase 2   NCT01647451   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
      2012   Phase 1   NCT01565408   Germany;Russian Federation;
NNC0142-0002   
   Janssen Research & Development, LLC
      2010   Phase 2   NCT01181050   Germany;Russian Federation;Ukraine;
      2009   Phase 1   NCT00927927   Germany;
NNC0151-0000-0000   
   Novo Nordisk A/S
      2012   -   EUCTR2009-011791-30-HU   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-011791-30-GB   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-DK   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-CZ   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
NNC0215-0384   
   Novo Nordisk A/S
      2013   Phase 1   NCT01955603   Germany;Hungary;Poland;Russian Federation;
      2012   Phase 1   NCT01611688   Germany;
NNC109-0012   
   Novo Nordisk A/S
      2011   Phase 2   NCT01282255   Czech Republic;Germany;Italy;Poland;Portugal;Romania;Spain;United Kingdom;
NNC151-0000   
   Novo Nordisk A/S
      2012   -   EUCTR2009-011791-30-HU   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-011791-30-GB   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-DK   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-CZ   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
NSAIDs   
   Hoffmann-La Roche
      2017   -   NCT03112213   Germany;
NSAIDs (permitted,not necessary)   
   Fen Li
      2016   Phase 4   NCT02878161   -
Namilumab   
   TAKEDA PHARMACEUTICAL COMPANY LTD.
      2015   Phase 2   JPRN-JapicCTI-152979   -
   Takeda
      2015   Phase 2   NCT02393378   Czech Republic;Czechia;Estonia;Russian Federation;Spain;United Kingdom;
      2014   Phase 2   NCT02379091   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Germany;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;
Namilumab (MT203)   
   Takeda
      2011   Phase 1   NCT01317797   Bulgaria;Netherlands;
Nanobubble drink   
   University of Oxford
      2021   -   NCT04844008   United Kingdom;
Nanocort   
   Sun Pharma Global FZE
      2016   Phase 3   EUCTR2015-002924-17-BE   Belgium;Netherlands;
      2015   Phase 3   EUCTR2015-002924-17-NL   Belgium;Netherlands;
Nanoparticulated Rebamipide   
   Cairo University
      2020   Phase 3   NCT04649697   -
Naprosyn   
   Asahi Kasei Pharma Corporation
      2011   -   EUCTR2010-021558-21-SK   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-HU   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2011   -   EUCTR2010-021558-21-GB   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-DE   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2010   -   EUCTR2010-021558-21-CZ   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2009   -   EUCTR2008-006075-75-HU   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-GB   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-DE   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-CZ   Czech Republic;Germany;Hungary;United Kingdom;
Naproxen   
   Asahi Kasei Pharma Corporation
      2011   -   EUCTR2010-021558-21-SK   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-HU   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2011   -   EUCTR2010-021558-21-GB   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-DE   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2010   -   EUCTR2010-021558-21-CZ   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2009   -   EUCTR2008-006075-75-HU   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-GB   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-DE   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-CZ   Czech Republic;Germany;Hungary;United Kingdom;
   Boehringer Ingelheim
      2000   Phase 3   NCT00279747   Austria;Belgium;France;Germany;Italy;Russian Federation;United Kingdom;
   Cubist Pharmaceuticals LLC
      2007   Phase 2   NCT00626275   United States;
   Pfizer
      2003   Phase 4   NCT00650455   Canada;United States;
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2006   Phase 4   NCT00346216   Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine;United States;
   Rheumatology clinic at Al-Kindy Teaching Hospital /Baghdad/Iraq
      2020   -   JPRN-UMIN000042632   Asia(except Japan);
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)   
   Sandoz
      2002   Phase 1   NCT00959439   -
Naproxen 500 mg tablets (PN 200 minus omeprazole)   
   POZEN
      2006   Phase 3   NCT00367211   United States;
Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)   
   Sandoz
      2002   Phase 1   NCT00959439   -
Naproxen oral suspension   
   Boehringer Ingelheim
      2000   Phase 3   NCT00034853   Argentina;Brazil;Mexico;Ukraine;United States;
Naproxen sodium 550mg tablet   
   Inova Health Care Services
      2018   Phase 4   NCT03699293   United States;
Nasopharyngeal swabs   
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04584541   France;
Natalizumab   
   Biogen
      2004   Phase 2   NCT00831649   -
      2004   Phase 2   NCT00083759   Canada;United States;
Natriumklorid 9mg/ml   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   -   EUCTR2013-003486-34-DK   Denmark;
Nerve block   
   Sohag University
      2019   -   NCT04130178   Egypt;
New Formulation Etanercept   
   Amgen
      2016   Phase 3   NCT02986139   Puerto Rico;United States;
New formulation adalimumab   
   AbbVie (prior sponsor, Abbott)
      2012   Phase 2   NCT01752855   Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Niclosamide   
   Faiq Gorial
      2017   Phase 1/Phase 2   NCT03160001   Iraq;
Nimesulide   
   Anhui Medical University
      2008   Phase 3 study   ChiCTR-TRC-10000850   China;
Nipocalimab   
   Janssen Research & Development, LLC
      2021   Phase 2   NCT04991753   Germany;Poland;Spain;United Kingdom;United States;
   Janssen-Cilag International NV
      2021   Phase 2   EUCTR2021-000510-42-ES   Germany;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-000510-42-DE   Germany;Poland;Spain;United Kingdom;United States;
NiuBangZi pill   
   Cui xuejun
      2018   Phase 2/Phase 3   NCT03173040   China;
Nivolumab   
   Alliance Foundation Trials, LLC.
      2019   Phase 1   NCT03656627   United States;
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States;
No   
   Vienna Medical University
      2006   -   EUCTR2006-000854-32-AT   Austria;
Non-Biologic DMARDs   
   Hoffmann-La Roche
      2014   Phase 3   NCT02046616   Denmark;Finland;Norway;Sweden;
      2014   Phase 3   NCT01987479   Netherlands;
Non-active stimulation   
   SetPoint Medical Corporation
      2021   Phase 3   NCT04539964   United States;
Non-anti-TNF biologics   
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States;
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00124982   Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
Non-biologic anti-rheumatic drugs   
   Pfizer
      2012   -   NCT01646385   -
Non-biological DMARD's   
   Karolinska Institutet
      2012   Phase 4   NCT01491815   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
Non-biological DMARDs   
   Hoffmann-La Roche
      2010   Phase 4   NCT01034397   Portugal;
Non-steroidal anti-inflammatory drug   
   Sucampo Pharma Americas, LLC
      2007   Phase 2   NCT00597818   United States;
Non-steroidal anti-inflammatory drug (NSAID)   
   Chinese Academy of Sciences
      2012   -   NCT01619176   China;
Non-steroidal anti-inflammatory drugs   
   Hoffmann-La Roche
      2005   Phase 3   NCT00720798   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Non-surgical periodontal therapy   
   Zohaib Akram
      2019   -   NCT05122117   Saudi Arabia;
Nonbiologic DMARDs of investigator's choice   
   Hoffmann-La Roche
      2009   Phase 3   NCT00891020   Puerto Rico;United Kingdom;United States;
None   
   AstraZeneca AB
      2008   -   EUCTR2007-001420-12-CZ   Czech Republic;France;Poland;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-SK   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-FR   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   -   EUCTR2007-001420-12-SE   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-PL   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-BE   Belgium;Czech Republic;France;Poland;Sweden;
   MERCK SHARP & DOHME CORP.
      2012   -   EUCTR2012-000439-17-LT   Brazil;Canada;Chile;Denmark;Germany;Hungary;India;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as
      2013   -   EUCTR2012-002181-12-SE   Australia;Austria;Brazil;Colombia;Denmark;France;Greece;Hungary;Italy;New Zealand;Peru;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   University of Leeds
      2005   Phase 4   EUCTR2005-000674-43-GB   United Kingdom;
None as of yet   
   Lexicon Pharmaceuticals, Inc.
      2009   -   EUCTR2009-012705-19-HU   Bulgaria;Czech Republic;Hungary;
      2009   -   EUCTR2009-012705-19-CZ   Bulgaria;Czech Republic;Hungary;
      2009   -   EUCTR2009-012705-19-BG   Bulgaria;Czech Republic;Hungary;
Normal Saline   
   Mesoblast, Ltd.
      2013   Phase 2   NCT01851070   Australia;United States;
Norspan   
   The Chinese University of Hong Kong
      2014   Phase 1 study   ChiCTR-TCS-14004252   -
Nulojix   
   Bristol-Myers Squibb
      2014   -   NCT02500498   -
OM 89.   
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
ORENCIA 125 mg solution for injection   
   King’s College London
      2014   Phase 2   EUCTR2013-003413-18-GB   Netherlands;United Kingdom;
   Leiden University Medical Center
      2017   Phase 2   EUCTR2013-003413-18-NL   Netherlands;United Kingdom;
ORENCIA 125 mg solution for injection in pre-filled syringe   
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
ORENCIA 125 mg, solution injectable en seringue préremplie   
   Groupement des Hôpitaux de l’Institut Catholique de Lille
      2017   Phase 4   EUCTR2017-000947-41-FR   France;
ORENCIA 250 mg polvo para concentrado para sol. para perfusión   
   Novartis Farmacéutica S.A.
      2011   -   EUCTR2011-000102-21-ES   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
ORENCIA 250mg powder for concentrate for solution for infusion   
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 3   EUCTR2016-000933-37-BG   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-SE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-PT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-NL   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-DE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-CZ   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-BE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-LV   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-HU   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-ES   Argentina;Australia;Belarus;Brazil;Canada;Chile;Colombia;European Union;Hungary;Israel;Korea, Democratic People's Republic of;Latvia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;United States;
ORENCIA Subcutaneous Injection   
   Bristol-Myers Squibb
      2016   -   NCT02758769   Japan;
ORENCIA*IV 2FL 250MG+2SIR   
   NOVARTIS FARMA
      2011   -   EUCTR2011-000102-21-IT   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
OTL38   
   University Medical Center Groningen
      2022   Phase 1   NCT03938701   Netherlands;
OXICODONE DC.IT   
   A.U.S.L. RIMINI
      2006   -   EUCTR2006-004062-13-IT   Italy;
Observational study   
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of;
Ocrelizumab   
   Chugai Pharmaceutical
      2008   Phase 2   NCT00779220   Japan;
   Chugai Pharmaceutical Co., Ltd.
      2009   Phase 3   JPRN-JapicCTI-090764   -
      -   Phase 3   JPRN-JapicCTI-070479   -
      -   Phase 2   JPRN-JapicCTI-080650   -
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2006-005330-20-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2008   Phase 3   EUCTR2007-005759-41-GB   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005759-41-FR   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005759-41-ES   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005353-30-GB   Austria;Italy;Lithuania;Spain;United Kingdom;
      2008   -   EUCTR2007-005759-41-DE   France;Germany;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005330-20-SK   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005330-20-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005330-20-BE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005147-28-GB   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-FR   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-DE   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-BE   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-AT   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   -   EUCTR2006-005353-30-LT   Argentina;Australia;Austria;Brazil;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2007   -   EUCTR2006-005353-30-AT   Austria;Italy;Lithuania;Spain;United Kingdom;
      2007   -   EUCTR2006-005330-20-SI   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-SE   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005147-28-GR   Austria;France;Germany;Greece;Spain;United Kingdom;
   Genentech, Inc.
      2009   Phase 2   NCT00808210   United States;
      2008   Phase 3   NCT00673920   United States;
      2007   Phase 3   NCT00485589   United States;
      2007   Phase 3   NCT00476996   Argentina;Australia;Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Panama;Peru;Poland;Slovakia;Slovenia;Spain;Sweden;Switzerland;Taiwan;United States;
      2006   Phase 3   NCT00406419   United States;
      2004   Phase 1/Phase 2   NCT00077870   United States;
   Hoffmann-La Roche
      2005   Phase 1/Phase 2   NCT02720120   Australia;Belgium;Canada;Netherlands;New Zealand;Russian Federation;Spain;United Kingdom;
   ROCHE
      2008   -   EUCTR2007-005759-41-IT   France;Germany;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-005353-30-IT   Austria;Italy;Lithuania;Spain;United Kingdom;
      2007   -   EUCTR2006-005330-20-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
Ocrelizumab / rhuMAb 2H7   
   F. Hoffmann-La Roche Limited
      2008   Phase 1;Phase 2   EUCTR2004-002132-26-GB   Spain;United Kingdom;
Ocrelizumabu   
   Chugai Pharmaceutical
      2008   Phase 2   NCT00779220   Japan;
Ofatumumab   
   GENMAB A/S
      2007   -   EUCTR2007-002945-18-IT   Czech Republic;Italy;
   Genmab A/S
      2008   Phase 3   EUCTR2007-002951-18-FR   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-SE   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-DK   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002950-42-BE   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   Phase 3   EUCTR2007-002951-18-IT   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-002951-18-ES   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-002951-18-NL   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-002950-42-LT   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-HU   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-ES   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002945-18-CZ   Czech Republic;
   GlaxoSmithKline
      2008   Phase 3   NCT00611455   Argentina;Australia;Belgium;Chile;Czech Republic;Czechia;Hungary;Peru;Poland;Romania;Russian Federation;South Africa;Spain;United Kingdom;
      2008   Phase 3   NCT00603525   Argentina;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Norway;Peru;Spain;Sweden;United Kingdom;
      2008   Phase 2   NCT00655824   Denmark;Hungary;Poland;United Kingdom;United States;
      2008   Phase 1   NCT00686868   Australia;Belgium;Canada;France;Germany;Hungary;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;United States;
   GlaxoSmithKline Research & Development
      2008   Phase 3   EUCTR2007-002951-18-GB   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-DE   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002950-42-GB   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2008   Phase 1;Phase 2   EUCTR2008-002046-27-FR   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-DE   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-BE   Belgium;France;Germany;Spain;
      2007   Phase 2   EUCTR2007-004878-31-GB   Denmark;Hungary;United Kingdom;
      2007   -   EUCTR2007-004878-31-DK   Denmark;Hungary;United Kingdom;
   GlaxoSmithKline Research & Development Ltd.
      2008   -   EUCTR2007-004878-31-HU   Denmark;Hungary;United Kingdom;
   GlaxoSmithKline Research and Development
      2008   -   EUCTR2007-002950-42-PL   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-CZ   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
   GlaxoSmithKline S.A.
      2008   -   EUCTR2008-002046-27-ES   Belgium;France;Germany;Spain;
Olikizumab   
   UCB Biosciences, Inc
      2011   -   EUCTR2010-020839-39-GB   United Kingdom;United States;
Olokizumab   
   R-Pharm
      2017   Phase 3   EUCTR2015-005309-35-LV   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-HU   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-GB   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005307-83-LV   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-HU   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005308-27-DE   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-LT   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-HU   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004719-36-BG   Belarus;Bulgaria;Russian Federation;Turkey;
   R-Pharm International LLC
      2017   Phase 3   EUCTR2015-005309-35-PL   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-LT   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-DE   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-CZ   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-CZ   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005307-83-CZ   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-BG   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International, LLC
      2021   Phase 1   NCT04246762   Bulgaria;Moldova, Republic of;
      2016   Phase 3   NCT02760368   Belarus;Bulgaria;Russian Federation;Turkey;
   R-Pharm International, LLC.
      2017   Phase 3   EUCTR2015-005309-35-BG   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
   UCB Biosciences Inc
      2011   -   EUCTR2010-022224-77-GB   Belgium;United Kingdom;United States;
   UCB Biosciences, Inc
      2011   -   EUCTR2010-020839-39-GB   United Kingdom;United States;
   UCB Biosciences, Inc.
      2011   Phase 2   EUCTR2010-022224-77-BE   Belgium;United Kingdom;United States;
   UCB Japan Co. Ltd.
      2011   Phase 2   NCT01463059   Japan;Korea, Republic of;Taiwan;
   UCB Pharma
      2012   Phase 2   NCT01533714   Japan;Korea, Republic of;Taiwan;
Olokizumab 64 mg SC q2w   
   R-Pharm International, LLC
      2017   Phase 3   NCT03120949   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Olokizumab 64 mg SC q4w   
   R-Pharm International, LLC
      2017   Phase 3   NCT03120949   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Olokizumab 64mg q2w   
   R-Pharm
      2016   Phase 3   NCT02760407   Argentina;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Olokizumab 64mg q4w   
   R-Pharm
      2016   Phase 3   NCT02760407   Argentina;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Olokizumab q2w   
   R-Pharm
      2017   Phase 3   NCT02760433   Argentina;Brazil;Colombia;Czech Republic;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
Olokizumab q4w   
   R-Pharm
      2017   Phase 3   NCT02760433   Argentina;Brazil;Colombia;Czech Republic;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
Olumiant   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 4   EUCTR2018-003351-37-IT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Eli Lilly and Company
      2020   Phase 3;Phase 4   EUCTR2018-003351-37-FR   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-PL   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-NL   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-LT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-HU   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GR   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GB   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DK   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DE   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-AT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-003686-17-SI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-003686-17-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   Phase 4   EUCTR2018-004558-30-PT   Portugal;Spain;
      2020   Phase 4   EUCTR2018-004558-30-DK   Denmark;Portugal;Spain;
      2019   Phase 4   EUCTR2018-004558-30-ES   Spain;
   Lilly S.A
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-ES   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Transparency in Healthcare
      2019   Phase 4   EUCTR2019-000505-72-NL   Netherlands;
Omega-3   
   Haukeland University Hospital
      2020   -   NCT04586933   Norway;
Omega-3 and Vitamin E supplementation   
   Shahid Beheshti Medical University
      2006   Phase 1   NCT00399282   Iran, Islamic Republic of;
Omega-3 fatty acid   
   Hanyang University
      2010   -   NCT01618019   Korea, Republic of;
Omegaven ( fish-oil emulsion   
   Humanis Klinikum Niederosterreich
      2004   Phase 3   NCT00412256   Austria;
Omeprazole   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Janssen Research & Development, LLC
      2012   Phase 1   NCT01636557   Germany;Korea, Republic of;Moldova, Republic of;South Africa;
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   R-Pharm International, LLC
      2021   Phase 1   NCT04246762   Bulgaria;Moldova, Republic of;
Oncoxin + Viusid   
   Catalysis SL
      2009   Phase 3   NCT00969527   Cuba;
Open-label Abatacept   
   Bristol-Myers Squibb
      2002   Phase 3   NCT00048932   United States;
Open-label Adalimumab   
   Abbott
      2009   Phase 3   NCT00870467   Japan;
Open-labelAdalimumabRescue   
   Abbott
      2009   Phase 3   NCT00870467   Japan;
Oral   
   Array Biopharma, now a wholly owned subsidiary of Pfizer
      2008   Phase 2   NCT00650767   Argentina;Brazil;Hungary;Peru;Poland;Romania;United States;
      2008   Phase 1   NCT00729209   United States;
Oral Corticosteroids   
   Hoffmann-La Roche
      2014   Phase 3   NCT02046603   United Kingdom;
Oral SCIO-469 capsule   
   Scios, Inc.
      2005   Phase 1   NCT00508768   -
Oral bovine type II collagen   
   University of Tennessee
      1999   Phase 2   NCT00000401   United States;
Oral corticosteroids   
   Hoffmann-La Roche
      2005   Phase 3   NCT00720798   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Oral methotrexate   
   Amgen
      2015   Phase 3   NCT02373813   Argentina;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
Orencia   
   Academisch Medisch Centrum Amsterdam
      2010   -   EUCTR2010-021435-14-NL   Netherlands;
   Bristol Myers Squibb International Corporation
      2011   Phase 3   EUCTR2008-001523-57-NO   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-HU   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-DE   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-GB   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-ES   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   -   EUCTR2008-001523-57-DK   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001523-57-FR   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-GB   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-DE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-BE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
   Bristol-Myers Squibb
      2018   -   NCT01694693   -
      2013   -   NCT02600468   -
      2013   -   NCT02600455   Japan;
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States;
   Bristol-Myers Squibb International Corporation
      2022   Phase 3   EUCTR2020-000350-96-DE   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-FR   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-CZ   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2007   -   EUCTR2006-003768-67-SE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-DE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-BE   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-005102-68-BE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
   Cambridge University Hospitals NHS Foundation Trust
      2018   Phase 2   EUCTR2016-002569-68-GB   United Kingdom;
   Karolinska Institutet
      2015   Phase 4   NCT02466581   Sweden;
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   Phase 4   EUCTR2011-004720-35-DK   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
      2012   Phase 4   NCT01491815   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
   Leiden University Medical Center
      2018   Phase 4   EUCTR2017-002878-38-NL   Netherlands;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Medical University of Vienna
      2012   Phase 4   NCT01638715   Austria;Czech Republic;Czechia;Russian Federation;Saudi Arabia;Switzerland;
   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III
      2012   Phase 4   EUCTR2012-000139-21-AT   Austria;Czech Republic;Russian Federation;Slovakia;Switzerland;
   Novartis Pharma AG
      2011   -   EUCTR2011-000102-21-SK   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
   Novartis Pharma Services AG
      2011   -   EUCTR2011-000102-21-HU   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-DE   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-CZ   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-BG   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Revmatologicky ustav Praha
      2015   Phase 4   EUCTR2015-000581-58-CZ   Czech Republic;
   The Karolinska Institute, ClinTRID
      2017   Phase 4   EUCTR2011-004720-35-NL   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2012   -   EUCTR2011-004720-35-SE   Sweden;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   The Karolinska Instutute, ClinTRID
      2013   Phase 4   EUCTR2011-004720-35-IS   Denmark;Finland;Iceland;Norway;Sweden;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
   Universitätsklinikum Erlangen
      2019   Phase 2   EUCTR2018-003877-91-DE   Germany;
Orencia (abatacept)   
   Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
      2009   -   EUCTR2008-005450-20-BE   Belgium;
Orencia 250mg powder for concentrate for solution for infusion   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2017   Phase 3   EUCTR2016-000933-37-IT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;European Union;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Orencia abatacept   
   Policlinico Gemelli-CIC- UCSC
      2015   Phase 4   EUCTR2015-000089-72-IT   Italy;
Originator   
   Opal Rheumatology Ltd.
      2018   -   NCT03470688   Australia;
Originator (legacy) drug   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada;
Originator rituximab - Rituxan ® or MabThera ®   
   Sandoz
      2015   Phase 3   NCT02514772   Germany;Hungary;Poland;United States;
Orncia   
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
Ortho-Novum® 1/35   
   Hoffmann-La Roche
      2009   Phase 3   NCT01044498   United States;
Otelixizumab   
   GlaxoSmithKline
      2010   Phase 1   NCT01077531   Russian Federation;Spain;United Kingdom;
Other Biologics   
   Hoffmann-La Roche
      2015   -   NCT02797769   -
Other DMARDs   
   Flinders University
      2017   Phase 4   NCT03254589   Australia;
Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac   
   Boehringer Ingelheim
      2001   -   NCT02180516   -
Other biological agent   
   University of Athens
      2017   -   NCT03288584   Greece;
Otilimab   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000868-18-IT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-IT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000868-18-ES   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-ES   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-ES   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-CZ   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Otilimab (GSK3196165)   
   GlaxoSmithKline
      2020   Phase 3   NCT04333147   Argentina;Australia;Belgium;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Hungary;India;Japan;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Overencapsulated Prednisolone Tablets   
   GlaxoSmithKline R&D Ltd
      2005   -   EUCTR2004-005115-29-DE   Germany;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2005   Phase 2   EUCTR2004-005115-29-GB   Germany;United Kingdom;
Oxiklorin   
   Karolinska Institutet
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
Oxycodone by patient-controlled analgesia (PCA)   
   Riku Antero Palanne
      2016   -   NCT03364088   Finland;
Ozoralizumab   
   Taisho Pharmaceutical Co.Ltd
      2019   Phase 3   JPRN-JapicCTI-194932   Japan;
   Taisho Pharmaceutical co., LTD
      2018   Phase 3   JPRN-JapicCTI-184031   Japan;
      2018   Phase 2-3   JPRN-JapicCTI-184029   Japan;
P38 (4) Map Kinase Inhibitor   
   F. Hoffmann-La Roche Ltd
      2006   Phase 2   EUCTR2005-003694-25-ES   Czech Republic;Italy;Spain;
      2006   Phase 2   EUCTR2005-003495-38-GR   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2006   -   EUCTR2005-003694-25-CZ   Czech Republic;Italy;Spain;
      2005   Phase 2   EUCTR2005-003495-38-IE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-003495-38-GB   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-003495-38-ES   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   -   EUCTR2005-003495-38-EE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   -   EUCTR2005-003495-38-DE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
P38 Inhibitor (4)   
   Hoffmann-La Roche
      2006   Phase 2   NCT00303563   Canada;Croatia;Czech Republic;Former Serbia and Montenegro;France;Italy;Mexico;Romania;Serbia;South Africa;Spain;Taiwan;United States;
      2005   Phase 2   NCT00316771   Australia;Brazil;Canada;Estonia;Germany;Greece;Ireland;Mexico;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
P38 Map Kinase Inhibitor   
   ROCHE
      2006   -   EUCTR2005-003694-25-IT   Czech Republic;Italy;Spain;
P38(4) Map Kinase Inhibitor   
   F. Hoffmann-La Roche Ltd
      2006   Phase 2   EUCTR2005-003694-25-ES   Czech Republic;Italy;Spain;
      2006   Phase 2   EUCTR2005-003495-38-GR   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2006   -   EUCTR2005-003694-25-CZ   Czech Republic;Italy;Spain;
      2005   Phase 2   EUCTR2005-003495-38-IE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-003495-38-GB   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-003495-38-ES   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   -   EUCTR2005-003495-38-EE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   -   EUCTR2005-003495-38-DE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
PARACETAMOLO DC.IT FU   
   A.U.S.L. RIMINI
      2006   -   EUCTR2006-004062-13-IT   Italy;
PARALEN 500   
   Merck & Co., Inc.
      2005   Phase 2   EUCTR2004-004302-24-CZ   Czech Republic;Finland;Germany;Italy;Spain;
PD 0360324   
   Pfizer
      2007   Phase 1   NCT00550355   Argentina;Bulgaria;Czech Republic;Mexico;Poland;Slovakia;Spain;United States;
PDA001   
   Celularity Incorporated
      2010   Phase 2   NCT01261403   United States;
PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ADSORBED ON ALUMINIUM HYDROXIDE   
   Eli Lilly and Company
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE   
   Eli Lilly and Company
      2011   -   EUCTR2010-022205-17-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE   
   Eli Lilly and Company
      2011   -   EUCTR2010-022205-17-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
PF-04171327   
   Pfizer
      2011   Phase 2   NCT01393639   Bulgaria;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2009   Phase 2   NCT00938587   Czech Republic;Czechia;Hong Kong;Hungary;Korea, Republic of;Russian Federation;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
   Pfizer Inc.
      2009   Phase 2   EUCTR2009-013223-37-CZ   Czech Republic;Hungary;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-023782-22-CZ   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2009   -   EUCTR2009-013223-37-HU   Hungary;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
      2011   -   EUCTR2010-023782-22-DE   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2010-023782-22-SK   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2011   -   EUCTR2010-023782-22-HU   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2011   -   EUCTR2010-023782-22-BG   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer S.A.
      2009   Phase 2   EUCTR2009-013223-37-ES   Czech Republic;Hungary;Spain;
   Pfizer, S.L.U.
      2011   -   EUCTR2010-023782-22-ES   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
PF-05280586   
   Pfizer
      2012   Phase 2   NCT01526057   Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2013   Phase 2   EUCTR2012-003223-38-GB   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-003223-38-DE   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-003223-38-ES   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2011-002896-40-PL   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-002896-40-GB   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      -   Phase 2   EUCTR2011-002896-40-ES   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US
      2012   -   EUCTR2011-002896-40-DE   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
PF-06410293   
   Pfizer
      2020   Phase 3   NCT04230213   Bosnia and Herzegovina;Bulgaria;Czechia;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2015   Phase 3   NCT02480153   Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Pfizer Inc
      2020   Phase 4   EUCTR2019-000284-24-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2019   Phase 3   EUCTR2019-000284-24-LT   Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
   Pfizer Inc.
      2015   Phase 3   EUCTR2014-000352-29-HR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
PF-06438179   
   Pfizer
      2014   Phase 3   NCT02222493   Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Czechia;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Jordan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
   Pfizer Inc.
      2015   Phase 3   EUCTR2013-004148-49-FR   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-PL   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-HU   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-GB   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-DE   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-CZ   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
PF-06650833   
   Pfizer
      2020   Phase 2   NCT04413617   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czechia;Georgia;Hungary;Poland;Slovakia;Spain;Sweden;Ukraine;
      2016   Phase 2   NCT02996500   Australia;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SK   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2017   Phase 2   EUCTR2016-002337-30-SK   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-CZ   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2017   Phase 2   EUCTR2016-002337-30-HU   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-HR   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-ES   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-DE   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-BG   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
PF-06651600   
   Pfizer
      2020   Phase 2   NCT04413617   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czechia;Georgia;Hungary;Poland;Slovakia;Spain;Sweden;Ukraine;
      2016   Phase 2   NCT02969044   Bulgaria;Czechia;Georgia;Germany;Hungary;Poland;Serbia;Slovakia;United States;
   Pfizer Inc 235 East 42nd Street, New York, NY10017 US
      2017   Phase 2   EUCTR2016-002862-30-SK   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Poland;Romania;Serbia;Slovakia;United States;
      2017   Phase 2   EUCTR2016-002862-30-HU   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Poland;Romania;Serbia;Slovakia;United States;
      2017   Phase 2   EUCTR2016-002862-30-DE   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Poland;Romania;Serbia;Slovakia;United States;
      2017   Phase 2   EUCTR2016-002862-30-CZ   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Poland;Romania;Serbia;Slovakia;United States;
      2017   Phase 2   EUCTR2016-002862-30-BG   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Poland;Romania;Serbia;Slovakia;United States;
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SK   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2017   Phase 2   EUCTR2016-002862-30-PL   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Poland;Romania;Serbia;Slovakia;United States;
PF-06835375   
   Pfizer
      2017   Phase 1   NCT03334851   Puerto Rico;United States;
PG   
   Cypress Bioscience, Inc.
      2009   -   NCT01038349   -
PG-760564   
   Procter & Gamble Pharmaceuticals
      2007   Phase 2   EUCTR2006-002216-10-GB   Czech Republic;Hungary;Netherlands;United Kingdom;
      2007   -   EUCTR2006-002216-10-NL   Czech Republic;Hungary;Netherlands;United Kingdom;
      2007   -   EUCTR2006-002216-10-HU   Czech Republic;Hungary;Netherlands;United Kingdom;
      2006   -   EUCTR2006-002216-10-CZ   Czech Republic;Hungary;Netherlands;United Kingdom;
   Procter and Gamble
      2006   Phase 2   NCT00369928   Czech Republic;Hungary;Netherlands;Poland;United Kingdom;United States;
PH-797804   
   Pfizer
      2008   Phase 2   NCT00620685   United States;
      2006   Phase 2   NCT00383188   Australia;Brazil;Chile;Czech Republic;Estonia;India;Korea, Republic of;Peru;Poland;Russian Federation;South Africa;Spain;
   Pfizer Ltd
      2006   -   EUCTR2006-003577-27-CZ   Czech Republic;Estonia;Spain;
   Pfizer Luxembourg SARL Branch Office Estonia
      2006   -   EUCTR2006-003577-27-EE   Czech Republic;Estonia;Spain;
   Pfizer S.A.
      2007   Phase 2   EUCTR2006-003577-27-ES   Czech Republic;Estonia;Spain;
PL 00095/5079R   
   F. Hoffmann-La Roche Ltd
      2006   Phase 2   EUCTR2005-003694-25-ES   Czech Republic;Italy;Spain;
      2006   -   EUCTR2005-003694-25-CZ   Czech Republic;Italy;Spain;
PLA + MTX switched to ABA+ MTX, DB   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00095147   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
PLA-695   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2006   Phase 1   NCT00440492   Canada;United States;
PLX3397   
   Plexxikon
      2010   Phase 1   NCT01090570   United States;
PLX5622   
   Plexxikon
      2011   Phase 1   NCT01329991   United States;
PN 200 tablets (500 mg naproxen and 20 mg omeprazole)   
   POZEN
      2006   Phase 3   NCT00367211   United States;
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE   
   Department of Infectious Diseases, Odense University Hospital
      2014   Phase 3   EUCTR2014-001299-79-DK   Denmark;
PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)   
   Department of Infectious Diseases, Odense University Hospital
      2014   Phase 3   EUCTR2014-001299-79-DK   Denmark;
PNEUMOVAX® 23   
   Eli Lilly and Company
      2011   -   EUCTR2010-022205-17-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
PR-06410293   
   Pfizer Inc.
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
PRALIA 60 mg Subcutaneous Injection Syringe(denosumab)   
   DAIICHISANKYO Co., Ltd.
      2017   -   JPRN-JapicCTI-173747   Japan;
PRALIA 60mg Subcutaneous Injection Syringe(denosumab)   
   DAIICHISANKYO Co., Ltd.
      2018   -   JPRN-JapicCTI-184229   Japan;
PRD4862257   
   Tampere University Hospital
      2018   Phase 4   EUCTR2017-002753-11-FI   Finland;
PRO283698   
   Genentech, Inc.
      2009   Phase 1   NCT00888745   Hungary;United Kingdom;United States;
PRTX-100   
   Protalex, Inc.
      2015   Phase 1/Phase 2   NCT02330445   United States;
PRTX-100 at 1.5 mcg   
   Protalex, Inc.
      2012   Phase 1   NCT01749787   United States;
PRTX-100 at 12.0 mcg   
   Protalex, Inc.
      2012   Phase 1   NCT01749787   United States;
PRTX-100 at 240 mcg   
   Protalex, Inc.
      2012   Phase 1   NCT01749787   United States;
PRTX-100 at 3.0 mcg   
   Protalex, Inc.
      2012   Phase 1   NCT01749787   United States;
PRTX-100 at 420 mcg   
   Protalex, Inc.
      2012   Phase 1   NCT01749787   United States;
PRTX-100 at 6.0 mcg   
   Protalex, Inc.
      2012   Phase 1   NCT01749787   United States;
Panax Quinquefolius   
   Zhejiang Provincal Hospital of TCM
      2019   Phase 2   ChiCTR1900026257   China;
Pandemrix,   
   Div KIR AMC
      2010   -   EUCTR2009-016789-10-NL   Netherlands;
Paracetamol   
   Merck & Co. Inc.
      2005   Phase 2   EUCTR2004-004302-24-ES   Czech Republic;Finland;Germany;Italy;Spain;
   Merck & Co., Inc.
      2005   Phase 2   EUCTR2004-004302-24-CZ   Czech Republic;Finland;Germany;Italy;Spain;
   Suomen MSD Oy
      2005   -   EUCTR2004-004302-24-FI   Czech Republic;Finland;Germany;Italy;Spain;
Paracetamol (acetaminophen)   
   Merck Sharp & Dohme (Sweden) AB
      2004   -   EUCTR2004-000074-31-SE   Sweden;
   Merck Sharp & Dohme BV
      2005   Phase 2   EUCTR2004-000074-31-BE   Belgium;Sweden;
Parecoxib   
   Peking Union Medical College Hospital
      2018   -   ChiCTR1800014872   China;
      2014   -   ChiCTR1800014846   China;
Paroxetine   
   COMBINATORX, INC
      2005   -   EUCTR2004-004995-35-IT   Czech Republic;Denmark;Germany;Italy;United Kingdom;
   CombinatoRx, Inc.
      2005   -   EUCTR2004-004995-35-DE   Czech Republic;Denmark;Germany;Italy;United Kingdom;
   Sadat City University
      2021   Phase 1/Phase 2   NCT04757571   Egypt;
Paroxetine & Prednisolone   
   CombinatoRx, Inc.
      2006   Phase 2   EUCTR2004-004995-35-GB   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2006   -   EUCTR2004-004995-35-DK   Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-004995-35-CZ   Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-004995-35-AT   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
Paroxetine Hydrochloride tablets 10 & 20 mg and Prednisolone 1 mg BP   
   CombinatoRx, Inc.
      2005   -   EUCTR2004-004995-35-AT   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
Paroxetine hydrochloride 10 & 20 mg and Prednisolone 1 mg BP   
   CombinatoRx, Inc.
      2006   Phase 2   EUCTR2004-004995-35-GB   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
Part A   
   GlaxoSmithKline
      2005   Phase 2   NCT00291928   Denmark;Finland;France;Hungary;Poland;United Kingdom;United States;
Part B   
   GlaxoSmithKline
      2005   Phase 2   NCT00291928   Denmark;Finland;France;Hungary;Poland;United Kingdom;United States;
Patient Current Care   
   University Hospital, Grenoble
      2021   -   NCT04117165   France;
Patient treated with DMARD   
   University Hospital, Toulouse
      2018   -   NCT03980639   France;
Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses   
   University of Dundee
      2011   -   EUCTR2007-000012-90-NL   Denmark;Netherlands;United Kingdom;
      2008   Phase 4   EUCTR2007-000012-90-GB   Denmark;Netherlands;United Kingdom;
      2007   Phase 4   EUCTR2007-000012-90-DK   Denmark;Netherlands;United Kingdom;
Peficitinib   
   Astellas Pharma China, Inc.
      2018   Phase 3   NCT03660059   China;Korea, Republic of;Taiwan;
   Astellas Pharma Global Development, Inc.
      2012   Phase 2   NCT01711814   Belgium;Bulgaria;Colombia;Czech Republic;Czechia;Hungary;Mexico;Poland;United States;
      2012   Phase 2   NCT01565655   Bulgaria;Czech Republic;Czechia;Hungary;Mexico;Poland;United States;
   Astellas Pharma Inc
      2019   -   NCT03971253   Japan;
      2014   Phase 3   NCT02308163   Japan;Korea, Republic of;Taiwan;
      2014   Phase 3   NCT02305849   Japan;
      2012   Phase 3   NCT01638013   Japan;Korea, Republic of;Taiwan;
      2012   Phase 2   NCT01649999   Japan;
      2012   Phase 2   NCT01554696   Belgium;Bulgaria;Colombia;Czech Republic;Czechia;Hungary;Mexico;Poland;United States;
      2010   Phase 1   NCT01754805   United States;
Pegsunercept   
   Amgen
      2001   Phase 2   NCT00037700   United States;
Pegsunercept (PEG sTNF-RI)   
   Amgen
      2002   Phase 2   NCT00111423   -
Pelubiprofen   
   Daewon Pharmaceutical Co., Ltd.
      2010   Phase 3   NCT01781702   -
Peri-neural Dexamethasone   
   University of Calgary
      2016   -   NCT02666443   Canada;
Permitted DMARDs   
   Hoffmann-La Roche
      2007   Phase 3   NCT00531817   Puerto Rico;United States;
Persantin   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001490-26-EE   Estonia;United Kingdom;
Persantin 100 mg and   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001930-18-EE   Estonia;
Pharmacokinetics of certolizumab pegol   
   UCB Biopharma S.P.R.L.
      2020   Phase 1   NCT04163016   Canada;France;Germany;Netherlands;Spain;Switzerland;United States;
Phase 1: Conventiaonal DMARD   
   Pfizer
      2009   Phase 4   NCT00848354   Argentina;Brazil;Chile;Colombia;Ecuador;Mexico;Panama;Spain;Venezuela;
Phase 1: Etanercept   
   Pfizer
      2009   Phase 4   NCT00848354   Argentina;Brazil;Chile;Colombia;Ecuador;Mexico;Panama;Spain;Venezuela;
Phase 1: Methotrexate   
   Pfizer
      2009   Phase 4   NCT00848354   Argentina;Brazil;Chile;Colombia;Ecuador;Mexico;Panama;Spain;Venezuela;
Phase 2: Optional ETN, SSZ, HCQ, MTX   
   Pfizer
      2009   Phase 4   NCT00848354   Argentina;Brazil;Chile;Colombia;Ecuador;Mexico;Panama;Spain;Venezuela;
Piclidenoson   
   Can-Fite BioPharma, Ltd.
      2019   Phase 3   EUCTR2016-003682-26-PL   Bosnia and Herzegovina;Bulgaria;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
Pig whipworm eggs   
   Immanuel Krankenhaus Berlin
      2013   Phase 2   EUCTR2011-006344-71-DE   Germany;
Pioglitazone   
   AstraZeneca
      2011   Phase 1   NCT01309854   United States;
   Ohio State University
      2015   Phase 1   NCT02535832   United States;
   University of Michigan
      2007   Phase 3   NCT00554853   United States;
   Vanderbilt University
      2009   -   NCT00763139   United States;
Pirfenidone   
   Brigham and Women's Hospital
      2017   Phase 2   NCT02808871   Australia;Canada;United Kingdom;United States;
   The First Affiliated Hospital of DaLian Medical University
      2021   Phase 4   ChiCTR2100046283   China;
   University Hospitals of Leicester NHS Trust
      2017   Phase 2   EUCTR2017-000149-30-GB   Australia;Canada;United Kingdom;United States;
Placebo   
   Abbott Japan Co., Ltd.
      2009   Phase 3   JPRN-JapicCTI-090751   -
   AstraZeneca
      -   Phase 2   JPRN-JapicCTI-121843   -
   Bristol-Myers Squibb K.K.
      2016   Phase 2   JPRN-JapicCTI-163317   Japan, Asia except Japan, North America, South America, Europe, Oceania;
      2013   Phase 4   JPRN-JapicCTI-132121   -
   Chugai Pharmaceutical Co., Ltd.
      -   Phase 2   JPRN-JapicCTI-080650   -
   DAIICHISANKYO Co.,Ltd.
      2013   Phase 3   JPRN-JapicCTI-132277   -
      2010   Phase 2   JPRN-JapicCTI-101263   -
   Eli Lilly Japan K.K.
      -   Phase 3   JPRN-JapicCTI-142405   -
      -   Phase 3   JPRN-JapicCTI-132156   -
      -   Phase 3   JPRN-JapicCTI-132138   -
      -   Phase 3   JPRN-JapicCTI-132134   -
      -   Phase 3   JPRN-JapicCTI-132125   -
   TAKEDA PHARMACEUTICAL COMPANY LTD.
      2015   Phase 2   JPRN-JapicCTI-152979   -
   Taisho Pharmaceutical co., LTD
      2018   Phase 2-3   JPRN-JapicCTI-184029   Japan;
Plaebo   
   Astellas Pharma China, Inc.
      2018   Phase 3   NCT03660059   China;Korea, Republic of;Taiwan;
Planar Image with both Hands in Field of View   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Plaquenil   
   Christine Bengtsson
      2015   Phase 2   EUCTR2014-005418-45-SE   Sweden;
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
   North Glasgow NHS Trust
      2004   -   EUCTR2004-002006-30-GB   United Kingdom;
   University Hospitals Birmingham NHS Foundation Trust
      2006   Phase 4   EUCTR2006-001428-38-GB   United Kingdom;
   VU University Medical Center
      2013   Phase 4   EUCTR2013-003658-26-NL   Netherlands;
Plaquenil 200 mg filmdrasjerte tabletter   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Plasma analysis for bacterial translocation   
   Centre Hospitalier Universitaire de Nimes
      2016   -   NCT01961310   France;
Platelet Rich Plasma   
   AZIENDA OSPEDALIERA SENESE
      2006   -   EUCTR2006-005391-40-IT   Italy;
Pneumo23 / Pneumovax   
   University Hospital, Montpellier
      2013   Phase 3   NCT01942174   France;Monaco;
Pneumococcal conjugate vaccine   
   University Hospital, Montpellier
      2016   -   NCT02547493   France;Monaco;
Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F   
   Department of Infectious Diseases, Odense University Hospital
      2014   Phase 3   EUCTR2014-001299-79-DK   Denmark;
Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F   
   Department of Infectious Diseases, Odense University Hospital
      2014   Phase 3   EUCTR2014-001299-79-DK   Denmark;
Pneumococcal polysaccharide vaccine   
   University Hospital, Montpellier
      2016   -   NCT02547493   France;Monaco;
Pneumococcal serotypes   
   Eli Lilly and Company
      2011   -   EUCTR2010-022205-17-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
Pneumovax   
   Department of Infectious Diseases, Odense University Hospital
      2014   Phase 3   EUCTR2014-001299-79-DK   Denmark;
Pneumovax 23   
   Radboud University Nijmegen Medical Centre
      2008   -   EUCTR2008-001282-28-NL   Netherlands;
Positron Emission Tomography   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Potassium supplement   
   Shahid Beheshti Medical University
      2007   Phase 1   NCT00461448   Iran, Islamic Republic of;
Power doppler ultrasonography   
   GlaxoSmithKline
      2004   -   NCT00242853   United Kingdom;
Pravastatin   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Gilead Sciences
      2020   Phase 1   NCT04608344   United States;
Pre-filled Syringe (PFS)   
   Sanofi
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
Pre-filled syringe   
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2006-006591-37-GR   Austria;Greece;
      2008   -   EUCTR2006-006591-37-AT   Austria;Greece;
      2007   Phase 3   EUCTR2006-005137-38-GB   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-006591-37-BE   Austria;Belgium;Greece;
      2007   -   EUCTR2006-005137-38-SE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-FI   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-DK   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Pred   
   Qilu Hospital of Shandong University
      2020   Phase 4   NCT04928066   China;
      2017   Phase 4   NCT03855007   China;
Pred + Meth   
   Hamad Medical Corporation
      2012   Phase 3   NCT01724268   Qatar;
PredniHEXAL   
   AstraZeneca AB
      2017   Phase 2   EUCTR2017-000838-64-SE   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-NL   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-DK   Denmark;Netherlands;Sweden;
PredniHEXAL® 5mg Tabletten, PredniHEXAL® 10mg Tabletten   
   Ruhr-Universität Bochum
      2013   Phase 3   EUCTR2012-004074-25-DE   Germany;
PredniHEXAL® 5mg Tabletten, PredniHEXAL® 20mg Tabletten   
   Ruhr-Universität Bochum
      2013   Phase 3   EUCTR2012-004074-25-DE   Germany;
Predniso   
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
Prednisolene tablets BP   
   COMBINATORX, INC
      2005   -   EUCTR2004-004995-35-IT   Czech Republic;Denmark;Germany;Italy;United Kingdom;
Prednisolon   
   Ruhr-Universität Bochum
      2013   Phase 3   EUCTR2012-004074-25-DE   Germany;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Prednisolon Pfizer   
   Karolinska Universitetssjukhuset
      2021   Phase 4   EUCTR2020-005096-12-SE   Sweden;
Prednisolone   
   AstraZeneca
      2018   Phase 2   NCT03368235   Denmark;Netherlands;Sweden;
      2016   Phase 1   NCT02760316   Germany;United Kingdom;
      2015   Phase 1   NCT02512575   Germany;
   AstraZeneca AB
      2017   Phase 2   EUCTR2017-000838-64-SE   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-NL   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-DK   Denmark;Netherlands;Sweden;
   COMBINATORX, INC
      2005   -   EUCTR2004-004995-35-IT   Czech Republic;Denmark;Germany;Italy;United Kingdom;
   Cinnagen
      2015   Phase 3   NCT03172325   Iran, Islamic Republic of;
   CombinatoRx, Inc.
      2005   -   EUCTR2004-004995-35-DE   Czech Republic;Denmark;Germany;Italy;United Kingdom;
   CombinatoRx, Incorporated
      2008   -   EUCTR2007-004399-38-LT   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-GB   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-EE   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-LT   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-HU   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-GB   Estonia;Hungary;Lithuania;United Kingdom;
      2007   -   EUCTR2007-003069-42-EE   Estonia;Hungary;Lithuania;United Kingdom;
   Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University
      2013   -   JPRN-UMIN000010126   Japan;
   GlaxoSmithKline
      2006   Phase 2   NCT00379990   Serbia;United Kingdom;
      2005   Phase 2   NCT00134693   Australia;France;Germany;Russian Federation;United Kingdom;
   GlaxoSmithKline Research & Development Limited
      2005   Phase 2   EUCTR2005-001977-82-GB   United Kingdom;
   Jawaharlal Institute of Postgraduate Medical Education & Research
      2016   Phase 3   NCT02930343   India;
      2015   Phase 4   NCT02644499   India;
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
   Prof. Dr. rer. nat. H.J. Trampisch
      2014   Phase 3   NCT02000336   Germany;
   Rheumazentrum Ruhrgebiet
      2012   Phase 2/Phase 3   NCT01395251   Germany;
   VU University Medical Center
      2016   Phase 4   NCT02585258   Finland;Germany;Hungary;Italy;Netherlands;Portugal;Romania;Slovakia;
   Zalicus
      2011   Phase 2   NCT01369745   United States;
      2007   Phase 2   NCT00551707   Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
   Zalicus, Inc.
      2012   -   EUCTR2011-002392-41-HU   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-002392-41-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Prednisolone & dipyridamole   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001930-18-EE   Estonia;
Prednisolone Labesfal   
   VU University Medical Center
      2016   Phase 4   EUCTR2015-002729-21-SK   Finland;Germany;Hungary;Portugal;Slovakia;
      2016   Phase 4   EUCTR2015-002729-21-PT   Finland;Germany;Hungary;Portugal;Slovakia;
      2016   Phase 4   EUCTR2015-002729-21-HU   Finland;Germany;Hungary;Portugal;Slovakia;
      2016   Phase 4   EUCTR2015-002729-21-FI   Finland;Germany;Hungary;Portugal;Slovakia;
      2016   Phase 4   EUCTR2015-002729-21-DE   Finland;Germany;Hungary;Portugal;Slovakia;
Prednisolone Tablets BP   
   CombinatoRx, Inc.
      2005   -   EUCTR2004-004995-35-CZ   Czech Republic;Denmark;Germany;Italy;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2005   Phase 2   EUCTR2004-005115-29-GB   Germany;United Kingdom;
Prednisolone Tablets USP   
   GlaxoSmithKline Research & Development Limited
      2005   Phase 4   EUCTR2005-000902-30-GB   United Kingdom;
Prednisolone-Dipyridamole   
   Zalicus
      2012   Phase 2   NCT01612377   Serbia;
Prednison   
   VU University Medical Center
      2013   Phase 4   EUCTR2013-003658-26-NL   Netherlands;
Prednisone   
   CHU Toulouse
      2016   Phase 4   EUCTR2016-001618-18-FR   France;
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
   Central Hospital of Jinhua
      2014   Phase 4   ChiCTR1900026116   China;
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Hoffmann-La Roche
      2016   Phase 4   NCT02573012   Egypt;France;Germany;Italy;Russian Federation;Serbia;Switzerland;Tunisia;Turkey;
   Merck KGaA
      2009   -   NCT01075711   Germany;
   Merck Sharp & Dohme Corp.
      2008   Phase 1   NCT00746512   United Kingdom;
   Narrows Institute for Biomedical Research
      2011   Phase 4   NCT04169100   United States;
   Nitec Pharma AG
      2008   Phase 3   EUCTR2007-003508-36-GB   Germany;Hungary;United Kingdom;
      2008   -   EUCTR2007-003508-36-HU   Germany;Hungary;United Kingdom;
      2008   -   EUCTR2007-003508-36-DE   Germany;Hungary;United Kingdom;
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
   P. Verschueren
      2009   Phase 4   NCT01172639   Belgium;
   Pfizer
      2011   Phase 2   NCT01393639   Bulgaria;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2009   Phase 2   NCT00938587   Czech Republic;Czechia;Hong Kong;Hungary;Korea, Republic of;Russian Federation;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
      2008   Phase 2   NCT00634933   Austria;Belgium;Canada;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;United States;
   Pfizer Inc.
      2009   Phase 2   EUCTR2009-013223-37-CZ   Czech Republic;Hungary;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2009   -   EUCTR2009-013223-37-HU   Hungary;Spain;
   Pfizer S.A.
      2009   Phase 2   EUCTR2009-013223-37-ES   Czech Republic;Hungary;Spain;
   RenJi Hospital
      2020   -   NCT04569890   China;
   TIPharma
      2007   -   EUCTR2007-002976-32-NL   Netherlands;
   United Bristol Healthcare NHS Trust
      2006   Phase 2   EUCTR2005-004385-16-GB   United Kingdom;
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
   University of South Florida
      2007   Phase 2/Phase 3   NCT00580229   United States;
   Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
      2009   -   EUCTR2007-006150-25-DE   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
      2008   -   EUCTR2007-006150-25-HU   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
   Zalicus
      2012   Phase 2   NCT01612377   Serbia;
      2011   Phase 2   NCT01369745   United States;
Prednisone Tablets USP,   
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2014-004673-16-DE   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Switzerland;Turkey;
      2015   Phase 4   EUCTR2014-004673-16-FR   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Slovenia;Switzerland;Tunisia;Turkey;
Prednisone acetate   
   Yunnan Hospital of Traditional Chinese Medicine /The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041777   China;
   Yunnan Traditional Chinese Medicine Hospital
      2021   Phase 0   ChiCTR2100041909   China;
Pregabalin   
   Kojima Toshihisa
      2016   -   JPRN-jRCTs041180071   Japan;
Prevenar 13   
   Department of Infectious Diseases, Odense University Hospital
      2014   Phase 3   EUCTR2014-001299-79-DK   Denmark;
   University Hospital, Montpellier
      2013   Phase 3   NCT01942174   France;Monaco;
Prevenar vaccination   
   Region Skane
      2008   Phase 4   NCT00828997   Sweden;
Prevenar vaccine   
   Dept of Rheumatology, Lund University Hospital, Lund, Sweden
      2008   -   EUCTR2007-006539-29-SE   Sweden;
Previously known as R935788   
   AstraZeneca AB
      2011   Phase 2   EUCTR2010-023692-26-SK   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023692-26-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      -   -   EUCTR2010-023692-26-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
Primus FGTI (Flexible Great toe Implant)   
   Tornier, Inc.
      2013   -   NCT02350881   Italy;
Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14   
   Lawson Health Research Institute
      2008   -   NCT00664820   Canada;
Progressive spacing of TNF-blocker injections   
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 4   NCT00780793   France;
Propolipid   
   Helsinki University Central Hospital
      2016   Phase 4   EUCTR2016-002035-15-FI   Finland;
Proposed INN - FILGOTINIB   
   Galapagos NV
      2017   Phase 2   EUCTR2012-003655-11-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
Propsoed INN - FILGOTINIB   
   Galapagos NV
      2014   -   EUCTR2012-003654-86-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
Protein   
   Johns Hopkins University
      2014   -   NCT02078375   United States;
Puerarin injection   
   Chengdu PLA General Hospital
      2014   -   NCT02264301   China;
      2013   Phase 2   NCT02254655   China;
Puerarin tablet   
   Chengdu PLA General Hospital
      2014   -   NCT02219191   China;
QAL964   
   Novartis Pharma Services AG
      2014   -   EUCTR2013-003493-27-HU   Hungary;Russian Federation;Ukraine;
      2014   -   EUCTR2013-003493-27-GR   Greece;Hungary;Romania;Russian Federation;Ukraine;
Qing Re Huo Xue (QRHX)   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT04170504   -
Qingkailing injection 40 ml   
   Chengdu PLA General Hospital
      2014   -   NCT02264301   China;
Quantiferon-TB Gold assay   
   Ospedale L. Sacco – Polo Universitario
      2007   -   NCT00491933   Italy;
Quensyl   
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
R788   
   Rigel Pharmaceuticals
      2006   Phase 2   NCT00326339   Mexico;United States;
R788 Sodium, R788 Na, R788   
   AstraZeneca AB
      2009   -   EUCTR2008-000744-13-BG   Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
      2008   Phase 2   EUCTR2008-000744-13-BE   Belgium;Bulgaria;France;Germany;Italy;
      -   -   EUCTR2008-000744-13-DE   Belgium;Bulgaria;France;Germany;Italy;
   Rigel Pharmaceuticals, Inc
      2009   -   EUCTR2008-000744-13-FR   Bulgaria;France;Germany;Italy;
   Rigel Pharmaceuticals, Inc.
      2008   -   EUCTR2008-000743-34-FR   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-DE   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-BE   Belgium;France;Germany;Italy;
      2008   -   EUCTR2008-000742-30-PL   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-HU   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-BG   Bulgaria;Hungary;Poland;
R788 sodium hexahydrate, RIG2-01, RIG-G   
   AstraZeneca AB
      2012   -   EUCTR2011-006070-73-DE   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-CZ   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-BG   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
R935788   
   AstraZeneca AB
      2012   -   EUCTR2011-006070-73-DE   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-CZ   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-BG   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2009   -   EUCTR2008-000744-13-BG   Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
      2008   Phase 2   EUCTR2008-000744-13-BE   Belgium;Bulgaria;France;Germany;Italy;
      -   -   EUCTR2008-000744-13-DE   Belgium;Bulgaria;France;Germany;Italy;
   RIGEL PHARMACEUTICALS INC
      2009   -   EUCTR2008-000744-13-IT   Bulgaria;France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-IT   France;Germany;Italy;
   Rigel Pharmaceuticals, Inc
      2009   -   EUCTR2008-000744-13-FR   Bulgaria;France;Germany;Italy;
   Rigel Pharmaceuticals, Inc.
      2008   -   EUCTR2008-000743-34-FR   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-DE   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-BE   Belgium;France;Germany;Italy;
      2008   -   EUCTR2008-000742-30-PL   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-HU   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-BG   Bulgaria;Hungary;Poland;
RAYOS (delayed-release prednisone)   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2014   -   NCT02287610   -
RC18 160 mg plus MTX   
   RemeGen
      2016   Phase 3   NCT03016013   China;
      2015   Phase 2   NCT02882087   China;
RECOMBINANT FACTOR FC FUSION PROTEIN   
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-ES   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-BG   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
REGN88   
   Regeneron Pharmaceuticals
      2008   Phase 1   NCT01055899   United States;
      2008   Phase 1   NCT01026519   Russian Federation;
      2008   Phase 1   NCT01011959   United States;
REMICADE (INFLIXIMAB)   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
REMICADE 100 mg polvo para concentrado para solución para perfusión   
   CELLTRION, Inc
      2010   Phase 3   EUCTR2010-018646-31-ES   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
REMICADE*EV F 100MG+F 2ML   
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2004   -   EUCTR2005-000492-18-IT   Italy;
REMICADE® (Infliximab)   
   Saint-Luc Universitary Hospital
      2007   -   EUCTR2007-004694-26-BE   Belgium;
REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy;
RGB-03   
   Gedeon Richter Plc
      2015   Phase 1;Phase 3   EUCTR2014-003255-54-CZ   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Israel;Poland;Romania;Russian Federation;Spain;Ukraine;
   Gedeon Richter Plc.
      2015   Phase 1   NCT02371096   -
RO 001-9265/F02-01   
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2014-004673-16-DE   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Switzerland;Turkey;
      2015   Phase 4   EUCTR2014-004673-16-FR   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Slovenia;Switzerland;Tunisia;Turkey;
RO 487-7533   
   ROCHE
      2004   -   EUCTR2004-003741-40-IT   Germany;Hungary;Italy;
      2004   -   EUCTR2004-003733-14-IT   Denmark;Finland;Italy;Spain;
RO 496-4913   
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2006-005330-20-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2008   Phase 3   EUCTR2007-005759-41-GB   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005759-41-ES   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005353-30-GB   Austria;Italy;Lithuania;Spain;United Kingdom;
      2008   -   EUCTR2007-005759-41-DE   France;Germany;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005330-20-SK   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005330-20-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005330-20-BE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005147-28-GB   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-DE   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-BE   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-AT   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   -   EUCTR2006-005353-30-LT   Argentina;Australia;Austria;Brazil;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2007   -   EUCTR2006-005353-30-AT   Austria;Italy;Lithuania;Spain;United Kingdom;
      2007   -   EUCTR2006-005330-20-SI   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-SE   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005147-28-GR   Austria;France;Germany;Greece;Spain;United Kingdom;
   ROCHE
      2007   -   EUCTR2006-005330-20-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
RO 496-4913/F03   
   F. Hoffmann-La Roche Ltd
      2008   Phase 3   EUCTR2007-005759-41-FR   France;Germany;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-FR   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
RO 551-6922   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-023587-40-DK   Denmark;European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-SE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-NL   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-GR   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-FI   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-DE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2010   Phase 4   EUCTR2009-015845-21-GB   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 4   EUCTR2009-015845-21-BE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-SE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-PT   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-GR   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-FI   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-DE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-CZ   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
RO-496-4913   
   ROCHE
      2008   -   EUCTR2007-005759-41-IT   France;Germany;Italy;Spain;United Kingdom;
RO001-9265/F04   
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2014-004673-16-DE   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Switzerland;Turkey;
      2015   Phase 4   EUCTR2014-004673-16-FR   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Slovenia;Switzerland;Tunisia;Turkey;
RO0029893   
   Roche Austria GmbH
      2011   -   EUCTR2011-001863-39-AT   Austria;
RO045-2294   
   Roche Pharma AG
      2011   -   EUCTR2010-022049-88-DE   Germany;
RO04877533   
   F Hoffmann-La Roche Ltd
      2008   -   EUCTR2008-001847-20-NL   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-ES   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   ROCHE
      2009   -   EUCTR2008-001847-20-IT   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   Roche Farma, S.A.
      2009   -   EUCTR2008-006443-39-ES   Spain;
RO04877533/F05/F04   
   F Hoffmann-La Roche Ltd
      2008   Phase 3   EUCTR2008-001847-20-FR   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
RO0506997   
   F.Hoffmann - La Roche Ltd
      2005   -   EUCTR2004-004022-27-ES   Spain;
RO4402257   
   F. Hoffmann-La Roche Ltd
      2006   Phase 2   EUCTR2005-003694-25-ES   Czech Republic;Italy;Spain;
      2006   Phase 2   EUCTR2005-003495-38-GR   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2006   -   EUCTR2005-003694-25-CZ   Czech Republic;Italy;Spain;
      2005   Phase 2   EUCTR2005-003495-38-IE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-003495-38-GB   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-003495-38-ES   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   -   EUCTR2005-003495-38-EE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
      2005   -   EUCTR2005-003495-38-DE   Estonia;Germany;Greece;Ireland;Spain;United Kingdom;
RO452294/V02   
   F Hoffmann-La Roche Ltd
      2009   Phase 2   EUCTR2008-005525-11-FR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
RO487-7533/F01-F05   
   ROCHE
      2009   -   EUCTR2008-008309-23-FR   France;
RO487-7533/F10-04   
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2014-004673-16-DE   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Switzerland;Turkey;
      2015   Phase 4   EUCTR2014-004673-16-FR   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Slovenia;Switzerland;Tunisia;Turkey;
RO4877533   
   F Hoffmann La-Roche AG
      2007   -   EUCTR2005-002909-23-PT   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-002909-23-GB   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-SI   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2006   -   EUCTR2005-002909-23-NO   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-IS   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-FI   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002909-23-ES   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F Hoffmann La-Roche Ltd.
      2005   -   EUCTR2004-003733-14-DK   Denmark;Finland;Italy;Spain;
   F Hoffmann-La Roche AG
      2006   -   EUCTR2005-002909-23-DE   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F Hoffmann-La Roche Ltd
      2009   Phase 2   EUCTR2008-005525-11-GR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-005525-11-ES   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-NL   France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-DE   France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-005525-11-GB   France;Germany;Greece;Netherlands;Spain;United Kingdom;
   F. Hoffmann La-Roche AG
      2005   Phase 3   EUCTR2005-001138-33-NO   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   Phase 3   EUCTR2005-001138-33-ES   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   Phase 3   EUCTR2004-005210-37-ES   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   Phase 3   EUCTR2004-003741-40-SK   Austria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-001138-33-PT   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-LT   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-DK   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2004-005210-37-SE   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-FI   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-DE   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-CZ   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-003741-40-HU   Germany;Hungary;Italy;
      2005   -   EUCTR2004-003741-40-DE   Germany;Hungary;Italy;
      2005   -   EUCTR2004-003733-14-ES   Denmark;Finland;Italy;Spain;
      2004   -   EUCTR2004-003741-40-AT   Austria;Germany;Hungary;Italy;
      -   -   EUCTR2005-001138-33-SI   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
   F. Hoffmann La-Roche Ltd
      2005   -   EUCTR2005-002423-13-SK   Austria;Bulgaria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-002423-13-HU   Bulgaria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-002423-13-AT   Austria;Bulgaria;Germany;Hungary;Italy;Slovakia;
   F. Hoffmann La-Roche Ltd.
      2005   Phase 3   EUCTR2004-003733-14-FI   Australia;Brazil;China;Denmark;Finland;France;Greece;Italy;Mexico;Norway;Poland;South Africa;Spain;United States;
   F. Hoffmann-La Roche
      2009   -   EUCTR2008-006924-68-IT   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
   F. Hoffmann-La Roche AG
      2005   Phase 3   EUCTR2005-000884-25-IS   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-000884-25-GB   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   -   EUCTR2005-000884-25-SE   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   -   EUCTR2005-000884-25-DE   Germany;Iceland;Italy;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2008-006924-68-AT   Austria;Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-006924-68-GB   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-NL   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-ES   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-002423-13-DE   Bulgaria;Germany;Hungary;Italy;Slovakia;
   ROCHE
      2009   -   EUCTR2008-000587-17-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Roche (Magyarország) Kft.
      2012   -   EUCTR2011-006125-14-HU   Hungary;
   Roche Austria GmbH
      2011   -   EUCTR2011-001863-39-AT   Austria;
   Roche Pharma AG
      2011   -   EUCTR2010-022049-88-DE   Germany;
      2008   -   EUCTR2008-000105-11-DE   Germany;
   University of Leeds
      2009   Phase 2   EUCTR2008-003011-12-GB   United Kingdom;
RO4877533 (TCZ)   
   F. Hoffmann- La Roche Ltd
      2009   -   EUCTR2008-000587-17-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Limited
      2007   -   EUCTR2007-001114-17-GB   United Kingdom;
   F. Hoffmann-La Roche Ltd
      2009   -   EUCTR2008-000587-17-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-000587-17-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2008-000587-17-ES   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-SE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-IE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Roche Oy
      2008   -   EUCTR2008-004126-16-FI   Finland;
RO4877533/F01   
   F Hoffmann-La Roche Ltd
      2009   Phase 2   EUCTR2008-005525-11-FR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
RO4877533/F04-F05   
   F. Hoffmann-La Roche Ltd
      2009   Phase 3   EUCTR2008-006924-68-FR   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-000587-17-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
RO496-4913   
   ROCHE
      2007   -   EUCTR2006-005353-30-IT   Austria;Italy;Lithuania;Spain;United Kingdom;
RO7010939   
   Genentech, Inc.
      2016   Phase 2   EUCTR2016-000335-40-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
RO7123520   
   Hoffmann-La Roche
      2016   Phase 2   NCT03001219   Argentina;Austria;Colombia;Czech Republic;Czechia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
RO7123520/F03-01   
   F. Hoffmann - Roche Ltd
      2017   Phase 2   EUCTR2016-002126-36-IT   Argentina;Austria;Colombia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2016-002126-36-ES   Argentina;Austria;Colombia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002126-36-DE   Argentina;Austria;Colombia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002126-36-AT   Argentina;Austria;Brazil;Chile;Colombia;Czech Republic;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO   
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
ROACTEMRA 20 mg/ml, concentrado para solución para perfusión   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-023587-40-ES   Denmark;Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2010   Phase 4   EUCTR2009-015845-21-ES   Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-018375-22-ES   Bulgaria;Germany;Italy;Lithuania;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-ES   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   Roche Farma, S.A.
      -   -   EUCTR2011-001626-15-ES   Spain;
RTNV148B IgG   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
RTX Group   
   Medical University of Vienna
      2015   Phase 4   NCT05116228   Austria;
RWJ-445380   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2006   Phase 2   NCT00425321   Argentina;Brazil;Czech Republic;Germany;Mexico;Poland;United States;
RWJ-445380 capsule   
   Janssen-Cilag International N.V.
      2007   -   EUCTR2006-003983-73-CZ   Czech Republic;Germany;
   Janssen-Cliag International N.V.
      -   -   EUCTR2006-003983-73-DE   Czech Republic;Germany;
RWJ-445380-002   
   Janssen-Cilag International N.V.
      2007   -   EUCTR2006-003983-73-CZ   Czech Republic;Germany;
   Janssen-Cliag International N.V.
      -   -   EUCTR2006-003983-73-DE   Czech Republic;Germany;
RYR   
   Chengdu PLA General Hospital
      2014   -   NCT02257047   China;
Radiofrequency   
   Assiut University
      2019   -   NCT03852355   Egypt;
Raloxifene hydrochloride   
   Sara Saeidi Shahri
      2016   -   NCT02982083   -
Ramelteon   
   Shunichi Shiozawa
      2013   -   JPRN-UMIN000018816   Japan;
Ramipril   
   University of Zurich
      2004   Phase 2/Phase 3   NCT00273533   Switzerland;
Rapamycin   
   the Second Hospital of Shanxi Medical University
      2017   -   ChiCTR-IPR-17010307   China;
Raptiva 100 mg/ml powder and solvent for solution for injection   
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal;
Rebamipide   
   Korea Otsuka Pharmaceutical Co.,Ltd.
      2007   Phase 3   NCT00576706   Korea, Republic of;
   October 6 University
      2022   Phase 1/Phase 2   NCT05166304   -
   Seoul National University Boramae Hospital
      2021   Phase 4   NCT04885751   -
Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001   
   University of New Mexico
      2004   -   NCT00651625   United States;
Recombinant TNF-a receptor: IgG Fc fusion protein   
   Zhejiang Hisun Pharmaceutical Co. Ltd.
      2018   -   NCT03636984   -
Recombinant human Mab of IgG4 subtype   
   UCB Biosciences Inc
      2011   -   EUCTR2010-022224-77-GB   Belgium;United Kingdom;United States;
   UCB Biosciences, Inc
      2011   -   EUCTR2010-020839-39-GB   United Kingdom;United States;
   UCB Biosciences, Inc.
      2011   Phase 2   EUCTR2010-022224-77-BE   Belgium;United Kingdom;United States;
   UCB Biosciences, Inc. A Member of the UCB Group of Companies
      2011   Phase 2   EUCTR2010-020839-39-BE   Belgium;United Kingdom;United States;
   UCB Celltech
      2009   -   EUCTR2009-010813-57-DE   Germany;
Recombinant human anti IL-22 monoclonal antibody IgG1   
   Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer company
      2009   -   EUCTR2008-006936-37-DE   Belgium;Germany;Hungary;Netherlands;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
      2009   Phase 2   EUCTR2008-006936-37-BE   Belgium;Germany;Hungary;Netherlands;
      2009   -   EUCTR2008-006936-37-NL   Belgium;Germany;Hungary;Netherlands;
      2009   -   EUCTR2008-006936-37-HU   Belgium;Germany;Hungary;Netherlands;
Recombinant human monoclonal antibody   
   Newcastle-upon-Tyne Hospitals NHS Foundation Trust
      2007   Phase 4   EUCTR2006-006127-40-GB   United Kingdom;
Recombinant human monoclonal antibody to inerleukin-1beta of the IgG1-K-class   
   Novartis Farmacéutica S.A.
      2009   Phase 2   EUCTR2008-005320-81-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma Services AG
      2009   -   EUCTR2008-005320-81-BE   Austria;Belgium;Germany;Spain;
      2008   -   EUCTR2008-005320-81-AT   Austria;Germany;Spain;
Recombinant human monoclonal antibody to interleukin-1beta of the IgG1-Kappa-class   
   Novartis Pharma Services AG
      2009   -   EUCTR2008-005320-81-DE   Austria;Germany;Spain;
Recombinant humanised anti-human monoclonal antibody directed against the IL-6R   
   Roche Products Limited
      2013   Phase 3   EUCTR2013-000054-22-GB   United Kingdom;
Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal   
   ROCHE
      2011   Phase 4   EUCTR2010-020065-24-IT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Czech Republic;Ecuador;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal antibody   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-020065-24-NL   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-LV   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-HU   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GR   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-AT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-LT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-019912-18-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
      2011   -   EUCTR2010-019912-18-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
Recombinant humanized anti-human Interleukin-6   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2010-019912-18-ES   Bulgaria;Greece;Hungary;Spain;
      2011   -   EUCTR2010-019912-18-GR   Bulgaria;Greece;Hungary;Spain;
Recombinant humanized anti-human Interleukin-6 Receptor (IL-6R) monoclonal antibody   
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2010-019912-18-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
      2011   -   EUCTR2010-019912-18-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
Recombinant humanized anti-human monoclonal antibody directed against the IL-6R   
   Roche a/s
      2014   Phase 3   EUCTR2013-002007-34-SE   Denmark;Finland;Sweden;
      2014   Phase 3   EUCTR2013-002007-34-FI   Denmark;Finland;Sweden;
      2013   Phase 3   EUCTR2013-002007-34-DK   Denmark;Finland;Sweden;
Reditux   
   Dr. Reddy’s Laboratories S.A.
      2020   Phase 3   EUCTR2019-002810-37-PL   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-LT   Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-DE   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
Release   
   The First Affiliated Hospital of Third Military Medical University
      2016   -   ChiCTR-IPR-16008793   China;
Remicade   
   AESCA Pharma Ges.m.b.H
      2005   -   EUCTR2005-004530-40-AT   Austria;
   Amgen Inc.
      2016   Phase 3   EUCTR2014-004704-29-PL   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-HU   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-ES   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-DE   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-CZ   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-BG   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
   Bristol Myers Squibb International Corporation
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
   CELLTRION, Inc
      2010   Phase 3   EUCTR2010-018646-31-SK   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-PT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-LV   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-LT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Indonesia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
      2010   -   EUCTR2010-018646-31-IT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-GB   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-BG   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-AT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   Celltrion
      2018   Phase 3   NCT03707535   China;
   Centocor BV
      2009   Phase 4   EUCTR2007-003288-36-GB   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-003288-36-ES   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 4   EUCTR2007-003288-36-FR   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-NL   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-FI   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-DE   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-AT   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
   Department of Clinical Biochemestry, Aarhus University Hospital
      2015   Phase 4   EUCTR2015-004173-32-DK   Denmark;
   Epirus Biopharmaceuticals (Switzerland) GmbH
      2016   Phase 3   NCT02683564   -
   Greater Glasgow Health Board
      2006   Phase 4   EUCTR2006-000363-28-GB   United Kingdom;
   Hvidovre Hospital, Dept. Rheumatology
      2006   -   EUCTR2005-001633-14-SE   Denmark;Sweden;
      2005   -   EUCTR2005-001633-14-DK   Denmark;Sweden;
   Integrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.
      2006   Phase 3   EUCTR2005-001889-13-NL   Austria;Belgium;Denmark;France;Germany;Netherlands;Portugal;Sweden;
      2006   Phase 3   EUCTR2005-001889-13-GR   Austria;Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
      2006   Phase 3   EUCTR2005-001889-13-FR   Austria;Belgium;Denmark;France;Germany;Netherlands;Portugal;Sweden;
      2006   -   EUCTR2005-001889-13-DK   Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
      2005   -   EUCTR2005-001889-13-AT   Austria;Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
   Karolinska Institute
      2008   -   EUCTR2008-005212-40-SE   Sweden;
   Kings College London
      2008   Phase 4   EUCTR2007-005464-26-GB   United Kingdom;
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
   Medical University of Vienna
      2012   Phase 4   NCT01638715   Austria;Czech Republic;Czechia;Russian Federation;Saudi Arabia;Switzerland;
   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III
      2012   Phase 4   EUCTR2012-000139-21-AT   Austria;Czech Republic;Russian Federation;Slovakia;Switzerland;
   Nichi-Iko Pharmaceutical Co., Ltd.
      2017   Phase 3   EUCTR2016-001064-11-PL   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001064-11-GB   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001064-11-ES   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001064-11-CZ   Czech Republic;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Pfizer Inc.
      2015   Phase 3   EUCTR2013-004148-49-FR   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-PL   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-HU   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-GB   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-DE   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-CZ   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004148-49-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Czech Republic;European Union;France;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Revmatologicky ustav Praha
      2015   Phase 4   EUCTR2015-000581-58-CZ   Czech Republic;
   Schering Plough Research Institute, a Division of Schering Corporation
      2006   Phase 3   EUCTR2005-001889-13-BE   Austria;Belgium;Denmark;France;Germany;Netherlands;Portugal;Sweden;
      2006   -   EUCTR2005-001889-13-PT   Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
   Schering-Plough Research Institute (SPRI)
      2007   -   EUCTR2005-001889-13-DE   Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
   Schering-Plough Research Institute, a division of Schering Corporation
      2005   -   EUCTR2005-001889-13-SE   Belgium;Denmark;France;Germany;Greece;Netherlands;Portugal;Sweden;
   Shanghai Biomabs Pharmaceutical Co., Ltd.
      2018   Phase 3   NCT03478111   China;
   University of California, Los Angeles
      2008   -   NCT00948610   United States;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
Remicade (infliximab)   
   Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
      2009   -   EUCTR2008-005450-20-BE   Belgium;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   NCT01936181   Bulgaria;Lithuania;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2014   -   EUCTR2014-002056-40-NO   Norway;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning.   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Remicade®   
   Biocad
      2016   Phase 3   NCT02762838   Belarus;India;Russian Federation;
   CHRU de Tours
      2007   -   EUCTR2007-002752-42-FR   France;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005733-37-GB   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   Phase 3   EUCTR2012-005733-37-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   Phase 3   EUCTR2012-005733-37-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005733-37-LV   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005733-37-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
Remsima   
   Department of Clinical Biochemestry, Aarhus University Hospital
      2015   Phase 4   EUCTR2015-004173-32-DK   Denmark;
Remsima (infliximab)   
   Mundipharma Pharmaceuticals B.V.
      2016   Phase 4   EUCTR2014-004904-31-BE   Belgium;Netherlands;
      2015   Phase 4   EUCTR2014-004904-31-NL   Netherlands;
Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2014   -   EUCTR2014-002056-40-NO   Norway;
Repository corticotropin injection   
   Arthritis Treatment Center, Maryland
      2013   Phase 4   NCT01966718   United States;
Response to anakinra associated with methotrexate   
   University Hospital, Rouen
      2003   -   NCT00213538   France;
Response to infliximab associated with methotrexate   
   University Hospital, Rouen
      2003   -   NCT00213564   France;
Reumatocept (etanercept)   
   EMS
      2013   Phase 3   NCT01394913   Brazil;
Revamilast   
   Glenmark Pharmaceuticals Ltd. India
      2011   Phase 2   NCT01430507   India;Philippines;Poland;Sri Lanka;United Kingdom;
   Glenmark Pharmaceuticals SA
      2011   -   EUCTR2011-000107-40-GB   India;Philippines;Poland;Sri Lanka;United Kingdom;
Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)   
   Alliancells Bioscience Corporation Limited
      2013   Phase 1/Phase 2   NCT01547091   China;
RhuMAb 2H7   
   F Hoffmann-La Roche Limited
      2005   -   EUCTR2004-002132-26-ES   Spain;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2006-005330-20-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2008   Phase 3   EUCTR2007-005759-41-GB   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005759-41-FR   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005759-41-ES   France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005353-30-GB   Austria;Italy;Lithuania;Spain;United Kingdom;
      2008   -   EUCTR2007-005759-41-DE   France;Germany;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005330-20-SK   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005330-20-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005330-20-BE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005147-28-GB   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-FR   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-DE   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-BE   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005147-28-AT   Austria;Belgium;France;Germany;Greece;Spain;United Kingdom;
      2007   -   EUCTR2006-005353-30-LT   Argentina;Australia;Austria;Brazil;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2007   -   EUCTR2006-005353-30-AT   Austria;Italy;Lithuania;Spain;United Kingdom;
      2007   -   EUCTR2006-005330-20-SI   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-SE   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005330-20-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005147-28-GR   Austria;France;Germany;Greece;Spain;United Kingdom;
RhuTNFR:Fc   
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
RhumAb to Il-17A (IgG1-k-class)   
   Novartis Pharma Services AG
      2009   -   EUCTR2009-011000-34-SK   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-HU   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-DE   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-CZ   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-BE   Belgium;Czech Republic;Germany;Hungary;Slovakia;
Rhustoxicodendron 30   
   Healthcare Homoeo Charitable Society
      2013   Phase 2   NCT01905735   India;
Ribazen   
   Nuon Therapeutics, Inc.
      2009   -   EUCTR2008-006917-25-DE   Bulgaria;Czech Republic;Germany;Poland;United Kingdom;
Riboflavin   
   Joseph B. Ciolino, MD
      2012   Phase 1/Phase 2   NCT01582880   United States;
Rifampicin   
   AstraZeneca
      2011   Phase 1   NCT01336218   United States;
Rimacalib   
   Dainippon Sumitomo Pharma Europe Ltd
      2005   -   EUCTR2005-003436-21-GB   Czech Republic;Germany;Hungary;United Kingdom;
   Dainippon Sumitomo Pharma Europe Ltd.
      2006   -   EUCTR2005-003436-21-DE   Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-003436-21-CZ   Czech Republic;Germany;Hungary;United Kingdom;
Risedronate   
   Division of rheumatology, endcrinology and nephrology, Hokkaido University Graduate School of Medicine
      2014   Phase 4   JPRN-UMIN000015794   Japan;
Ritlecitinib/JAK 3   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
Ritumax®   
   Biointegrator LLC
      2016   Phase 1   NCT03061838   Russian Federation;
Rituxan   
   Amgen Inc
      2017   Phase 1;Phase 3   EUCTR2013-005543-90-EE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2015   Phase 1;Phase 3   EUCTR2013-005543-90-BG   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-PL   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-HU   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-DE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
   Archigen Biotech Limited
      2016   Phase 1   NCT02819726   Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;India;Korea, Republic of;Mexico;Poland;Spain;United States;
   Boehringer Ingelheim International GmbH
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-NO   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002894-48-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GB   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-EE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   CELLTRION, Inc.
      2014   Phase 3   EUCTR2013-004555-21-SK   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-PT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-LV   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-HU   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-GR   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-DE   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
   Celltrion
      2014   Phase 3   NCT02149121   Austria;Korea, Republic of;
   Dr. Reddy's Laboratories Limited
      2014   Phase 1/Phase 2   NCT02296775   India;Ukraine;
   Mabion S.A.
      2021   Phase 3   EUCTR2020-002765-34-BE   Belgium;Bulgaria;Georgia;Poland;Serbia;Ukraine;
   Pfizer
      2012   Phase 2   NCT01526057   Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;Taiwan;United Kingdom;United States;
   Sandoz
      2011   Phase 1/Phase 2   NCT01274182   Argentina;Austria;Belgium;Brazil;Estonia;France;Germany;Hungary;India;Italy;Romania;Spain;Turkey;United States;
   University of California, San Francisco
      2009   -   NCT00844714   United States;
Rituxan (INN: Rituximab), brand name in the US   
   Hexal AG
      2011   Phase 2   EUCTR2010-021184-32-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
Rituxan (INN: Rituximab), brand name in the United States   
   Hexal AG
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-GB   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-021184-32-EE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2011   Phase 2   EUCTR2010-021184-32-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2010   Phase 2   EUCTR2010-021184-32-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
Rituxan (US, Canada, Japan), MabThera (rest of the world)   
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
Rituxan®   
   ARCHIGEN BIOTECH LIMITED
      2017   Phase 1;Phase 3   EUCTR2014-005368-13-IT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
   Archigen Biotech Limited
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-HU   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-ES   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-DE   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
   Boehringer Ingelheim
      2012   Phase 3   NCT01682512   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Mabion SA
      2021   Phase 3   NCT04680962   -
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2013   Phase 2   EUCTR2012-003223-38-GB   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-003223-38-DE   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-003223-38-ES   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2011-002896-40-PL   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-002896-40-GB   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      -   Phase 2   EUCTR2011-002896-40-ES   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US
      2012   -   EUCTR2011-002896-40-DE   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
Rituxan® (rituximab)   
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
Rituximab   
   Biocad
      2012   Phase 3   NCT01759030   Belarus;Colombia;India;Russian Federation;Ukraine;
   Boehringer Ingelheim International GmbH
      2014   -   EUCTR2013-002622-23-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Celltrion
      2012   Phase 1   NCT01534884   Korea, Republic of;
   Chinese University of Hong Kong
      2006   Phase 2   NCT00555542   China;
   Division of Clinically Immunology and Rheumatology, AMC
      2009   -   EUCTR2009-010955-29-NL   Netherlands;
   Eric Matteson
      2007   Phase 3   NCT00578565   United States;
   F Hoffmann-La Roche Ltd
      2009   Phase 2   EUCTR2008-005525-11-GR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-005525-11-FR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-NL   France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-DE   France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-005525-11-GB   France;Germany;Greece;Netherlands;Spain;United Kingdom;
   F. Hoffmann - La Roche Ltd.
      2005   -   EUCTR2005-002395-15-IT   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   F. Hoffmann- La Roche Ltd.
      2005   -   EUCTR2005-002396-33-IT   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
   F. Hoffmann-La Roche Ltd.
      2006   Phase 3   EUCTR2005-002396-33-GB   Belgium;Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-002395-15-GB   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003632-22-ES   Spain;
      2006   -   EUCTR2005-002396-33-SK   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-HU   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-FI   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-DE   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002395-15-SE   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-FI   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-DK   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-DE   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-CZ   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002392-32-DE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-002396-33-BE   Belgium;Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-002392-32-IE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-002392-32-GB   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   -   EUCTR2005-002396-33-ES   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2005   -   EUCTR2005-002395-15-ES   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002395-15-BE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002392-32-SI   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   -   EUCTR2005-002392-32-SE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
   Frank Behrens
      2010   Phase 3   NCT01244958   Germany;
   Gaylis, Norman B., M.D.
      2007   Phase 2   NCT00425932   United States;
   Genentech, Inc.
      2007   Phase 3   NCT00443651   United States;
      2006   Phase 3   NCT00299104   United States;
      2006   Phase 3   NCT00266227   United States;
      2006   Phase 2   NCT00282308   United States;
      2005   Phase 3   NCT00299130   United States;
      2005   Phase 2   NCT00243412   United States;
      2003   Phase 2   NCT00074438   United States;
   Hoffmann-La Roche
      2012   -   NCT01613027   Greece;
      2011   Phase 4   NCT01382940   United States;
      2011   -   NCT01641952   Romania;
      2011   -   NCT01592292   Korea, Republic of;
      2010   -   NCT01071798   Germany;United States;
      2008   -   NCT02622503   Finland;
      2007   Phase 4   NCT00462345   Korea, Republic of;
      2007   Phase 3   NCT00578305   Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;United Kingdom;
      2007   -   NCT02699892   Serbia;
      2006   Phase 3   NCT01272908   Canada;Sweden;
      2006   Phase 3   NCT01126541   France;
      2004   Phase 3   NCT00468377   United States;
      2002   Phase 2   NCT02093026   Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Germany;Israel;Italy;Mexico;New Zealand;Poland;Spain;Sweden;United Kingdom;United States;
      2001   Phase 2   NCT02693210   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
   Joint Research & Development Office (QMUL)
      2018   Phase 3   EUCTR2017-004079-30-PT   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-ES   Belgium;Italy;Portugal;Spain;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Mabion SA
      2013   Phase 3   NCT02468791   Bosnia and Herzegovina;Georgia;Poland;Serbia;Ukraine;
   Mashhad University of Medical Sciences
      2010   Phase 4   NCT01593332   Iran, Islamic Republic of;
   Merck KGaA
      2008   Phase 2   NCT00664521   Finland;France;Netherlands;Sweden;United Kingdom;
   Merck Serono International
      2008   Phase 2   EUCTR2007-003647-75-FR   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-SE   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-NL   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-FI   Finland;France;Netherlands;Sweden;United Kingdom;
   Merck Serono SA - Geneva
      2008   Phase 2   EUCTR2007-003647-75-GB   Finland;France;Netherlands;Sweden;United Kingdom;
   NHS Greater Glasgow and Clyde
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Phase 1/Phase 2   NCT00396812   United States;
   Prof. Abid Z. Farooqi
      2010   Phase 4   NCT02731560   -
   ROCHE
      2007   -   EUCTR2007-001754-11-IT   Italy;
   Roche Pharma AG
      2007   -   EUCTR2006-006746-33-DE   Germany;
      2006   -   EUCTR2006-001000-37-DE   Germany;
   Sint Maartenskliniek
      2020   Phase 4   EUCTR2020-002507-19-NL   Netherlands;
   South Tees Hospitals NHS Foundation Trust
      2011   Phase 4   EUCTR2010-020499-50-GB   United Kingdom;
   University Hospital, Rouen
      2011   Phase 4   NCT01765374   France;
   University Hospital, Tours
      2015   Phase 3   NCT02304354   France;
   University of California, San Diego
      2008   Phase 2   NCT00147966   United States;
   University of Glasgow
      2010   Phase 4   NCT01021735   United Kingdom;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
      2007   Phase 3   EUCTR2006-005640-81-GB   United Kingdom;
      2006   Phase 4   EUCTR2005-004582-41-GB   United Kingdom;
   University of Manitoba
      2007   -   NCT00963703   Canada;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
Rituximab (EU)   
   Amgen
      2016   Phase 3   NCT02792699   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
Rituximab (US)   
   Amgen
      2016   Phase 3   NCT02792699   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
Rituximab - MabThera   
   Vienna Medical University
      2006   -   EUCTR2006-000854-32-AT   Austria;
Rituximab MabThera   
   Vienna Medical University
      2006   -   EUCTR2006-000854-32-AT   Austria;
Rituximab [MabThera/Rituxan]   
   Hoffmann-La Roche
      2011   Phase 3   NCT01332994   Germany;
      2010   Phase 4   NCT01117129   Spain;
      2009   Phase 2   NCT00845832   Belgium;France;Germany;Greece;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2008   Phase 4   NCT01000610   Tunisia;
      2007   Phase 4   NCT00934648   Morocco;
      2007   Phase 4   NCT00576433   Russian Federation;
      2007   Phase 4   NCT00504777   Taiwan;
      2007   Phase 4   NCT00502853   Italy;
      2007   Phase 4   NCT00424502   Hungary;
      2007   Phase 3   NCT00502840   Germany;
      2006   Phase 3   NCT02006706   Serbia;
      2006   Phase 3   NCT00502996   Argentina;Brazil;Chile;Colombia;Ecuador;El Salvador;Mexico;Peru;Uruguay;Venezuela;
      2006   Phase 3   NCT00422383   Australia;Belgium;Brazil;Canada;China;Finland;France;Germany;Hungary;Italy;Netherlands;New Zealand;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2006   Phase 2   NCT00422942   Netherlands;Spain;
      2005   Phase 3   NCT00503425   Israel;
      2004   Phase 3   NCT02097745   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom;United States;
Rituximab [MabThera]   
   Hoffmann-La Roche
      2006   Phase 3   NCT02079532   Germany;
Rituximab [Mabthera/Rituxan]   
   Hoffmann-La Roche
      2010   Phase 4   NCT01117129   Spain;
      2009   -   NCT01075477   Finland;United States;
Rituximab, MTX, folic acid   
   Celltrion
      2013   Phase 1   NCT01873443   Korea, Republic of;
Rituximab, observational study amon patients with active RA   
   Kuopio University Hospital
      2004   -   NCT00854321   Finland;
Rituximab-EU+ Rituximab-Pfizer x 2 Courses   
   Pfizer
      2012   -   NCT01643928   Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;Switzerland;Ukraine;United Kingdom;United States;
Rituximab-Pfizer   
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2013   Phase 2   EUCTR2012-003223-38-GB   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-003223-38-DE   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-003223-38-ES   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2011-002896-40-PL   Argentina;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US
      2012   -   EUCTR2011-002896-40-DE   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Israel;Italy;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States;
Rituximab-Pfizer (PF-05280586) x 3 courses   
   Pfizer
      2012   -   NCT01643928   Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;Switzerland;Ukraine;United Kingdom;United States;
Rituximab-US + Rituximab-Pfizer x 2 Courses   
   Pfizer
      2012   -   NCT01643928   Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;Switzerland;Ukraine;United Kingdom;United States;
Rivaroxaban   
   Department of Orthopaedics, West China Hospital, Sichuan University
      2018   -   ChiCTR1800014584   China;
Rixathon   
   Sint Maartenskliniek
      2020   Phase 4   EUCTR2020-002507-19-NL   Netherlands;
Ro 002-9893/F02   
   F. Hoffmann-La Roche Ltd.
      2010   Phase 3   EUCTR2009-012759-12-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-SE   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-PT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-IE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-HU   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-GR   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-ES   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-FI   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DK   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-AT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
   Roche Farma, S.A.
      -   -   EUCTR2011-001626-15-ES   Spain;
Ro 45-2294   
   F. Hoffmann-La Roche Ltd.
      2006   Phase 3   EUCTR2005-002396-33-GB   Belgium;Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-002395-15-GB   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002396-33-SK   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-HU   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-FI   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002396-33-DE   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2005-002395-15-SE   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-FI   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-DK   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-DE   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002395-15-CZ   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002392-32-DE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-002396-33-BE   Belgium;Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-002392-32-IE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-002392-32-GB   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   -   EUCTR2005-002396-33-ES   Finland;Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
      2005   -   EUCTR2005-002395-15-ES   Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002395-15-BE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002392-32-SI   Germany;Ireland;Slovenia;Sweden;United Kingdom;
      2005   -   EUCTR2005-002392-32-SE   Germany;Ireland;Slovenia;Sweden;United Kingdom;
   Roche Pharma AG
      2007   -   EUCTR2006-006746-33-DE   Germany;
      2006   -   EUCTR2006-001000-37-DE   Germany;
Ro 48-77533   
   ROCHE
      2005   -   EUCTR2005-001138-33-IT   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-000884-25-IT   Germany;Iceland;Italy;Sweden;United Kingdom;
Ro 487-7533   
   ROCHE
      2009   -   EUCTR2009-011105-17-IT   Italy;
Ro 487-7533/F01   
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2010-018375-22-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-023587-40-DK   Denmark;European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-SE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-NL   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-GR   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-FI   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-DE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2010   Phase 4   EUCTR2009-015845-21-GB   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 4   EUCTR2009-015845-21-BE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-012759-12-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-018375-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018331-18-GB   United Kingdom;
      2010   -   EUCTR2009-015845-21-SE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-PT   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-GR   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-FI   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-DE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-CZ   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-SE   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-PT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-IE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-HU   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-GR   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-FI   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DK   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-AT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
   Roche Oy
      2010   -   EUCTR2010-019935-37-FI   Finland;
Ro 487-7533/F10   
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2010-018375-22-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2010-019912-18-ES   Bulgaria;Greece;Hungary;Spain;
      2011   -   EUCTR2010-019912-18-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
      2011   -   EUCTR2010-019912-18-GR   Bulgaria;Greece;Hungary;Spain;
      2011   -   EUCTR2010-019912-18-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
      2010   Phase 3   EUCTR2010-018375-22-ES   Bulgaria;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2010-018375-22-IT   Bulgaria;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2010-018375-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
Ro 487-7533/F10-02   
   N.V. Roche S.A.
      2013   Phase 3   EUCTR2013-002150-79-BE   Belgium;
Ro 487-7533/F10-04   
   ROCHE HELLAS S.A.
      2013   Phase 3   EUCTR2013-000359-42-GR   Greece;
   Roche Farma S.A
      2013   Phase 3   EUCTR2013-002429-52-IE   Ireland;Portugal;Spain;
      2013   Phase 3   EUCTR2013-002429-52-ES   Ireland;Portugal;Spain;
   Roche Farma S.A.
      2013   Phase 3   EUCTR2013-002429-52-PT   Ireland;Portugal;Spain;
   Roche Nederland B.V.
      2013   Phase 3   EUCTR2013-000342-19-NL   Netherlands;
   Roche Products Limited
      2013   Phase 3   EUCTR2013-000054-22-GB   United Kingdom;
   Roche S.p.A.
      2013   -   EUCTR2013-001569-17-IT   Italy;
   Roche a/s
      2014   Phase 3   EUCTR2013-002007-34-SE   Denmark;Finland;Sweden;
      2014   Phase 3   EUCTR2013-002007-34-FI   Denmark;Finland;Sweden;
      2013   Phase 3   EUCTR2013-002007-34-DK   Denmark;Finland;Sweden;
Ro 496-4913   
   F Hoffmann-La Roche Limited
      2005   -   EUCTR2004-002132-26-ES   Spain;United Kingdom;
   F. Hoffmann-La Roche Limited
      2008   Phase 1;Phase 2   EUCTR2004-002132-26-GB   Spain;United Kingdom;
Ro Actemra   
   F. Hoffmann - La Roche Ltd
      2006   -   EUCTR2005-002909-23-IT   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III
      2012   Phase 4   EUCTR2012-000139-21-AT   Austria;Czech Republic;Russian Federation;Slovakia;Switzerland;
   Revmatologicky ustav Praha
      2015   Phase 4   EUCTR2015-000581-58-CZ   Czech Republic;
Ro-Actemra   
   Medical University of Vienna
      2012   Phase 4   NCT01638715   Austria;Czech Republic;Czechia;Russian Federation;Saudi Arabia;Switzerland;
   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III
      2012   Phase 4   EUCTR2012-000139-21-AT   Austria;Czech Republic;Russian Federation;Slovakia;Switzerland;
   Revmatologicky ustav Praha
      2015   Phase 4   EUCTR2015-000581-58-CZ   Czech Republic;
Ro487-7533   
   ROCHE
      2009   -   EUCTR2009-012185-32-IT   Italy;
RoActemra   
   Ablynx NV
      2015   Phase 2   EUCTR2014-003012-36-HU   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-ES   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-DE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-CZ   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-BG   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-BE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
   Bio-Thera Solutions, Ltd.
      2019   Phase 3   EUCTR2018-002202-31-BG   Bulgaria;China;Georgia;Poland;Ukraine;
   Cliniques Universitaires Saint-Luc, Université catholique de Louvain
      2015   -   EUCTR2015-001246-28-BE   Belgium;
   F Hoffmann La-Roche AG
      2006   -   EUCTR2005-002909-23-SI   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2006   -   EUCTR2005-002909-23-DK   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F Hoffmann La-Roche Ltd.
      2006   -   EUCTR2005-002909-23-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2006   -   EUCTR2005-002909-23-LT   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   F Hoffmann-La Roche AG
      2006   -   EUCTR2005-002909-23-DE   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F. Hoffmann - La Roche Ltd
      2006   -   EUCTR2005-002909-23-IT   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F. Hoffmann La-Roche Ltd
      2005   -   EUCTR2005-002423-13-AT   Austria;Bulgaria;Germany;Hungary;Italy;Slovakia;
      -   -   EUCTR2005-002423-13-BG   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Switzerland;Thailand;
   F. Hoffmann La-Roche Ltd.
      2005   Phase 3   EUCTR2004-003733-14-FI   Australia;Brazil;China;Denmark;Finland;France;Greece;Italy;Mexico;Norway;Poland;South Africa;Spain;United States;
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2014-004673-16-DE   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Switzerland;Turkey;
      2015   Phase 4   EUCTR2014-004673-16-FR   Egypt;France;Germany;Italy;Lebanon;Russian Federation;Serbia;Slovenia;Switzerland;Tunisia;Turkey;
      2013   -   EUCTR2013-002341-11-GB   United Kingdom;
      2009   Phase 3   EUCTR2008-006924-68-GR   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-006924-68-GB   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-006924-68-FR   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-PT   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-HU   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-CZ   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-000587-17-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002423-13-DE   Bulgaria;Germany;Hungary;Italy;Slovakia;
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2010-023587-40-IT   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2010   -   EUCTR2010-018375-22-IT   Bulgaria;Germany;Italy;Lithuania;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-IT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
   F.Hoffmann La Roche Ltd
      2005   -   EUCTR2005-002423-13-IT   Bulgaria;Germany;Hungary;Italy;Slovakia;
   FRANCISCO J. BLANCO GARCÍA
      2013   -   EUCTR2012-004482-40-ES   Spain;
   Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)
      2016   Phase 4   EUCTR2012-002535-28-NL   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2015   Phase 4   EUCTR2012-002535-28-ES   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2014   Phase 4   EUCTR2012-002535-28-BE   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2013   Phase 4   EUCTR2012-002535-28-GB   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London
      2015   Phase 4   EUCTR2012-002535-28-IT   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2014   Phase 4   EUCTR2012-002535-28-PT   Belgium;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Karolinska Institutet
      2015   Phase 4   NCT02466581   Sweden;
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   Phase 4   EUCTR2011-004720-35-DK   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
      2012   Phase 4   NCT01491815   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
   N.V. Roche S.A.
      2013   Phase 3   EUCTR2013-002150-79-BE   Belgium;
   OSSERVATORIO EPIDEMIOLOGICO GISEA
      2012   -   EUCTR2012-001760-30-IT   Italy;
   ROCHE
      2009   -   EUCTR2009-012185-32-IT   Italy;
      2009   -   EUCTR2009-011105-17-IT   Italy;
      2009   -   EUCTR2008-008309-23-FR   France;
   Reade
      2019   Phase 1;Phase 4   EUCTR2018-004605-57-NL   Netherlands;
   Roche (Magyarország) Kft.
      2012   -   EUCTR2011-006125-14-HU   Hungary;
   Roche Austria GmbH
      2011   -   EUCTR2011-001863-39-AT   Austria;
   Roche Farma S.A
      2013   Phase 3   EUCTR2013-002429-52-IE   Ireland;Portugal;Spain;
      2013   Phase 3   EUCTR2013-002429-52-ES   Ireland;Portugal;Spain;
   Roche Farma, S.A.
      2009   -   EUCTR2008-006443-39-ES   Spain;
   Roche Farmacêutica Química, Lda.
      2009   -   EUCTR2009-012218-30-PT   Portugal;
   Roche Nederland B.V.
      2009   -   EUCTR2009-013316-12-NL   Netherlands;
   Roche Pharma AG
      2008   -   EUCTR2008-000105-11-DE   Germany;
   Roche Products Limited
      2013   Phase 3   EUCTR2013-000054-22-GB   United Kingdom;
      2012   Phase 4   EUCTR2011-005260-20-GB   United Kingdom;
   Roche a/s
      2014   Phase 3   EUCTR2013-002007-34-SE   Denmark;Finland;Sweden;
      2013   Phase 3   EUCTR2013-002007-34-DK   Denmark;Finland;Sweden;
   The Karolinska Institute, ClinTRID
      2017   Phase 4   EUCTR2011-004720-35-NL   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2012   -   EUCTR2011-004720-35-SE   Sweden;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   The Karolinska Instutute, ClinTRID
      2013   Phase 4   EUCTR2011-004720-35-IS   Denmark;Finland;Iceland;Norway;Sweden;
   The University of Leeds
      2013   Phase 4   EUCTR2011-004017-17-GB   United Kingdom;
   UCL Cliniques Universitaires Saint Luc
      2010   Phase 2   EUCTR2010-019873-13-BE   Belgium;
   University Medical Center Utrecht
      2019   Phase 4   EUCTR2017-003037-28-NL   Netherlands;
   University of Southern Denmark
      2021   Phase 1;Phase 2   EUCTR2020-005998-27-DK   Denmark;
RoActemra (R)   
   Fresenius Kabi SwissBioSim GmbH
      2021   Phase 3   EUCTR2019-004369-42-DE   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004369-42-PL   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-HU   Bulgaria;Czech Republic;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2020   Phase 3   EUCTR2019-004369-42-CZ   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-BG   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
RoActemra 162 mg solution injectable en seringue préremplie   
   Groupement des Hôpitaux de l’Institut Catholique de Lille
      2017   Phase 4   EUCTR2017-000947-41-FR   France;
RoActemra 20 mg/ml Concentrate for solution for infusion   
   Roche Pharma AG
      2011   -   EUCTR2010-022049-88-DE   Germany;
RoActemra 20 mg/ml concentrado para solución para perfusión   
   FUNDACIÓN ESPAÑOLA DE REUMATOLOGIA
      2014   Phase 4   EUCTR2013-004051-20-ES   Spain;
RoActemra 20 mg/ml concentrate for solution for infusion.   
   UCB Biosciences, Inc
      2011   -   EUCTR2010-020839-39-GB   United Kingdom;United States;
   UCB Biosciences, Inc. A Member of the UCB Group of Companies
      2011   Phase 2   EUCTR2010-020839-39-BE   Belgium;United Kingdom;United States;
   sanofi-aventis recherche & développement
      2013   Phase 3   EUCTR2012-003536-23-NO   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-IT   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-GB   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-SE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-PL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-NL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-HU   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-FI   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-ES   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-EE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-CZ   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-BE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
RoActemra(R)   
   Fresenius Kabi SwissBioSim GmbH
      2021   Phase 3   EUCTR2019-004369-42-DE   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004369-42-SK   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-PL   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-HU   Bulgaria;Czech Republic;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2020   Phase 3   EUCTR2019-004369-42-CZ   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
      2020   Phase 3   EUCTR2019-004369-42-BG   Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
RoActemra®   
   Aarhus University Hospital, Department of Rheumatology U
      2012   Phase 4   EUCTR2011-006040-79-DK   Denmark;
   F Hoffmann La-Roche Ltd.
      2005   -   EUCTR2004-003733-14-DK   Denmark;Finland;Italy;Spain;
   F Hoffmann-La Roche Ltd.
      2009   -   EUCTR2008-001847-20-SE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-001847-20-GR   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-001847-20-DE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2008-001847-20-GB   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-LV   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-EE   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-DK   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2010-018375-22-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-023587-40-DK   Denmark;European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   Phase 4   EUCTR2010-020065-24-NL   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-LV   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-HU   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GR   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-ES   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-AT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023587-40-SE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-NL   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-GR   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-023587-40-FI   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-DE   European Union;Finland;Germany;Greece;Italy;Netherlands;Russian Federation;Spain;Sweden;United States;
      2011   -   EUCTR2010-020065-24-LT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2010   Phase 4   EUCTR2009-015845-21-GB   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 4   EUCTR2009-015845-21-BE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-012759-12-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-018375-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018331-18-GB   United Kingdom;
      2010   -   EUCTR2009-015845-21-SE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-PT   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-GR   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-FI   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-DE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-CZ   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-SE   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-PT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-IE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-HU   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-GR   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-FI   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DK   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-AT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
   ROCHE
      2011   Phase 4   EUCTR2010-020065-24-IT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Czech Republic;Ecuador;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
   Roche Oy
      2010   -   EUCTR2010-019935-37-FI   Finland;
   Roche Slovensko s.r.o.
      2009   -   EUCTR2009-011520-53-SK   Slovakia;
   Roche a/s
      2011   -   EUCTR2011-002363-15-IS   Denmark;Iceland;
      2011   -   EUCTR2011-002363-15-DK   Denmark;Iceland;
   UCB Biosciences, Inc
      2011   -   EUCTR2010-020839-39-GB   United Kingdom;United States;
   UCB Biosciences, Inc. A Member of the UCB Group of Companies
      2011   Phase 2   EUCTR2010-020839-39-BE   Belgium;United Kingdom;United States;
RoActemra®EV Product Code: PRD82321   
   University of Leeds
      2009   Phase 2   EUCTR2008-003011-12-GB   United Kingdom;
RoActerma   
   Bio-Thera Solutions, Ltd.
      2019   Phase 3   EUCTR2018-002202-31-BG   Bulgaria;China;Georgia;Poland;Ukraine;
RoActmera   
   AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
      2018   Phase 3   EUCTR2017-004079-30-IT   Belgium;Italy;Portugal;Spain;
   Joint Research & Development Office (QMUL)
      2018   Phase 3   EUCTR2017-004079-30-PT   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-ES   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-BE   Belgium;Italy;Portugal;Spain;
      2014   Phase 3   EUCTR2014-003529-16-GB   United Kingdom;
Rob 803   
   OxyPharma
      2007   Phase 2   NCT00525213   Belgium;Bulgaria;Former Serbia and Montenegro;Georgia;Latvia;Lithuania;Poland;Romania;Serbia;Sweden;United Kingdom;
Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-BG   Bulgaria;Latvia;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-LT   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-004834-33-LV   Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 (capsules 12.5 mg)   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-BG   Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 (capsules 15 mg)   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-BG   Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 (capsules 25 mg)   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-BG   Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 (capsules 6.25 mg)   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-BG   Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 12.5mg capsule   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-LT   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-GB   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-004834-33-BE   Belgium;Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 15mg capsule   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-LT   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-GB   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-004834-33-BE   Belgium;Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 25mg capsule   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-LT   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-GB   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-004834-33-BE   Belgium;Bulgaria;Latvia;Poland;United Kingdom;
Rob 803 6.25mg capsule   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-LT   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
Rob 803 6.5mg capsule   
   OxyPharma AB
      2007   Phase 2   EUCTR2006-004834-33-GB   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-004834-33-BE   Belgium;Bulgaria;Latvia;Poland;United Kingdom;
Rofecoxib   
   Merck Sharp & Dohme Corp.
      2004   Phase 4   NCT00157872   China;
Ropivacaine   
   Hokusuikai Kinen Hospital
      2018   -   JPRN-UMIN000033059   Japan;
   Nekoyama Miyao Hospital
      2017   -   JPRN-UMIN000029759   Japan;
      2017   -   JPRN-UMIN000029003   Japan;
      2013   -   JPRN-UMIN000012257   Japan;
   Nekoyama miyao hospital
      2012   -   JPRN-UMIN000011181   Japan;
      2012   -   JPRN-UMIN000010902   Japan;
   West China Hospital, Sichuan University
      2021   Phase 0   ChiCTR2000036316   China;
      2021   Phase 0   ChiCTR2000036164   china;
      2020   -   ChiCTR2000035179   China;
      2020   -   ChiCTR2000035146   China;
Rosiglitazone Extended Release Tablets   
   GlaxoSmithKline Research & Development Ltd.
      2005   -   EUCTR2004-000482-35-LT   Lithuania;United Kingdom;
      2004   Phase 2   EUCTR2004-000482-35-GB   Lithuania;United Kingdom;
Rosiglitazone XR   
   GlaxoSmithKline
      2004   Phase 2   NCT00379600   Lithuania;United Kingdom;
Rosiglitazone maleate   
   GlaxoSmithKline Research & Development Ltd.
      2005   -   EUCTR2004-000482-35-LT   Lithuania;United Kingdom;
      2004   Phase 2   EUCTR2004-000482-35-GB   Lithuania;United Kingdom;
Rosuvastatin   
   AstraZeneca
      2012   Phase 1   NCT01725230   United States;
   Chinese University of Hong Kong
      2007   Phase 2   NCT00555230   China;
   Diakonhjemmet Hospital
      2013   -   NCT01389388   Norway;
   Gilead Sciences
      2020   Phase 1   NCT04608344   United States;
   University of Dundee
      2005   -   EUCTR2004-001909-10-GB   United Kingdom;
      2004   Phase 2/Phase 3   NCT00679510   United Kingdom;
Roxithromycin   
   Nazilli State Hospital
      2006   Phase 4   NCT00439062   Turkey;
Rupatadine   
   Sherief Abd-Elsalam
      2018   Phase 3   NCT03770923   Egypt;
S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide   
   Pfizer Ltd
      2006   -   EUCTR2006-003577-27-CZ   Czech Republic;Estonia;Spain;
   Pfizer Luxembourg SARL Branch Office Estonia
      2006   -   EUCTR2006-003577-27-EE   Czech Republic;Estonia;Spain;
   Pfizer S.A.
      2007   Phase 2   EUCTR2006-003577-27-ES   Czech Republic;Estonia;Spain;
S.c. injections of bovine intestinal Alkaline Phosphatase   
   Alloksys Life Sciences B.V.
      2011   Phase 1/Phase 2   NCT01416493   United Kingdom;
SAIT101   
   Archigen Biotech Limited
      2016   Phase 1   NCT02819726   Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;India;Korea, Republic of;Mexico;Poland;Spain;United States;
   Samsung Electronics Co. Ltd.
      2012   -   EUCTR2011-004171-36-PL   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-HU   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-GB   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-ES   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-CZ   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
SAIT101 (proposed rituximab biosimilar)   
   Archigen Biotech Limited
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-DE   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
SAIT101 (rituximab biosimilar)   
   ARCHIGEN BIOTECH LIMITED
      2017   Phase 1;Phase 3   EUCTR2014-005368-13-IT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
   Archigen Biotech Limited
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-HU   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2016   Phase 1;Phase 3   EUCTR2014-005368-13-ES   Bosnia and Herzegovina;Bulgaria;Czech Republic;Germany;Hungary;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
SAN-300 0.5 mg/kg QW   
   Bausch Health Americas, Inc.
      2013   Phase 2   NCT02047604   United States;
SAN-300 1.0 mg/kg QW   
   Bausch Health Americas, Inc.
      2013   Phase 2   NCT02047604   United States;
SAN-300 2.0 mg/kg QOW   
   Bausch Health Americas, Inc.
      2013   Phase 2   NCT02047604   United States;
SAN-300 4.0 mg/kg QOW   
   Bausch Health Americas, Inc.
      2013   Phase 2   NCT02047604   United States;
SAN-300 4.0 mg/kg QW   
   Bausch Health Americas, Inc.
      2013   Phase 2   NCT02047604   United States;
SANDIMMUN NEORAL*30CPS   
   PFIZER
      2007   -   EUCTR2007-001984-31-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
SANDIMMUN NEORAL*50CPS   
   PFIZER
      2007   -   EUCTR2007-001984-31-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
SAR153191   
   SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT
      2013   -   EUCTR2011-003538-16-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
   SANOFI-AVENTIS S.P.A
      2011   Phase 3   EUCTR2010-019262-86-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Italy;Korea, Democratic People's Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Sanofi-aventis Recherche & D?veloppement
      2010   -   EUCTR2010-021020-94-IT   Czech Republic;Germany;Hungary;Italy;Spain;
   Sanofi-aventis Recherche & Développement
      2011   Phase 2   EUCTR2009-016266-90-ES   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Portugal;Romania;Spain;
      2011   -   EUCTR2010-021020-94-HU   Czech Republic;Germany;Hungary;Italy;Spain;
      2011   -   EUCTR2010-021020-94-DE   Czech Republic;Germany;Hungary;Italy;Spain;
      2010   Phase 2;Phase 3   EUCTR2009-016266-90-RO   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Portugal;Romania;Spain;
      2010   -   EUCTR2010-021020-94-ES   Czech Republic;Germany;Hungary;Italy;Spain;
      2010   -   EUCTR2010-021020-94-CZ   Czech Republic;Germany;Hungary;Italy;Spain;
      2010   -   EUCTR2009-016266-90-NL   Austria;Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Portugal;Spain;
      2010   -   EUCTR2009-016266-90-LT   Austria;Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Portugal;Romania;Spain;
      2010   -   EUCTR2009-016266-90-GR   Austria;Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Portugal;Romania;Spain;
      2010   -   EUCTR2009-016266-90-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Portugal;Romania;Spain;
   sanofi-aventis Recherche & Développement
      2011   -   EUCTR2010-019262-86-ES   Austria;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Spain;
      2010   Phase 3   EUCTR2010-019262-86-GR   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Lithuania;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   sanofi-aventis recherche & développement
      2013   Phase 3   EUCTR2011-003538-16-ES   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   Phase 3   EUCTR2011-003538-16-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-SK   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-PL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-LT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-CZ   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2011   Phase 2;Phase 3   EUCTR2009-016266-90-BE   Argentina;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
      2011   -   EUCTR2009-016266-90-PT   Argentina;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
SAR153191 (REGN88)   
   Sanofi
      2011   Phase 1   NCT01328522   United States;
      2010   Phase 3   NCT01146652   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   sanofi-aventis Recherche & Développement
      2014   Phase 3   EUCTR2012-004339-21-PL   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
      2014   Phase 3   EUCTR2010-019262-86-SE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2010-019262-86-GB   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2010-019262-86-BE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2010-019262-86-NO   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001984-66-NO   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001984-66-GB   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-019262-86-SK   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-019262-86-CZ   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LV   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-IT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-HU   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-GR   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-FI   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-ES   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-DE   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-CZ   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-019262-86-PT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-019262-86-AT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019262-86-NL   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019262-86-DE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-LT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-HU   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-FI   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-EE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   sanofi-aventis recherche & développement
      2015   Phase 3   EUCTR2014-002541-22-HU   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-ES   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-DE   Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-CZ   Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2014-002541-22-GB   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002790-22-CZ   Argentina;Chile;Czech Republic;Estonia;Hungary;Poland;Russian Federation;United States;
      2014   -   EUCTR2013-002790-22-HU   Argentina;Chile;Czech Republic;Estonia;Hungary;Poland;Russian Federation;United States;
      2014   -   EUCTR2013-002790-22-EE   Argentina;Chile;Czech Republic;Estonia;Hungary;Poland;Russian Federation;United States;
      2013   Phase 3   EUCTR2012-003536-23-NO   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-IT   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-GB   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-SE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-PL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-NL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-HU   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-FI   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-ES   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-EE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-CZ   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-BE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2009-016266-90-AT   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-HU   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-FI   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-EE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-DE   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
SB 681323   
   GlaxoSmithKline
      2006   Phase 2   EUCTR2005-002219-26-HU   Denmark;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
SB-681323   
   GLAXO SMITHKLINE
      2005   -   EUCTR2005-002219-26-IT   Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
   GlaxoSmithKline
      2005   Phase 2   NCT00320450   Denmark;Germany;Hong Kong;Hungary;Italy;Norway;Poland;Spain;Sweden;United Kingdom;
      2005   Phase 2   NCT00134693   Australia;France;Germany;Russian Federation;United Kingdom;
SB-681323 Tablets   
   GlaxoSmithKline R&D Ltd
      2006   Phase 2   EUCTR2005-002219-26-NO   Denmark;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2005   Phase 2   EUCTR2005-002219-26-DK   Denmark;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002219-26-SE   Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002219-26-DE   Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-005115-29-DE   Germany;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2006   Phase 2   EUCTR2005-002219-26-GB   Denmark;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2005   Phase 2   EUCTR2004-005115-29-GB   Germany;United Kingdom;
   GlaxoSmithKline S.A.
      2005   Phase 2   EUCTR2005-002219-26-ES   Denmark;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
SB-681323 oral tablets   
   GlaxoSmithKline
      2005   Phase 1   NCT00419809   Australia;
SB2 (infliximab biosimilar)   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005733-37-GB   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   Phase 3   EUCTR2012-005733-37-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   Phase 3   EUCTR2012-005733-37-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005733-37-LV   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005733-37-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;India;Korea, Republic of;Latvia;Lithuania;Mexico;Philippines;Poland;Romania;Ukraine;United Kingdom;
SB2 (proposed biosimilar to infliximab)   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   NCT01936181   Bulgaria;Lithuania;
SB4 (etanercept biosimilar)   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-LT   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
SB4 (proposed biosimilar to etanercept)   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   NCT01895309   Poland;United Kingdom;
SB5   
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland;
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
SB5 (proposed biosimilar to adalimumab)   
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   NCT02167139   Lithuania;Poland;
SBI-087   
   Pfizer
      2009   Phase 2   NCT01008852   Argentina;Canada;Chile;Greece;Hungary;Japan;Mexico;Poland;Serbia;Spain;Turkey;United States;
      2008   Phase 1   NCT00815906   Japan;
      2008   Phase 1   NCT00641225   Canada;United States;
   Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
      2010   -   EUCTR2009-010516-15-PL   Greece;Hungary;Poland;Spain;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2010   Phase 2   EUCTR2009-010516-15-GR   Greece;Hungary;Poland;Spain;
      2010   Phase 2   EUCTR2009-010516-15-ES   Greece;Hungary;Poland;Spain;
      2009   -   EUCTR2009-010516-15-HU   Greece;Hungary;Poland;Spain;
SC golimumab   
   Merck Sharp & Dohme Corp.
      2009   Phase 3   NCT00975130   Argentina;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Monaco;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;
SC12267   
   4SC AG
      2009   -   EUCTR2009-012953-39-PL   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-CZ   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2009-012953-39-BG   Bulgaria;Czech Republic;Poland;
      2006   -   EUCTR2006-003142-42-DE   Germany;
SC12267 (4SC-101)   
   4SC AG
      2009   Phase 2   NCT01010581   Bulgaria;Czech Republic;Poland;Romania;
SCH 900259   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2010   -   EUCTR2009-011137-26-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   Schering-Plough Research Institute, A Division of Schering Corporation
      2010   Phase 3   EUCTR2009-011137-26-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-PL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-SK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-ES   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-IE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   Shering Plough Research Institute, A division of Schering Plough Corporation
      2010   -   EUCTR2009-011137-26-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
SCH900259   
   Shering Plough Research Institute, A division of Schering Plough Corporation
      2010   -   EUCTR2009-011137-26-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
SCIO-469   
   Scios, Inc.
      2004   Phase 2   NCT00089921   United States;
      2002   Phase 2   NCT00043732   United States;
SD-QIV   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2016   Phase 4   NCT02936180   Canada;
SHR0302   
   Jiangsu HengRui Medicine Co., Ltd.
      2020   Phase 3   NCT04333771   China;
      2017   Phase 2   NCT03254966   China;
      2016   Phase 1   NCT02892370   China;
      2016   Phase 1   NCT02665910   China;
      2015   Phase 1   NCT02423538   China;
SHR0302?[14C]SHR0302   
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 1   NCT05047341   China;
SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
SIMPONI 50 mg solución inyectable en pluma precargada   
   Sanofi-aventis Recherche & Développement
      2010   -   EUCTR2010-021020-94-ES   Czech Republic;Germany;Hungary;Italy;Spain;
SKI-O-703   
   Oscotec Inc.
      2019   Phase 2   NCT04057118   Czechia;Poland;Russian Federation;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003330-32-PL   Czech Republic;Korea, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
SKI-O-703 capsule   
   Oscotec Inc.
      2015   Phase 1   NCT02717988   United States;
SM03   
   SinoMab Pty Ltd
      2017   Phase 3   NCT04312815   China;
      2014   Phase 2   NCT04192617   China;
      2012   Phase 1   NCT04704492   China;
SMP-114   
   Dainippon Sumitomo Pharma Europe LTd.
      2006   Phase 2   NCT00296257   Czech Republic;Germany;Hungary;Netherlands;Poland;United Kingdom;
   Dainippon Sumitomo Pharma Europe Ltd
      2005   -   EUCTR2005-003436-21-GB   Czech Republic;Germany;Hungary;United Kingdom;
   Dainippon Sumitomo Pharma Europe Ltd.
      2006   -   EUCTR2005-003436-21-DE   Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-003436-21-CZ   Czech Republic;Germany;Hungary;United Kingdom;
   Sumitomo Pharmaceuticals Europe Limited
      2005   -   EUCTR2005-003436-21-HU   Czech Republic;Germany;Hungary;United Kingdom;
SPECT Imaging (180 Minutes post-injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
SPECT Imaging (60 Minutes post-injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
SSR150106   
   Sanofi
      2007   Phase 2   NCT00545454   Bulgaria;Croatia;Czech Republic;Czechia;Former Serbia and Montenegro;Romania;Russian Federation;Slovakia;Ukraine;
SSR150106XB   
   sanofi-aventis recherche & développement
      2008   Phase 2   EUCTR2007-000760-24-SK   Czech Republic;Slovakia;
      2007   Phase 2   EUCTR2007-000760-24-CZ   Czech Republic;
STA 5326 mesylate   
   Synta Pharmaceuticals Corp.
      2005   Phase 2   NCT00642629   Netherlands;
Salazopyrin EN   
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
Salazopyrin EN 500 mg enterotabletter   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Salazopyrine   
   University Hospitals Leuven
      2009   Phase 4   EUCTR2008-007225-39-BE   Belgium;
Salazosulfapyridine   
   Higashi-Hiroshima Memorial Hospital
      2009   Phase 4   JPRN-UMIN000002169   Japan;
   St Luke'
   s International Hospital
Salirumab   
   Shinshu University
      2018   Phase 2   NCT03784261   Japan;
Sar   
   sanofi-aventis recherche & développement
      2010   -   EUCTR2009-016266-90-FI   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-EE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
Sarilumab   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000868-18-IT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   Gaylis, Norman B., M.D.
      2018   Phase 3   NCT03535402   United States;
   GlaxoSmithKline
      2019   Phase 3   NCT04134728   Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
   Regeneron Pharmaceuticals
      2014   Phase 1   NCT02097524   United States;
   Sanofi
      2015   Phase 3   NCT02373202   Japan;
      2015   Phase 3   NCT02332590   Chile;Czech Republic;Czechia;France;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
      2013   Phase 3   NCT01764997   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2012   Phase 3   NCT01709578   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
      2010   Phase 2/Phase 3   NCT01061736   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Philippines;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   Phase 2   NCT01217814   Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Southern Denmark
      2021   Phase 1/Phase 2   NCT04842981   Denmark;
   sanofi-aventis Recherche & Développement
      2014   Phase 3   EUCTR2012-004339-21-PL   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
      2014   Phase 3   EUCTR2010-019262-86-SE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2010-019262-86-GB   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2010-019262-86-BE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2010-019262-86-NO   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001984-66-NO   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001984-66-GB   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-019262-86-SK   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-019262-86-CZ   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LV   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-IT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-HU   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-GR   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-FI   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-ES   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-DE   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-CZ   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-019262-86-PT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-019262-86-AT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019262-86-NL   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019262-86-DE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-LT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-HU   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-FI   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019262-86-EE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   sanofi-aventis recherche & développement
      2015   Phase 3   EUCTR2014-002541-22-HU   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-ES   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-DE   Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002541-22-CZ   Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2014-002541-22-GB   Argentina;Chile;Czech Republic;Germany;Hungary;Israel;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002790-22-CZ   Argentina;Chile;Czech Republic;Estonia;Hungary;Poland;Russian Federation;United States;
      2014   -   EUCTR2013-002790-22-HU   Argentina;Chile;Czech Republic;Estonia;Hungary;Poland;Russian Federation;United States;
      2014   -   EUCTR2013-002790-22-EE   Argentina;Chile;Czech Republic;Estonia;Hungary;Poland;Russian Federation;United States;
      2013   Phase 3   EUCTR2012-003536-23-NO   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-IT   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-GB   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-003538-16-ES   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   Phase 3   EUCTR2011-003538-16-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-003536-23-SE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-PL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-NL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-HU   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-FI   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-ES   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-EE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-CZ   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-BE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2011-003538-16-SK   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-PL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-LT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Estonia;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-CZ   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2013   -   EUCTR2011-003538-16-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Ecuador;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2011   Phase 2;Phase 3   EUCTR2009-016266-90-BE   Argentina;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
      2011   -   EUCTR2009-016266-90-PT   Argentina;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
      2011   -   EUCTR2009-016266-90-AT   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-HU   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-FI   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-EE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2010   -   EUCTR2009-016266-90-DE   Argentina;Australia;Austria;Belarus;Brazil;Canada;Chile;Colombia;Czech Republic;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Philippines;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]   
   Instituto de Investigación Marqués de Valdecilla
      2020   Phase 4   NCT04350216   -
Sarilumab SAR153191 (REGN88)   
   Sanofi
      2018   -   NCT03378219   Canada;United States;
      2015   Phase 1   NCT02404558   Japan;
      2014   Phase 3   NCT02293902   Japan;
      2014   Phase 3   NCT02121210   Chile;Czech Republic;Czechia;Estonia;Hungary;Poland;Russian Federation;United States;
      2014   Phase 1   NCT02017639   Korea, Republic of;Moldova, Republic of;United States;
      2013   Phase 3   NCT01768572   Argentina;Belgium;Brazil;Czech Republic;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 1   NCT01850680   Japan;
Scorpio NRG posterior stabilized (PS)   
   Stryker Japan K.K.
      2015   -   NCT02552082   Japan;
Seal oil   
   Laval University
      2022   -   NCT04688398   -
Seasonal Influenza vaccine   
   Seoul National University Hospital
      2015   Phase 4   NCT02748785   Korea, Republic of;
Seasonal influenza vaccine   
   Tel-Aviv Sourasky Medical Center
      2013   Phase 4   NCT01980836   Israel;
Secukinmab   
   Novartis Pharmaceuticals
      2009   Phase 2   NCT00928512   Belgium;Czech Republic;Germany;Hungary;Japan;Korea, Republic of;Poland;Puerto Rico;Russian Federation;Slovakia;Taiwan;United States;
Secukinumab   
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
   NOVARTIS FARMA
      2011   -   EUCTR2011-000275-13-IT   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000102-21-IT   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2010-024516-34-IT   Bulgaria;Canada;Hungary;Italy;United States;
   Novartis Farma S.p.A.
      2013   -   EUCTR2013-000944-25-IT   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
   Novartis Farmacéutica S.A.
      2011   -   EUCTR2011-000102-21-ES   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
   Novartis Pharma AG
      2011   -   EUCTR2011-000275-13-HU   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000275-13-GB   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000275-13-BE   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000102-21-SK   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2010-024516-34-SK   Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
      2011   -   EUCTR2010-024516-34-HU   Bulgaria;Canada;Hungary;Italy;United States;
      2011   -   EUCTR2010-024516-34-BG   Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
   Novartis Pharma K.K.
      2013   Phase 3   JPRN-JapicCTI-132209   -
      2012   Phase 3   JPRN-JapicCTI-132091   -
      -   Phase 3   JPRN-JapicCTI-111601   -
   Novartis Pharma Services AG
      2013   -   EUCTR2013-000944-25-HU   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
      2011   Phase 2   EUCTR2011-001220-38-GB   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   Phase 2   EUCTR2011-001220-38-BE   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   -   EUCTR2011-001220-38-DE   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   -   EUCTR2011-000102-21-HU   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-DE   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-CZ   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-BG   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01426789   Belgium;Germany;Russian Federation;United Kingdom;United States;
Secukinumab (AIN457)   
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01901900   Argentina;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Puerto Rico;Thailand;United States;
      2012   Phase 3   NCT01770379   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;Puerto Rico;South Africa;United States;
      2012   Phase 3   NCT01640938   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   Phase 3   NCT01377012   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Puerto Rico;Romania;Thailand;Turkey;United Kingdom;United States;
      2011   Phase 2   NCT01359943   Bulgaria;Canada;Hungary;Italy;Poland;Puerto Rico;Slovakia;United States;
See D.3.9.3 'Other descriptive name' below   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-PL   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-DK   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-CZ   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-BG   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
Sham Stimulation   
   Galvani Bioelectronics
      2021   -   NCT05003310   United States;
Sham vagus nerve stimulation   
   Xijing Hospital
      2019   -   NCT04037111   China;
Shingrix   
   Region Skane
      2019   Phase 4   NCT03886038   Sweden;
Short Chain Fatty Acids (SCFA) Dietary Supplement   
   NYU Langone Health
      2021   -   NCT05152615   United States;
Sildenafil   
   Kimberly Liang
      2017   Phase 2   NCT02908490   United States;
SimpleJectTM   
   Amgen
      2002   Phase 4   NCT00121043   -
Simplex® Bone Cement   
   Zimmer Biomet
      2006   -   NCT00589485   United States;
Simponi   
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
   MedImmune Limited
      2013   Phase 2   EUCTR2011-005649-10-GB   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
   MedImmune Ltd
      2013   -   EUCTR2011-005649-10-SK   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-PT   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-HU   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-DE   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-CZ   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005649-10-GR   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005649-10-ES   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2010   -   EUCTR2009-011137-26-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   SCHERING PLOUGH RESEARCH INSTITUTE, A DIVISION OF SCHERING CORPORATION
      2012   -   EUCTR2011-000311-34-IT   Canada;Finland;Germany;Greece;Italy;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Sanofi-aventis Recherche & Développement
      2011   -   EUCTR2010-021020-94-HU   Czech Republic;Germany;Hungary;Italy;Spain;
      2011   -   EUCTR2010-021020-94-DE   Czech Republic;Germany;Hungary;Italy;Spain;
      2010   -   EUCTR2010-021020-94-CZ   Czech Republic;Germany;Hungary;Italy;Spain;
   Schering-Plough Research Institute, A Division of Schering Corporation
      2010   Phase 3   EUCTR2009-011137-26-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-PL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   Sint Maartenskliniek
      2020   Phase 4   EUCTR2019-004101-27-NL   Netherlands;
Simponi 50 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Simponi®   
   Merck Sharp & Dohme Corp.
      2010   -   NCT01313858   Germany;
Simvastatin   
   AstraZeneca
      2012   Phase 1   NCT01725230   United States;
   Hoffmann-La Roche
      2005   Phase 1   NCT00365001   New Zealand;United States;
   King Edward Medical University
      2017   Phase 4   NCT04177173   Pakistan;
   MD, PhD, Annemarie Lyng Svensson
      2014   -   NCT02246257   Denmark;
   Sanofi
      2014   Phase 1   NCT02017639   Korea, Republic of;Moldova, Republic of;United States;
Sirolimus   
   Children's Hospital of Philadelphia
      2006   Phase 1/Phase 2   NCT00392951   United States;
   The Second Hospital of Shanxi Medical University
      2019   Phase 4   ChiCTR1900024261   China;
   the Second Hospital of Shanxi Medical University
      2017   -   ChiCTR-IPR-17011566   China;
Sirukuma   
   Janssen Pharmaceutical K.K.
      2013   Phase 3   JPRN-JapicCTI-153073   -
Sirukumab   
   JANSSEN-CILAG INTERNATIONAL N.V.
      2012   -   EUCTR2010-022243-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
   Janssen Pharmaceutical K.K.
      2013   Phase 3   JPRN-JapicCTI-153073   -
      2012   Phase 3   NCT01689532   Japan;
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02019472   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2013   Phase 3   NCT01856309   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;France;Germany;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2012   Phase 3   NCT01606761   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   NCT01604343   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2012   Phase 1   NCT01636557   Germany;Korea, Republic of;Moldova, Republic of;South Africa;
   Janssen-Cilag International N.V.
      2015   Phase 3   EUCTR2012-001176-10-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-LT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-HU   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-ES   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-DE   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2012-001176-10-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-022242-24-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2013   -   EUCTR2010-022243-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022243-38-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022242-24-LT   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2012   -   EUCTR2010-022243-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
Sodium aurothiomalate (intramuscular gold)   
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
Sodium chloride   
   Patrick Durez
      2007   -   NCT01245361   Belgium;
Sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Sofusa DoseConnect   
   Sorrento Therapeutics, Inc.
      2021   Phase 1   NCT04559412   United States;
Solu-Medrone   
   Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
      2009   -   EUCTR2007-006150-25-DE   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
      2008   -   EUCTR2007-006150-25-HU   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2008   Phase 2   EUCTR2007-006150-25-FR   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   Phase 2   EUCTR2007-006150-25-BE   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-NL   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-AT   Austria;Belgium;France;Germany;Hungary;Netherlands;
Solu-Medrone 2 Gram   
   University of Leeds
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
      2006   Phase 4   EUCTR2005-004582-41-GB   United Kingdom;
Somatropin [rDNA origin] for injection   
   Nationwide Children's Hospital
      2007   Phase 2/Phase 3   NCT00511329   United States;
Spinal anesthesia with tourniquet   
   Riku Antero Palanne
      2016   -   NCT03364088   Finland;
Spinal anesthesia without tourniquet   
   Riku Antero Palanne
      2016   -   NCT03364088   Finland;
Stable weekly dose of methotrexate   
   Amgen
      2009   Phase 2   NCT00950989   Bulgaria;Canada;Czech Republic;Hungary;Latvia;Mexico;Poland;United Kingdom;United States;
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)   
   Hoffmann-La Roche
      2009   Phase 3   NCT00951275   Italy;
Statins   
   Sherief Abd-Elsalam
      2018   Phase 3   NCT03770702   Egypt;
Stem Cell Transplantation   
   Stem Cells Arabia
      2016   Phase 1   NCT03067870   -
Steroid Drug   
   Assiut University
      2019   Phase 3   NCT04344405   Egypt;
Steroids   
   Assiut University
      2019   -   NCT03852355   Egypt;
Stool analysis   
   Centre Hospitalier Universitaire de Nimes
      2016   -   NCT01961310   France;
Stools   
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04584541   France;
Subcutaneous (SC) Abatacept   
   Bristol-Myers Squibb
      2008   Phase 3   NCT00559585   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
Subcutaneous (SC) abatacept   
   Bristol-Myers Squibb
      2009   Phase 2/Phase 3   NCT01001832   Japan;
Subcutaneous Abatacept   
   Orrin M Troum, M.D. and Medical Associates
      2011   Phase 2/Phase 3   NCT01333878   United States;
Subcutaneous tocilizumab   
   Centre Hospitalier Régional d'Orléans
      2016   Phase 4   NCT02765074   France;
Subcutaneous tocilizumab 162mg/biweekly   
   Atsushi Kawakami
      2021   Phase 3   NCT05090410   Japan;
Subcutaneous(SC) Abatacept   
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2016   Phase 3   NCT02722694   China;
Subcutanious administration   
   GlaxoSmithKline
      2010   Phase 1   NCT01101555   Russian Federation;
Sublingual nitroglycerine   
   University of Michigan
      2007   Phase 3   NCT00554853   United States;
Sulfasalazine   
   Flinders University
      2017   Phase 4   NCT03254589   Australia;
   Hoffmann-La Roche
      2013   Phase 3   NCT01941095   Greece;
   Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences
      2013   -   ChiCTR-TRC-13002981   -
   Jawaharlal Institute of Postgraduate Medical Education & Research
      2016   Phase 3   NCT02930343   India;
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
   North Glasgow NHS Trust
      2004   -   EUCTR2004-002006-30-GB   United Kingdom;
   P. Verschueren
      2009   Phase 4   NCT01172639   Belgium;
   Sanofi
      2018   Phase 4   NCT03449758   France;
      2015   Phase 3   NCT02373202   Japan;
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
      2013   Phase 3   NCT01768572   Argentina;Belgium;Brazil;Czech Republic;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   NCT01709578   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Ecuador;Germany;Greece;Guatemala;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
   University of Alabama at Birmingham
      2004   Phase 4   NCT00259610   United States;
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
   University of Leeds
      2019   Phase 4   NCT03813771   United Kingdom;
      2011   Phase 4   NCT02433184   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   VA Office of Research and Development
      2007   -   NCT00405275   Canada;United States;
   Vastra Gotaland Region
      2017   -   NCT03440892   Sweden;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 4   NCT00422227   Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;
Sulfasalazine + Hydroxychloroquine   
   Karolinska Institutet
      2006   -   NCT05051137   Sweden;
Sulfate   
   General Hospital of Chengdu Military Region
      2014   Phase 1 study   ChiCTR-TRC-14004520   China;
Sulphasalazine   
   TIPharma
      2007   -   EUCTR2007-002976-32-NL   Netherlands;
Sulphasalazine + Hydroxychloroquine OR Prednisolone   
   Karolinska Institutet
      2015   Phase 4   NCT02466581   Sweden;
Sunflower oil   
   University of Jena
      2013   -   NCT01742468   Germany;
Suspension IR   
   Pfizer
      2008   Phase 1   NCT00782600   United States;
Synovial biopsy   
   Barts & The London NHS Trust
      2010   -   NCT02528292   United Kingdom;
   Odense University Hospital
      2016   -   NCT02652299   Denmark;
Synthetic DMARD(s)   
   Diakonhjemmet Hospital
      2013   Phase 4   NCT01881308   Norway;
Systemic non-biological treatments   
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States;
T-614   
   Eisai Co., Ltd.
      2009   Phase 3   NCT00965757   Japan;
T0001   
   Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
      2015   Phase 1   NCT02481180   China;
TA-650   
   Mitsubishi Tanabe Pharma Corporation
      2005   Phase 3   NCT00691028   -
TA-650 (Infliximab)   
   Mitsubishi Tanabe Pharma Corporation
      -   Phase 3   JPRN-JapicCTI-050146   -
TAB08   
   Theramab LLC
      2013   Phase 1/Phase 2   NCT01990157   Russian Federation;
TACI - FC5   
   SERONO INTERNATIONAL SA
      2007   -   EUCTR2006-004140-23-IT   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
TACI-Fc5   
   Merck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-DE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
      2008   -   EUCTR2006-004140-23-GB   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 2   EUCTR2006-004140-23-SK   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-PT   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-CZ   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-BE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Serono SA, an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-FI   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch ofLaboratories Serono S.A. an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-SE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int.a branch of Laboratoires Serono SA an affiliate of Merck KgaA, Darmstadt, Germany
      2006   -   EUCTR2006-004140-23-NL   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono International
      2008   Phase 2   EUCTR2007-003647-75-FR   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2007-002536-29-ES   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003647-75-SE   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-NL   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-FI   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-002536-29-PT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-GR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-DE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-CZ   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BG   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BE   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   Phase 2   EUCTR2007-002536-29-FI   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-SE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-AT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      -   -   EUCTR2007-002536-29-PL   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Merck Serono International S.A.
      2007   -   EUCTR2006-004140-23-GR   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono SA - Geneva
      2008   Phase 2   EUCTR2007-003647-75-GB   Finland;France;Netherlands;Sweden;United Kingdom;
   Serono International S.A.
      2007   Phase 2   EUCTR2006-004140-23-ES   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-BG   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
TAK-715   
   Takeda Europe R&D Centre Ltd. (TEuR&D)
      2004   Phase 2   EUCTR2004-002157-30-SK   Denmark;Finland;Slovakia;
      2004   -   EUCTR2004-002157-30-FI   Denmark;Finland;
      2004   -   EUCTR2004-002157-30-DK   Denmark;Finland;
TAK-715 and methotrexate   
   Takeda
      2004   Phase 2   NCT00760864   -
TAK-783   
   Takeda Global R&D (Europe) Ltd
      2008   -   EUCTR2006-003054-26-HU   Czech Republic;Hungary;Latvia;
      2007   -   EUCTR2006-003054-26-LV   Czech Republic;Hungary;Latvia;
      2007   -   EUCTR2006-003054-26-CZ   Czech Republic;Hungary;Latvia;
TAK-783 and methotrexate   
   Takeda
      2007   Phase 2   NCT00760968   Czech Republic;Latvia;Romania;Russian Federation;Slovakia;Ukraine;
TAS5315 high dose   
   Taiho Pharmaceutical Co., Ltd.
      2018   Phase 2   NCT03605251   Japan;
TAS5315 low dose   
   Taiho Pharmaceutical Co., Ltd.
      2018   Phase 2   NCT03605251   Japan;
TBE-vaccine   
   Sormland County Council, Sweden
      2010   Phase 2   NCT01131910   Finland;Sweden;
TC-A PS Total Knee Replacement System   
   Smith & Nephew Medical (Shanghai) Ltd
      2014   -   NCT02139345   China;
TC-PLUS Solution PS Total Knee Replacement System   
   Smith & Nephew Medical (Shanghai) Ltd
      2014   -   NCT02139345   China;
TC99m-tilmanocept   
   Navidea Biopharmaceuticals
      2022   Phase 3   NCT05246280   United States;
      2019   Phase 2   NCT03938636   United States;
TDMARDs   
   Pfizer
      2012   -   NCT01438892   United States;
THA   
   National Hospital Organization Nagoya Medical Center
      2018   -   JPRN-UMIN000030760   Japan;
   Shonan Kamakura Joint Reconstruction Center
      2011   -   JPRN-UMIN000006653   Japan,North America;
TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED)   
   Mälarsjukhuset Eskilstuna
      2010   -   EUCTR2010-019438-28-SE   Sweden;
TJ003234 injection   
   I-Mab Biopharma Co. Ltd.
      2020   Phase 1   NCT04457856   China;
TL011   
   Teva Pharmaceutical Industries
      2012   -   EUCTR2011-005021-48-PL   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-NL   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-HU   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-ES   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-CZ   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
      2012   -   EUCTR2011-005021-48-BG   Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;
TL011, anti CD20, for the treatment of rheumatoid arthritis   
   Teva Pharmaceutical Industries
      2010   Phase 1/Phase 2   NCT01123070   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
TLL-018   
   Hangzhou Highlightll Pharmaceutical Co., Ltd
      2022   Phase 2   NCT05133297   China;
TMI-005   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   Phase 2   NCT00095342   Canada;United States;
TMI-005 (WAY-177005)   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
      2005   -   EUCTR2004-002215-80-HU   Hungary;
      2005   -   EUCTR2004-000012-13-EE   Czech Republic;Estonia;Italy;
      2004   Phase 2   EUCTR2004-000012-13-CZ   Czech Republic;Estonia;Italy;
TMI-005 WAY-177005   
   WYETH LEDERLE
      2005   -   EUCTR2004-000012-13-IT   Czech Republic;Estonia;Italy;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)   
   Dr. Larry W. Moreland
      2015   Phase 4   NCT02353780   United States;
TNF Inhibitor   
   Brigham and Women's Hospital
      2021   -   NCT04798287   United States;
      2021   -   NCT04772248   United States;
   Eli Lilly and Company
      2020   Phase 4   NCT04086745   United States;
      2019   Phase 4   NCT03915964   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Gilead Sciences
      2016   Phase 2   NCT02862574   Australia;Hungary;Taiwan;United States;
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
TNF alpha blockers   
   Centre Hospitalier Universitaire de Nimes
      2014   -   NCT02927509   -
TNF alpha inhibitors   
   Prof. Roberto Giacomelli
      2013   Phase 4   NCT02236481   Italy;
TNF antagonist   
   Brigham and Women's Hospital
      2011   Phase 4   NCT01400516   United States;
TNF blockers (infliximab, adalimumab, etanercept)   
   University of Sao Paulo
      2008   Phase 4   NCT01072058   Brazil;
TNF blockers monotherapy   
   Centre Hospitalier Universitaire de Nimes
      2015   -   NCT02927535   -
TNF inhibitor/TCZ   
   Hoffmann-La Roche
      2016   -   NCT02679001   Sweden;
TNF inhibitors   
   Columbia University
      2011   Phase 4   NCT01548768   United States;
   Diakonhjemmet Hospital
      2013   Phase 4   NCT01881308   Norway;
TNF kinoid   
   Neovacs
      2009   Phase 2   NCT01040715   Argentina;Belgium;Bulgaria;Chile;Croatia;France;Romania;Switzerland;
TNF start   
   Region Skane
      2016   -   NCT03775824   -
TNF-K   
   Neovacs SA
      2013   Phase 2   EUCTR2013-001999-38-CZ   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2013-001999-38-PL   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2013-001999-38-HU   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2013-001999-38-BE   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2010   -   EUCTR2009-012041-35-BG   Argentina;Belgium;Bulgaria;Chile;Croatia;France;Romania;
      2010   -   EUCTR2009-012041-35-BE   Argentina;Belgium;Bulgaria;Chile;Croatia;France;Romania;
      2009   -   EUCTR2009-012041-35-FR   Bulgaria;France;
TNF-Kinoid   
   Neovacs
      2013   Phase 2   NCT01911234   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
   Neovacs SA
      2013   Phase 2   EUCTR2013-001999-38-CZ   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2013-001999-38-PL   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2013-001999-38-HU   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2013-001999-38-BE   Belgium;Czech Republic;Georgia;Hungary;Lebanon;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;
      2010   -   EUCTR2009-012041-35-BG   Argentina;Belgium;Bulgaria;Chile;Croatia;France;Romania;
      2010   -   EUCTR2009-012041-35-BE   Argentina;Belgium;Bulgaria;Chile;Croatia;France;Romania;
      2009   -   EUCTR2009-012041-35-FR   Bulgaria;France;
TNF-a antagonists, non-TNFs, DMARD non-biologics   
   Biologics & Biosimilars Collective Intelligence Consortium
      2012   -   NCT02922192   -
TNF-a inhibitor OR JAK inhibitor   
   Vastra Gotaland Region
      2020   -   NCT04378621   Sweden;
TNF-alpha Inhibitor   
   University of Erlangen-Nürnberg Medical School
      2015   -   NCT02778789   Germany;
TNF-alpha antagonist and other biotherapy   
   Central Hospital, Nancy, France
      2007   -   NCT02886689   France;
TNF-alpha antagonists   
   Assistance Publique - Hôpitaux de Paris
      2004   -   NCT00224562   France;
TNF-blockers suspension in patients with rheumatoid arthritis   
   University Hospital of Ferrara
      2013   -   NCT03736044   -
TNFR:Fc   
   National Eye Institute (NEI)
      1999   Phase 3   NCT00012506   United States;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-LT   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
TNFa Kinoid   
   Neovacs
      2009   Phase 2   NCT01040715   Argentina;Belgium;Bulgaria;Chile;Croatia;France;Romania;Switzerland;
TNFi-biologic class   
   University of Alabama at Birmingham
      2021   Phase 2   NCT04692493   United States;
TNR-001   
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
TOCILIZUMAB SC   
   Joint Research & Development Office (QMUL)
      2018   Phase 3   EUCTR2017-004079-30-PT   Belgium;Italy;Portugal;Spain;
TOFACITINIB CITRATE   
   PFIZER INC
      2017   Phase 3   EUCTR2016-001825-15-IT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Poland;Slovakia;Spain;
   Pfizer Inc, 235 East 42nd Street, New York 10017
      2013   -   EUCTR2011-005689-39-HU   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SK   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-SK   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-CZ   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002337-30-SK   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-CZ   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2014   Phase 2   EUCTR2011-005689-39-SK   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-NL   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-DE   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   Phase 2   EUCTR2011-005689-39-ES   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   -   EUCTR2011-005689-39-CZ   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2017   Phase 2   EUCTR2016-002337-30-HU   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-HR   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-ES   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-DE   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-BG   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-PL   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-GB   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BG   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BE   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
   Tampere University Hospital
      2018   Phase 4   EUCTR2017-002753-11-FI   Finland;
TOFACITINIB CITRATE CP-690550   
   Pfizer Inc.
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
TRIAMCINOLONACETONID EP   
   Charité University medicine Berlin
      2015   Phase 2   EUCTR2015-000538-31-DE   Germany;
TRU-015   
   Pfizer
      2008   Phase 2   NCT00634933   Austria;Belgium;Canada;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;United States;
   Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
      2009   -   EUCTR2007-006150-25-DE   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
      2008   -   EUCTR2007-006150-25-HU   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2008   Phase 2   EUCTR2007-006150-25-FR   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   Phase 2   EUCTR2007-006150-25-BE   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-NL   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-AT   Austria;Belgium;France;Germany;Hungary;Netherlands;
TS-152   
   Taisho Pharmaceutical Co., Ltd.
      2019   Phase 3   NCT04077567   Japan;
   Taisho Pharmaceutical co., LTD
      2018   Phase 3   JPRN-JapicCTI-184031   Japan;
      2018   Phase 2-3   JPRN-JapicCTI-184029   Japan;
TSO   
   Immanuel Krankenhaus Berlin
      2013   Phase 2   EUCTR2011-006344-71-DE   Germany;
Tabalumab Auto-Injector   
   Eli Lilly and Company
      2012   Phase 3   NCT01676701   Argentina;Czech Republic;Czechia;Poland;Puerto Rico;Russian Federation;United States;
Tabalumab Prefilled Syringe   
   Eli Lilly and Company
      2012   Phase 3   NCT01676701   Argentina;Czech Republic;Czechia;Poland;Puerto Rico;Russian Federation;United States;
Tacrolimus   
   Astellas Pharma Inc
      2012   -   NCT01870908   Japan;
      2011   Phase 4   NCT01511003   Korea, Republic of;
      2009   Phase 4   NCT01224041   Korea, Republic of;
      2008   Phase 4   NCT01224418   Korea, Republic of;
      2006   Phase 4   NCT00319917   Japan;
   Astellas Pharma Korea, Inc.
      2019   Phase 4   NCT03737708   Korea, Republic of;
   Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University
      2013   -   JPRN-UMIN000010126   Japan;
   Department of Rheumatology and infectious disease, Kitasato university school of medicine
      2012   -   JPRN-UMIN000008572   Japan;
   Juntendo University
      2012   -   JPRN-UMIN000007205   Japan;
   National hospital organization Chiba east national hospital Clinical Research Center
      2013   -   JPRN-UMIN000012690   Japan;
   Qiang Shu
      2015   Phase 4   NCT02837978   China;
   Rheumatosurgery, Osaka City University Medical School
      2006   -   JPRN-UMIN000000512   Japan;
   Sanofi
      2015   Phase 3   NCT02373202   Japan;
   Tokyo Medical and Dental University
      2012   -   JPRN-UMIN000006702   Japan;
Tacrolimus (Prograf®)   
   Astellas Pharma Inc
      2002   Phase 3   NCT00036153   Canada;United States;
Tacrolimus with Methotrexate   
   Chong Kun Dang Pharmaceutical
      2012   Phase 4   NCT01746680   Korea, Republic of;
Tasocitinib (proposed INN)   
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2010   -   EUCTR2009-014296-40-AT   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
Tasocitinib citrate   
   Pfizer Inc.
      2011   -   EUCTR2010-020890-18-CZ   Czech Republic;Hungary;
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-020890-18-HU   Czech Republic;Hungary;
Tasocitinib plus Methotrexate   
   Pfizer
      2010   Phase 2   NCT01164579   Argentina;Chile;Croatia;Czech Republic;Hungary;Mexico;Poland;Puerto Rico;United States;
Tc 99m tilmanocept   
   Navidea Biopharmaceuticals
      2021   Phase 2   NCT04078191   United Kingdom;United States;
Tc99m tilmanocept   
   Navidea Biopharmaceuticals
      2021   Phase 2   NCT04947137   United States;
Tc99m-tilmanocept   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Tea   
   Chengdu PLA General Hospital
      2014   -   NCT02257047   China;
Technetium labelled glucosamine   
   University of Sydney
      2012   -   NCT01789151   Australia;
Teriparatide   
   Brigham and Women's Hospital
      2011   Phase 4   NCT01400516   United States;
Tetanus + pnemococcal vaccines alone   
   Bristol-Myers Squibb
      2004   Phase 1   NCT00279734   United States;
Tetanus Toxoid Adsorbed Vaccine   
   Genentech, Inc.
      2010   Phase 4   NCT01163747   United States;
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)   
   Tel-Aviv Sourasky Medical Center
      2011   Phase 4   NCT01301703   Israel;
Tetanus toxoid adsorbed booster vaccine   
   Genentech, Inc.
      2006   Phase 2   NCT00282308   United States;
Tetraccycline-hydrochloride   
   Hammersmith Hospitals NHS trust
      2005   Phase 3   EUCTR2004-004893-96-GB   United Kingdom;
Tetracycline   
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Tetrandrine   
   Peking University People's Hospital
      2022   -   NCT05245448   China;
   The First People's Hospital of Yancheng
      2020   Phase 0   ChiCTR2000030400   China;
The effectiveness of Xeljanz in rheumatoid arthritis patients   
   Shinshu University
      2014   Phase 4   NCT02157012   Japan;
Therapy with disease-modifying anti rheumatic drugs (DMARD)   
   University of Zurich
      2011   -   NCT01292616   Switzerland;
Ticagrelor   
   NYU Langone Health
      2016   Phase 4   NCT02874092   United States;
Tilmanocept   
   Navidea Biopharmaceuticals
      2017   Phase 1   NCT03241446   -
      2016   Phase 1   NCT02683421   United States;
Tirabrutinib   
   Gilead Sciences
      2016   Phase 1   NCT02626026   United States;
To be confirmed   
   Kowa Research Europe Ltd
      2004   -   EUCTR2004-000362-12-CZ   Czech Republic;
Tocilizmab   
   Shinshu University
      2018   Phase 2   NCT03784261   Japan;
Tocilizumab   
    Clinical Immunology, Jichi Medical University
    Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity
    Clinical ImmunologySaitama Medical Center, Saitama Medical Universitity
   AA amyloidosis clinical research conference
      2008   -   JPRN-UMIN000002421   Japan;
   Ablynx
      2015   Phase 2   NCT02287922   Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
   Astellas Pharma Korea, Inc.
      2019   Phase 4   NCT03737708   Korea, Republic of;
   Biologic Mate Study Group
      2014   -   JPRN-UMIN000015616   Japan;
   Brigham and Women's Hospital
      2020   -   NCT04529863   United States;
   Centre Hospitalier Universitaire de Besancon
      2013   Phase 4   NCT02843789   France;
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 3   JPRN-JapicCTI-142505   -
   Daihei Kida
      2013   -   JPRN-UMIN000010033   Japan;
   Department of Orthopaedic Surgery,Graduate School of Medicine, Osaka City University Medical School
      2013   Phase 4   JPRN-UMIN000012073   Japan;
   Department of Rheumatology &
   Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University
      2011   -   JPRN-UMIN000005590   Japan;
   Department of Rheumatosurgery, Osaka City University Medical School
      2009   Phase 4   JPRN-UMIN000002340   Japan;
   Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
      2011   -   JPRN-UMIN000013750   Japan;
   Division of Rheumatology &
   Dr. Larry W. Moreland
      2015   Phase 4   NCT02353780   United States;
   F Hoffmann La-Roche AG
      2007   -   EUCTR2005-002909-23-PT   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-002909-23-GB   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-SI   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2006   -   EUCTR2005-002909-23-NO   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-IS   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-FI   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-DK   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002909-23-ES   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F Hoffmann La-Roche Ltd.
      2006   -   EUCTR2005-002909-23-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2006   -   EUCTR2005-002909-23-LT   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Lithuania;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-002909-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Russian Federation;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   F Hoffmann-La Roche AG
      2006   -   EUCTR2005-002909-23-DE   Czech Republic;Denmark;Finland;Germany;Iceland;Italy;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   F Hoffmann-La Roche Ltd
      2009   Phase 2   EUCTR2008-005525-11-GR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-005525-11-FR   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-005525-11-ES   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-NL   France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-005525-11-DE   France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001847-20-FR   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2008-005525-11-GB   France;Germany;Greece;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2008-001847-20-NL   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-ES   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   F Hoffmann-La Roche Ltd.
      2009   -   EUCTR2008-001847-20-SE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-001847-20-GR   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-001847-20-DE   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2008-001847-20-GB   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-LV   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2008   -   EUCTR2008-001847-20-EE   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-001847-20-DK   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
   F. Hoffmann La-Roche AG
      2005   Phase 3   EUCTR2005-001138-33-NO   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   Phase 3   EUCTR2005-001138-33-ES   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   Phase 3   EUCTR2004-005210-37-ES   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   Phase 3   EUCTR2004-003741-40-SK   Austria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-001138-33-PT   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-LT   Denmark;Italy;Lithuania;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-001138-33-DK   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2004-005210-37-SE   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-FI   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-DE   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-005210-37-CZ   Czech Republic;Finland;Germany;Spain;Sweden;
      2005   -   EUCTR2004-003741-40-HU   Germany;Hungary;Italy;
      2005   -   EUCTR2004-003741-40-DE   Germany;Hungary;Italy;
      2005   -   EUCTR2004-003733-14-ES   Denmark;Finland;Italy;Spain;
      2004   -   EUCTR2004-003741-40-AT   Austria;Germany;Hungary;Italy;
      -   -   EUCTR2005-001138-33-SI   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
   F. Hoffmann La-Roche Ltd
      2005   -   EUCTR2005-002423-13-SK   Austria;Bulgaria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-002423-13-HU   Bulgaria;Germany;Hungary;Italy;Slovakia;
      2005   -   EUCTR2005-002423-13-AT   Austria;Bulgaria;Germany;Hungary;Italy;Slovakia;
      -   -   EUCTR2005-002423-13-BG   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Switzerland;Thailand;
   F. Hoffmann La-Roche Ltd.
      2005   Phase 3   EUCTR2004-003733-14-FI   Australia;Brazil;China;Denmark;Finland;France;Greece;Italy;Mexico;Norway;Poland;South Africa;Spain;United States;
   F. Hoffmann- La Roche Ltd
      2009   -   EUCTR2008-000587-17-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche AG
      2005   Phase 3   EUCTR2005-000884-25-IS   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-000884-25-GB   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   -   EUCTR2005-000884-25-SE   Germany;Iceland;Italy;Sweden;United Kingdom;
      2005   -   EUCTR2005-000884-25-DE   Germany;Iceland;Italy;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2008-006924-68-AT   Austria;Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-006924-68-GR   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-006924-68-GB   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-006924-68-FR   Austria;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-PT   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-NL   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-HU   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-ES   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-006924-68-CZ   Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-000587-17-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-000587-17-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2008-000587-17-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-SE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-002423-13-DE   Bulgaria;Germany;Hungary;Italy;Slovakia;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-020065-24-NL   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-LV   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-HU   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GR   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-ES   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-AT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023587-40-NL   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-IT   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-023587-40-FI   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2011   -   EUCTR2010-020065-24-LT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2010   Phase 4   EUCTR2009-015845-21-GB   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 4   EUCTR2009-015845-21-BE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-012759-12-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-SE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-PT   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-GR   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-FI   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-DE   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015845-21-CZ   Belgium;Czech Republic;Finland;Germany;Greece;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-SE   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-PT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-012759-12-IE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-HU   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012759-12-GR   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-IT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012759-12-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-FI   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DK   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   -   EUCTR2009-012759-12-DE   Austria;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-012759-12-AT   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
   Genentech, Inc.
      2012   Phase 3   NCT01662063   Puerto Rico;United States;
      2010   Phase 4   NCT01163747   United States;
   General Internal Medicine, Tenri Hospital
      2010   -   JPRN-UMIN000004412   Japan;
   Hoffmann-La Roche
      2017   Phase 3   NCT03155347   China;
      2017   -   NCT03291457   Belgium;
      2017   -   NCT03112213   Germany;
      2016   Phase 4   NCT02682823   United States;
      2016   Phase 4   NCT02573012   Egypt;France;Germany;Italy;Russian Federation;Serbia;Switzerland;Tunisia;Turkey;
      2016   -   NCT02648035   Greece;
      2015   -   NCT02797769   -
      2015   -   NCT02608112   France;
      2015   -   NCT02552940   Belgium;Luxembourg;
      2015   -   NCT02534311   Slovakia;
      2015   -   NCT02402686   Hungary;
      2014   Phase 3   NCT02046616   Denmark;Finland;Norway;Sweden;
      2014   Phase 3   NCT02046603   United Kingdom;
      2014   Phase 3   NCT02031471   Belgium;Luxembourg;
      2014   Phase 3   NCT02001987   France;
      2014   Phase 3   NCT01988012   Israel;
      2014   Phase 3   NCT01987479   Netherlands;
      2014   -   NCT02234960   Poland;
      2013   Phase 4   NCT01715831   Brazil;
      2013   Phase 3   NCT01951170   Australia;
      2013   Phase 3   NCT01941940   Italy;
      2013   Phase 3   NCT01941095   Greece;
      2013   Phase 3   NCT01855789   United States;
      2013   Phase 3   NCT01668966   Brazil;
      2012   Phase 4   NCT01661140   United Kingdom;
      2012   Phase 3   NCT01772316   Spain;
      2012   Phase 3   NCT01734993   France;
      2012   Phase 3   NCT01665430   Poland;
      2012   Phase 3   NCT01655381   France;
      2012   -   NCT01741688   Peru;
      2012   -   NCT01705730   Belgium;
      2012   -   NCT01670045   Greece;Indonesia;
      2012   -   NCT01664104   Italy;
      2012   -   NCT01617005   Montenegro;
      2012   -   NCT01579006   Israel;
      2012   -   NCT01562327   Argentina;
      2012   -   NCT01474291   France;Monaco;
      2011   Phase 4   NCT01331837   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Czechia;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 3   NCT01232569   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
      2011   Phase 2   NCT01468077   Denmark;Iceland;
      2011   -   NCT01462162   Spain;
      2010   Phase 4   NCT01119859   Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Norway;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   -   NCT01362062   India;
      2009   Phase 3   NCT01044498   United States;
      2009   Phase 3   NCT01007435   Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, The Former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;United States;
      2009   Phase 3   NCT00996606   Italy;
      2009   -   NCT02809833   Germany;
      2009   -   NCT02721004   Austria;
      2008   Phase 3   NCT00754559   Germany;
      2007   Phase 3   NCT00535782   Canada;Puerto Rico;United Kingdom;United States;
      2007   Phase 3   NCT00531817   Puerto Rico;United States;
      2005   Phase 3   NCT00721123   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Switzerland;Thailand;
      2005   Phase 3   NCT00720798   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   JW Pharmaceutical
      2010   Phase 3   NCT01256736   Korea, Republic of;
      2009   Phase 3   NCT01211834   Korea, Republic of;
   Japan Labour Health and Welfare Organization,Yokohama Rosai Hospital
      2012   -   JPRN-UMIN000008404   Japan;
   JiangSu Qyuns Therapeutics Co., Ltd
      2019   Phase 1   ChiCTR1900021808   China;
   Juntendo University, Juntendo Koshigaya Hospital
      2012   -   JPRN-UMIN000014484   Japan;
   Kawakami Atsushi
      2021   -   JPRN-jRCTs071200107   Japan;
   Keio University
      2009   -   JPRN-UMIN000002744   Japan;
   Kinki University Faculty of Medicine, Division of Hematology and Rheumatology
      2012   -   JPRN-UMIN000007380   Japan;
   Kyushu University
      2012   -   JPRN-UMIN000017230   Japan;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   Massachusetts General Hospital
      2016   Phase 4   NCT02659150   -
   National hospital organization Chiba east national hospital Clinical Research Center
      2013   -   JPRN-UMIN000012690   Japan;
   Patrick Durez
      2010   -   NCT01245452   Belgium;
   ROCHE
      2009   -   EUCTR2009-012185-32-IT   Italy;
      2009   -   EUCTR2009-011105-17-IT   Italy;
      2009   -   EUCTR2008-001847-20-IT   Denmark;Estonia;France;Germany;Greece;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-000587-17-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-001138-33-IT   Denmark;Italy;Norway;Portugal;Slovenia;Spain;
      2005   -   EUCTR2005-000884-25-IT   Germany;Iceland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-003741-40-IT   Germany;Hungary;Italy;
      2004   -   EUCTR2004-003733-14-IT   Denmark;Finland;Italy;Spain;
   Reade Rheumatology Research Institute
      2020   Phase 4   NCT03895879   Netherlands;
   Regeneron Pharmaceuticals
      2014   Phase 1   NCT02097524   United States;
   Roche Austria GmbH
      2011   -   EUCTR2011-001863-39-AT   Austria;
   Roche Farma, S.A.
      2009   -   EUCTR2008-006443-39-ES   Spain;
   Roche Oy
      2008   -   EUCTR2008-004126-16-FI   Finland;
   Roche Pharma AG
      2011   -   EUCTR2010-022049-88-DE   Germany;
      2008   -   EUCTR2008-000105-11-DE   Germany;
   Roche Products Limited
      2012   Phase 4   EUCTR2011-005260-20-GB   United Kingdom;
   Roche Slovensko s.r.o.
      2009   -   EUCTR2009-011520-53-SK   Slovakia;
   Roche a/s
      2011   -   EUCTR2011-002363-15-DK   Denmark;Iceland;
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
   Sanofi
      2015   Phase 1   NCT02404558   Japan;
      2013   Phase 3   NCT01768572   Argentina;Belgium;Brazil;Czech Republic;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
   Spanish Foundation of Rheumatology
      2014   Phase 4   NCT02087696   Spain;
   St.Marianna University School of Medicine
      2014   -   JPRN-UMIN000015175   Japan;
   Sungkyunkwan University
      2020   -   NCT04115423   Korea, Republic of;
   Tel-Aviv Sourasky Medical Center
      2018   Phase 4   NCT03781310   Israel;
   The University of Leeds
      2013   Phase 4   EUCTR2011-004017-17-GB   United Kingdom;
   UCL Cliniques Universitaires Saint Luc
      2010   Phase 2   EUCTR2010-019873-13-BE   Belgium;
   University of California, Los Angeles
      2014   Phase 4   NCT01717859   United States;
   University of Erlangen-Nürnberg Medical School
      2015   -   NCT02778789   Germany;
   University of Leeds
      2013   Phase 4   NCT04157010   United Kingdom;
      2009   Phase 2   EUCTR2008-003011-12-GB   United Kingdom;
   University of Southern Denmark
      2021   Phase 1/Phase 2   NCT04842981   Denmark;
   Vastra Gotaland Region
      2017   -   NCT03440892   Sweden;
   sanofi-aventis recherche & développement
      2013   Phase 3   EUCTR2012-003536-23-NO   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-IT   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003536-23-GB   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-SE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-PL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-NL   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-HU   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-FI   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-ES   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-EE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-CZ   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003536-23-BE   Argentina;Belgium;Brazil;Colombia;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States;
   the Second Hospital of Shanxi Medical University
      2016   -   ChiCTR-INR-16009546   China;
Tocilizumab (Actemra or RoActemra)   
   UCB Pharma
      2010   Phase 2   NCT01242488   Belgium;United Kingdom;United States;
Tocilizumab (Actemra)   
   F. Hoffmann-La Roche Ltd
      2008   -   EUCTR2008-000587-17-IE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Tocilizumab (Actemra®)   
   University of Athens
      2017   -   NCT03288584   Greece;
Tocilizumab (TCZ)   
   Maria Stoenoiu
      2015   Phase 3   NCT02837146   Belgium;
Tocilizumab + methotrexate(MTX)   
   Chugai Pharma Taiwan
      2010   Phase 3   NCT01258712   Taiwan;
Tocilizumab 162mg/0.9ml SC PFS SC   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2010-019912-18-ES   Bulgaria;Greece;Hungary;Spain;
      2011   -   EUCTR2010-019912-18-GR   Bulgaria;Greece;Hungary;Spain;
Tocilizumab 162mg/0.9ml jeringa SC   
   F. Hoffmann-La Roche Ltd.
      2010   Phase 3   EUCTR2010-018375-22-ES   Bulgaria;Germany;Italy;Lithuania;Spain;United Kingdom;
Tocilizumab 162mg/0.9ml syringe SC   
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2010-018375-22-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
      2010   -   EUCTR2010-018375-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2010-018375-22-IT   Bulgaria;Germany;Italy;Lithuania;Spain;United Kingdom;
      2010   -   EUCTR2010-018375-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
Tocilizumab IV   
   Hoffmann-La Roche
      2010   Phase 3   NCT01194414   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
Tocilizumab Injection   
   Beijing VDJBio Co., LTD.
      2021   Phase 1/Phase 2   NCT05232396   China;
Tocilizumab Prefilled Syringe   
   Lille Catholic University
      2018   Phase 4   NCT03227419   France;
   Syneos Health
      2021   Phase 1   NCT04885829   Australia;New Zealand;
Tocilizumab Roche   
   F Hoffmann La-Roche Ltd.
      2005   -   EUCTR2004-003733-14-DK   Denmark;Finland;Italy;Spain;
   F. Hoffmann-La Roche Ltd
      2008   Phase 3   EUCTR2008-000587-17-ES   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Tocilizumab SC   
   Hoffmann-La Roche
      2010   Phase 3   NCT01194414   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
   N.V. Roche S.A.
      2013   Phase 3   EUCTR2013-002150-79-BE   Belgium;
   ROCHE HELLAS S.A.
      2013   Phase 3   EUCTR2013-000359-42-GR   Greece;
   Roche Farma S.A
      2013   Phase 3   EUCTR2013-002429-52-ES   Ireland;Portugal;Spain;
   Roche Farma S.A.
      2013   Phase 3   EUCTR2013-002429-52-PT   Ireland;Portugal;Spain;
   Roche Nederland B.V.
      2013   Phase 3   EUCTR2013-000342-19-NL   Netherlands;
   Roche Products Limited
      2013   Phase 3   EUCTR2013-000054-22-GB   United Kingdom;
   Roche S.p.A.
      2013   -   EUCTR2013-001569-17-IT   Italy;
   Roche a/s
      2014   Phase 3   EUCTR2013-002007-34-SE   Denmark;Finland;Sweden;
      2014   Phase 3   EUCTR2013-002007-34-FI   Denmark;Finland;Sweden;
      2013   Phase 3   EUCTR2013-002007-34-DK   Denmark;Finland;Sweden;
Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI)   
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2010-019912-18-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
      2011   -   EUCTR2010-019912-18-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS)   
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2010-019912-18-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
      2011   -   EUCTR2010-019912-18-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Dominican Republic;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Peru;Philippines;Russian Federation;South Africa;Spain;Switzerland;Thailand;United States;
Tocilizumab [RoActemra/Actemra]   
   Hoffmann-La Roche
      2014   Phase 3   NCT02011334   Argentina;Brazil;Colombia;Dominican Republic;Ecuador;Mexico;Uruguay;Venezuela;
      2013   Phase 4   NCT01878318   Venezuela;
      2013   Phase 3   NCT01995201   Ireland;Portugal;Spain;
      2012   Phase 3   NCT01730456   Macedonia, The Former Yugoslav Republic of;
      2012   Phase 3   NCT01664598   Russian Federation;
      2012   Phase 3   NCT01649804   Hungary;
      2012   Phase 3   NCT01587989   Austria;
      2011   Phase 4   NCT01399697   Spain;
      2011   Phase 4   NCT01283971   Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 4   NCT01251120   Finland;
      2011   Phase 4   NCT01219933   Belgium;
      2011   Phase 3   NCT01353859   Greece;Indonesia;
      2011   Phase 3   NCT01332994   Germany;
      2011   Phase 3   NCT01326962   Saudi Arabia;
      2011   Phase 3   NCT01245439   Turkey;
      2011   Phase 3   NCT01235507   Bosnia and Herzegovina;
      2010   Phase 4   NCT02010216   Kazakhstan;
      2010   Phase 4   NCT01195272   United Kingdom;
      2010   Phase 4   NCT01149057   Israel;
      2010   Phase 4   NCT01089023   Bahrain;Iran, Islamic Republic of;Kuwait;Qatar;United Arab Emirates;
      2010   Phase 4   NCT01034397   Portugal;
      2010   Phase 3   NCT01610791   Morocco;
      2010   Phase 3   NCT01214733   South Africa;
      2010   Phase 3   NCT01063062   Egypt;
      2010   Phase 3   NCT01034137   Netherlands;
      2009   Phase 4   NCT01010503   Slovakia;
      2009   Phase 4   NCT00996203   Russian Federation;
      2009   Phase 3   NCT00977106   France;
      2009   Phase 3   NCT00951275   Italy;
      2009   Phase 3   NCT00891020   Puerto Rico;United Kingdom;United States;
      2009   Phase 3   NCT00883753   Australia;Austria;Canada;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Saudi Arabia;Spain;Turkey;United Kingdom;
      2009   Phase 3   NCT00810199   Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Monaco;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;United States;
      2009   Phase 3   NCT00754572   Argentina;Brazil;Chile;Colombia;Costa Rica;Ecuador;Mexico;Peru;Uruguay;Venezuela;
      2009   Phase 2   NCT00887341   Spain;
      2009   Phase 2   NCT00845832   Belgium;France;Germany;Greece;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2009   Phase 1   NCT00965653   Canada;New Zealand;Spain;United Kingdom;
      2008   Phase 3   NCT00848120   Philippines;
      2008   Phase 3   NCT00810277   Finland;
      2008   Phase 3   NCT00773461   China;
      2008   Phase 3   NCT00750880   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Luxembourg;Netherlands;Poland;Portugal;Romania;Saudi Arabia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2005   Phase 3   NCT00109408   Argentina;Australia;Canada;China;Croatia;Denmark;Former Serbia and Montenegro;France;Israel;Italy;Lithuania;Mexico;Norway;Peru;Portugal;Serbia;Slovenia;South Africa;Spain;United States;
      2005   Phase 3   NCT00106574   Argentina;Australia;Brazil;Canada;China;Costa Rica;Czech Republic;Finland;France;Germany;Hong Kong;Mexico;Panama;Russian Federation;South Africa;Spain;Sweden;Thailand;United States;
      2005   Phase 3   NCT00106548   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;France;Germany;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Spain;Switzerland;Thailand;
      2005   Phase 3   NCT00106535   Australia;Brazil;China;Denmark;Finland;France;Greece;Italy;Mexico;Norway;Poland;Puerto Rico;South Africa;Spain;Switzerland;United States;
      2005   Phase 3   NCT00106522   Australia;Belgium;Canada;France;Germany;Iceland;Italy;Mexico;Netherlands;Puerto Rico;Sweden;Switzerland;United Kingdom;United States;
      2005   Phase 1   NCT00365001   New Zealand;United States;
Tocilizumab [RoActemra]   
   Hoffmann-La Roche
      2011   Phase 3   NCT01254331   Tunisia;
Tocilizumab plus methotrexate   
   SURPRISE Study Group
      2009   Phase 4   NCT01120366   Japan;
Tocilizumab+Methotrexate(MTX)   
   Chugai Pharma Taiwan
      2011   Phase 3   NCT01347983   Taiwan;
Tocilizumabum   
   Revmatologicky ustav Praha
      2015   Phase 4   EUCTR2015-000581-58-CZ   Czech Republic;
Tofacitinb   
   PFIZER INC
      2017   Phase 3   EUCTR2016-001825-15-IT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Poland;Slovakia;Spain;
Tofacitinib   
   AbbVie (prior sponsor, Abbott)
      2012   Phase 1   NCT01741493   United States;
   Arthritis Alapítvány
      2016   -   EUCTR2015-002523-26-HU   Hungary;
   Brigham and Women's Hospital
      2021   -   NCT04798287   United States;
      2021   -   NCT04772248   United States;
      2020   -   NCT04529876   United States;
   Department of Rheumatology, Anqing Hospital Affiliated to Anhui Medical University
      2020   Phase 4   ChiCTR2000033214   -
   Division of rheumatology, hiroshima clinic
      2016   Phase 4   JPRN-UMIN000027242   Japan;
   Dr. Frank Behrens
      2019   Phase 4   NCT04485325   Germany;
   Dr. Mohammad Mamun Khan
      2019   Phase 4   NCT04464642   Bangladesh;
   GlaxoSmithKline
      2019   Phase 3   NCT03980483   Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT03970837   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Graduate School of Medicine and School of Medicine, Chiba Universitythe department of allergy and clinical immunology
      2015   Phase 4   JPRN-UMIN000017440   Japan;
   Hangzhou Highlightll Pharmaceutical Co., Ltd
      2022   Phase 2   NCT05133297   China;
   Hanyang University
      2016   -   NCT03011281   Korea, Republic of;
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
   Kyusyu University Hospital Medicine and biosystemic science
      2014   -   JPRN-UMIN000020663   Japan;
   Lawson Health Research Institute
      2020   Phase 4   NCT03976245   Canada;
   National Institute of Respiratory Diseases, Mexico
      2022   Phase 2   NCT05246293   Mexico;
   Norman B. Gaylis, MD
      2015   Phase 3   NCT02566967   United States;
   Peking University First Hospital
      2021   Phase 4   ChiCTR2100048185   China;
   Pfizer
      2020   Phase 2   NCT04413617   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czechia;Georgia;Hungary;Poland;Slovakia;Spain;Sweden;Ukraine;
      2019   -   NCT03981900   France;
      2017   -   NCT03387423   Germany;
      2016   Phase 2   NCT02996500   Australia;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2014   Phase 4   NCT02092467   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3   NCT02281552   Japan;
      2014   Phase 2   NCT02147587   United Kingdom;United States;
      2010   Phase 2   NCT01164579   Argentina;Chile;Croatia;Czech Republic;Hungary;Mexico;Poland;Puerto Rico;United States;
   Pfizer Inc.
      2011   -   EUCTR2010-020890-18-CZ   Czech Republic;Hungary;
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-020890-18-HU   Czech Republic;Hungary;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
      2010   -   EUCTR2009-016987-34-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
   Qilu Hospital of Shandong University
      2020   Phase 4   NCT04928066   China;
   Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2019   Phase 4   ChiCTR2000039799   China;
   School of Medicine, University of Occupational and Environmental Health, Japan
      2014   -   JPRN-UMIN000015462   Japan;
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2021   Phase 4   NCT04927000   China;
   University Hospital, Lille
      2020   -   NCT04175886   France;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   Vastra Gotaland Region
      2020   Phase 4   NCT04311567   Sweden;
   hiroshima clinic
      2015   -   JPRN-UMIN000027241   Japan;
Tofacitinib (Xeljanz)   
   Pfizer
      2013   -   NCT01932372   Japan;
Tofacitinib (Xeljanz®)   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
Tofacitinib 5 MG [Xeljanz]   
   Shinshu University
      2018   Phase 2   NCT03755466   Japan;
   University Hospital, Montpellier
      2021   -   NCT04530305   France;
Tofacitinib 5mg po bid   
   University of California, Los Angeles
      2016   Phase 4   NCT02321930   United States;
Tofacitinib XR   
   Erasmus Medical Center
      2022   Phase 4   EUCTR2021-004131-84-NL   Netherlands;
   Pfizer
      2021   -   NCT04876781   -
Tofacitinib citate (Phase III formulation)   
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Tofacitinib citrate   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000797-39-IT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000867-26-PL   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-GB   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-ES   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-BG   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LV   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-HU   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-GB   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-ES   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-CZ   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Tofacitinib citrate (Phase III formulation)   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2010   Phase 2;Phase 3   EUCTR2006-005035-19-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Tofacitinib citrate (Proposed commercial formulation - debossed)   
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Tofacitinib citrate (Proposed commercial formulation debossed)   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Tofacitinib citrate (Proposed commercial formulation – debossed)   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2010   Phase 2;Phase 3   EUCTR2006-005035-19-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Tofacitinib citrate (Proposed commercial formulation- debossed)   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Tofacitinib citrate (clinical trial image)   
   Pfizer Inc.
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Tofacitinib citrate (commercial image)   
   Pfizer Inc.
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Tofacitinib citrate( Phase III formulation)   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Tofacitinib or Baricitinib   
   Hanyang University
      2020   -   NCT04449224   Korea, Republic of;
Tofacitinib with methotrexate   
   Pfizer
      2014   Phase 4   NCT02187055   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Tofacitinib without methotrexate   
   Pfizer
      2014   Phase 4   NCT02187055   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Tofacitinib/baricitinib   
   Vastra Gotaland Region
      2017   -   NCT03440892   Sweden;
TolDC   
   Newcastle University
      2012   Phase 1   NCT01352858   United Kingdom;
Tolerogenic dendritic cells   
   Russian Academy of Medical Sciences
      2016   Phase 1   NCT03337165   Russian Federation;
Tolicizumab   
   ROCHE
      2009   -   EUCTR2008-008309-23-FR   France;
Tolicizumab Roche   
   F. Hoffmann-La Roche Ltd
      2008   Phase 3   EUCTR2008-000587-17-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Topical compound tripterygium   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2011   -   NCT01961505   -
Topical tripterygium gel   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2012   -   NCT02818361   China;
Total hip arthoplasty (THA)   
   Zimmer Biomet
      2021   -   NCT04349046   Belgium;France;
Traditional antirheumatic drugs   
   Sadat City University
      2020   -   NCT04434118   Egypt;
Tramadol   
   Kojima Toshihisa
      2016   -   JPRN-jRCTs041180071   Japan;
   Osaka City University Medical School, Department of Orthopedic Surgery
      2014   -   JPRN-UMIN000012364   Japan;
Tramadol hydrochloride + acetaminophen   
   Janssen Korea, Ltd., Korea
      2005   Phase 4   NCT00246168   -
Tranexamic acid   
   Guanghua Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine
      2019   Phase 4   ChiCTR1900025013   China;
   Hokusuikai Kinen Hospital
      2018   -   JPRN-UMIN000030237   Japan;
      2017   -   JPRN-UMIN000029797   Japan;
Tranilast   
   Imperial College London
      2008   Phase 1   NCT00717808   United Kingdom;
   Nuon Therapeutics, Inc.
      2009   Phase 2   NCT00882024   Argentina;Bulgaria;Czech Republic;Germany;Mexico;Serbia;United Kingdom;United States;
      2009   -   EUCTR2008-006917-25-PL   Bulgaria;Czech Republic;Germany;Poland;United Kingdom;
      2009   -   EUCTR2008-006917-25-GB   Bulgaria;Czech Republic;Germany;Poland;United Kingdom;
      2009   -   EUCTR2008-006917-25-DE   Bulgaria;Czech Republic;Germany;Poland;United Kingdom;
      2009   -   EUCTR2008-006917-25-CZ   Bulgaria;Czech Republic;Germany;Poland;United Kingdom;
      2009   -   EUCTR2008-006917-25-BG   Bulgaria;Czech Republic;Germany;Poland;United Kingdom;
Transcutaneous electrical vagus nerve stimulation   
   Xijing Hospital
      2019   -   NCT04037111   China;
Transthoracic echocardiographic   
   Assistance Publique Hopitaux De Marseille
      2011   Phase 3   NCT01954381   France;
Treat to target   
   Chinese University of Hong Kong
      2020   -   NCT04324892   -
Treatment A   
   Pfizer
      2010   Phase 1   NCT01184092   Singapore;
      2010   Phase 1   NCT01184001   Singapore;
Treatment B   
   Pfizer
      2010   Phase 1   NCT01184092   Singapore;
      2010   Phase 1   NCT01184001   Singapore;
Treatment C   
   Pfizer
      2010   Phase 1   NCT01184092   Singapore;
Treatment I   
   Sun Pharmaceutical Industries Limited
      2015   Phase 3   NCT02534896   Belgium;Netherlands;
Treatment II   
   Sun Pharmaceutical Industries Limited
      2015   Phase 3   NCT02534896   Belgium;Netherlands;
Treatment III   
   Sun Pharmaceutical Industries Limited
      2015   Phase 3   NCT02534896   Belgium;Netherlands;
Treatment of MTX   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2017   Phase 2/Phase 3   NCT03337815   China;
Treatment of MTX and HCQ   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2014   Phase 2/Phase 3   NCT02551575   China;
Treatment of MTX and TwHF   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2017   Phase 2/Phase 3   NCT03324412   -
Treatment of TCM   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2014   Phase 2/Phase 3   NCT02551575   China;
Treatment of TwHF   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2017   Phase 2/Phase 3   NCT03337815   China;
Tregalizumab   
   Biotest
      2013   Phase 2   NCT01999192   Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
   Biotest AG
      2013   Phase 2   EUCTR2013-000114-38-CZ   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-SK   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-LT   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-HU   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-EE   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-DE   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-BG   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
Trexan   
   UCB PHARMA SA/NV.
      2012   -   EUCTR2011-001729-25-IT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   UCB Pharma SA
      2012   Phase 3   EUCTR2011-001729-25-SE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-IE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-GB   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-NL   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-HU   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-ES   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-DE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-CZ   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-AT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab   
   Helsinki University
      2003   Phase 4   NCT00908089   Finland;
Triam 40 mg Lichtenstein   
   Charité University medicine Berlin
      2015   Phase 2   EUCTR2015-000538-31-DE   Germany;
Triamcinolone   
   AZIENDA OSPEDALIERA SENESE
      2006   -   EUCTR2006-005391-40-IT   Italy;
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
Triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)   
   Sohag University
      2020   Phase 4   NCT04361513   Egypt;
Triamcinolone hexacetonid (Lederspan)   
   Center for Research and Development Uppsala University/County Council of Gävleborg
      2014   Phase 4   EUCTR2014-000993-20-SE   Sweden;
Triamcinolone hexacetonide   
   Federal University of São Paulo
      2013   -   NCT01851278   Brazil;
Triamcinolone hexacetonide (Lederspan)   
   Center for Research and Development Uppsala University/County Council of Gävleborg
      2014   Phase 4   EUCTR2014-000993-20-SE   Sweden;
Trichuris suis ova   
   Immanuel Krankenhaus Berlin
      2013   Phase 2   EUCTR2011-006344-71-DE   Germany;
Tripterygium Wilfordii   
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03589833   China;
   The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
      2020   Phase 4   ChiCTR2100050865   China;
Tripterygium wilfordii Hook F   
   Peking Union Medical College Hospital
      2012   Phase 2/Phase 3   NCT01613079   China;
Tripterygium wilfordii Hook F (TwHF)   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT04136262   China;
Trivalent inactivated influenza vaccine   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01436370   United States;
TsDMARD class   
   University of Alabama at Birmingham
      2021   Phase 2   NCT04692493   United States;
Tuberculin skin test   
   Ospedale L. Sacco – Polo Universitario
      2007   -   NCT00491933   Italy;
Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)   
   Sungkyunkwan University
      2020   -   NCT04115423   Korea, Republic of;
Tumor Necrosis Factor Inhibitors   
   Brigham and Women's Hospital
      2020   -   NCT04529902   United States;
TwHF   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2003   Phase 2   NCT00062465   United States;
UC-MSC+DMARDS   
   Alliancells Bioscience Corporation Limited
      2013   Phase 1/Phase 2   NCT01547091   China;
UC-MSCs   
   Xijing Hospital
      2017   -   NCT03798028   China;
UCB4940   
   UCB Biopharma Sprl
      2016   Phase 2   EUCTR2016-000393-37-BG   Bulgaria;Georgia;Hungary;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;United Kingdom;
   UCB Celltech, UK Registered Branch of UCB Pharma SA
      2015   Phase 2   EUCTR2014-003307-30-HU   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
      2015   Phase 2   EUCTR2014-003307-30-GB   Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
      2015   Phase 2   EUCTR2014-003307-30-CZ   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
      2015   -   EUCTR2014-003307-30-SK   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
UK-427,857   
   PFIZER
      2007   -   EUCTR2007-001035-58-IT   Italy;Portugal;Spain;
   Pfizer Inc, 235 East 42nd Street,New York, NY 10017
      2007   -   EUCTR2007-001035-58-PT   Italy;Portugal;Spain;
   Pfizer, S. A.
      2007   Phase 2   EUCTR2007-001035-58-ES   Italy;Portugal;Spain;
US-licensed Humira®   
   Boehringer Ingelheim
      2015   Phase 3   NCT02137226   Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
UVEDOSE   
   CHU de Clermont-Ferrand
      2011   -   EUCTR2009-012615-18-FR   France;
Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)   
   Alliancells Bioscience Corporation Limited
      2013   Phase 1/Phase 2   NCT01547091   China;
Umbilical cord mesenchymal stem cells   
   Translational Biosciences
      2013   Phase 1/Phase 2   NCT01985464   Panama;
Upadacitinib   
   AbbVie
      2019   Phase 2   NCT03823378   Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 3   NCT02955212   Brazil;China;Korea, Republic of;
      2018   Phase 2   NCT03682705   Belgium;Canada;Czechia;Germany;Hungary;Ireland;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2017   Phase 3   NCT03086343   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   NCT02706951   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;Estonia;Greece;Hungary;Israel;Italy;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   NCT02706873   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Finland;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02706847   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 2/Phase 3   NCT02720523   Japan;
      2015   Phase 3   NCT02675426   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   NCT02629159   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   NCT02066389   Bulgaria;Chile;Czech Republic;Czechia;Hungary;Israel;Latvia;Mexico;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-002306-31-HU   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-HU   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-000666-10-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-000933-37-BG   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-000666-10-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-SE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-PT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-NL   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-DE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-CZ   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-BE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-LV   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-HU   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003376-75-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003335-35-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-IE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-SI   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-PT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-PL   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-LV   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-LT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-IE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-HR   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-GB   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-CZ   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-BG   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-BE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-003334-27-SK   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-003333-95-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-003530-33-GB   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-003530-33-BG   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-003530-33-BE   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-HU   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-CZ   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
   Kawakami Atsushi
      2021   Phase 4   JPRN-jRCTs071200079   Japan;
   Ottawa Hospital Research Institute
      2022   Phase 4   NCT05153200   -
Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level   
   CHU de Reims
      2018   -   NCT03852888   France;
Ursodeoxycholic acid (UDCA)   
   Tanta University
      2021   Phase 2   NCT04834557   -
Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.   
   Centocor Ortho Biotech Services, L.L.C.
      2004   Phase 4   NCT00378261   -
Ustekinumab   
   Janssen-Cilag International NV
      2013   -   EUCTR2011-001122-18-BG   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   Phase 2   EUCTR2011-001122-18-CZ   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   -   EUCTR2011-001122-18-HU   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
Ustekinumab + MTX (Group 2)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01645280   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
Ustekinumab + MTX (Group 3)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01645280   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
VAY736   
   Novartis Pharmaceuticals
      2010   Phase 1   NCT02675803   Germany;
VIB4920   
   Viela Bio
      2019   Phase 2   NCT04163991   Poland;United States;
      2016   Phase 1   NCT02780388   Poland;United States;
VIBEX MTX   
   Antares Pharma Inc.
      2012   Phase 2   NCT01618955   United States;
VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE   
   DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
      2016   Phase 3   EUCTR2015-000570-35-IT   Italy;
VIREAD 30 CPR   
   DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
      2016   Phase 3   EUCTR2015-000570-35-IT   Italy;
VX-509   
   Vertex Pharmaceuticals Incorporated
      2013   Phase 2;Phase 3   EUCTR2012-004342-14-DK   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2013   Phase 2/Phase 3   NCT01830985   Estonia;Lithuania;South Africa;United States;
      2013   Phase 2   NCT01754935   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2013   -   EUCTR2012-004342-14-LT   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2013   -   EUCTR2012-004342-14-EE   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2013   -   EUCTR2012-003439-41-NL   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2013   -   EUCTR2012-003439-41-LT   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2013   -   EUCTR2012-003439-41-EE   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2013   -   EUCTR2012-003439-41-DK   Denmark;Estonia;Lithuania;Netherlands;South Africa;United States;
      2012   Phase 2   NCT01590459   Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2012   Phase 2   EUCTR2011-004419-22-BG   Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2012   -   EUCTR2011-004419-22-SK   Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2012   -   EUCTR2011-004419-22-HU   Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2012   -   EUCTR2011-004419-22-EE   Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2012   -   EUCTR2011-004419-22-DE   Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2012   -   EUCTR2011-004419-22-CZ   Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;United States;
      2010   Phase 2   NCT01052194   Belgium;Croatia;Germany;Hungary;Poland;Puerto Rico;Romania;Russian Federation;Serbia;United States;
      2010   Phase 2   EUCTR2009-017438-32-BE   Belgium;Germany;Hungary;Poland;
      2010   -   EUCTR2009-017438-32-PL   Germany;Hungary;Poland;
      2010   -   EUCTR2009-017438-32-HU   Germany;Hungary;Poland;
      -   -   EUCTR2009-017438-32-DE   Belgium;Croatia;Germany;Hungary;Poland;Romania;Russian Federation;Serbia;United States;
VX-702   
   Vertex Pharmaceuticals Incorporated
      2006   Phase 2   NCT00395577   Bulgaria;Croatia;Former Serbia and Montenegro;Poland;Russian Federation;Slovenia;
      2006   -   EUCTR2006-004715-22-SI   Slovenia;
      2005   Phase 2   NCT00205478   Bulgaria;Croatia;Czech Republic;Former Serbia and Montenegro;Poland;Russian Federation;Slovakia;Slovenia;Ukraine;
      2005   Phase 2   EUCTR2005-000549-13-SK   Czech Republic;Slovakia;
      2005   -   EUCTR2005-000549-13-CZ   Czech Republic;
Vaccination against TBE   
   Sormland County Council, Sweden
      2010   Phase 2   NCT01131910   Finland;Sweden;
Valdecoxib   
   Pfizer
      2003   Phase 4   NCT00650455   Canada;United States;
Vancomycin   
   New York University School of Medicine
      2010   -   NCT01198509   United States;
Vanguard 360 TiNbN Femur with PS bearing   
   Zimmer Biomet
      2012   -   NCT01542580   Belgium;Denmark;France;Germany;Italy;Spain;United Kingdom;United States;
Vanguard 360 TiNbN Femur with PSC bearing   
   Zimmer Biomet
      2012   -   NCT01542580   Belgium;Denmark;France;Germany;Italy;Spain;United Kingdom;United States;
Vanguard DA 360   
   Zimmer Biomet
      2012   -   NCT01542580   Belgium;Denmark;France;Germany;Italy;Spain;United Kingdom;United States;
Vanguard SSK 360 with PS Bearing   
   Zimmer Biomet
      2012   -   NCT01542580   Belgium;Denmark;France;Germany;Italy;Spain;United Kingdom;United States;
Vanguard SSK 360 with PSC bearing   
   Zimmer Biomet
      2012   -   NCT01542580   Belgium;Denmark;France;Germany;Italy;Spain;United Kingdom;United States;
Varicella Zoster Vaccine   
   Kevin Winthrop
      2014   Phase 2   NCT03604406   United States;
Veltuzumab   
   Takeda
      2011   Phase 2   NCT01390545   Argentina;Canada;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Spain;United Kingdom;United States;
Veltuzumab solution 75mg/ml   
   Nycomed GmbH
      2011   -   EUCTR2010-022378-15-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2010-022378-15-GB   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-ES   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-DE   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-CZ   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
Venlafaxine Hydrochloride   
   Newcastle upon Tyne Hospitals NHS Trust
      2005   -   EUCTR2004-002482-20-GB   United Kingdom;
Venous blood sample   
   Assistance Publique Hopitaux De Marseille
      2009   -   NCT00947492   France;
Vidofludimus   
   4SC AG
      2009   -   EUCTR2009-012953-39-BG   Bulgaria;Czech Republic;Poland;
Vitamin D   
   Assiut University
      2019   Phase 3   NCT04344405   Egypt;
   Brigham and Women's Hospital
      2011   Phase 4   NCT01400516   United States;
      2011   -   NCT01351805   United States;
   Department of Orthopaedic Surgery Shinshu University School of Medicine
      2016   -   JPRN-UMIN000022364   Japan;
   Odense University Hospital
      1999   -   NCT02932644   -
   University of Aarhus
      2015   Phase 2   NCT02944799   Denmark;
   University of Wisconsin, Madison
      2005   -   NCT00423358   United States;
   Yokohama City University Medical Center
      2014   -   JPRN-UMIN000014737   Japan;
Vitamin D 2   
   Rajavithi Hospital
      2021   -   NCT04909931   Thailand;
Vitamin D in arm B   
   Indiana University
      2009   Phase 2   NCT00279461   United States;
Vitamin D3   
   Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
      2021   -   NCT05078502   Bangladesh;
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Vitamin K   
   Janssen Research & Development, LLC
      2012   Phase 1   NCT01636557   Germany;Korea, Republic of;Moldova, Republic of;South Africa;
Voltarol SR   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Voltarol SR (generics also available in the EU)   
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Voltrarol SR   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Warfarin   
   AstraZeneca
      2011   Phase 1   NCT01311622   United Kingdom;
   Janssen Research & Development, LLC
      2012   Phase 1   NCT01636557   Germany;Korea, Republic of;Moldova, Republic of;South Africa;
Warfarin+ Vitamin K   
   R-Pharm International, LLC
      2021   Phase 1   NCT04246762   Bulgaria;Moldova, Republic of;
Water   
   Centre Hospitalier Universitaire de Besancon
      2017   -   NCT03911830   France;
   Soroka University Medical Center
      2013   -   NCT01861782   Israel;
   University of Pecs
      2020   -   NCT04275206   Hungary;
   Zhejiang Chinese Medical University
      2013   Phase 1 study   ChiCTR-ONRC-13003578   China;
Water exercises   
   Federal University of São Paulo
      2009   Phase 3   NCT01447264   Brazil;
Whale blubber oil   
   National Institute of Nutrition and Seafood Research, Norway
      2008   -   NCT00805116   Norway;
Whey Protein&Prebiotic Supplement   
   Dr. Veena Ranganath
      2016   -   NCT02881307   United States;
Whole body Protein turnover   
   University of Texas Southwestern Medical Center
      2006   -   NCT00286689   United States;
Whole body planar SPECT imaging (15 Minutes post-injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Whole body planar SPECT imaging (18-20 Hours post-injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Whole body planar SPECT imaging (180 Minutes post-injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Whole body planar SPECT imaging (60 Minutes post-injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
XELJANZ 5 mg film-coated tablets   
   AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
      2019   Phase 4   EUCTR2018-003162-13-IT   Italy;
XELJANZ 5Mg Tablet   
   Chong Kun Dang Pharmaceutical
      2019   Phase 1   NCT03868072   Korea, Republic of;
XENP5871   
   Xencor Inc.
      2013   -   EUCTR2012-003057-29-CZ   Czech Republic;Hungary;Slovakia;
      2012   Phase 2   EUCTR2012-003057-29-HU   Czech Republic;Hungary;Slovakia;
      2012   -   EUCTR2012-003057-29-SK   Czech Republic;Hungary;Slovakia;
XOMA 052   
   XOMA (US) LLC
      2009   Phase 2   NCT00777816   United States;
Xeljanz   
   Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
      2019   Phase 4   EUCTR2018-004539-54-DE   Germany;
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000797-39-IT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2020   Phase 3   EUCTR2019-000867-26-DE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-PL   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-HU   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-GB   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-ES   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-EE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-BG   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LV   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-HU   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-GB   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-ES   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-CZ   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
   Tampere University Hospital
      2018   Phase 4   EUCTR2017-002753-11-FI   Finland;
   Västra Götalandsregionen
      2020   Phase 4   EUCTR2019-004179-38-SE   Sweden;
Xeljanz XR   
   Erasmus Medical Center
      2022   Phase 4   EUCTR2021-004131-84-NL   Netherlands;
Xeljanz® 11mg Prolonged Release Tablet   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SK   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
Xinfeng capsule   
   The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
      2013   -   NCT01774877   China;
XmAb5871_   
   Xencor Inc.
      2013   -   EUCTR2012-003057-29-CZ   Czech Republic;Hungary;Slovakia;
      2012   Phase 2   EUCTR2012-003057-29-HU   Czech Republic;Hungary;Slovakia;
      2012   -   EUCTR2012-003057-29-SK   Czech Republic;Hungary;Slovakia;
XmAb®5871   
   Xencor Inc.
      2013   -   EUCTR2012-003057-29-CZ   Czech Republic;Hungary;Slovakia;
      2012   Phase 2   EUCTR2012-003057-29-HU   Czech Republic;Hungary;Slovakia;
      2012   -   EUCTR2012-003057-29-SK   Czech Republic;Hungary;Slovakia;
Xolair   
   Leiden University Medical Center, Department of Rheumatology
      2010   -   EUCTR2009-017306-36-NL   Netherlands;
YLB113   
   YL Biologics Ltd
      2016   Phase 3   EUCTR2015-002809-12-BG   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-LV   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-HU   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-ES   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-CZ   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
YRA-1909 high dose   
   Yungjin Pharm. Co., Ltd.
      2017   Phase 2   NCT03275025   Korea, Republic of;
YRA-1909 low dose   
   Yungjin Pharm. Co., Ltd.
      2017   Phase 2   NCT03275025   Korea, Republic of;
YRA-1909 mid dose   
   Yungjin Pharm. Co., Ltd.
      2017   Phase 2   NCT03275025   Korea, Republic of;
Yellow Fever vaccine (17D)   
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;
Yisaipu   
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03589833   China;
Z102   
   Zalicus
      2011   Phase 2   NCT01369745   United States;
   Zalicus, Inc.
      2012   -   EUCTR2011-002392-41-HU   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-002392-41-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Z102 (Prednisolone and Dipyridamole).   
   Zalicus, Inc.
      2011   -   EUCTR2011-000436-28-PL   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-HU   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-BG   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
ZD 4522   
   University of Dundee
      2005   -   EUCTR2004-001909-10-GB   United Kingdom;
Zoledronate   
   Shanghai Traditional Medicine University Affiliated Guanghua Hospital
      2018   -   ChiCTR1800019277   China;
Zoledronic acid   
   Carmen Gómez-Vaquero
      2014   Phase 3   NCT02123264   Spain;
   Osaka City University Graduate School of Medicine
      2018   -   JPRN-UMIN000030828   Japan;
Zolpidem   
   Mito medical center, Mito Kyodo General Hospital, University of Tsukuba
      2020   -   JPRN-UMIN000039116   Japan;
Zostavax (varicella zoster virus) vaccine   
   Oklahoma Medical Research Foundation
      2012   Phase 1   NCT01506661   United States;
Zostavax vaccine   
   HaEmek Medical Center, Israel
      2017   Phase 4   NCT03016884   Israel;
Zostavax®   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2016   Phase 3;Phase 4   EUCTR2014-000358-13-DE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;